CLINICAL AND SCIENTIFIC EVIDENCE OF THE EPI® TECHNIQUE

Pain Medicine, 00(0), 2020, 1–17
doi: 10.1093/pm/pnaa342
Review Article

Effectiveness of Ultrasound-Guided Percutaneous Electrolysis for Musculoskeletal Pain: A Systematic Review and Meta-Analysis

Guido F. Gómez-Chiguano, PT, MSc* Marcos J. Navarro-Santana, PT, MSc[†,‡] Joshua A. Cleland, PT, PhD[§] Jose L. Arias-Buría, PT, PhD,[¶,‖] César Fernández-de-las-Peñas, PT, PhD[¶,‖] Ricardo Ortega-Santiago, PT, PhD,[¶,‖] and Gustavo Plaza-Manzano, PT, PhD[†,‖,‖‖]

*Escuela Internacional de Doctorado, Universidad Rey Juan Carlos, Madrid, Spain; [†]Department of Radiology, Rehabilitation and Physiotherapy, Universidad Complutense de Madrid, Madrid, Spain; [‡]Rehabilitación San Fernando, Madrid, Spain; [§]Doctor of Physical Therapy Program, Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA; [¶]Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain; [‖]Cátedra Institucional en Docencia, Clínica e Investigación en Fisioterapia: Terapia Manual, Punción Seca y Ejercicio Terapéutico, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain; [‖‖]Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain

Correspondence to: César Fernández-de-las-Peñas, PT, PhD, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Avenida de Atenas s/n, 28922 Alcorcón, Madrid, Spain. Tel: +34 91 488 88 84; Fax: +34 91 488 89 57; E-mail: cesarfdlp@yahoo.es/cesar.fernandez@urjc.es.

Funding sources: No funds were received for this study.

Conflicts of interest: The authors have no conflicts of interest to report.

Author contributions: All of the authors contributed to the study concept and design. Marcos J. Navarro-Santana, Guido F. Gómez-Chiguano, and Jose L. Arias-Buría conducted the literature review and performed the main statistical analysis. All of the authors contributed to the interpretation of the data. César Fernández-de-las-Peñas and Joshua A. Cleland wrote the first draft of the manuscript. All of the authors reviewed the intellectual content and read and approved the final version of the manuscript.

Abstract

Objective. To evaluate the effects of ultrasound-guided percutaneous electrolysis alone or as an adjunct to other interventions on pain and pain-related disability for musculoskeletal pain conditions. **Databases and Data Treatment**. Search of MEDLINE database, Allied and Complementary Medicine Database, EMBASE database, Cumulative Index to Nursing & Allied Health Literature database, EBSCO database, PubMed database, Physiotherapy Evidence Database, Cochrane Library database, Scopus database, and Web of Science database. Randomized controlled trials in which at least one group received ultrasound-guided percutaneous electrolysis for treatment of musculoskeletal pain. To be eligible, studies had to include humans and collect outcomes on pain intensity and pain-related disability for musculoskeletal pain syndromes. Data were extracted by two reviewers. The risk of bias was assessed by the Cochrane Guidelines and the quality of evidence was reported using the Grading of Recommendations Assessment, Development and Evaluation approach. Standardized mean differences (SMDs) and random effects were calculated. **Results**. Ten studies were included. The meta-analysis found that ultrasound-guided percutaneous electrolysis reduced the mean pain intensity by –2.06 (95% confidence interval [CI], –2.69 to –1.42) and the pain intensity as assessed with a visual analog scale or a numeric pain rating scale with a large size effect (SMD = –1.15; 95% CI, –1.48 to –0.81) and also improved pain-related disability with a large size effect (SMD = 0.95; 95% CI, 0.73–1.18) as compared with comparison groups. No differences in effect sizes were found among the short-term, midterm, and long-term follow-ups. The risk of bias was generally low, but the heterogeneity of the overall result downgraded the evidence level. Trials included heterogeneous musculoskeletal pain conditions and short-term, midterm, and long-term follow-ups. **Conclusion**. Moderate evidence suggests positive effects of ultrasound-guided percutaneous electrolysis for pain and pain-related disability in musculoskeletal pain conditions relative to a comparison group in the short term, midterm, and long term.

Key words: . Percutaneous Electrolysis; Musculoskeletal Pain; Meta-Analysis

Introduction

Musculoskeletal pain results in a large economic burden, a loss in quality of life, and difficulty during daily activities [1–3]. The incidence of musculoskeletal pain in Europe has been found to be 19% [4], whereas the prevalence ranges from 35% to 51% [5]. Musculoskeletal pain includes a myriad of conditions related to pain arising from bones (fractures), muscles (myofascial pain), ligaments (sprains), or tendons (tendinopathies). It can be primary musculoskeletal pain—i.e., related to a specific pathology, such as knee or hip osteoarthritis—or secondary musculoskeletal pain—i.e., not attributed to a specific identified pathology, such as shoulder or neck pain [6]. When the nerve tissue is affected, it is usually called "neuropathic pain."

Multimodal approaches are typically recommended for musculoskeletal pain. Several nonpharmacologic interventions, including exercise, pain education, and cognitive and psychological approaches, are used for the treatment of chronic musculoskeletal pain [7, 8]. The use of electrical current has also been proposed as a therapeutic strategy for the management of musculoskeletal pain; it was first introduced to the medical community by Wall and Sweet [9]. The most common form of electrotherapy to manage musculoskeletal pain is transcutaneous electrical nerve stimulation, which consists of the application of a pulsed electrical current across the surface of the skin to potentially activate underlying nerves [10]. The application of a pulsed electrical current throughout a needle is called percutaneous electrical nerve stimulation (PENS), which includes a range of applications depending on the frequency of the electrical current (low or high frequency) or the place where the needles are inserted (e.g., dermatome or myotome). Other authors use the term "electro-acupuncture" for the application of a pulsed electrical current with a needle applied over acupuncture points. All of these applications have a common denominator: the use of a pulsed electrical current. PENS uses solid filament needles, whereas other interventions, such as tendon tenotomies, use beveled, cutting-edge needles or an electric scalpel.

One emerging therapeutic strategy that also uses electrical current with a needle is percutaneous electrolysis [11]. Percutaneous electrolysis consists of the application of a galvanic continuous—not pulsed—electrical current through a solid filament needle in a targeted tissue such as the tendon or muscle [11]. Percutaneous electrolysis combines the mechanical effect resulting from the insertion of the solid needle and the biological effect derived from the application of the galvanic current [11]. The theoretical background for applying percutaneous electrolysis is the ability to induce a controlled inflammatory response by a nonthermal electrolytic reaction through a cathodic flow with the aim to facilitate phagocytosis and posterior regeneration of the affected tissue [11]. Due to the use of a continuous galvanic current with the goal of producing a nonthermal electrolytic reaction, percutaneous electrolysis should be ultrasound guided to apply the continuous galvanic current in the targeted tissue [11] (Figure 1). In fact, other invasive procedures, such as percutaneous needle tenotomy, should also be conducted using the direct visual guidance of ultrasound, as it creates small holes and slices in a tendon.



Figure 1. Ultrasound-guided application of percutaneous electrolysis on the supraspinatus tendon. The image shows how the needle reaches the area of the tendon and the nonthermal electrolytic reaction with the application of the continuous galvanic electrical current (white).

Several case studies have suggested that percutaneous electrolysis, combined with exercise, is effective for the management of different musculoskeletal disorders [12–15]. In the last few years, the number of clinical trials in this area has increased, but (to the best of our knowledge) there is not a meta-analysis on this topic in the literature.

Therefore, this systematic review and meta-analysis evaluates the effects of ultrasound-guided percutaneous electrolysis alone or as an adjunct with other interventions on pain intensity and pain-related disability in people with musculoskeletal pain.

Methods

This systematic review and meta-analysis adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [16]. The international OPS Registry registration link is https://doi.org/10.17605/OSF.IO/W359E.

Systematic Literature Search

Electronic literature searches were conducted on the MEDLINE database, Allied and Complementary Medicine Database, EMBASE database, Cumulative Index to Nursing & Allied Health Literature database, EBSCO database, PubMed database, Physiotherapy Evidence Database (PEDro), Cochrane Library database, Scopus database, and Web of Science database from their inception to August 1, 2020. When the searched

databases allowed limits, searches were restricted to randomized clinical trials. We also manually screened the reference lists of the articles identified in the database searches and included these in the analysis. Bibliographical database search strategies were conducted with the assistance of an experienced health science librarian.

Population

The population for this study was composed of adults with a musculoskeletal pain condition, excluding neuropathic conditions, who were older than 18 years.

Intervention

The intervention consisted of any form of percutaneous electrolysis (i.e., the application of continuous galvanic current with a needle). Other interventions using pulsed current, such as PENS or electro-acupuncture, were excluded. For this aim, the search strategy included one of the following key words: *ultrasound-guided percutaneous electrolysis OR needle percutaneous electrolysis OR percutaneous needle electrolysis OR (percutaneous AND electrolysis) OR intratissue percutaneous electrolysis OR ultrasound-guided galvanic electrolysis*.

Comparator

Acceptable comparators were any type of placebo, sham, or no intervention. For this aim, the search strategy included one of these key words: *sham OR placebo OR control OR no intervention*. In addition, we also included a comparison of percutaneous electrolysis with another active intervention.

Outcomes

The primary outcome measure was *pain OR pain-related disability OR function*.

The search strategy for each database is available in Supplementary Data.

Selection Criteria

The systematic review included randomized clinical trials in which at least one group received any form of ultrasound-guided percutaneous electrolysis in a sample of patients with musculoskeletal pain. Patients with systemic medical underlying conditions causing pain, such as infection, neoplasms, metastasis, fracture, rheumatoid arthritis, or osteoporosis, were excluded. Additionally, patients with neuropathic pain or pain associated with neurological disorders were also excluded.

The specific inclusion criteria included 1) adult population (>18 years old) with musculoskeletal pain; 2) one group receiving any type of ultrasound-guided percutaneous electrolysis intervention; 3) an acceptable comparator with a sham, placebo, or control or another active intervention; and 4) pain intensity (e.g., as measured with a visual analog scale [VAS] or a numeric pain rating scale [NPRS]) or pain-related disability (e.g., as assessed with a specific disease questionnaire) as a primary outcome of the study. We excluded clinical trials, including 1) studies that analyzed pain related to neurological disorders; 2) retrospective clinical studies; and 3) studies that were not published as journal articles.

Screening, Selection Process, and Data Extraction

Articles identified from the different databases were independently reviewed by two authors. First, the duplicates were removed. Second, the titles and abstracts of the articles were screened for potential eligibility. Third, a full-text read of potentially eligible studies was conducted. The authors were required to reach a consensus on the included trials. In the case of discrepancy between both reviewers, a third author participated in the process to reach a consensus and to decide whether the study should be included.

Data from each trial were extracted independently by two authors using a standardized form. The data analyzed included the study design, sample size, population, diagnosis, interventions, outcomes, and follow-up periods. Both authors had to reach a consensus on each item on the data extraction form. If disagreement occurred, a third author made the final determination.

Assessment of Methodological Quality and Risk of Bias

Risk of bias and the methodological quality of the included trials were independently assessed by two researchers using the Cochrane Risk of Bias (RoB) assessment tool [17] and the PEDro scale [18], respectively.

The RoB tool includes the following types of bias: selection bias (randomization sequence generation, allocation concealment); performance bias (blinding participants, blinding therapists); detection bias (blinding outcome assessor); attrition bias (incomplete outcome data); reporting bias (source of funding bias or selective outcome reporting); and other bias (sample size) [17]. Each item was classified as low risk, high risk, or unclear according to the Cochrane Collaboration tool [17].

The PEDro scale assessed the following items: random allocation, concealed allocation, between-group similarity at baseline, participant blinding, therapist blinding, assessor blinding, dropout rate, intention-to-treat statistical analysis, between-group statistical comparison, and point measures and variability data [18]. A PEDro score of 6 of 10 points is the cutoff point for determining the high or low quality of a trial.

Quality of Evidence

To evaluate the quality of the evidence for percutaneous electrolysis, we used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach [19]. The quality of evidence was classified as high, moderate, low, or very low based on the presence

of study limitations (RoB), indirectness of evidence, inconsistency of results or unexplained heterogeneity, imprecision of results, and high probability of publication bias [20]. The quality of evidence was classified as high when all items were negative; moderate when one item included serious risk; low when two to three items showed serious risk or one to two items showed very serious risk; or very low when all items had a serious risk or more than two items showed a very serious risk. This evaluation was independently performed by two authors, with a third author available if the two authors could not reach a consensus.

Data Synthesis and Analysis

The meta-analysis was conducted using Review Manager statistical software (RevMan version 5.3). Data synthesis was categorized by groups according to the follow-up period as short-term (less than 1 month), midterm (1–3 months), and long-term (3–6 months) if the data were available.

We extracted the sample size, means, and standard deviations for each variable. When the trial reported only standard errors, these were converted to standard deviations. When necessary, the mean scores and standard deviations were estimated from graphs. Also, if the study reported a nonparametric value (median and interquartile range), using the method described by Wan et al. [21] and Luo et al. [22], the results were converted to the mean [22] and standard deviation [21].

For the outcome of pain intensity—using either an NPRS or a VAS—we calculated the mean difference (MD) between the percutaneous electrolysis group and the comparison group and converted this to the standardized mean difference (SMD). For pain-related disability, we included any outcome reporting self-perception of function or disability and due to the heterogeneity of the variety of the included outcomes, we decided to use only the SMD for the between-group comparison.

The between-group MDs of the trials were converted to the SMD with a 95% confidence interval (CI). A random-effects model was used to determine the overall effect size (SMD). An effect size (SMD) of 0.8 or greater was considered large, between 0.5 to 0.8 was considered moderate, and between 0.2 to 0.5 was considered small. In general, P values less than 0.05 were considered statistically significant. The overall effect sizes and calculations of the effect size on pain intensity and pain-related disability were obtained for the short term (0–1 months), for the midterm (1–3 months), and for the long term (3–6 months).

The heterogeneity of the studies was assessed using the I^2 statistic. The Cochrane Group has established the following interpretation of the I^2 statistic: 0–40% may not be relevant or important heterogeneity, 30–60% suggests moderate heterogeneity, 50–90% represents substantial heterogeneity, and 75–100% represents considerable heterogeneity [23].

Results

Study Selection

The electronic searches identified 126 potential studies for review. After removing duplicates, 73 studies remained. Fifty-five (n=55) were excluded because study protocols were being reviewed (Supplementary Data) or based on examination of their titles or abstracts, leaving 18 articles for further full-text analysis. Another eight were excluded because congress communication had occurred [24–27], the study included an inadequate comparator group or it was not a randomized clinical trial [13, 28, 29], or the study was a retrospective study [30]. Finally, a total of 10 trials [31–40] were included in the qualitative and quantitative analyses (Figure 2).

Study Characteristics

The characteristics of the participants of the included studies are listed in Table 1. The musculoskeletal conditions were heterogeneous, including nonspecific shoulder pain [32, 33, 36, 40], patellar tendinopathy [31], groin pain [37], plantar heel pain [34], whiplash-associated pain [35], temporomandibular pain [38], and lateral epicondylalgia [39]. All trials applied percutaneous electrolysis, but there was higher diversity in terms of the number or frequency of sessions, the intensity of the electrical current, and the type of comparator. Supplementary Data summarizes the percutaneous electrolysis parameters applied in each trial. Seven studies combined percutaneous electrolysis with an exercise program [31–34, 37, 39, 40], whereas only three trials analyzed the isolated effects of percutaneous electrolysis [35,36,38] (Table 2).

Methodological Quality

The methodological quality scores ranged from 5 to 9 (mean, 6.8; SD = 1.2) out of a maximum of 10 points. Eight studies (80%) were considered to be of high methodological quality (≥6 points). The most frequent biases were blinding of the therapists, followed by allocation concealment and assessor blinding. Table 3 lists the details of the PEDro scale.

Risk of Bias

The details of the risk-of-bias assessment of the included trials are shown in Figure 3. Only one trial was able to blind therapists [34], and six had a substantial risk of bias in the item of blinding participants. In general, the risk of bias of the trials included in this meta-analysis was low, except for the blinding of the participant or therapist.



Figure 2. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

Effects of Percutaneous Electrolysis on Pain

The overall effect of percutaneous electrolysis vs a comparison group showed a statistically significant ($P<0.001$) effect for reducing pain (MD = –2.06; 95% CI, –2.69 to –1.42; Figure 4) with a large effect of size (SMD = –1.15; 95% CI, –1.48 to –0.81; n=838; $Z=6.67$; $P<0.001$; Figure 5) but with considerable heterogeneity ($I^2=79\%$) between the studies. The results were significant at follow-up each time: the mean reduction of pain (MD) was –1.94 (95% CI, –3.13 to –0.76; n=408; $Z=3.21$; $P=0.001$) in the short term; –2.09 (95% CI, –2.90 to –1.29; n=251; $Z=5.09$; $P<0.001$) in the midterm; and –2.28 (95% CI, –3.27 to –1.30; n=179; $Z=4.54$; $P<0.001$) in the long term, but always with considerable heterogeneity between studies ($I^2>75\%$). All effect sizes were also large at all follow-ups (Figure 5). Table 2 summarizes the main results of each of the included trials.

Effects of Percutaneous Electrolysis on Pain-Related Disability

The overall effect of percutaneous electrolysis vs a comparative group showed a statistically significant ($P<0.001$) large effect size (SMD = 0.95; 95% CI, 0.73–1.18; n=706; $Z=8$–46; $P<0.001$) on pain-related disability with a moderate heterogeneity ($I^2=45\%$) between the trials (Figure 6). Again, significant effect sizes were observed at each follow-up period. In the short term, the effect size was moderate (SMD = 0.76; 95% CI, 0.44–1.07; n=380; $Z=4.71$; $P<0.001$) with moderate heterogeneity ($I^2=50\%$). In the midterm (SMD = 1.21; 95%

Table 1. Participant characteristics of the included trials

Type of Pain	Group	Sample Size	Gender, Male (Female)	Age, Years	Pain Duration
Shoulder Pain					
Arias-Buría et al. [32]	G1	17	4 (13)	58±7	11.2±2.7 months
	G2	19	5 (14)	57±6	10.6±2.6 months
Moreno [36]	G1	10	NR	39.6±3.7	>3 months
	G2	10	NR	40.4±3.2	>3 months
	G3	10	NR	39.9±4.15	>3 months
	G4	10	NR	39.8±4.65	>3 months
de Miguel Valtierra et al. [33]	G1	25	11 (14)	54.9±13.7	12.6±14.4 months
	G2	25	12 (13)	55.3±11.1	11.2±10.6 months
Rodríguez-Huguet et al. [40]	G1	18	16 (2)	39.2±11.35	NR
	G2	18	11 (7)	40.9±8.4	NR
Lateral Elbow Pain					
Rodríguez-Huguet et al. [39]	G1	16	10 (6)	40.45±15.5	NR
	G2	16	10 (6)	35.9±12.1	NR
Patellar Tendinopathy					
Abat et al. [31]	G1	32	27 (5)	31.2±6.5	28.8±32.4 months
	G2	32	24 (8)	30.5±5.9	29.5±31.5 months
Groin Pain					
Moreno et al. [37]	G1	11	11 (0)	26.9±4.5	0–4 weeks: 5 4–10 weeks: 4 10–26 weeks: 2 >26 weeks: 0
	G2	13	13 (0)	25.2±4.9	0–4 weeks: 6 4–10 weeks: 3 10–26 weeks: 3 >26 weeks: 1
Whiplash-Associated Pain					
García-Naranjo et al. [35]	G1	50	20 (30)	35.3±8.1	5.6±1.6 days
	G2	50	16 (34)	40.9±9.2	6.1±1.2 days
Plantar Heel Pain					
Fernández-Rodríguez et al. [34]	G1	38	15 (23)	45.1±11.4	>3 months
	G2	29	10 (19)	46.6±11.1	>3 months
Temporomandibular Pain					
Lopez-Martos et al. [38]	G1	20	5 (15)	38.5 (18–57), IQR	>6 months
	G2	20	2 (18)	36 (19–58), IQR	>6 months
	G3	20	1 (19)	42 (25–62), IQR	>6 months

NR = not reported; IQR = interquartile range.

CI, 0.89–1.52; n=183; Z=7.41; P<0.001) and the long term (SMD = 1.20; 95% CI, 0.84–1.56; n=143; Z=6.53; P<0.001), the effect sizes were large, with no heterogeneity between the trials (I^2=0%). Table 2 summarizes the main results of each of the included trials.

Quality of Evidence (GRADE)

Table 4 lists the details of the GRADE assessment, showing risk of bias, inconsistency of the results, indirectness of evidence, imprecision of results, and high probability of publication bias. The serious inconsistency of the results (heterogeneity) and the series imprecision was downgraded to a moderate level of evidence of the overall effect of ultrasound-guided percutaneous electrolysis for pain and pain-related disability.

Adverse Events of Percutaneous Electrolysis

The most common adverse effect reported was postelectrolysis soreness. Arias-Buría et al. [32] reported that 35% of patients receiving percutaneous electrolysis experienced muscle soreness after the first two interventions, whereas de Miguel Valtierra et al. [33] observed this event in 24% of patients. Postelectrolysis soreness disappeared 24–36 hours after the procedure without treatment [32, 33]. Lopez-Martos et al. [38] reported that one patient presented a self-limiting hematoma. Moreno et al. [37] reported that patients experienced a slight increase in pain intensity the following 12 hours after percutaneous electrolysis intervention, but no adverse events were reported. No adverse events were observed in the studies conducted by Abat et al. [31] and Fernández-Rodríguez et al. [34]. Finally, the remaining four studies [35, 36, 39, 40] did not provide data about adverse events.

Discussion

The objective of this meta-analysis was to determine the effects of ultrasound-guided percutaneous electrolysis on the management of musculoskeletal pain syndromes. The results found moderate-quality evidence that percutaneous electrolysis has a large effect on reducing pain and

Table 2. Effects of percutaneous electrolysis on pain and pain-related disability for musculoskeletal pain conditions

Study	Intervention(s)	Sample Size	Intervention Duration, Sessions or Weeks	Comparison and Outcome Measure	Between-Group Differences (95% CI) [SMD]*
Shoulder Pain					
Arias-Buría et al. [32]	G1: PE and eccentric exercise	17	1 × 4 weeks	Mean pain intensity (0–10)	2 weeks: –1.5 (0.7, 2.2) [–1.2]
	G2: Eccentric exercise	19	1 × 4 weeks	G1 vs G2	5 weeks: –1.70 (–2.80, –0.6) [–0.96]
				G1 vs G2	
				Worst pain intensity (0–10)	2 weeks: –0.3 (2.0, –1.4) [–0.11]
				G1 vs G2	5 weeks: –2.3 (–1.2, 3.3) [–1.34]
				G1 vs G2	
				Worst pain intensity (0–10)	2 weeks: –0.2 (–1.4, 1.1) [–0.10]
				G1 vs G2	5 weeks: –1.1 (–1.5, 0.3) [–0.51]
				G1 vs G2	
				DASH (0–100)	2 weeks: 12.2 (5.6, 18.9) [1.18]
				G1 vs G2	5 weeks: 9.5 (1.9, 17.2) [0.80]
				G1 vs G2	
Moreno [36]	G1: Control group	10	1 × 3 weeks	Pain intensity (VAS)	3 weeks: –3.80 (–4.28, –3.32) [–6.64]
	G2: PE at TrP	10		G2 vs G1	3 weeks: –2.90 (–3.40, –2.40) [–4.85]
	G3: PE at tendon	10		G3 vs G1	3 weeks: –1.75 (–2.65, –0.85) [–1.64]
	G4: PE at TrP and tendon	10		G4 vs G1	
de Miguel Valtierra et al. [33]	G1: Manual therapy, exercise, and PE	25	Manual therapy: 1 × 4 weeks	Mean pain intensity (NPRS)	6 weeks: –1.4 (–2.4, –0.4) [–0.65]
		25	Exercise: Twice per day × 5	G1 vs G2	17 weeks: –2.6 (–4.0, –1.5) [–0.91]
	G2: Manual therapy and exercise		PE: 1 × 5 weeks	G1 vs G2	29 weeks: –2.7 (–4.2, –1.2) [–1.03]
				G1 vs G2	
				Least pain intensity (NPRS)	6 weeks: –1.8 (–2.6, –1.0) [–0.79]
				G1 vs G2	17 weeks: –3.0 (–4.2, –1.8) [–1.15]
				G1 vs G2	29 weeks: –2.8 (–3.6, –2.0) [–1.05]
				G1 vs G2	
				Worst pain intensity (NPRS)	6 weeks: –1.3 (–2.0, –0.6) [–0.56]
				G1 vs G2	17 weeks: –3.2 (–3.8, –2.6) [–1.18]
				G1 vs G2	29 weeks: –3.1 (–3.6, –2.6) [–1.29]
				G1 vs G2	
				Disability (SPADI)	6 weeks: –12.5 (–18.9, –6.1) [–1.06]
				G1 vs G2	17 weeks: –16.9 (–25.2, –8.6) [–1.08]
				G1 vs G2	29 weeks: –17.3 (–25.5, –9.1) [–1.18]
				G1 vs G2	
				Disability (DASH)	6 weeks: 1.7 (–0.3, 3.7) [0.46]
				G1 vs G2	17 weeks: –2.8 (–7.8, 2.2) [–0.20]
				G1 vs G2	29 weeks: –9.9 (–0.3, 3.7) [–0.41]
				G1 vs G2	
Rodríguez-Huguet et al. [40]	G1: PE and eccentric exercise	18	1 × 4 weeks	Pain (NPRS)	4 weeks: –1.38 (–2.75, –0.01) [–0.64]
	G2: DN and eccentric exercise	18	1 × 4 weeks	G1 vs G2	8 weeks: –0.96 (–2.32, –0.91) [–0.45]
				G1 vs G2	52 weeks: –1.65 (–2.7, –0.58) [–0.98]
				G1 vs G2	
Lateral Elbow Pain					
	G1: PE and eccentric exercise	18	1 × 4 weeks	Pain (NPRS)	4 weeks: –1.81 (–2.86, –0.76) [–1.16]

(continued)

Study	Intervention(s)	Sample Size	Intervention Duration, Sessions or Weeks	Comparison and Outcome Measure	Between-Group Differences (95% CI) [SMD]*
Rodríguez-Huguet et al. [39]	G2: DN and eccentric exercise	18	1 × 4 weeks	G1 vs G2 G1 vs G2	12 weeks: –2.18 (–3.34, –1.02) [–1.27]
Patellar Tendinopathy					
Abat et al. [31]	G1: PE and eccentric exercise (VISA-P<90) G2: Conventional physiotherapy (VISA-P<90) G3: PE (VISA-P>90) G4: Conventional physiotherapy (VISA-P>90)	8 19 22 11	0.5 × 6 weeks 3 × 8 weeks 0.5 × 6 weeks 3 × 8 weeks	VISA-P G1 vs G2 VISA-P G3 vs G4	6–8 weeks: 1.40 (–10.27, 13.07) [0.10] 6–8 weeks: 1.90 (0.26, 3.54) [0.93]
Groin Pain					
Moreno et al. [37]	G1: PE and active physical therapy program G2: Active physical therapy program	10 13	Two sessions during phase 1 of the active physical therapy program. The mean of the duration of treatment was 37.9±8.5 weeks The mean of the duration of treatment was 48.8±9.4 weeks	Pain intensity at palpation of the insertion of the adductor longus (NPRS) G1 vs G2 G1 vs G2 G1 vs G2 G1 vs G2 Pain intensity to isometric contraction against resistance (NPRS) G1 vs G2 G1 vs G2 G1 vs G2 G1 vs G2 Patient-Specific Functional Scale (PSFS) G1 vs G2 G1 vs G2 G1 vs G2 G1 vs G2	6–8 weeks: –0.90 (–1.96, 0.16) [–0.65] 14–16 weeks: –1.70 (–2.56, –0.84) [–1.47] 22–24 weeks: –1.30 (–2.04, –0.56) [–1.39] 30–32 weeks: –0.90 (–1.89, 0.09) [–0.68] 6–8 weeks: –0.90 (–1.98, 0.18) [–0.61] 14–16 weeks: –1.50 (–2.61, –0.39) [–1.03] 22–24 weeks: –1.50 (–2.38, –0.62) [–1.25] 30–32 weeks: –1.10 (–1.93, –0.27) [–0.98] 6–8 weeks: 4.10 (0.25, 0.18) [0.80] 14–16 weeks: 12.20 (5.92, 18.48) [1.38] 22–24 weeks: 7.50 (2.66, 12.34) [1.15] 30–32 weeks: 5.50 (1.01, 9.99) [0.91]
Whiplash-Associated Pain					
García-Naranjo et al. [35]	G1: PE G2: Standard physiotherapy	50 50	1 × 3 weeks 5 × 4 weeks	Pain intensity (VAS) G1 vs G2 Disability (NPQ) G1 vs G2	–4 weeks: 0.20 (–0.39, 0.79) [0.13] 3–4 weeks: –6.20 (–12.74, 0.34) [–0.37]
Plantar Heel Pain					
Fernández-Rodríguez et al. [34]	G1: PE plus exercise G2: Sham PE plus exercise	38 29	1 × 5 weeks 1 × 5 weeks	Mean pain intensity (NPRS) G1 vs G2 G1 vs G2 G1 vs G2 Disability (FAAM) G1 vs G2 G1 vs G2 G1 vs G2	6 weeks: –4.00 (–5.16, –2.84) [–1.55] 17 weeks: –3.70 (–4.65, –2.75) [–1.73] 29 weeks: –3.30 (–4.03, –2.57) [–2.08] 6 weeks: 27.40 (18.01, 36.79) [1.36] 17 weeks: 25.90 (–4.65, –2.75) [1.47] 29 weeks: 20.20 (–4.03, –2.57) [1.37]

(continued)

Study	Intervention(s)	Sample Size	Intervention Duration, Sessions or Weeks	Comparison and Outcome Measure	Between-Group Differences (95% CI) [SMD]*
Temporomandibular Pain					
Lopez-Martos et al. [38]	G1: PE	20		Pain on rest (VAS)	4 weeks: –2.53 (–3.95, –1.11) [–1.08]
				G1 vs G2	6 weeks: –1.57 (–2.83, –0.31) [–0.76]
				G1 vs G3	10 weeks: –1.39 (–2.26, –0.52) [–0.91]
				G2 vs G3	4 weeks: –3.07 (–5.00, –1.14) [–0.97]
					6 weeks: –3.97 (–5.45, –2.49) [–1.63]
					10 weeks: –3.50 (–4.76, –2.24) [–1.69]
					4 weeks: –0.54 (–2.03, 0.95) [–0.22]
					6 weeks: –2.40 (–3.66, –1.14) [–1.16]
					10 weeks: –2.11 (–3.28, –0.94) [–1.10]
	G2: Dry needling	20		Pain on mastication (VAS)	4 weeks: –1.53 (–2.70, –0.36) [–0.79]
				G1 vs G2	6 weeks: –1.12 (–2.71, 0.47) [–0.43]
				G1 vs G3	10 weeks: –1.00 (–2.48, 0.48) [–0.41]
				G2 vs G3	4 weeks: –2.71 (–4.74, –0.68) [–0.81]
					6 weeks: –3.97 (–6.23, –1.71) [–1.07]
					10 weeks: –2.44 (–4.47, –0.41) [–0.73]
					4 weeks: –1.18 (–3.00, 0.64) [–0.39]
					6 weeks: –2.85 (–4.73, –0.97) [–0.92]
					10 weeks: –1.44 (–3.47, 0.59) [–0.43]
	G3: Sham dry needling	20			
				Disability (TMJ)	4 weeks: 9.55 (–3.36, 22.46) [0.45]
				G1 vs G2	6 weeks: 14.59 (0.27, 28.91) [0.62]
				G1 vs G3	10 weeks: 16.21 (4.07, 28.35) [0.81]
				G2 vs G3	4 weeks: 26.40 (4.06, 48.74) [0.72]
					6 weeks: 35.85 (14.00, 57.70) [1.01]
					10 weeks: 33.63 (15.59, 51.67) [1.13]
					4 weeks: 16.85 (–3.33, 37.03) [0.51]
					6 weeks: 21.26 (2.85, 39.67) [0.70]
					10 weeks: 17.42 (1.51, 33.33) [0.67]

CI = confidence interval; SMD = standardized mean difference; PE = percutaneous electrolysis; DASH = Disabilities of the Arm, Shoulder, and Hand Questionnaire; VAS = visual analog scale; NPRS = numeric pain rating scale; SPADI = Shoulder Pain and Disability Index; DN = dry needling; VISA-P = Victorian Institute of Sport Assessment—Patella; NPQ = Northwick Park Neck Questionnaire; FAAM = Foot and Ankle Ability Measure; TMJ = Temporomandibular Joint Dysfunction Scale; TrP = Trigger point.

*Follow-up from baseline.

Table 3. Methodological score of randomized clinical trials using the Physiotherapy Evidence Database (PEDro) scale

Study	1	2	3	4	5	6	7	8	9	10	Total
Shoulder Pain											
Arias-Buría et al. [32]	Y	Y	Y	Y	N	N	N	Y	Y	Y	7
Moreno [36]	N	N	Y	N	N	N	Y	Y	Y	Y	5
de Miguel Valtierra et al. [33]	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	9
Rodríguez-Huguet et al. [40]	Y	Y	Y	N	N	Y	Y	N	Y	Y	7
Lateral Elbow Pain											
Rodríguez-Huguet et al. [39]	Y	Y	Y	N	N	Y	Y	N	Y	Y	7
Patellar Tendinopathy											
Abat et al. [31]	Y	N	N	Y	N	N	Y	N	Y	Y	5
Groin Pain											
Moreno et al. [37]	Y	Y	N	N	N	Y	Y	N	Y	Y	6
Whiplash-Associated Pain											
García-Naranjo et al. [35]	Y	Y	Y	N	N	Y	Y	Y	Y	Y	8
Plantar Heel Pain											
Fernández-Rodríguez et al. [34]	Y	N	Y	Y	Y	N	Y	N	Y	Y	7
Temporomandibular Pain											
Lopez-Martos et al. [38]	Y	N	Y	Y	N	N	Y	Y	Y	Y	7

Y = yes; N = no.

1 = random allocation of participants; 2 = concealed allocation; 3 = similarity between groups at baseline; 4 = participant blinding; 5 = therapist blinding; 6 = assessor blinding; 7 = dropout rate less than 15%; 8 = intention-to-treat analysis; 9 = between-group statistical comparisons; 10 = point measures and variability data.



Figure 3. Plots of risk of bias of the included studies.



Figure 4. Comparison (mean difference) of the effects of percutaneous electrolysis vs the comparison group on pain intensity.

moderate-quality evidence for a large effect of improving pain-related disability in individuals with musculoskeletal pain. The risk of bias of the trials included in the current meta-analysis was low, but the inconsistency of the results (heterogeneity) downgraded one level of evidence quality (GRADE).

Effectiveness of Percutaneous Electrolysis

This is the first meta-analysis (to the best of our knowledge) analyzing the impact of percutaneous electrolysis on pain intensity and pain-related disability for musculoskeletal pain. Percutaneous electrolysis is a novel therapeutic intervention, different from PENS and electroacupuncture, recently recommended for the treatment of soft tissue pain conditions [11]. We found that ultrasound-based percutaneous electrolysis was more effective than a comparison intervention for pain relief and improved pain-related disability in the short term, mid-term, and long term. Seven trials (70%) used percutaneous electrolysis as an adjunct with another intervention, such as exercise alone [31, 32, 34, 37, 39, 40] or manual therapy and exercise combined [33], whereas three trials (30%) applied percutaneous electrolysis alone [35, 36, 38]. Most trials (90%) reported differences in pain or pain-related disability in favor of percutaneous electrolysis as compared with the comparative group [31–34, 36–40]. Only the study by García-Naranjo et al. [35] reported no differences in the short term when comparing percutaneous electrolysis with multimodal therapy, including an exercise program for individuals with whiplash-associated pain. In this study, both groups reported significant improvements in pain and function; however, considering that the intervention group consisted of three sessions of isolated percutaneous electrolysis, a greater number of treatment sessions may support a better effect in favor of percutaneous electrolysis [35]. All trials compared percutaneous electrolysis with other intervention [31–35, 37–40] except the study by Moreno [36], which compared percutaneous electrolysis with a control group without intervention. This, along with the small sample size, may explain why the study by Moreno [36] reported a size effect that was larger than that of the remaining trials.



Figure 5. Comparison (standardized mean difference) of the effects of percutaneous electrolysis vs the comparison group on pain intensity.

It is important to determine if the observed changes are clinically relevant. We observed a mean decrease of pain intensity greater than 2 points at the short-term, midterm, and long-term follow-ups, with a decrease in the overall mean score of –2.06 points (95% CI, –2.69 to –1.42). Salaffi et al. [41] reported that a reduction of 1 point or a reduction of 15% from baseline scores represents the minimal clinically important difference (MCID) for the NPRS in patients with musculoskeletal pain. The decrease in pain found with the application of percutaneous electrolysis was higher than the determined MCID of 1 point. Furthermore, specific conditions included in some trials (e.g., shoulder pain [42] or neck pain [43]) have a similar MCID of 1.2 points. These results support the clinical relevance of the observed changes with this intervention.

A potential topic for research may be the cost-effectiveness of ultrasound-guided percutaneous electrolysis. García-Naranjo et al. [35] suggested a possible cost-effective benefit of including percutaneous electrolysis with other physical therapy interventions, but this hypothesis requires further study. Similarly, Minaya-Muñoz et al. [29], in an open-label study, also showed the potential cost benefits of combining percutaneous electrolysis with exercise for people with lateral epicondylalgia. Finally, Iborra-Marcos et al. [30] noted that treatment with corticosteroid injections was more expensive per session than ultrasound-guided percutaneous electrolysis, but no statistical cost analysis was performed.

Mechanisms of Percutaneous Electrolysis

The underlying mechanisms explaining the effects of percutaneous electrolysis are not clearly understood. Percutaneous electrolysis has been shown to be able to activate protein expression of cytochrome C, vascular endothelial growth factor and its receptor 2, and the nuclear transcription factor peroxisome proliferator-activated receptor gamma [44]. It has also been shown to inhibit the action of IL-1, TNF, and COX-2 [45]. All of



Figure 6. Comparison (standardized mean difference) of the effects of percutaneous electrolysis vs the comparison group on pain-related disability.

these factors are indicative of an inflammatory response that facilitates proper phagocytosis and posterior tissue healing regeneration. Considering that degenerative tissue changes are a common finding in painful tendons [46], it would make sense that this intervention could help in the healing process of chronic tendinopathies. Nevertheless, tissue change is not the only explanation of clinical improvement [47], and many times changes in tendon structure do not predict the evolution of the symptoms [48]. In addition, the degenerative part of the tendon cannot respond properly to mechanical stimuli [49]; therefore, the degenerative area may not be able to adapt and increase its load. These hypotheses are in accordance with the study by Fernández-Rodríguez et al. [34], who found a reduction in plantar fascia thickness after the application of percutaneous electrolysis and exercise in patients with plantar heel pain; however, the observed changes were not sufficiently large to be considered a true improvement. Some case series including individuals with lateral epicondylalgia that received percutaneous electrolysis intervention and eccentric exercise also reported a reduction of 56% of hypoechogenicity [14]. In fact, because tendons have low metabolism, it is difficult to explain the clinical improvement throughout only the changes in the tissue structure in the short term. In such a scenario, neuroplastic changes (induced by the mechanical stimulus of percutaneous electrolysis or exercise) and muscle adaptations (induced by exercise therapy) [50] could explain the clinical effects. Future studies should investigate tissue changes and their association with clinical outcome changes after the application of percutaneous electrolysis.

A second potential mechanism of percutaneous electrolysis is neurophysiological. Ronzio et al. [27] found a significant hypoalgesic effect (increase pressure pain threshold) in the group receiving percutaneous microelectrolysis when compared with a sham group (needle insertion without electrical current), suggesting that percutaneous electrolysis may have immediate effects on pain modulation. In fact, some studies have reported autonomic activation after application of percutaneous electrolysis by observing parasympathetic activation during the intervention [51, 52].

Table 4. GRADE evidence for percutaneous electrolysis to treat pain and pain-related disability for musculoskeletal pain conditions

Number of Studies	Risk of Bias*	Inconsistency†	Indirectness of Evidence‡	Imprecision§	Publication Bias¶	Quality of Evidence	MD or SMD (95% CI)
Percutaneous Electrolysis vs Comparative Intervention on Pain							
Overall effects, nine trials (n=838)	No	Serious (I^2=79%)	No	No	No	Moderate	MD = –2.06 (–2.69 to –1.42) SMD = –1.15 (–1.48 to –0.81)
Short-term effects, nine trials (n=408)	No	Very serious (I^2=94%)	No	No	No	Moderate	MD = –1.94 (–3.13 to –0.76) SMD = –1.07 (–1.65 to –0.49)
Midterm effects, five trials (n=251)	No	Serious (I^2=74%)	No	No	No	Moderate	MD = –2.09 (–2.90 to –1.29) SMD = –1.20 (–1.61 to –0.78)
Long-term effects, four trials (n=179)	No	Serious (I^2=73%)	No	Serious	No	Low	MD = –2.28 (–3.27 to –1.30) SMD = –1.32 (–1.92 to –0.72)
Percutaneous Electrolysis vs Comparative Intervention on Pain-Related Disability							
Overall effects, seven trials (n=707)	No	Serious (I^2=45%)	No	No	No	Moderate	SMD = 0.95 (0.73–1.18)
Short-term effects, seven trials (n=380)	No	Serious (I^2=50%)	No	No	No	Moderate	SMD = 0.76 (0.44–1.07)
Midterm effects, four trials (n=183)	No	No (I^2=0%)	No	Serious	No	Moderate	SMD = 1.21 (0.89–1.52)
Long-term effects, three trials (n=143)	No	No (I^2=0%)	No	Serious	No	Moderate	SMD = 1.20 (0.84–1.55)

GRADE = Grading of Recommendations Assessment, Development and Evaluation; MD = mean difference; SMD = standardized mean difference.

*"No" = most information is from results at low risk of bias; "Serious" = crucial limitation for one criterion or some limitations for multiple criteria sufficient to lower confidence in the estimate of effect; "Very serious" = crucial limitation for one or more criteria sufficient to substantially lower confidence in the estimate of effect.

†"Serious" = $I^2 > 40\%$; "Very serious" = $I^2 > 80\%$.

‡No indirectness of evidence was found in any study.

§Based on sample size. "Serious" = n<250 subjects; "Very serious" = n<250 and the estimated effect is little or absent.

¶Based on funnel plots. No publication bias was found. Funnel plots are not shown because the number of trials was less than 10.

Safety of Percutaneous Electrolysis

Because this is a new intervention, we wondered if percutaneous electrolysis would be a safe intervention that would not produce serious adverse effects. The most common adverse effect was postelectrolysis soreness (30% of patients). This adverse event may be mostly produced by the insertion of the needle (as is also common during other procedures such as dry needling) [53] or the application of a galvanic electrical current; however, this postelectrolysis soreness disappeared without any treatment after 12–36 hours [32, 33, 37]. One trial reported the presence of postelectrolysis hematoma in one patient [38]. No other adverse events were reported. The retrospective study by Iborra-Marcos et al. [30] described two individuals with a vasovagal episode. All of the observed events can be categorized as minor [54]. Therefore, it seems that percutaneous electrolysis could be considered a safe intervention. In addition, the fact that percutaneous electrolysis is recommended to be ultrasound guided increases its safety. Future studies should investigate if the ultrasound-guided application is beneficial in relation to adverse events as compared with the application of non–ultrasound-guided techniques.

Strengths and Limitations

Although this is the first (to the best of our knowledge) meta-analysis analyzing the effects of ultrasound-guided percutaneous electrolysis on pain or pain-related disability in musculoskeletal pain conditions, the results should be considered in light of potential strengths and limitations. The strengths of this meta-analysis include a comprehensive literature search, methodological rigor, data extraction, rigorous statistical analysis, and the inclusion of randomized controlled trials of high quality in the quantitative analysis. However, the number of randomized controlled trials examining the effects of percutaneous electrolysis on musculoskeletal pain was relatively small (n=10; e.g., only one trial for plantar heel pain, whiplash-related pain, or lateral epicondylalgia). In addition, not only was the number of trials small, but the trials also evaluated the application of percutaneous electrolysis with different dosages (i.e., time, sessions, electrical current intensity). Another potential limitation is the heterogeneity and imprecision of the results of some of the included trials; therefore, the results should be considered with caution at this stage.

Clinical Implications

This meta-analysis found a moderate level of evidence supporting the application of ultrasound-guided percutaneous electrolysis for musculoskeletal pain in general. However, this should be considered with caution, as we do not know if percutaneous electrolysis could potentially be beneficial in some subgroups of patients with musculoskeletal pain. In fact, the current meta-analysis included several musculoskeletal pain conditions, and

only one study has been published on some of them. Furthermore, the pain conditions included in this meta-analysis were heterogeneous. According to suggested mechanisms proposed for explaining the effects of percutaneous electrolysis, it is expected that musculoskeletal pain conditions with an involvement of the tendon would benefit from this intervention. In fact, percutaneous electrolysis was originally developed for the management of chronic tendinopathies with the aim to promote and/or facilitate the healing process after the induction of the nonthermal electrolytic reaction [11]. In this meta-analysis, most of the trials included musculoskeletal pain conditions where the tendon could be partially (i.e., shoulder pain or lateral epicondylalgia) or completely (i.e., patellar tendinopathy or plantar heel pain) involved in the symptoms. Clinicians should apply proper clinical reasoning for the application of percutaneous electrolysis.

In addition, we do not currently know the real effects of percutaneous electrolysis when compared with sham percutaneous electrolysis. Some of the trials included in this meta-analysis compared percutaneous electrolysis with a needling approach without the application of the electrical current, suggesting that at least some clinical effects are related to the continuous galvanic electrical current. There is a need for well-designed randomized clinical trials examining the effects of percutaneous electrolysis vs sham and the combination of percutaneous electrolysis with other interventions. In fact, a study protocol investigating this topic in patients with patellar tendinopathy has recently been published [55].

One of the most important topics to consider for the proper clinical application of percutaneous electrolysis is the appropriate parameters (i.e., treatment duration, intensity of electrical current, or number of sessions), and studies should be conducted to create reproducible results. We do not have enough data to determine which treatment parameters are the most effective for the application of percutaneous electrolysis on each particular pain condition. A recent animal study reported that higher doses of electrical current are more effective for decreasing electromyographic findings of myofascial trigger points in rats [56]. Future studies should investigate the appropriate parameters of percutaneous electrolysis for the management of different musculoskeletal pain conditions.

Conclusion

This meta-analysis found moderate evidence suggesting a large positive effect of percutaneous electrolysis for reducing pain and moderate evidence for a large decrease in pain-related disability for musculoskeletal pain conditions in the short term, midterm, and long term. Future studies are needed to clarify the dosage and which musculoskeletal pain conditions would be most likely to benefit from this intervention.

Supplementary Data

Supplementary Data may be found online at http://painmedicine.oxfordjournals.org.

References

1. Bevan S. Economic impact of musculoskeletal disorders (MSDs) on work in Europe. Best Pract Res Clin Rheumatol 2015;29 (3):356–73.
2. Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain 2012;13(8):715–24.
3. Henschke N, Kamper SJ, Maher CG. The epidemiology and economic consequences of pain. Mayo Clin Proc 2015;90 (1):139–47.
4. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain 2006;10(4):287–333.
5. Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: A systematic review and meta-analysis of population studies. BMJ Open 2016;6 (6):e010364.
6. Perrot S, Cohen M, Barke A, Korwisi B, Rief W, Treede R-D. The IASP classification of chronic pain for ICD-11: Chronic secondary musculoskeletal pain. Pain 2019;160(1):77–82.
7. Booth J, Moseley GL, Schiltenwolf M, Cashin A, Davies M, Hübscher M. Exercise for chronic musculoskeletal pain: A biopsychosocial approach. Musculoskeletal Care 2017;15 (4):413–21.
8. Lin I, Wiles L, Waller R, et al. What does best practice care for musculoskeletal pain look like? Eleven consistent recommendations from high-quality clinical practice guidelines: Systematic review. Br J Sports Med 2020;54(2):79–10.
9. Wall P, Sweet W. Temporary abolition of pain in man. Science 1967;155(3758):108–9.
10. Johnson M. Transcutaneous electrical nerve stimulation: Mechanisms, clinical application and evidence. Rev Pain 2007;1 (1):7–11.
11. Sanchez-Ibáñez JM. Clinical course in the treatment of chronic patellar tendinopathy through ultrasound guided percutaneous electrolysis intratissue (EPI®): Study of a population series of cases in sport. Atlantic International University. 2009.
12. Abat F, Diesel WJ, Gelber PE, Polidori F, Monllau JC, Sanchez-Ibañez JM. Effectiveness of the Intratissue Percutaneous Electrolysis (EPI®) technique and isoinertial eccentric exercise in the treatment of patellar tendinopathy at two years follow-up. Muscles Ligaments Tendons J 2014; 4(2):188–93.
13. Abat F, Gelber PE, Polidori F, Monllau JC, Sanchez-Ibañez JM. Clinical results after ultrasound-guided intratissue percutaneous electrolysis (EPI®) and eccentric exercise in the treatment of patellar tendinopathy. Knee Surg Sports Traumatol Arthrosc 2015; 23(4):1046–52.
14. Valera-Garrido F, Minaya-Muñoz F, Medina-Mirapeix F. Ultrasound-guided percutaneous needle electrolysis in chronic lateral epicondylitis: Short-term and long-term results. Acupunct Med 2014;32(6):446–54.
15. Abat F, Gelber P, Monllau J, Sánchez-Ibáñez, J. Large tear of the pectoralis major muscle in an athlete. Results after treatment with intratissue percutaneous electrolysis (EPI®). J Sports Med Doping Stud 2014;4(2).
16. Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP; the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009;6 (7):e1000097.

17. Higgins JPT, Altman DG, Gotzsche, PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
18. Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M. Reliability of the PEDro scale for rating quality of randomized controlled trials. Phys Ther 2003;83(8):713–21.
19. Schünemann HJ, Oxman AD, Brozek J, et al. GRADE: Assessing the quality of evidence for diagnostic recommendations. BMJ Evidence-Based Med 2008;13(6):162–3.
20. Austin TM, Richter RR, Sebelski CA. Introduction to the GRADE approach for guideline development: Considerations for physical therapist practice. Phys Ther 2014;94(11):1652–9.
21. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14 (1):1–13.
22. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res 2018;27(6):1785–805.
23. Deeks JJ, Higgins JPT, Altman DG; Cochrane Statistical Methods Group. Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, eds. Cochrane Handbook for Systematic Reviews of Interventions. 2017. Available at: www.training.cochrane.org/handbook.
24. Gonzalez-Perez LM, Canivell-Zabaleta M, Rodriguez-Posada F, et al. Study comparing intratissue percutaneous electrolysis, deep dry needling and botulinum toxin for the management of temporomandibular myofascial pain. Int J Oral Maxillofac Surg 2019;48:280.
25. Gonzalez-Perez LM, Infante-Cossio P, Montes-Latorre E, et al. Clinical results after deep dry needling versus intratissue percutaneous electrolysis technique for the treatment of temporomandibular myofascial pain. Int J Oral Maxillofac Surg 2017;46 :358.
26. Ronzio O, da Silva Coldibeli E, Soares Fernandes M, Froes Meyer P, da Silva R. Effects of percutaneous microelectrolysis (MEP®) on pain, rom and morning stiffness in patients with achilles tendinopathy. Eur J Physiother 2017;19(suppl 1):62–3.
27. Ronzio O, Villa C, Gómez D, et al. Effects in pressure-pain threshold of percutaneous galvanic microcurrent in the trapezius trigger points. Physiotherapy 2015;101(suppl 1):e1297–8.
28. Mattiussi G, Moreno C. Percutaneous electrochemical debridement of the plantaris tendon. J Am Podiatr Med Assoc 2018;108 (5):437–41.
29. Minaya Muñoz F, Valera Garrido F, Sánchez Ibáñez JM, Medina i Mirapeix F. Estudio de coste-efectividad de la electrólisis percutánea intratisular (EPI®) en las epicondilalgias. Fisioterapia 2012;34(5):208–15.
30. Iborra-Marcos Á, Ramos-Álvarez JJ, Rodriguez-Fabián G, et al. Intratissue percutaneous electrolysis vs corticosteroid infiltration for the treatment of plantar fasciosis. Foot Ankle Int 2018;39 (6):704–11.
31. Abat F, Sánchez-Sánchez JL, Martín-Nogueras AM, et al. Randomized controlled trial comparing the effectiveness of the ultrasound-guided galvanic electrolysis technique (USGET) versus conventional electro-physiotherapeutic treatment on patellar tendinopathy. J Exp Orthop 2016;3(1).
32. Arias-Buría JL, Truyols-Domínguez S, Valero-Alcaide R, Salom-Moreno J, Atín-Arratibel MA, Fernández-de-las-Peñas C. Ultrasound-guided percutaneous electrolysis and eccentric exercises for subacromial pain syndrome: A randomized clinical trial. Evidence-Based Complement Altern Med 2015;2015:1–9.
33. de Miguel Valtierra L, Salom Moreno J, Fernández-de-las-Peñas C, Cleland JA, Arias-Buría JL. Ultrasound-guided application of percutaneous electrolysis as an adjunct to exercise and manual therapy for subacromial pain syndrome: A randomized clinical trial. J Pain 2018;19(10):1201–10.
34. Fernández-Rodríguez T, Fernández-Rolle Á, Truyols-Domínguez S, Benítez-Martínez JC, Casaña-Granell J. Prospective randomized trial of electrolysis for chronic plantar heel pain. Foot Ankle Int 2018;39(9):1039–46.
35. García Naranjo J, Barroso Rosa S, Loro Ferrer JF, Liminana Canal JM, Suarez Hernandez, E. A novel approach in the treatment of acute whiplash syndrome: Ultrasound-guided needle percutaneous electrolysis. A randomized controlled trial. Orthop Traumatol Surg Res 2017;103(8):1229–34.
36. Moreno MD. Results of the electrolysis percutaneous intratissue in the shoulder pain: Infraspinatus, a randomized controlled trial. Rev Cuba Ortop y Traumatol 2016;30(1):76–87.
37. Moreno C, Mattiussi G, Núñez FJ, Messina G, Rejc E. Intratissue percutaneous electolysis combined with active physical therapy for the treatment of adductor longus enthesopathy-related groin pain: A randomized trial. J Sports Med Phys Fitness 2017;57(10):1318–29.
38. Lopez-Martos R, Gonzalez-Perez L, Ruiz-Canela-Mendez P, Urresti-Lopez F, Gutierrez-Perez J, Infante-Cossio P. Randomized, double-blind study comparing percutaneous electrolysis and dry needling for the management of temporomandibular myofascial pain. Med Oral Patol Oral y Cir Bucal 2018; 23(4):e454–62.
39. Rodríguez-Huguet M, Góngora-Rodríguez J, Lomas-Vega R, et al. Percutaneous electrolysis in the treatment of lateral epicondylalgia: A single-blind randomized controlled trial. J Clin Med 2020;9(7):2068.
40. Rodríguez-Huguet M, Góngora-Rodríguez J, Rodríguez-Huguet P, et al. Effectiveness of percutaneous electrolysis in supraspinatus tendinopathy: A single-blinded randomized controlled trial. J Clin Med 2020;9(6):1837.
41. Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 2004;8 (4):283–91.
42. Mintken PE, Glynn P, Cleland JA. Psychometric properties of the shortened disabilities of the Arm, Shoulder, and Hand Questionnaire (QuickDASH) and Numeric Pain Rating Scale in patients with shoulder pain. J Shoulder Elb Surg 2009;18(6):920–6.
43. Cleland JA, Childs JD, Whitman JM. Psychometric properties of the Neck Disability Index and Numeric Pain Rating Scale in patients with mechanical neck pain. Arch Phys Med Rehabil 2008;89(1):69–74.
44. Abat F, Valles SL, Gelber PE, et al. Mecanismos moleculares de reparación mediante la técnica Electrólisis Percutánea Intratisular en la tendinosis rotuliana. Rev Esp Cir Ortop Traumatol 2014;58(4):201–5.
45. Abat F, Valles SL, Gelber PE, et al. An experimental study of muscular injury repair in a mouse model of notexin-induced lesion with EPI® technique. BMC Sports Sci Med Rehabil 2015;7 (1):1–7.
46. McAuliffe S, McCreesh K, Culloty F, Purtill H, O'Sullivan K. Can ultrasound imaging predict the development of Achilles and patellar tendinopathy? A systematic review and meta-analysis. Br J Sports Med 2016;50(24):1516–23.
47. Van Ark M, Rio E, Cook J, et al. Clinical improvements are not explained by changes in tendon structure on ultrasound tissue characterization after an exercise program for patellar tendinopathy. Am J Phys Med Rehabil 2018;97(10):708–14.
48. De Jonge S, Tol JL, Weir A, Waarsing JH, Verhaar JAN, De Vos RJ. The tendon structure returns to asymptomatic values in non-operatively treated Achilles tendinopathy but is not associated with symptoms. Am J Sports Med 2015;43(12):2950–8.

49. Docking SI, Cook J. How do tendons adapt? Going beyond tissue responses to understand positive adaptation and pathology development: A narrative review. J Musculoskelet Neuronal Interact 2019;19(3):300–10.
50. Rio E, Docking SI. Adaptation of the pathological tendon: You cannot trade in for a new one, but perhaps you don't need to? Br J Sports Med 2018;52(10):622–3.
51. García Bermejo P, De La Cruz Torres B, Naranjo Orellana J, Albornoz Cabello M. Autonomic responses to ultrasound-guided percutaneous needle electrolysis: Effect of needle puncture or electrical current? J Altern Complement Med 2018;24(1):69–75.
52. García Bermejo P, de la Cruz Torres B, Naranjo Orellana J, Albornoz Cabello M. Autonomic activity in women during percutaneous needle electrolysis. Eur J Integr Med 2017;11 :53–8.
53. Brady S, McEvoy J, Dommerholt J, Doody C. Adverse events following trigger point dry needling: A prospective survey of chartered physiotherapists. J Man Manip Ther 2014;22(3):134–40.
54. Carlesso LC, MacDermid JC, Santaguida LP. Standardization of adverse event terminology and reporting in orthopaedic physical therapy: Application to the cervical spine. J Orthop Sports Phys Ther 2010;40(8):455–63.
55. López-Royo MP, Gómez-Trullén EM, Ortiz-Lucas M, et al. Comparative study of treatment interventions for patellar tendinopathy: A protocol for a randomised controlled trial. BMJ Open 2020;10(2):e034304.
56. Margalef R, Bosque MMonclús P, et al. Percutaneous application of galvanic current in rodents reverses signs of myofascial trigger points. Evid Based Complement Alternat Med 2020;2020:4173218.

Knee Surg Sports Traumatol Arthrosc
DOI 10.1007/s00167-014-2855-2

KNEE

Clinical results after ultrasound-guided intratissue percutaneous electrolysis (EPI®) and eccentric exercise in the treatment of patellar tendinopathy

F. Abat · P. E. Gelber · F. Polidori · J. C. Monllau · J. M. Sanchez-Ibañez

Received: 15 September 2013 / Accepted: 12 January 2014

Abstract
Purpose To investigate the outcome of ultrasound (US)-guided intratissue percutaneous electrolysis (EPI®) and eccentric exercise in the treatment of patellar tendinopathy during a long-term follow-up.
Methods Forty patients with patellar tendinopathy were prospectively evaluated over a 10-year follow-up period. Pain and function were evaluated before treatment, at 3 months and at 2, 5 and 10 years using the Victorian Institute of Sport Assessment–Patella (VISA-P) score, the Tegner score and Blazina's classification. According to VISA-P score at baseline, patients were also dichotomized into Group 1 (<50 points) and Group 2 (≥50 points). There were 21 patients in Group 1 and 19 in Group 2. Patient satisfaction was measured according to the Roles and Maudsley score.
Results The VISA-P score improved globally by 41.2 points ($p < 0.01$) after a mean 4.1 procedures. In Group 1, VISA-P score improved from 33.1 ± 13 to 78.9 ± 14.4 at 3-month and to 88.8 ± 10.1 at 10-year follow-up ($p < 0.001$). In Group 2, VISA-P score improved from 69.3 ± 10.5 to 84.9 ± 9 at 3-month and to 96.0 ± 4.3 at 10-year follow-up ($p < 0.001$). After 10 years, 91.2 % of the patients had a VISA-P score >80 points. The same level (80 % of patients) or the Tegner score at no more than one level lower (20 % of patients) was restored, and 97.5 % of the patients were satisfied with the procedure.
Conclusion Treatment with the US-guided EPI® technique and eccentric exercises in patellar tendinopathy resulted in a great improvement in knee function and a rapid return to the previous level of activity after few sessions. The procedure has proved to be safe with no recurrences on a long-term basis.
Level of evidence Therapeutic study, Level IV.

Keywords Intratissue percutaneous electrolysis · EPI · Eccentric exercises

Introduction

Patellar tendinopathy or jumper's knee is a frequent condition that most commonly affects the tendon's origin on the inferior pole of the patella [2, 4, 10]. Once considered an inflammatory condition, it is currently considered a degenerative process due to the presence of myxoid degeneration, the disruption of the collagen fibres and signs of hypoxia in tenocytes and resident macrophages [6, 17].

The overall prevalence of patellar tendinopathy is around 14 % in the sports population [3, 16], but may be as high as 40 % in highly demanding athletes [8]. The tendon's overuse in sports that involve running, jumping or rapid change in direction is considered the main risk factor for developing the said condition [16].

Current treatment options include eccentric training [15, 18, 29], open or arthroscopic surgery, extracorporeal shockwave therapy [25], ultrasound (US)-guided sclerosis [12], non-steroidal anti-inflammatory drugs, platelet-rich

F. Abat (✉) · F. Polidori · J. M. Sanchez-Ibañez
CEREDE-Sports Medicine, Dr. Roux 8-10, 08017 Barcelona, Spain
e-mail: FERRANABAT@GMAIL.COM; drabat@cerede.es

P. E. Gelber · J. C. Monllau
Department of Orthopedic Surgery, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

P. E. Gelber · J. C. Monllau
ICATME-Hospital Universitari Quirón Dexeus, Universitat Autònoma de Barcelona, Barcelona, Spain

Published online: 30 January 2014

plasma injection [30] and aprotinin [1]. These studies have also suggested that, in general, patients with a worse functional status before treatment obtain inferior final outcomes. However, due to the limited evidence-based therapies, there are still several controversies regarding the real efficacy of these treatment modalities [1].

Intratissue percutaneous electrolysis (EPI®) treatment is a pioneering US-guided technique developed by one of the authors. It leads to a non-thermal electrochemical ablation through a cathodic flow directly at the clinical focus of degeneration. EPI® causes an organic reaction leading to a highly localized inflammation, exclusively at the region of treatment that conduces to a rapid regeneration of the injured tendon [26].

The present study provides the first analysis of the results of EPI® in the treatment of patellar tendinopathy at 10 years follow-up. This study could be clinically relevant given the lack of effective techniques in the treatment of patellar tendinopathy.

The aim of this study was to investigate the outcome of the US-guided EPI® technique in terms of pain, function and the return to the previous level of activity in patients with patellar tendinopathy. The mean follow-up of 10 years provides information on safety and the rate of recurrence. The main hypothesis was that the US-guided EPI® technique would quickly improve the outcome in patients with patellar tendinopathy and that this improvement would be maintained over a long period of time. The second hypothesis was that good outcomes would be obtained regardless of the initial degree of functional impairment. It was also hypothesized that the patients would be restored to their pre-injury activity level.

Materials and methods

From January 2002 to October 2002, 41 patients with patellar tendinopathy were included in the investigation. Demographic data and patient information (age, gender, affected and dominant side, kind of sport or activity level) were recorded.

The inclusion criteria were a history of patellar tendon pain, tenderness upon palpation, functional limitation directly related to the studied tendon and sonographic confirmation of tendon degeneration. A tendon injury located at the inferior pole of the patella was considered a requisite. Other inclusion criteria were more than 4 weeks of symptoms and an age of <60 years old. Patients were classified according to Blazina's scale [22]. Exclusion criteria were pain at the proximal pole of the patella (frequently included in jumper's knee), chronic articular disease, a concomitant knee pathology, contraindications to the EPI® technique and the concomitant administration of certain drugs (at least 2 weeks before receiving treatment). The inclusion and exclusion criteria are summarized in Table 1.

Ultrasound examination

All the patients went through an exhaustive US examination of the tendon and adjacent structures using a high-resolution greyscale US (Fig. 1) with Doppler power and linear multi-frequency probe (6–15 MHz). The injured and the contralateral knees were studied in all patient. The US efficacy for the proper diagnosis of patellar tendinopathy was previously reported [11, 36, 37].

Intratissue percutaneous electrolysis (EPI®) protocol

The EPI® technique was applied using a specifically developed medically certified (Directive 93/42/EEC) device (EPI Advanced Medicine, Barcelona, Spain), which produces modulated galvanic electricity through the negative electrode cathodic flow. This is applied using a modified electrosurgical scalpel that uses acupuncture needles (0.3 mm in diameter) with different lengths. The intensity can be adjusted by changing the duration or the milliamps of the device. Conversely, the polarity of the machine is fixed (i.e. only the cathodic flow is usable). During the procedure, performed by the same experienced operator, the patients are supine so as to minimize any potential vagal reaction.

Isopropyl alcohol was used to prepare the skin despite the bacteriostatic action of the EPI® system. Polyvidone iodine was avoided to prevent a tattoo effect of the

Table 1 Inclusion and exclusion criteria

Inclusion criteria	Exclusion criteria
<60 years old	Chronic articular disease
History of patellar tendon pain >4 weeks	Concomitant knee pathology (e.g. cruciate ligament injury of meniscal tear)
Tenderness to palpation	Contraindications of EPI® technique (i.e. pregnancy, knee prosthesis, osteosynthesis, cardiac disease, malign tumour or coagulopathy)
Functional limitation directly related to the tendon injury	Concomitant administration of drug (i.e. fluoroquinolones, anticoagulants, corticosteroids or non-steroidal anti-inflammatory
Sonographic confirmation of tendon degeneration	
Injury located at the inferior pole of the patella	
Blazina's classification ≥grade I	



Fig. 1 High-resolution colour Doppler ultrasound of patellar tendinopathy. **a** Longitudinal and **b** transversal views of the involved tendon showing a high degree of neovascularization before the EPI® treatment. The same patient 3 months after initiation of the EPI® procedures had a remarkable decrease in the vascularization of the patellar tendon clearly seen in these longitudinal (**c**) and transversal (**d**) views



Fig. 2 Intratissue percutaneous electrolysis (EPI®) procedure. The 0.3-mm needle (*Asterisks*) is being guided by high-resolution greyscale ultrasound to puncture the injured region of the tendon

cathodic flow. Finally, three US-guided precise punctures at 3 mA (Fig. 2) were performed until a complete debridement of the treated area was obtained. The debridement was assessed with the sonographic images. After the first EPI® treatment, the patients underwent consecutive sessions of EPI® every 2 weeks and 2 weekly sessions of an eccentric exercise training using the resistance isoinertial leg-press machine (YoYo™ Technology AB, Stockholm, Sweden). Eccentric exercises were performed in three sets of ten repetitions twice a week in order to obtain maturation of collagen fibres [24, 31]. Each repetition was performed with the concentric phase with both extremities, whereas the eccentric phase was only performed with the affected limb at a maximum of 60° of knee flexion.

Patients received US-guided EPI® treatment up to a maximum of ten sessions. The treatment finished either when the patients were symptom free or if there was no improvement in terms of pain or function after those ten sessions.

Treatment evaluation

All the patients were evaluated before treatment and prospectively when their treatments were finished (at the third month), at 2-year, at 5-year and at 10-year follow-up.

The primary outcome measure was knee function using the Victorian Institute of Sport Assessment–Patella (VISA-P) score, a specific validated questionnaire to quantify pain and knee function and ability to play sport in patients with patellar tendinopathy [9, 34]. The VISA-P score ranged from a maximum of 100 in asymptomatic patients to the theoretical minimum of 0. The authors of the score suggested that a score between 80 and 100 points might be considered as the optimal outcome category. Functional evaluation was further assessed with Blazina's classification [22]. This classification categorizes the symptomatic patients as in *phase I* (pain only after activity), *phase II* (discomfort during activity), *phase III* (pain during activity that interferes with participation) and *phase IV* (complete tendon disruption). The Tegner score was also used to assess the influence of the treatment in terms of restoring the previous sports activity level. All the written questionnaires were personally filled out by all patient before treatment, at the end of the treatment (at 3-month) and at the 2-year follow-up. The questionnaires corresponding to the 5- and 10-year follow-up evaluations were all filled out through a telephone interview. Patient satisfaction was

measured according to the Roles and Maudsley score [23]. In this score, patients are classified as *Excellent* (no pain, full movement and full activity), *Good* (occasional discomfort, full movement and full activity), *Fair* (some discomfort after prolonged activity) or *Poor* (pain limiting activities).

All those patients that scored <50 points with the VISA-P questionnaire at baseline were denominated Group 1, whereas the remaining patients scoring equal to or higher than 50 points were denominated Group 2. This classification allows to display the results in different degrees of injury of the patellar tendon: more (VISA-P < 50 points) or less affected (VISA-P > 50 points).

The Clinical Research Ethics Committee of ICATME-Institut Universitari Dexeus, University of Barcelona, approved the study (09/06/0049). All the patients signed informed consent to participate in the study as well as for the evaluation and publication of their results.

Statistical analysis

Categorical variables are presented as number of cases and percentages. Continuous variables are presented as mean ± SD (range). The relationships between categorical variables were described using contingency tables, and inference was studied using the chi-square test or Fisher's exact test. The relation between the VISA-P score and dichotomous variables was assessed using the Mann–Whitney test, showing the median value. Analysis of variance (ANOVA) was used to compare the evolution between groups. Statistical significance was set at 0.05 two-sided. Statistical analysis was performed using SPSS 19 (SPSS Inc., Chicago, IL, USA).

Results

One patient was lost during the first 3 months of follow-up. The remaining 40 patients were available at the 3-month and at the 2-year evaluations. At the 5-year evaluation, another three patients were lost (37 patients available, 90.2 % of the cases) and another three patients at the 10-year assessment (34 patients available, 82.9 % of the cases).

Patient description

Twenty-one patients (52.5 %) were included in Group 1 and the remaining 19 (47.5 %) in Group 2. Both groups were comparable in terms of age, gender, side and functional scores at baseline (Table 2). Sports involvement is summarized in Table 3. No relation (n.s.) between the injured tendon and the dominant extremity, the type of sport, the age of the patient and gender, and the VISA-P values obtained after the treatments was observed.

The mean duration of symptoms prior to the treatment was 69.4 ± 65.6 weeks (range 4–288 weeks). The athletes were off sports activities due to their patellar tendinopathy for a mean time of 40.6 ± 50.9 weeks (range 0–192 weeks). Treatment duration averaged 7.5 ± 2.6 weeks (range 1–10 weeks), and the patients required a mean of 4.1 ± 2.6 EPI® procedures (range 1–10). According to Blazina's classification, one patient (2.5 %) was of stage I at baseline, seven patients (17.5 %) stage II and the remaining 32 patients (80 %) stage III. At the 3-month evaluation, once all the treatments were finished, five patients (12.5 %) were classified as of stage I and six patients (15 %) stage II. All the remaining 30 cases (72.5 %) were considered completely cured (less than Blazina's stage I). At the 2-year follow-up evaluation, 31 cases (77.5 %) were asymptomatic (less than Blazina's stage I) and nine (22.5 %) were in stage I. Analysis

Table 2 Patient characteristics at baseline

	Group 1 $n = 21$ (52.5 %)	Group 2 $n = 19$ (47.5 %)	p value
Age (years)			
Mean ± SD	26.0 ± 8.49	25.7 ± 8.12	n.s.
Gender % (n)			
Male	81.0 (17)	94.7 (18)	n.s.
Female	19.0 (4)	5.3 (1)	
Dominant extremity % (n)			
Right	81.0 (17)	89.5 (17)	n.s.
Left	19.0 (4)	10.5 (2)	
Injured knee % (n)			
Right	38.1 (8)	15.8 (3)	n.s.
Left	47.6 (10)	68.4 (13)	
Bilateral	14.3 (3)	15.8 (3)	
Baseline VISA-P			
Mean ± SD	32.5 ± 12	69.5 ± 10.05	<0.001

Values expressed as mean ± SD or frequencies and percentages

Table 3 Patient sports involvement at baseline

	Series $n = 40$
Blazina's stage	
Median (range)	3 (2–3)
Sports type % (n)	
Soccer	60 (24)
Other	40 (16)
Sports level % (n)	
Professional (first division)	12.5 (5)
Semi-professional (second division or similar)	67.5 (27)
Recreational	20 (8)

Values expressed as mean ± SD or frequencies and percentages



Fig. 3 Linear diagram of the mean Victorian Institute of Sport Assessment–Patella (VISA-P) scores for Group 1, Group 2 and all the patients (*Global*) at baseline (*Initial*), at 3 months and at 2, 5 and 10 years

of the patients using the Blazina's classification remained unchanged throughout the remaining follow-up evaluations of the period studied (n.s.).

Clinical outcomes over time

The VISA-P (Fig. 3) and Tegner scores before treatment, at 3 months and at 2, 5 and 10 years of follow-up are summarized in Table 4. Group 1 improved by 45.8 points ($p < 0.001$) at 3 months to obtain a mean VISA-P score of 78.9 ± 14.4. In Group 2, the mean improvement in VISA-P score at 3 months was 15.6 points at 3 months ($p < 0.001$). The Tegner level did not drop over the 10 years of the study period, and no differences between the intermediate evaluations (n.s.) were observed either.

According to the Roles and Maudsley score, patient satisfaction at 3 months of follow-up was considered *Excellent* in 32 cases (80 %), *Good* in seven cases (17.5 %) and *Fair* in one case (2.5 %). These values persisted without significant differences throughout the period studied. No recurrences, adverse episodes or any additional modality of treatments were reported after the 10 years of follow-up.

At the 3-month follow-up evaluation, 32 (80 %) patients restored their previous activity level according to Tegner scale (n.s.). In eight patients (20 %), there was a decrease in only one single level on the same scale. These values were maintained over the remaining period studied (n.s.).

Discussion

Treatment with EPI® in combination with eccentric exercises has been shown to effectively improve the symptoms of patellar tendinopathy quickly and steadily for at least 10 years. It confirmed the first hypothesis. This improvement in patients that had different severities of VISA-P scores at baseline was equally obtained in terms of symptomatology, knee function and return to sports activity, which is also in concordance with the second hypothesis. The results observed in the first study reporting on the clinical use of EPI® are encouraging [26]. Its effects are based on a local and non-thermal electrochemical therapy that induces a localized short inflammatory response through an electrolytic reaction produced by a cathodic flow. Consequently, this causes an organic reaction leading to the regeneration of the injured tendon [26].

Conservative treatment was traditionally considered the first option of treatment of tendinopathies. Many different techniques were used [1, 8], such as modification of activity, eccentric physical training, patellar straps, cold and heat compression transfriction massage and stretching for quadriceps, hamstrings and patellar tendons. Despite some good results reported with eccentric programmes [18, 28], it is still unclear as to the more effective exercise protocol, its frequency, load and dosage. While Zwerver et al. [37], in a recent randomized clinical trial, concluded that no benefit came of extracorporeal high-energy shockwave therapy during competition, Rompe et al. [25] reported, at 4-month follow-up, that eccentric loading

Table 4 Victorian Institute of Sport Assessment–Patella (VISA-P) values during follow-up

Time	VISA-P score			Tegner score		
	Group 1	Group 2	Global	Group 1	Group 2	Global
Baseline ($n = 40$)	33.1 (±13)	69.3 (±10.5)	51.2 (±21.7)	8.1 (6–10)	7.8 (4–9)	7.9 (4–10)
3 months ($n = 40$)	78.9* (±14.4)	84.9* (±9)	81.9* (±12.2)	7.7 (4–10)	7.6 (3–9)	7.7 (3–10)
2 years ($n = 40$)	83.2 (±13.6)	88.6 (±7.4)	85.9 (±11.1)	8.1 (5–10)	7.7 (4–9)	7.8 (4–10)
5 years ($n = 37$)	85.2 (±12.2)	91.9 (±5.6)	88.6 (±10)	7.9 (5–10)	7.6 (4–9)	7.8 (4–10)
10 years ($n = 34$)	88.8 (±10.1)	96.0 (±4.3)	92.4 (±8.5)	7.7 (5–10)	7.3 (4–9)	7.5 (4–10)

Victorian Institute of Sport Assessment–Patella (VISA-P) values expressed as mean (±SD). Tegner values are expressed as median (range)

* $p < 0.001$. No statistically significant differences were observed in the results between any intermediate outcome measurements other than from baseline

alone was less effective when compared with a combination of eccentric loading and repetitive low-energy shockwave treatment. Similarly, low-intensity US is not currently considered a reliable method for the treatment of patellar tendinopathy [14, 15, 35].

Different injection treatments for patellar tendinopathy have been proposed. While some studies on the effect of dry needling, autologous blood and high volume have been put forward as providing functional improvements, steroid treatment has shown a relapse of symptoms after few months, not to mention the deleterious effect on the tendon histology [32]. Recent investigations have observed slightly better outcomes after treatment with platelet-rich plasma injections in association with an eccentric training programme than an eccentric training programme alone in short-term studies [7, 30, 32]. Some authors had initially reported pain relief after sclerosing injections of polidocanol [10], but recent studies have shown contradictory results [33]. Hoksrud et al. reported their results with US-guided sclerosis of neovessels in 29 patients with 44 months of follow-up [12] and in 101 patients with 24 months of follow-up [13]. The patients needed several injections over 8 months of treatment, and only a moderate improvement in knee function was observed. One-third of their patients obtained a VISA-P score <50 points, and only few patients were completely cured. Conversely, in the present investigation with short- and long-term reported outcomes, even the patients with lowest VISA-P score (<50 points) at baseline significantly improved to around 80 points at 3 months and to around 90 points at 10 years. These final outcomes were comparable with those obtained by the patients with better VISA-P scores before treatment. This is of considerable relevance because the professional sports patients included in this series started from lower VISA-P values and they still obtained excellent scores. Overall, 80 % ($n = 32$) of the treated patients returned to the same level of sports activity at 3 months, and the remaining eight patients only decreased a single level in the Tegner score.

Regarding surgical treatment of patellar tendinopathy, some open [5, 21] and arthroscopic [5, 20, 27] techniques have also been recommended when conservative treatment fails. However, surgery usually provides unpredictable and inconsistent results [4, 15], which is often no more effective than an isolated eccentric exercise programme [2], and it does not allow the athletes to resume their previous sports at the same level, at least within the first year of treatment [19].

The main strengths of the current study are that, as far as we know, it is the first investigation reporting on any treatment modality for patellar tendinopathy over the course of 10 years. Few patients were lost during this long follow-up period. In addition, it is also the first study reporting on the clinical outcome using the EPI® technique in the treatment of tendinopathy at long term follow-up. The promising results obtained with the EPI® procedure showed excellent functional results assessed with the VISA-P score as well as with the Blazina's classification in around 80 % of the patients at 3 months and over 90 % at 10 years. It also allowed a full recovery to the previous activity level in most patients. This outcome's improvement with the use of EPI® in the treatment of patellar tendinopathy was achieved after a short period of time (mean 7.5 weeks) and with a few number of treatment sessions (mean 4.1 EPI® treatments).

Besides the low sample size, one of the most relevant limitations of the current study is the lack of a control group. Comparison with a placebo-treated group of patients would have made for much stronger conclusions. However, most of our patients were professional or semi-professional athletes referred by other physicians after failure of conservative therapy. It seems highly unlikely that this sort of patients would be willing to accept placebo treatment for a long enough period. Another weakness might be that the combination of treatment with eccentric exercises might have positively affected the results attributed to the EPI® technique. Although this could more logically affect the results during the first months of follow-up, it does not seem that it should have had any influence in the long-term results. Regardless of the aforementioned limitations, this study provides the first analysis of the EPI® technique on the treatment of patellar tendinopathy, with promising results after a long follow-up period.

The clinical relevance of the reported results was that EPI® technique brought about a major improvement in pain and function in comparison with the so far known techniques and offers a good treatment option in patellar tendinopathy.

Conclusion

Treatment with the US-guided EPI® technique and eccentric exercises in patellar tendinopathy resulted in a great improvement in knee function and a rapid return to the previous level of activity after few sessions. The procedure has proved to be safe with no recurrences on a long-term basis.

References

1. Andres BM, Murrell GA (2008) Treatment of tendinopathy: what works, what does not, and what is on the horizon. Clin Orthop Relat Res 466:1539–1554
2. Bahr R, Fossan B, Loken S, Engebretsen L (2006) Surgical treatment compared with eccentric training for patellar tendinopathy (jumper's knee): a randomized, controlled trial. J Bone Jt Surg Am 88:1689–1698

3. Cannell LJ, Taunton JE, Clement DB, Smith C, Khan KM (2001) A randomised clinical trial of the efficacy of drop squats or leg extension/leg curl exercises to treat clinically diagnosed jumper's knee in athletes: pilot study. Br J Sports Med 35:60–64
4. Coleman BD, Khan KM, Maffulli N, Cook JL, Wark JD (2000) Studies of surgical outcome after patellar tendinopathy: clinical significance of methodological deficiencies and guidelines for future studies. Victorian Institute of Sport Tendon Study Group. Scand J Med Sci Sports 10:2–11
5. Coleman BD, Khan KM, Kiss ZS, Bartlett J, Young DA, Wark JD (2000) Open and arthroscopic patellar tenotomy for chronic patellar tendinopathy: a retrospective outcome study, Victorian Institute of Sport Tendon Study Group. Am J Sports Med 28:183–190
6. Coombes BK, Bisset L, Vicenzino B (2010) Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet 376:1751–1767
7. Filardo G, Kon E, Della Villa S, Vincentelli F, Fornasari PM, Marcacci M (2010) Use of platelet-rich plasma for the treatment of refractory jumper's knee. Int Orthop 34:909–915
8. Fredberg U, Bolvig L, Andersen NT (2008) Prophylactic training in asymptomatic soccer players with ultrasonographic abnormalities in Achilles and patellar tendons: the Danish Super League Study. Am J Sports Med 36:451–460
9. Hernandez-Sanchez S, Hidalgo MD, Gomez A (2011) Cross-cultural adaptation of VISA-P score for patellar tendinopathy in Spanish population. J Orthop Sports Phys Ther 41:581–591
10. Hoksrud A, Ohberg L, Alfredson H, Bahr R (2006) Ultrasound-guided sclerosis of neovessels in painful chronic patellar tendinopathy: a randomized controlled trial. Am J Sports Med 34:1738–1746
11. Hoksrud A, Ohberg L, Alfredson H, Bahr R (2008) Color Doppler ultrasound findings in patellar tendinopathy (jumper's knee). Am J Sports Med 36:1813–1820
12. Hoksrud A, Bahr R (2011) Ultrasound-guided sclerosing treatment in patients with patellar tendinopathy (jumper's knee). 44-Month follow-up. Am J Sports Med 39:2377–2380
13. Hoksrud A, Torgalsen T, Harstad H, Haugen S, Andersen TE, Risberg MA, Bahr R (2012) Ultrasound-guided sclerosis of neovessels in patellar tendinopathy: a prospective study of 101 patients. Am J Sports Med 40:542–547
14. Khanna A, Nelmes RT, Gougoulias N, Maffulli N, Gray J (2009) The effects of LIPUS on soft-tissue healing: a review of literature. Br Med Bull 89:169–182
15. Larsson ME, Käll I, Nilsson-Helander K (2012) Treatment of patellar tendinopathy—a systematic review of randomized controlled trials. Knee Surg Sports Traumatol Arthrosc 20: 1632–1646
16. Lian OB, Engebretsen L, Bahr R (2005) Prevalence of jumper's knee among elite athletes from different sports: a cross-sectional study. Am J Sports Med 33:561–567
17. Maffulli N, Khan KM, Puddu G (1998) Overuse tendon conditions: time to change a confusing terminology. Arthroscopy 14:840–843
18. Malliaras P, Barton CJ, Reeves ND, Langberg H (2013) Achilles and patellar tendinopathy loading programmes: a systematic review comparing clinical outcomes and identifying potential mechanisms for effectiveness. Sports Med 43:267–286
19. Panni AS, Tartarone M, Mafulli N (2000) Patellar tendinopathy in athletes. Outcome of nonoperative and operative management. Am J Sports Med 28:392–397
20. Pascarella A, Alam M, Pascarella F, Latte C, Giuseppe Di Salvatore M, Maffulli N (2011) Arthroscopic management of chronic patellar tendinopathy. Am J Sports Med 39:1975–1983
21. Popp JE, Yu JS, Kaeding CC (1997) Recalcitrant patellar tendinitis: magnetic resonance imaging, histological evaluation, and surgical treatment. Am J Sports Med 25:218–222
22. Roels J, Martens M, Mulier JC, Burssens A (1978) Patellar tendinitis (jumper's knee). Am J Sports Med 6:362–368
23. Roles N, Maudsley R (1972) Radial tunnel syndrome. Resistant tennis elbow as a nerve entrapment. J Bone Jt Surg 54-B:499–508
24. Romero-Rodriguez D, Gual G, Tesch PA (2011) Efficacy of an inertial resistance training paradigm in the treatment of patellar tendinopathy in athletes: a case-series study. Phys Ther Sport 12:43–48
25. Rompe JD, Furia J, Maffulli N (2009) Eccentric loading versus eccentric loading plus shock-wave treatment for midportion achilles tendinopathy: a randomized controlled trial. Am J Sports Med 37:463–470
26. Sanchez-Ibañez JM (2009) Clinical course in the treatment of chronic patellar tendinopathy through ultrasound guided intratissue percutaneous electrolysis (EPI®): study of a population series of cases in sport [PhD thesis]. Honolulu, USA, Atlantic International University
27. Santander J, Zarba E, Iraporda H, Puleo S (2012) Can arthroscopically assisted treatment of chronic patellar tendinopathy reduce pain and restore function? Clin Orthop Relat Res 470:993–997
28. Silbernagel KG, Brorsson A, Lundberg M (2011) The majority of patients with Achilles tendinopathy recover fully when treated with exercise alone: a 5-year follow-up. Am J Sports Med 39:607–613
29. Steunebrink M, Zwerver J, Brandsema R, Groenenboom P, van den Akker-Scheek I, Weir A (2013) Topical glyceryl trinitrate treatment of chronic patellar tendinopathy: a randomised, double-blind, placebo-controlled clinical trial. Br J Sports Med 47:34–39
30. Taylor DW, Petrera M, Hendry M, Theodoropoulos JS (2011) A systematic review of the use of platelet-rich plasma in sports medicine as a new treatment for tendon and ligament injuries. Clin J Sport Med 21:344–352
31. Tous-Fajardo J, Maldonado RA, Quintana JM, Pozzo M, Tesch PA (2006) The flywheel leg-curl machine: offering eccentric overload for hamstring development. Int J Sports Physiol Perform 1:293–298
32. van Ark M, Zwerver J, van den Akker-Scheek I (2011) Injection treatments for patellar tendinopathy. Br J. Sport Med 45:1068–1076
33. van Sterkenburg MN, de Jonge MC, Sierevelt IN, van Dijk CN (2010) Less promising results with sclerosing ethoxysclerol injections for midportion achilles tendinopathy: a retrospective study. Am J Sports Med 38:2226–2232
34. Visentini PJ, Khan KM, Cook JL, Kiss ZS, Harcourt PR, Wark JD (1998) The VISA score: an index of severity of symptoms in patients with jumper's knee (patellar tendinosis). Victorian Institute of Sport Tendon Study Group. J Sci Med Sport 1:22–28
35. Warden SJ, Metcalf BR, Kiss ZS, Cook JL, Purdam CR, Bennell KL, Crossley KM (2008) Low-intensity pulsed ultrasound for chronic patellar tendinopathy: a randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford) 47:467–471
36. Warden SJ, Kiss ZS, Malara FA, Ooi AB, Cook JL, Crossley KM (2007) Comparative accuracy of magnetic resonance imaging and ultrasonography in confirming clinically diagnosed patellar tendinopathy. Am J Sports Med 35:427–436
37. Zwerver J, Hartgens F, Verhagen E, van der Worp H, van den Akker-Scheek I, Diercks RL (2011) No effect of extracorporeal shockwave therapy on patellar tendinopathy in jumping athletes during the competitive season: a randomized clinical trial. Am J Sports Med 39:1191–1199

Revista Española de Cirugía Ortopédica y Traumatología

www.elsevier.es/rot

INVESTIGACIÓN

Mecanismos moleculares de reparación mediante la técnica Electrólisis Percutánea Intratisular en la tendinosis rotuliana

F. Abat[a,*], S.L. Valles[b], P.E. Gelber[c,d], F. Polidori[a], T.P. Stitik[e], S. García-Herreros[b], J.C. Monllau[c,d] y J.M. Sanchez-Ibánez[a]

[a] *Departamento de Traumatología y Rehabilitación Deportiva, CEREDE Sports Medicine, Barcelona, España*
[b] *Departamento de Fisiología, Facultad de Medicina de Valencia, Valencia, España*
[c] *Servicio de Cirugía Ortopédica y Traumatología, Hospital de la Santa Creu i Sant Pau, Universidad Autónoma de Barcelona, Barcelona, España*
[d] *Institut Català de Traumatologia i Medicina de l'Esport (ICATME)-Instituto Universitario Dexeus, Universidad Autónoma de Barcelona, Barcelona, España*
[e] *Departamento de Medicina Física y Rehabilitación, New Jersey Medical School, Newark, New Jersey, Estados Unidos de América*

Recibido el 1 de diciembre de 2013; aceptado el 8 de enero de 2014
Disponible en Internet el 10 de mayo de 2014

PALABRAS CLAVE
Tendinopatía;
Electrólisis Percutánea Intratisular;
Mecanismos moleculares;
Regeneración;
Tendón

Resumen
Objetivo: Investigar los mecanismos moleculares de respuesta tisular tras el tratamiento con la técnica Electrólisis Percutánea Intratisular (EPI®) en la tendinosis inducida por colagenasa tipo I en ratas Sprague Dawley.
Métodos: En una muestra de 24 ratas Sprague Dawley de 7 meses de edad y 300 g se indujo tendinosis mediante la inyección en el tendón rotuliano de 50 μg de colagenasa tipo I. Se procedió a dividir la muestra en 4 grupos: un grupo control, un grupo colagenasa y 2 grupos de tratamiento con técnica EPI® a 3 y 6 mA, respectivamente. Se aplicó una sesión de tratamiento EPI® y tras 3 días se procedió al análisis de los tendones mediante técnicas de inmunodetección y electroforesis. Se analizaron las proteínas citocromo C, Smac/Diablo, factor de crecimiento endotelial vascular y su receptor 2. También se analizó el factor de transcripción nuclear peroxisoma proliferador activado del receptor gamma.
Resultados: Se observó un aumento estadísticamente significativo en la expresión del citocromo C, Smac/Diablo, factor de crecimiento endotelial vascular, su receptor 2 y peroxisoma proliferador activado del receptor gamma en los grupos a los que se les aplicó la técnica EPI® respecto al grupo control.
Conclusiones: La técnica EPI® produce, en la lesión tendinosa inducida con colagenasa tipo I en ratas, un aumento de los mecanismos moleculares antiinflamatorios y angiogénicos.

* Autor para correspondencia.
Correo electrónico: drabat@cerede.es (F. Abat).

1888-4415/$ - see front matter
http://dx.doi.org/10.1016/j.recot.2014.01.002

KEYWORDS
Tendinopathy;
Intratissue Percutaneous Electrolysis;
Molecular mechanisms;
Regeneration;
Tendon

Molecular repair mechanisms using the Intratissue Percutaneous Electrolysis technique in patellar tendonitis

Abstract
Objective: To investigate the molecular mechanisms of tissue response after treatment with the Intratissue Percutaneous Electrolysis (EPI®) technique in collagenase-induced tendinopathy in Sprague-Dawley rats.
Methods: Tendinopathy was induced by injecting 50 μg of type I collagenase into the patellar tendon of 24 Sprague Dawley rats of 7 months of age and weighting 300 g. The sample was divided into 4 groups: the control group, collagenase group, and two EPI® technique treatment groups of 3 and 6 mA, respectively. An EPI® treatment session was applied, and after 3 days, the tendons were analysed using immunoblotting and electrophoresis techniques. An analysis was also made of cytochrome C protein, Smac/Diablo, vascular endothelial growth factor and its receptor 2, as well as the nuclear transcription factor peroxisome proliferator-activated receptor gamma.
Results: A statistically significant increase, compared to the control group, was observed in the expression of cytochrome C, Smac/Diablo, vascular endothelial growth factor, its receptor 2 and peroxisome proliferator-activated receptor gamma in the groups in which the EPI® technique was applied.
Conclusions: EPI® technique produces an increase in anti-inflammatory and angiogenic molecular mechanisms in collagenase-induced tendon injury in rats.

Introducción

La tendinosis rotuliana afecta a un número importante de atletas cuyo denominador común es realizar saltos o movimientos balísticos[1]. Actualmente se considera la tendinosis un proceso degenerativo más que un proceso inflamatorio, y a pesar de que se han descrito múltiples opciones terapéuticas, ninguna se ha establecido como método estándar[2,3].

El uso de modelos experimentales basados en la inducción de tendinosis mediante colagenasa (metaloproteinasa capaz de romper los enlaces peptídicos del colágeno) ha sido aplicado previamente[4]. Para el estudio experimental de las tendinosis se ha utilizado previamente la valoración de proteínas como el citocromo C, Smac/Diablo, factor de crecimiento endotelial vascular (VEGF), su receptor 2 (VEGFR-2) y el factor de transcripción nuclear peroxisoma proliferador activado del receptor gamma (PPAR-γ). El citocromo C es una proteína monomérica capaz de activar las caspasas desencadenantes de las últimas fases de la apoptosis en las tendinopatías[5]. La Smac/Diablo es una proteína mitocondrial, cuya liberación al citosol celular induce la apoptosis, presumiblemente siguiendo las mismas rutas de salida que el citocromo C[6]. El VEGF es una proteína señalizadora implicada en la angiogénesis y vasculogénesis que ha demostrado, in vitro, estimular la división y la migración de células endoteliales[7]. El VEGFR-2 es un receptor tirosina-quinasa que actúa como el mediador más importante de la respuesta angiogénica del VEGF[8]. Por último PPAR-γ, de la familia de los factores de transcripción nucleares (superfamilia de receptores esteroideos), ha demostrado producir una disminución de la respuesta inflamatoria[9].

La técnica Electrólisis Percutánea Intratisular (EPI®) produce una ablación electrolítica no termal que induce una respuesta inflamatoria controlada, permitiendo activar los mecanismos celulares implicados en la fagocitosis y en la regeneración del tejido blando dañado[10].

Dado que trabajos recientes han demostrado buenos resultados clínicos con la técnica a estudio[11], el objetivo del presente análisis fue investigar mediante técnicas de inmunodetección y electroforesis los mecanismos moleculares de respuesta tisular implicados en el tratamiento con técnica EPI®, tras la inducción de tendinosis con colagenasa en ratas Sprague Dawley.

Material y método

Para llevar a cabo el estudio se utilizaron 24 hembras de rata Sprague Dawley de 7 meses de edad y aproximadamente 300 g de peso. El estudio cumplió con los requisitos éticos y fue aprobado por el Comité de Bioética de la Universidad de Medicina (A-1301314899794). Se siguieron las normas del Real Decreto 1201/2005, de 10 de octubre, relativo a la protección de los animales utilizados para experimentación (BOE n.º 252. p. 34367-34391).

Los animales se distribuyeron en 4 grupos: 6 ratas de control que no recibieron ninguna intervención (grupo control), 6 ratas inyectadas con colagenasa que no recibieron tratamiento con técnica EPI® (grupo colagenasa), 6 ratas inyectadas con colagenasa y tratadas con técnica EPI® a 3 mA de intensidad (grupo EPI®-3 mA), y 6 ratas inyectadas con colagenasa y tratadas con técnica EPI® a 6 mA de intensidad (grupo EPI®-6 mA).

La técnica EPI® consistió en la aplicación ecoguiada a través de una aguja de 0,32 mm de una corriente continua mediante un dispositivo especialmente diseñado y certificado para tal fin (Directiva CE 93/42/EEC. EPI Advanced Medicine®, Barcelona, España).

Modelo experimental

Se inyectó en la zona proximal del tendón rotuliano de las ratas 50 μg de colagenasa de tipo I (Laboratorios Sigma-Aldrich, St. Louis, MO, EE. UU.), produciendo una tendinosis comprobada por ecografía siguiendo el protocolo definido por la European Society of Musculoskeletal Radiology para el estudio de tendinopatías[12].

Para la realización de la técnica EPI® se realizaron 3 punciones ecoguiadas de 4 s de duración cada una, en la zona proximal del tendón rotuliano de las ratas, con una intensidad de 3 o 6 mA, dependiendo del grupo a estudio. Tras 7 días las ratas fueron sacrificadas y se extrajo quirúrgicamente una muestra del tendón siguiendo el procedimiento estándar.

Se utilizó el método Lowry[13] para determinar la concentración de proteína en la muestra de tejido en rangos de 0,01-1 mg/ml, y se analizaron las muestras por inmunodetección y espectrofotometría (λ = 660 nm). Se analizaron las proteínas citocromo C, Smac/Diablo, VEGF y VEGFR-2. A su vez, se estudió el factor de transcripción nuclear PPAR-γ. Se validaron los resultados por estudio *western blot* contra tubulina, expresando los resultados en unidades de densitometría relativas.

Análisis estadístico

Los resultados se expresan como media ± desviación estándar. El análisis estadístico se realizó mediante la prueba t-test. Se realizó análisis ANOVA para valorar las relaciones entre las variables, así como pruebas post-hoc y de Dunnett para comparar los diferentes grupos con el grupo control y la prueba de Scheffé para comparar todos los grupos entre sí. El nivel de significación se fijó en el 5% ($p < 0,05$). El análisis estadístico se realizó con el programa SPSS® versión 17 (SPSS Inc., Chicago, Illinois, EE. UU.).

Resultados

El estudio del citocromo C (fig. 1) mostró niveles elevados de esta proteína en todos los grupos en comparación con el grupo control ($p < 0,001$). Se encontraron diferencias estadísticamente significativas al comparar el grupo EPI®-3 mA y el grupo EPI®-6 mA ($p < 0,013$), al igual que al compara el grupo EPI®-6 mA y el grupo colagenasa ($p = 0,002$).



Figura 1 Histograma del análisis de la proteína citocromo C. Media ± desviación estándar expresadas en unidades de densitometría relativas. El asterisco determina significación al comparar con el grupo control, y la almohadilla, al comparar con el grupo colagenasa.



Figura 2 Histograma del análisis de la proteína Smac/Diablo. Media ± desviación estándar expresadas en unidades de densitometría relativas. El asterisco determina significación al comparar con el grupo control, y la almohadilla, al comparar con el grupo colagenasa.



Figura 3 Histograma del análisis de la proteína VEGF. Media ± desviación estándar expresadas en unidades de densitometría relativas. El asterisco determina significación al comparar con el grupo control, y la almohadilla, al comparar con el grupo colagenasa.

La proteína Smac/Diablo (fig. 2) mostró una sobreexpresión de la misma ($p < 0,001$), detectando diferencias estadísticamente significativas al comparar los 2 grupos de tratamiento (EPI®-3 mA y EPI®-6 mA) con el grupo colagenasa ($p < 0,001$).

El análisis del VEGF (fig. 3) mostró un aumento significativo ($p < 0,001$) en todos los grupos a estudio. A su vez se detectó un aumento significativo ($p < 0,001$) del VEGFR-2 (fig. 4).

Por último, la PPAR-γ (fig. 5) presentó un aumento significativo en comparación con el grupo control ($p < 0,001$), presentando diferencias estadísticamente significativas al comparar los grupo EPI®-3 mA ($p = 0,009$) y EPI®-6 mA ($p < 0,001$) con el grupo colagenasa.

Discusión

El principal hallazgo de este trabajo fue que la técnica EPI® produjo una sobreexpresión de las proteínas citocromo C, Smac/Diablo, VEGF, VEGFR-2 y del factor de transcripción nuclear PPAR-γ.

A pesar de que actualmente no exista un tratamiento para la tendinosis considerado como estándar, se han descrito múltiples técnica destinadas a tal fin. Entre ellas se encuentra el ejercicio excéntrico, la cirugía (abierta



Figura 4 Histograma del análisis de la proteína VEGFR-2. Media ± desviación estándar expresadas en unidades de densitometría relativas. El asterisco determina significación al comparar con el grupo control, y la almohadilla, al comparar con el grupo colagenasa.



Figura 5 Histograma del análisis de la proteína PPAR-γ. Media ± desviación estándar expresadas en unidades de densitometría relativas. El asterisco determina significación al comparar con el grupo control, y la almohadilla, al comparar con el grupo colagenasa.

o artroscópica), las ondas de choque, la esclerosis de las neovascularizaciones, los antiinflamatorios no esteroideos o la aplicación de plasma rico en plaquetas o aprotina, entre otras[2,3].

La técnica EPI® es una corriente eléctrica no termal que induce una respuesta regenerativa del tejido dañado[10]. Por inestabilidad iónica se crea la formación de moléculas de hidróxido de sodio, produciendo debajo del electrodo activo o aguja catódica una modificación del pH y un aumento de la presión de oxígeno, permitiendo la fagocitosis y la activación biológica de la reparación del tendón, que se encontraba alterada por la cronicidad del proceso degenerativo[10,11].

Trabajos anteriores con terapia electrolítica, como el de Gravante et al.[14], demostraron los efectos de estas técnicas en la respuesta inflamatoria. Un metaanálisis de Gardner et al.[15] demostró que la estimulación eléctrica en heridas crónicas y úlceras de decúbito producía una curación más rápida, mientras que Zhao et al.[16] observaron cómo un campo eléctrico aplicado a cultivos de células endoteliales estimulaba la producción de VEGF, así como la elongación y migración celular, resultados que concuerdan con los mostrados en el presente trabajo. Posteriormente, Yang et al.[17] observaron que la aplicación de corriente directa en tejido blando lesionado es fundamental en la gestión y migración de células epiteliales en la respuesta de cicatrización.

La teoría de la lesión tendinosa secundaria al sobreuso parece ser la más aceptada[1]. Al igual que autores como Alfredson et al.[18] o Tan y Chan[19], consideramos la tendinosis como un proceso degenerativo más que como un proceso inflamatorio. De acuerdo con Fu et al.[20], el aumento de las proteínas VEGF, Smac/Diablo, citocromo C, VEGFR-2 y la proteína antiinflamatoria PPAR-γ está relacionado con la respuesta inflamatoria y la reparación tisular. Dado que la tendinosis es un proceso degenerativo, el tratamiento con la técnica EPI® podría estar justificado[10,11,21–23].

El presente estudio mostró una mayor capacidad de sobreexpresión del citocromo C, marcador de apoptosis relacionado con las tendinosis[5], tras la aplicación de la técnica EPI®. La proteína Smac/Diablo es exportada al citosol desde la mitocondria, produciendo apoptosis a través de la activación de caspasas[6] y daño en el ADN como resultado de la unión al receptor CD95[24]. Los datos presentados muestran cómo los grupos que recibieron tratamiento con la técnica EPI® presentaron un aumento de la expresión de esta proteína. Tal y como describieron Huang et al.[25], el aumento de la apoptosis vía las proteínas Smac/Diablo y la inducción de VEGF a través de VEGFR-2 es probablemente debido al aumento de la inhibición de las células B en el desarrollo de la médula ósea y de la diferenciación de las células T del timo.

Tras el tratamiento con la técnica EPI® se ha observado un aumento de las proteínas antiinflamatorias como la PPAR-γ[9], que tienen un papel primordial en la inhibición de la expresión de moléculas proinflamatorias secretadas por los macrófagos como el TNF-α, IL-6 e IL-1β[26], produciendo una respuesta molecular en el tejido tratado altamente beneficiosa en el transcurso de una tendinosis. A su vez, esto resulta en un aumento de la expresión del VEGF y VEGFR-2, mediadores responsables de la angiogénesis y respuesta antiinflamatoria[7,27]. La literatura identifica los receptores VEGFR-1 y VEGFR-2 como los mayor expresados en el tendón de Aquiles humano[8]. Nuestros resultados muestran un aumento del VEGFR-2 tras el tratamiento con la técnica EPI®, lo que evidencia una modificación en la vía de apoptosis celular y un aumento de la angiogénesis.

Una limitación de este estudio fue el uso de modelos experimentales en animales, por lo que los resultados obtenidos podrían no ser completamente extrapolables a humanos[28]. Sin embargo, los resultados de este estudio son alentadores y ponen de relieve la necesidad de realizar estudios adicionales que incluyan microdiálisis molecular y estudio histológico del tejido tratado[18,29]. Se debe destacar el moderado número de animales de experimentación, si bien los resultados han demostrado una adecuada potencia estadística. Otra limitación podría ser el estudio de 6 alteraciones moleculares en una dolencia tan compleja y desconocida como la que se presenta.

Conclusiones

La técnica EPI® produce, en la lesión tendinosa inducida con colagenasa tipo I en ratas, un aumento de los mecanismos moleculares antiinflamatorios y angiogénicos.

Nivel de evidencia

Nivel de evidencia I.

Responsabilidades éticas

Protección de personas y animales. Los autores declaran que los procedimientos seguidos se conformaron a las normas éticas del comité de experimentación humana responsable y de acuerdo con la Asociación Médica Mundial y la Declaración de Helsinki.

Confidencialidad de los datos. Los autores declaran que en este artículo no aparecen datos de pacientes.

Derecho a la privacidad y consentimiento informado. Los autores declaran que en este artículo no aparecen datos de pacientes.

Conflicto de intereses

El autor J.M. Sanchez-Ibáñez posee la patente de los dispositivos EPI®. Ha participado en la realización del tratamiento, así como en la redacción del manuscrito, pero no ha participado en la obtención de las muestras, el análisis molecular ni el estudio estadístico de los datos obtenidos.

Bibliografía

1. Lian OB, Engebretsen L, Bahr R. Prevalence of jumper's knee among elite athletes from different sports: A cross-sectional study. Am J Sports Med. 2005;33:561–7.
2. Andres BM, Murrell GA. Treatment of tendinopathy: What works, what does not, and what is on the horizon. Clin Orthop Relat Res. 2008;466:1539–54.
3. Larsson ME, Käll I, Nilsson-Helander K. Treatment of patellar tendinopathy–A systematic review of randomized controlled trials. Knee Surg Sports Traumatol Arthrosc. 2012;20:1632–46.
4. Dahlgren LA, van der Meulen MC, Bertram JE, Starrak GS, Nixon AJ. Insulin-like growth factor-I improves cellular and molecular aspects of healing in a collagenase-induced model of flexor tendinitis. J Orthop Res. 2002;20:910–9.
5. Yuan J, Murrell GA, Trickett A, Wang MX. Involvement of cytochrome c release and caspase-3 activation in the oxidative stress-induced apoptosis in human tendon fibroblasts. Biochim Biophys Acta. 2003;1641:35–41.
6. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000;102:43–53.
7. Sahin H, Tholema N, Petersen W, Raschke MJ, Stange R. Impaired biomechanical properties correlate with neoangiogenesis as well as VEGF and MMP-3 expression during rat patellar tendon healing. J Orthop Res. 2012;30:1952–7.
8. Petersen W, Pufe T, Zantop T, Tillmann B, Tsokos M, Mentlein R. Expression of VEGFR-1 and VEGFR-2 in degenerative Achilles tendons. Clin Orthop Relat Res. 2004;420:286–91.
9. De Mos M, Koevoet WJ, Jahr H, Verstegen MM, Heijboer MP, Kops N, et al. Intrinsic differentiation potential of adolescent human tendon tissue: An in-vitro cell differentiation study. BMC Musculoskelet Disord. 2007;8:16.
10. Sánchez-Ibáñez JM. Evolución clínica en el tratamiento de la entesopatía rotuliana crónica mediante electro-estimulación percutánea ecodirigida: estudio de una serie de casos en población deportiva [tesis doctoral]. León: Universidad de León; 2013.
11. Sánchez-Sánchez JL. Estudio comparativo de un tratamiento fisioterápico convencional con uno que incluya la técnica Electrolisis Percutánea Intratisular en pacientes con tendinopatía crónica del tendón rotuliano [tesis doctoral]. Salamanca: Universidad de Salamanca; 2011.
12. Beggs I, Bianchi S, Bueno A, Cohen M, Court-Payen M, Grainger A, et al. ESSR Ultrasound Group Protocols. Musculoskeletal Ultrasound Technical Guidelines: Knee [consultado 28 Oct 2013]. Disponible en: http://www.essr.org/html/img/pool/knee.pdf
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–75.
14. Gravante G, Ong SL, Metcalfe MS, Sorge R, Overton J, Lloyd DM, et al. Cytokine response of electrolytic ablation in an ex vivo perfused liver model. ANZ J Surg. 2010;80:537–41.
15. Gardner SE, Frantz RA, Schmidt FL. Effect of electrical stimulation on chronic wound healing: A meta-analysis. Wound Repair Regen. 1999;7:495–503.
16. Zhao M, Bai H, Wang E, Forrester JV, McCaig CD. Electrical stimulation directly induces pre-angiogenic responses in vascular endothelial cells by signaling through VEGF receptors. J Cell Sci. 2004;117:397–405.
17. Yang K, Zhao Z, Gross RW, Han X. Systematic analysis of choline-containing phospholipids using multi-dimensional mass spectrometry-based shotgun lipidomics. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:2924–36.
18. Alfredson H, Ljung BO, Thorsen K, Lorentzon R. In vivo investigation of ECRB tendons with microdialysis technique–No signs of inflammation but high amounts of glutamate in tennis elbow. Acta Orthop Scand. 2000;71:475–9.
19. Tan SC, Chan O. Achilles and patellar tendinopathy: Current understanding of pathophysiology and management. Disabil Rehabil. 2008;30:1608–15.
20. Fu SC, Rolf C, Cheuk YC, Lui PP, Chan KM. Deciphering the pathogenesis of tendinopathy: A three-stages process. Sports Med Arthrosc Rehabil Ther Technol. 2010;2:30.
21. Lian Ø, Scott A, Engebretsen L, Bahr R, Duronio V, Khan K. Excessive apoptosis in patellar tendinopathy in athletes. Am J Sports Med. 2007;35:605–11.
22. Scott A, Lian Ø, Bahr R, Hart DA, Duronio V, Khan KM. Increased mast cell numbers in human patellar tendinosis: Correlation with symptom duration and vascular hyperplasia. Br J Sports Med. 2008;42:753–7.
23. Zhao M, Song B, Pu J, Wada T, Reid B, Tai G, et al. Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. Nature. 2006;442:457–60.
24. Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M, et al. Apoptosis and cancer: Mutations within caspase genes. J Med Genet. 2009;46:497–510.
25. Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L, et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood. 2007;110:624–31.
26. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82–6.
27. Nakama LH, King KB, Abrahamsson S, Rempel DM. VEGF, VEGFR-1, and CTGF cell densities in tendon are increased with cyclical loading: An in vivo tendinopathy model. J Orthop Res. 2006;24:393–400.
28. Lui PP, Maffulli N, Rolf C, Smith RK. What are the validated animal models for tendinopathy? Scand J Med Sci Sports. 2011;21:3–17.
29. Maffulli N, del Buono A, Spiezia F, Longo UG, Denaro V. Light microscopic histology of quadriceps tendon ruptures. Int Orthop. 2012;36:2367–71.

Sports Medicine & Doping Studies

Abat et al., J Sports Med Doping Stud 2014, 4:2
http://dx.doi.org/10.4172/2161-0673.1000139

Research Article Open Access

Large Tear of the Pectoralis Major Muscle in an Athlete. Results after Treatment with Intratissue Percutaneous Electrolysis (EPI®)

Abat F[1], Gelber PE[2,3], Monllau JC[2,4], Sánchez-Ibáñez JM[5]

[1]Department of Sports Orthopedics, Cerede Sports Medicine, Barcelona, Spain

[2]Department of Orthopedics, ICATME – InstitutUniversitariQuironDexeus, University Autonoma of Barcelona. Barcelona, Spain

[3]Department of Orthopedic Surgery, Hospital de la Santa CreuiSant Pau, University Autonoma of Barcelona, Barcelona, Spain.

[4]Department of Orthopedics and Traumatology, Parc de Salut Mar, University Autonoma of Barcelona, Barcelona, Spain

[5]Department of Sports Rehabilitation, Cerede Sports Medicine, Barcelona, Spain

***Corresponding author:** Abat Ferran, Department of Sports Orthopedics, Cerede Sports Medicine.c/ Dr. Roux 8-10. 08017, Barcelona, Spain, Tel: +34934523510; E-mail: drabat@cerede.es

Received date: April 09, 2014; **Accepted date:** May 25, 2014; **Published date:** May 31, 2014

Abstract

Background: Injuries to the pectoral is major muscle can result in functional limitation. Previous reports on conservative treatment on large tears of the pectoral is major muscle showed inconsistent results with several treatment modalities. The best option to treat this pathology is still under discussion.

Methods: A 30 year-old male patient with a large pectoral is major muscle tear was treated with ultrasound-guided EPI® technique once a week and eccentric exercise. Echography study was performed during the follow-up. Functional evaluation was assessed with Tegner scale, the criteria described by Bak et al. and the subjective outcomes described by Anthony et al.

Results: Ultrasound scan showed a correct arrangement of muscle fibers. Functional evaluation showed excellent results and at four weeks of treatment, the patient had returned to their level of activity prior to the injury.

Conclusion: Treatment with the US-guided EPI® technique on pectoral is major muscle tear resulted in a high improvement in function and a rapid return to the previous level of activity after few sessions. The procedure has proven to be safe with no recurrences at one-year follow-up.

Keywords: Pectoralis major; Muscle; Tear; Athlete; Treatment; Intratissue percutaneous electrolysis; EPI

Introduction

Injuries to the pectoral is major muscle are important because as they can result in functional and aesthetic deficiencies of the upper extremity. They typically arise through indirect means, with the muscle being in a state of maximum elongation and contraction at a point of sudden overload [1-3]. This type of injury has been observed in activities like weight lifting, wrestling, American football and water skiing [4,5].

A purely clinical assessment of the pectoralis major injury may be deficient, so additional tests with imaging are needed to refine the diagnosis. Magnetic resonance imaging has been successfully used to assess the characteristics of injuries to the pectoral is major [6]. Similarly, ultrasound has been used to determine the extent and location of the lesion [7,8]. However, diagnosing with imaging is not without problems due to the anatomical complexity of the distal tendon of the pectoral is major as this has a 180° twist that comprises the sternal and clavicular portions [7,8]. The anatomical location of the muscle tear is very important because an avulsion of the tendon at its insertion into the humerus requires surgical repair, while myotendinous junction lesions are usually treated with conservative treatment [2,5,9].

Among the conservative treatment options, Intratissue percutaneous electrolysis (EPI®) stands out. This is a minimally invasive medical and physiotherapeutic technique that involves the application of a high-intensity galvanic current through a conductive stylus that provokes a rapid and localized regenerative process in the target tissue [10,11]. This allows for phagocytosis and the subsequent repair of affected tissue while making it possible to aspirate the hematic content of the injury and reducing the production of a secondary fibrotic lesion [12]. This is vitally important because it decreases the fibrous scar that occurs in muscle injuries and therefore the risk of re-rupture.

With this paper, the aim is to present the clinical and functional results in the treatment of an athlete affected by a large partial tear of the pectoralis major muscle treated with the EPI® technique.

Materials and Methods

A 30 year-old male patient who came to our clinic with pain and a functional limitation in the upper left extremity. The pain appeared suddenly during his usual gymnastic practice when performing a pull-up on the horizontal bar. The patient had no relevant medical history

or concomitant therapies and had never received injections to the affected area.

Clinical examination showed a clear indentation in the musculature of the left pectoralis major that became more pronounced when the patient pressed their palms together to contract the large pectoral muscles bilaterally. An obvious indentation was seen on the left upon comparing it to the right pectoral, which indicated a major tear of the muscle.

Ultrasound evaluation of the pectoral is major was performed longitudinally and transversally to the muscle fibers and the tendons were evaluated from origin to insertion. The distal pectoral tendon was identified and evaluated on the transverse plane at the level of the bicipital groove of the humerus, where the pectoral tendon and the tendon of the long head of biceps brachii cross. Equally, an evaluation of the flow was performed with high-resolution color Doppler. The images were compared to the contralateral side, placing the patient's shoulder in abduction and external rotation for the examination.

The ultrasound study was performed by two specialists in musculoskeletal ultrasound using a color Doppler device and lineal probe of 5-16 Mhz and longitudinal and transverse views. At the same time, a radiographic study of the shoulder was performed with AP projection, an axillary "Y" view as well as in internal and external rotation.

The functional assessment was performed according to the criteria described by Bak et al. [13] in which results for patients without symptoms with normal range mobility without cosmetic changes, without adduction weakness and able to return to their sport activity were considered as excellent. Those results with almost normal range of mobility without cosmetic changes and less than a 20% deficit in peak torque in the isokinetic test were considered good. The poor results are those in which there is limited range of mobility, poor cosmetic results and the patient is unable to return to their sport activity. Finally, those results where the pain persists and revision surgery is needed were considered bad.

As a second item in the functional assessment, the test for assessing subjective outcomes described by Schepsis et al. [14] was used for the evaluation of lesions of the pectoral is major. Patient follow-up was conducted over a year while getting clinical and functional results before treatment, at one month as well as 2, 6 and 12 months. The Tegner scale was used to rate the level of activity of patients before and after the injury.

Treatment was consisted of the application of the ultrasound-guided EPI® technique once a week and eccentric exercise twice a week. The EPI® technique was performed with the patient supine using the device designed specifically to carry out this technique, the EPI Medical Tissue Remover® (EPI Advanced Medicine, Barcelona. Spain).

A 40mm-long sterile 20G needles were used. The application was performed by means of stratified ultrasound-guided puncturing. In the first treatment session, a puncture was performed in the center of the hematic injury to do the first EPI® pulse of 5 seconds duration (Figure 1a), activating then the vacuum system (Figure 1b) of the device itself so as to get quick closure of the muscle injury.

Once the closure of the lesion was successful (Figure 1c), EPI® was continued at the edges of the lesion without removing the needle and applying 4 pulses of 10 seconds each in the geographical margins of the lesion. In 3 subsequent weekly sessions, 0.3x30 mm needles were used to apply the EPI® technique to minimize the pain of the puncture, using 4 pulses of 10 seconds in the length of remnant muscle scar.

Results

According to the classification of Tietjen [15], it was a pectoral is major muscle injury type II at the mid-portion of the muscle. Ultrasound examination detected a marked accumulation of fluid (hypoechoic) in the pectoral is major muscle (Figure 1). The diameter of the lesion was 30x7 millimeters with plenty of hematic content. The radiographic studies showed no abnormalities or bony avulsions.



Figure 1: Sequence of images with high definition ultrasound with a 5-16Mhz lineal probe in a longitudinal view where the application of the ultrasound-guided EPI® technique in the focus of the hematoma (a) is observed. Upon activating the EPI® the hematoma begins to dissolve with the smoke effect appearing (arrow). After the first 5 seconds of treatment, the MTR® suction system (b) is activated to obtain a complete evacuation of the hematoma, leaving the injury virtually sealed (c).

In the functional evaluation, according to the criteria of Bak et al. [13], the good results that were seen at one month passed to excellent at 2 months and remained at the same level at 12 months.

The results obtained according to the criteria of Schepsis et al. [14] are shown in Table 1. Four weeks after the treatment starts, the patient had returned to their level of activity prior to the injury that was 8 points on the Tegner scale. These results were maintained in controls at 2, 6 and 12 months.

Question	1 month FU	2 months FU	6 months FU	1 year FU
Pain Relief	98	98	98	98
Range of Motion	95	100	100	100
Return to strength	96	97	100	100
Cosmetic satisfaction	86	86	95	95
Treatment Satisfaction	98	100	100	100
Average answers from the subjective questionnaire described forSchepsis et al. Values presented as percentages based on 100%.				

Table 1: Results obtained according to the criteria of Schepsiset al. [14] during the follow-up

The ultrasound scan performed during follow-up showed a correct arrangement of muscle fibers without evidence of fibrous scarring or accumulations of hematic residuals (Figure 2). During the procedure, no medical complications related to treatment presented.



Figure 2: Ultrasound control with a 5-16Mhz lineal probe in a longitudinal panoramic view at 1 month after treatment in which a correct disposition of the pectoralis major muscle fibers without evidence of fibrotic scarring or complications.

Discussion

This paper shows that the treatment of injury in the pectoral is major of a gymnast treated with the Intratissue percutaneous electrolysis (EPI®) technique obtained excellent results and allowed for an early return to sports activity.

The pectoral is major muscle is a powerful internal rotator, flexor, and adductor of the arm and has its origin in the collarbone, sternum and the cartilages of the first six ribs. The pectoral is major muscle fibers converge in three bundles that rotate 180° that join to form a tendon which inserts into the lateral aspect of the humeral bicipital groove [8]. Patients with lesions of the pectoral is major muscle are clinically characterized by pain, bruising, swelling, and decreased range of motion. Clinically speaking, it is difficult to assess the extent and location of this type of injury except through ultrasound or magnetic resonance imaging evaluation. It is possible that a small initial injury of the pectoral is major muscle associated with lifting weights is not identified by ultrasound, but the patient may have pain in the anterior region of the chest [7,8,16,17]. In these cases, the immediate suspension of strength training is important so as to avoid further muscle ruptures of a serious nature within the first 6 weeks [1,4].

Tears of this muscle occur more frequently in the myotendinous junction or the insertion of the humerus and partial tears are more frequent than complete tears. The most commonly used clinical classification of this lesion is described by Tietjen [15]. It focuses on both the type of injury and the location of the lesion in relation to the origin or insertion. A type I injury refers to a concussion; a partial tear refers to type II, and type III to a complete rupture. On the other hand, it also stands out if the location of the lesion is in the sternal origin in the muscle, at the myotendinous junction or the humeral insertion.

The injuries of the pectoral is major muscle usually occurs during a high intensity eccentric action when the muscle is exposed to high tensile forces [4,5,7]. The main sports injury associated with the pectoral is major muscle are weightlifting, wrestling, gymnastics or wind-surfing.

Although MRI has been used to evaluate injuries of the pectoral is major muscle [6,7], ultrasound may also be useful in the assessment of this type of injury. Ahypoechoic image corresponding to hematic collection inside the rupture of the pectoral is major muscle can be seen [18].

Treatment options for an injury of the pectoral is major muscle are based on an accurate assessment of the extent and location of the lesion. Treatment is usually conservative in partial tears and sometimes in total ruptures in non-athletes. Surgical repair is used for complete tears and ruptures of the distal tendon in athlete patients [1-4]. The chosen method of treatment varies greatly depending on the literature consulted.

The Intratissue percutaneous electrolysis (EPI®) technique has proven effective in the treatment of soft tissue injuries [10,11] and experimental studies [12] have demonstrated that the early use of this technique reduces the fibrotic reactions secondary to these lesions. By using a high-intensity galvanic current, directed through a needle, rapid regeneration of damaged tissue is achieved. At the same time, the suction capacity provided by the EPI Medical Tissue Remover® device during the application of the technique makes it possible to evacuate the hematic content of the lesion, thereby facilitating healing and preventing potential later complications.

In the case presented, the ultrasound findings showed a large partial tear of the pectoral is major muscle with a large collection of blood. After treatment with the eco-guided Intratissue percutaneous electrolysis (EPI®) technique, the hematic fluid significantly decreased and proper remodeling of injured tissue was obtained, allowing the athlete to return to sports competition at 4 weeks after injury. The study with ultrasonographic images showed a repair of the myotendinous junction of the pectoral is major muscle with no signs of the formation of fibrotic scar tissue and no signs of hypoechoic thickening of the tendon.

Conclusion

Treatment with the US-guided EPI® technique on pectoral is major muscle tear resulted in a high improvement in function and a rapid return to the previous level of activity after few sessions. The procedure has proven to be safe with no recurrences at one-year follow-up.

Acknowledgments

We are grateful to E. Goode for his help in correcting the manuscript.

References

1. de Castro Pochini A, Andreoli CV, Belangero PS, Figueiredo EA, Terra BB, et al. (2014) Clinical considerations for the surgical treatment of pectoralis major muscle ruptures based on 60 cases: a prospective study and literature review. Am J Sports Med 42: 95-102.
2. Ziskoven C, Patzer T, Ritsch M, Krauspe R, Kircher J (2011) [Current treatment options for complete ruptures of the pectoralis major tendon]. Sportverletz Sportschaden 25: 147-152.
3. Garrigues GE, Kraeutler MJ, Gillespie RJ, O'Brien DF, Lazarus MD (2012) Repair of pectoralis major ruptures: single-surgeon case series. Orthopedics 35: e1184-1190.
4. de Castro Pochini A, Ejnisman B, Andreoli CV, Monteiro GC, Silva AC, et al. (2010) Pectoralis major muscle rupture in athletes: a prospective study. Am J Sports Med 38: 92-98.
5. ElMaraghy AW, Devereaux MW (2012) A systematic review and comprehensive classification of pectoralis major tears. J Shoulder Elbow Surg 21: 412-422.
6. El-Essawy MT, Al-Jassir FF, Al-Nakshabandi NA (2010) Magnetic resonance imaging assessment of the pectoralis major muscle rupture. Saudi Med J 31: 937-938.

7. Provencher MT, Handfield K, Boniquit NT, Reiff SN, Sekiya JK, et al. (2010) Injuries to the pectoralis major muscle: diagnosis and management. Am J Sports Med 38: 1693-1705.
8. Ball V, Maskell K, Pink J (2012) Case series of pectoralis major muscle tears in joint special operations task force-Philippines soldiers diagnosed by bedside ultrasound. J Spec Oper Med 12: 5-9.
9. Fleury AM, Silva AC, de Castro Pochini A, Ejnisman B, Lira CA, et al. (2011) Isokinetic muscle assessment after treatment of pectoralis major muscle rupture using surgical or non-surgical procedures. Clinics (Sao Paulo) 66: 313-320.
10. Abat F, Gelber PE, Polidori F, Monllau JC, Sanchez-Ibañez JM (2014) Clinical results after ultrasound-guided intratissue percutaneous electrolysis (EPI®) and eccentric exercise in the treatment of patellar tendinopathy. Knee Surg Sports Traumatol Arthrosc.
11. Abat F, Diesel WJ, Gelber PE, Polidori F, Monllau JC, et al. (2014) Effectiveness of the Intratissue Percutaneous Electrolysis (EPI®) technique and isoinertial eccentric exercise in the treatment of patellar tendinopathy at two years follow-up. Muscles Ligaments Tendons J.
12. Abat F, Valles SL, Gelber PE, Polidori F, Stitik TP, et al. (2014) Molecular repair mechanisms using the Intratissue Percutaneous Electrolysis technique in patellar tendonitis. Rev Esp Cir Ortop Traumatol .
13. Bak K, Cameron EA, Henderson IJ (2000) Rupture of the pectoralis major: a meta-analysis of 112 cases. Knee Surg Sports Traumatol Arthrosc 8: 113-119.
14. Schepsis AA, Grafe MW, Jones HP, Lemos MJ (2000) Rupture of the pectoralis major muscle. Outcome after repair of acute and chronic injuries. Am J Sports Med 28: 9-15.
15. Tietjen R (1980) Closed injuries of the pectoralis major muscle. J Trauma 20: 262-264.
16. Hasegawa K, Schofer JM (2010) Rupture of the pectoralis major: a case report and review. J Emerg Med 38: 196-200.
17. Ho LC, Chiang CK, Huang JW, Hung KY, Wu KD (2009) Rupture of pectoralis major muscle in an elderly patient receiving long-term hemodialysis: case report and literature review. Clin Nephrol 71: 451-453.
18. Lee SJ, Jacobson JA, Kim SM, Fessell D, Jiang Y, et al. (2013) Distal pectoralis major tears: sonographic characterization and potential diagnostic pitfalls. J Ultrasound Med 32: 2075-2081.

Effectiveness of the Intratissue Percutaneous Electrolysis (EPI®) technique and isoinertial eccentric exercise in the treatment of patellar tendinopathy at two years follow-up

Ferran Abat[1]
Wayne-J Diesel[2]
Pablo-E Gelber[3]
Fernando Polidori[1]
Joan-Carles Monllau[3]
Jose-Manuel Sanchez-Ibañez[1]

[1] CEREDE, Sports Medicine, Barcelona, Spain
[2] Tottenham Hotspur FC, Hotspur Way, Enfield, Middlesex, UK
[3] Department of Orthopedic Surgery, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. ICATME – Institut Universitari Dexeus, Universitat Autònoma de Barcelona, Barcelona, Spain

Corresponding author:
Ferran Abat
CEREDE, Sports Medicine, Barcelona
Dr. Roux 8-10, 080017 Barcelona, Spain
E-mail: drabat@cerede.es

Summary

Objectives: **to show the effect of Intratissue Percutaneous Electrolysis (EPI®) combined with eccentric programme in the treatment of patellar tendinopathy.**
Methods: **prospective study of 33 athlete-patients consecutively treated for insertional tendinopathy with Intratissue Percutaneous Electrolysis (EPI®) and followed for 2 years. Functional assessment was performed at the first visit, at three months and two years with the Tegner scale and VISA-P.**
Results: **an average improvement in the VISA-P of 35 points was obtained. The mean duration of treatment was 4.5 weeks. Some 78.8% of the patients returned to the same level of physical activity as before the injury by the end of treatment, reaching 100% at two years.**
Conclusion: **intratissue percutaneous electrolysis (EPI®) combined with an eccentric-based rehab program offers excellent results in terms of the clinical and functional improvement of the patellar tendon with low morbidity in a short-term period.**
Level of Evidence: **Therapy, level 4.**

KEY WORDS: EPI, intratissue percutaneous electrolysis, patellar, tendinopathy, tenopathy, eccentric.

Introduction

The treatment of tendinopathy is a clinical challenge that some authors describe as one of the biggest problems in sports medicine[1,2]. Some studies suggest the use of the term tendinosis as it has proven to be more a degenerative condition rather than inflammatory[3]. Furthermore, authors like Maffulli[4,5] recommend using the term tendinopathy or tenopathy because it is a broader term that describes changes in and around the tendon. Recent studies emphasize the complex three-dimensional structure of the tendon[6].
Patellar tendon injuries are generally found on the insertional level at the attachment of the tendon at the inferior pole of the patella. It usually presents with pain in the tendon, tenderness to palpation and anterior knee pain[1]. Patellar tenopathy has a variable rate of prevalence and can reach 40 to 50% in sports like volleyball or those that involve jumping or braking[1,2]. The important degenerative changes in the development of tendinopathy are significant. They may even arrive at producing changes in the muscle ultrastructure after tendon rupture[7,8].
Intratissue Percutaneous Electrolysis (EPI®) is an ultrasound-guided physiotherapeutic and medical technique that produces a non-thermal electrochemical ablation using a cathode flow directly oriented toward the tendon degeneration. The EPI® treatment causes an organic reaction that produces localized inflammation, exclusively in the treatment zone, that leads to rapid regeneration of injured tendon[9,10].
Different techniques are currently used to treat patellar tenopathy[11-13]. The purpose of this paper is to show the effect of Intratissue percutaneous electrolysis (EPI®) guided by ultrasound together with an eccentric programme in the treatment of patellar tendinopathy. The working hypothesis is that EPI® combined with eccentric exercises improves the clinical aspect and functionality in patellar tendinopathy over a short period of time.

Method

It was a prospective study of 33 patients diagnosed with insertional patellar tendinopathy treated by the same therapist. The diagnosis of all patients was

based on clinical examination and a color Doppler ultrasound study with a linear probe (6-15MHz).
The patients' demographic variables and pre-injury and post-treatment functional statuses were studied. The clinical research ethics committee of our institution (08/062/0048) approved the study. To be included in the study, patients had to sign informed consent agreeing to treatment as well as the prospect of having pain in the lower insertional pole of the patella, living with the presence of pain for a minimum of 4 weeks, accepting the inability to continue participating in their sport and confirming an age of under 60 years old. Patients who presented with chronic arthropathy or another associated knee injury (such as a cruciate ligament injury or meniscopathy) were excluded. The use of anti-inflammatory drugs or corticosteroids was restricted throughout the first three months of the study. Patients received the Intratissue percutaneous electrolysis (EPI®) technique treatment until there was clinical improvement or no improvement in the symptomology was seen after 10 sessions.

Follow-up evaluation

Functional assessment was performed using the validated scale of the *Victorian Institute of Sport Assessment for the patellar tendon* (VISA-P)[14] and the Tegner scale. The VISA-P score ranges from 0 to a theoretical 100 when the patient is asymptomatic. The Tegner scale classifies patients according to their level of activity where zero is no activity or walking on a flat smooth floor and 10 is competitive sport at the highest level. The values of the scales were compiled from the written questionnaires given during patients' visits to the clinic; at the initial consultation, at discharge, at 3 months and in the evolutional control at 2 years. Patients were divided into two groups according to their initial symptomatology based on the VISA-P score. Group 1 was made up of patients whose VISA-P value was less than 50 and Group 2 was those whose VISA-P value was greater than 50. This division makes it possible to display the results depending on the degree of injury (more affected VISA-P<50 or less affected VISA-P >50).
At the same times as the functional assessment, patient satisfaction the EPI® treatment was evaluated with the Roles and Maudsley scale[15]. It classifies the degree of satisfaction as excellent (no pain and full activity), good (occasional discomfort with full activity), reasonable (occasional discomfort after prolonged activity) or poor (pain that limits activity).

Treatment Protocol

The EPI® technique described here should be performed with a specifically developed medically (EPI Advanced Medicine. Barcelona. Spain) certified device[9,10] (Directive 93/42/EEC) (Fig. 1A). It produces an adjustable galvanic current through a negative flow cathode electrode. For transmission of the flow to the treatment area, needles of from 0.30 to 0.32 mm in diameter and a modified electric scalpel are used (Fig. 1B). The intensity can be adjusted by changing both the duration and the milliamperes that are administered. Placement of the patient supine to minimize potential vagal reactions following the puncture is recommended. A thorough ultrasound inspection with a 6-15 MHz linear probe and color Doppler, following the European Society of Musculoskeletal Radiology guidelines[16], was performed to permit the identification of any existent neovascularization (Figs. 2 A,B) and changes in terms of structural improvement and decreased neovascularization obtained with the EPI® treatment (Figs. 2 C,D). Preparation of the skin with isopropyl alcohol before puncture is required despite the bacteriostatic action the device has. Subsequently, 3 milliamps echo-guided punc-



Figure 1. **A**. Device designed specifically to administer Intratissue percutaneous electrolysis (arrow). Echo-guided punctures (*) for the administration to specific areas of treatment with a 0.3mm needle located with ultrasound targeting the treatment area. **B**. The image belongs to higher hyperechogenicity of the needle, increasing when the cathode flow passes form EPI® through it (*).



Figure 2. Ultrasound high-resolution Gray-scale longitudinal view with 6-15 MHz lineal probe image of the proximal patellar tendon pre-treatment with EPI® (**A**) and 3 months of treatment (**B**) in the same patient. In the pre-treatment image (**A**) intensive hypoechoic zones (arrow) and thickened tendon is shown. At the lower pole of the patella, cortical irregularities were detected. In post EPI® treatment image (**B**) a significant decrease of the hypoechoic zones and echotexture improvement was detected (arrow).

tures are made with the device to obtain controlled debridement of the injured tendon. The debridement was assessed with the sonographic images.

All patients received a weekly session of EPI® and two weekly sessions of eccentric exercise using isoinertial resistance machines (YoYo^{TM} Technology AB, Stockholm, Sweden) consisting of 3 sets of 10 repetitions. Each repetition was performed with the concentric phase with both extremities whereas the eccentric phase was only performed with the affected limb at a maximum 60º of knee flexion as recommended by Romero-Rodriguez[17].

Statistical Analysis

Initially, the comparison of the basal situation of the study patients was taken up. Quantitative variables were described based on their mean value and standard deviation (SD). The comparison was terminated with a t-test of independent data, without assuming the existence of homoscedasticity. For ordinal variables, the median of each group as well as the minimum and maximum values were provided. For categorical variables, the percentage and the number of cases and inference using Fisher's exact test or Chi-square was calculated. An ANOVA study was used to analyze the different variables and the sphericity correction was carried out with the Greenhouse-Geisser test. Statistical analysis was performed with SPSS v.18 (SPSS Inc., Chicago, Illinois) with statistical significance set at 0.05.

Results

Thirty-three patients were available for the final assessment at two years. Both groups were comparable in terms of in age (p=0.536), gender (p=0.335), dominant limb (p=0.398) or affected side (p=0.093). The mean age was 25.3 years (range 16-53). The patellar tendon affectation was located in the dominant limb in 48.5% (n=16) of the patients. The patients consisted of some 12.1% (n=4) women and 87.9% (n=29) men. Some 57.6% (n=19) of the patients were football players, 3% (n=1) basketball players, 3% (n=1) played volleyball and the remaining 36.4% (n=12) engaged in other sports often involving vertical jumping. A sportsperson from first division or a similar classification by type of sport was considered professional. Second division sportspeople who were always paid for to practice it were considered semi-professional and amateurs were those who practiced sport with no economic incentive. Some 12.1% (n=4) were practicing their sport at the professional level, another 66.7% (n=22) at the semi-professional level and 21.2% (n=7) at the amateur level.

The mean duration of the symptoms of pain in the patellar tendon before coming to our center was 19 months (range 1-72 months). Patients had to have left their sport because of that pain for a mean period of 11.6 months (range 0-48). Treatment with EPI® lasted an average of 4.5 weeks (range 1-10) with a need for an average 4.4 sessions (range 1-10). According to the Roles and Maudsley scale, patient satisfaction at end of treatment at 3 months was excellent in 26 cases (78.8%), good in 6 cases (18.2%) and fair in 1 case (3%). At two years follow up, 87.9% of the patients (n=29) scored their satisfaction as excellent and the remaining 12.1% (n=4) as good. No adverse effects occurred during treatment or follow-up.

Functional Results

The overall pretreatment value of the VISA-P (Fig. 3) was 50.7 ± 21.6 points (range 10-90). This value in-



Figure 3. Column chart of the VISA-P values throughout follow up.



Figure 4. Lineal representation of the mean Tegner values during the follow-up.

creased significantly to 81.4 ± 12.8 points (range 55-100) at 3 months (p<0.001) and maintained a slight improvement with 85.7 ± 11.9 points (range 60-100) at 2 years (p<0.001). Upon studying the value of the VISA-P groups, the fact that group 1 had a pretreatment value of 31.5 ± 10.9 points (range 10-48), improving to 77.5 ± 15.3 points (range 55-99) at 3 months (p<0.001) and to 81.8 ± 14.5 points (range 60-99) at 2 years (p<0.001) was observed. Similar behavior was seen in group 2 where the initial value of the VISA-P was 68.7 ± 10.3 points (range 52-90), improving to 85.1 ± 9 points (range 60-100) at 3 months (p <0.001) and to 89.4 ± 7.6 points (range 70-100) at 2 years (p<0.001). In the comparison between the two groups, it can be seen that at both 3 months (p=0.091) and two years (p=0.065), there are no differences in values on the VISA-P scale. The Greenhouse-Geisser test showed a statistical significance of p <0.001 for the different VISA-P values throughout the time intervals for the two groups. In turn, there were no statistically significant differences when comparing those patients who performed professional sports versus those who performed at the semi-professional or amateur level.

The average pre-injury Tegner value was 7.9 points (range 4-10), showing a value of 7.6 points (range 3-10) after three months of treatment, showing no statistically significant differences (p=0.677) compared to the assessment at two years of 7.8 points (range 4-10). Group 1 (Fig. 4) started from a Tegner of 8 points (range 6-10) before treatment and reached 7.6 points (range 4-10) at 3 months and 7.9 points (range 5-10) at 2 years (p=0.824). Group 2 showed a similar trend, starting from a pretreatment value of 7.8 (range 4-9), standing at 7.6 points (range 3-9) at 3 months and 7.7 points (range 4.9) (p=0.824) at two years. Of those patients who were considered professional athletes (pre-injury Tegner 10 points) at three months, 100% (n=4) returned to the same level of sport activity and stayed at the same level in the control at two years. Of the semi-professional group, with a pre-injury Tegner average of 8.1 (range 7-9), 81.8% (n=18) were able to practice their sport at the same level as before the injury at 3 months and 18.2% (n=4) were practicing at the control of two years. In the amateur group, which started from a pre-injury Tegner of 6 points (range 4-8), 57.1% (n=4) were able to return to their sport at the same level, while 42.9% (n=3) did it at the control at 2 years. Some 78.8% of the patients returned to the same level of physical activity as before the injury by the end of treatment, reaching 100% at two years. The relationship between treatment duration and Tegner values obtained are not significant (p=0.677). The difference between the groups is not significant (p=0.824).

Discussion

The principal finding of this study was the fact that when Intratissue percutaneous electrolysis (EPI®) was combined with eccentric exercise, superior results were found compared to studies using eccentrics only[18-20]. Equally good outcomes were achieved in a short period of time without comorbidities are shown in the presented treatment of insertional patellar tendinopathy.

The main limitation of this study is focused on combining intratissue percutaneous electrolysis (EPI®) with eccentric exercise. However, this combination is frequent in studies of tendinopathy. Thereupon, future studies should compare Eccentrics only versus Eccentrics plus EPI®. The lack of control group (difficult in private practice) and external validation must also be highlighted. Finally, a study with a mean follow-up time (two years) is presented. Thus, an RCT with a longer follow up would be necessary to demonstrate that this benefit lasts over time. Despite these limitations, this study provides the first analysis for up to two years of the treatment of patellar tendinopathy with intratissue percutaneous electrolysis (EPI®) in combination with eccentrics.

Percutaneous electro-stimulation with an electrolytic effect, denominated intratissue percutaneous electrol-

ysis (EPI®), is a minimally invasive technique that involves the application of a galvanic current of high intensity through an acupuncture needle that stimulates a local inflammatory process in soft tissue. It makes phagocytosis and the repair of the affected tissue possible[9,10]. As shown in this work, electrolysis combined with eccentrics has brought about a notable improvement (average 35 point increase in the VISA-P) that allows for the resumption of sports activity to pre-injury levels in few sessions (mean 4.4), a short recovery period (average of 4.5 weeks) and low morbidity.

Multiple therapies for the treatment of patellar tendinopathy have been put forward but not one of them has been set as the standard treatment[18-30]. The role of physiotherapy in the treatment of tenopathies remains unclear and it is not possible to draw any conclusions about its effectiveness based on scientific evidence[19,20]. Eccentric exercises are included within the few measures that have demonstrated efficacy in the treatment of these conditions. The problem is that the results are expressed in the medium and long term, between 3 to 6 months, with a mean cure of 40% to 60%[20]. Diathermy raises the temperature of the deep tissue from 41 to 45°C by means of electromagnetic energy. Recent research in long head biceps tendinopathy showed that hyperthermia is effective in the short-term, but it requires long-term monitoring to confirm its therapeutic efficacy[28]. Extracorporeal shock wave is also used for sports physiotherapy and for the treatment of tenopathies. However, a meta-analysis performed by Maffulli et al.[19] concluded that, on the basis of present knowledge, it is not recommended as a suitable protocol for the specific treatment of tenopathies.

In the case of the patellar tendon tenopathy, most patients opt for surgical treatment when conservative treatment fails. This achieves good or excellent results in 45% of the cases. These results are not higher than those obtained with eccentric exercise[18]. Recently, some novel methods have been proposed for the treatment of tenopathy. They include the likes of injections with platelet rich plasma (PRP)[27], injections with polidocanol[26] and injections of aprotinin[29]. Then again, these techniques require further study to demonstrate their effectiveness and consistency in the medium or long term.

Conclusion

The combination of Intratissue percutaneous electrolysis (EPI®) and eccentric exercise offers excellent results in terms of clinical and functional improvement in patellar tendinopathy with low morbidity in a half study period.

Acknowledgments

We are grateful to G. Gich for assisting in the statistical analysis. We also thank Eric Goode for his help in correcting the manuscript.

References

1. Zwerver J, Bredeweg SW, van den Akker-Scheek I. Prevalence of Jumper's knee among nonelite athletes from different sports: a cross-sectional survey. Am J Sports Med. 2011;39(9):1984-1988.
2. Renstrom PAHF, Woo SL-Y. Tendinopathy: a major medical problem in sport. In: Woo S, Renström P, Arnoczky S eds Tendinopathy in Athletes. Oxford, IK: Wiley-Blackwell 2008:1-9.
3. Soslowsky LJ, Thomopoulos S, Tun S et al. Overuse activity injures the supraspinatus tendon in an animal model: a histologic and biomechanical study. J Shoulder Elbow Surg. 2000;9(2):79-84.
4. van Dijk CN, van Sterkenburg MN, Wiegerinck JI, Karlsson J, Maffulli N. Terminology for Achilles tendon related disorders. Knee Surg Sports Traumatol Arthrosc. 2011;19(5):835-841.
5. Khan KM, Cook JL, Kannus P, Maffulli N, Bonar SF. Time to abandon the "tendinitis" myth. BMJ. 2002;324(7338):626-627.
6. Tresoldi I, Oliva F, Benvenuto M, et al. Tendon's ultrastructure. Muscles Ligaments Tendons J. 2013;3(1):2-6.
7. Zhang Q, Joshi SK, Manzano G, Lovett DH, Kim HT, Liu X. Original article Muscle extracellular matrix degradation and contractibility following tendon rupture and disuse. Muscles Ligaments Tendons J. 2013;3(1):35-41.
8. Zhang Q, Joshi SK, Manzano G, Lovett DH, Kim HT, Liu X. Original article Muscle extracellular matrix degradation and contractibility following tendon rupture and disuse. Muscles Ligaments Tendons J. 2013;3(1):35-41.
9. Sanchez-Ibañez JM. Clinical course in the treatment of chronic patellar tendinopathy through ultrasound guided percutaneous electrolysis intratissue (EPI®): study of a population series of cases in sport [PhD. Thesis]. Universidad de Leon. Leon. Spain 2013.
10. Sánchez- Sánchez JL. Comparative study of conventional physical therapy with one that includes Intratissue Percutaneous Electrolysis ® technique in patients with chronic patellar tendinopathy [PhD. Thesis], Universidad de Salamanca. Salamanca. Spain. 2011.
11. Loppini M, Maffulli N. Conservative management of tendinopathy: an evidence-based approach. Muscles Ligaments Tendons J. 2012;1(4):134-137.
12. Andres BM, Murrell GA. Treatment of tendinopathy: what works, what does not, and what is on the horizon. Clin Orthop Relat Res. 2008;466(7):1539-1554.
13. Larsson ME, Käll I, Nilsson-Helander K. Treatment of patellar tendinopathy-a systematic review of randomized controlled trials. Knee Surg Sports Traumatol Arthrosc. 2012;20(8):1632-1646.
14. Hernandez-Sanchez S, Hidalgo MD, Gomez A. Cross-cultural adaptation of VISA-P score for patellar tendinopathy in Spanish population. J Orthop Sports Phys Ther. 2011;41(8):581-591.
15. Roles NC, Maudsley RH. Radial tunnel syndrome: resistant tennis elbow as a nerve entrapment. J Bone Joint Surg Br. 1972;54(3):499-508.
16. Beggs I, Bianchi S, Bueno A, et al. ESSR Ultrasound Group Protocols. Musculoskeletal Ultrasound Technical Guidelines: Knee.
17. Romero-Rodriguez D, Gual G, Tesch PA. Efficacy of an inertial resistance training paradigm in the treatment of patellar tendinopathy in athletes: a case-series study. Phys Ther Sport. 2011;12(1):43-48.
18. Bahr R, Fossan B, Løken S, Engebretsen L. Surgical treatment compared with eccentric training for patellar tendinopathy (Jumper's Knee). A randomized, controlled trial. J Bone Joint Surg Am. 2006;88(8):1689-1698.
19. Rompe JD, Nafe B, Furia JP, Maffulli N. Eccentric loading, shock-wave treatment, or a wait-and-see policy for tendinopa-

thy of the main body of tendon Achillis: a randomized controlled trial. Am J Sports Med. 2007;35(3):374-383.
20. Malliaras P, Barton CJ, Reeves ND, Langberg H. Achilles and patellar tendinopathy loading programmes: a systematic review comparing clinical outcomes and identifying potential mechanisms for effectiveness. Sports Med. 2013;43(4):267-286.
21. Frizziero A, Fini M, Salamanna F, Veicsteinas A, Maffulli N, Marini M. Effect of training and sudden detraining on the patellar tendon and its enthesis in rats. BMC Musculoskelet Disord. 2011;12:20.
22. Alaseirlis DA, Konstantinidis GA, Malliaropoulos N, Nakou LS, Korompilias A, Maffulli N. Arthroscopic treatment of chronic patellar tendinopathy in high-level athletes. Muscles Ligaments Tendons J. 2013;2(4):267-272.
23. Pascarella A, Alam M, Pascarella F, Latte C, Di Salvatore MG, Maffulli N. Arthroscopic management of chronic patellar tendinopathy. Am J Sports Med. 2011;39(9):1975-1983.
24. Furia JP, Rompe JD, Cacchio A, Del Buono A, Maffulli N. A single application of low-energy radial extracorporeal shock wave therapy is effective for the management of chronic patellar tendinopathy. Knee Surg Sports Traumatol Arthrosc. 2013;21 (2):346-350.
25. Crisp T, Khan F, Padhiar N, et al. High volume ultrasound guided injections at the interface between the patellar tendon and Hoffa's body are effective in chronic patellar tendinopathy: A pilot study. Disabil Rehabil. 2008;30(20-22):1625-1634.
26. Willberg L, Sunding K, Forssblad M, Fahlström M, Alfredson H. Sclerosing polidocanol injections or arthroscopic shaving to treat patellar tendinopathy/jumper's knee? A randomised controlled study. Br J Sports Med. 2011;45(5):411-415.
27. Yuan T, Zhang CQ, Wang JH. Augmenting tendon and ligament repair with platelet-rich plasma (PRP). Muscles Ligaments Tendons J. 2013;3(3):139-149.
28. Oliva F, Via AG, Rossi S. Short-term effectiveness of bi-phase oscillatory waves versus hyperthermia for isolated long head biceps tendinopathy. Muscles Ligaments Tendons J. 2012;1(3):112-117.
29. Orchard J, Massey A, Brown R, Cardon-Dunbar A, Hofmann J. Successful management of tendinopathy with injections of the MMP-inhibitor aprotinin. Clin Orthop Relat Res. 2008;466(7):1625-1632.
30. Warden SJ, Metcalf BR, Kiss ZS, et al. Low-intensity pulsed ultrasound for chronic patellar tendinopathy: a randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford). 2008;47(4):467-471.

OA Sports Medicine
Open Access

Review

Treatment Techniques

Patellar tendinopathy: a critical review of current therapeutic options

F Abat[1]*, JM Sanchez-Ibañez[2]

Abstract

Introduction

The treatment of patellar tendinopathy remains a subject of ongoing debate in the field of sports medicine. It was initially thought that the tendon injury produced was characterised as an inflammatory process, but this thinking has evolved to reasoning it as a cellular degenerative process so as to explain the poor evolution that tendon injuries generally show. Traditionally, conservative treatment by means of eccentric exercise was advocated, going on to surgery when good results were not obtained. The use of minimally invasive techniques has grown in popularity over recent years. Currently, there is a significant therapeutic arsenal at our disposal in clinical practice that ranges from the use of shock waves, growth factors, sclerosis of neovessels using polidocanol or techniques such as intratissue percutaneous electrolysis (EPI®). Despite the abundance of literature on the treatment of tendinopathy, there are few studies of high scientific evidence. Thus, the choice of a therapeutic method as a gold standard remains a point of debate. This present critical review, focused on the treatment of patellar tendinopathy, aims to shine a light on the different studies of each of these treatment options by analysing each ones level of scientific evidence.

Conclusion

Larger randomised controlled trials on the various treatment options and even comparative studies between them are needed to determine what the treatment of choice for patellar tendinopathy should be.

* Corresponding author
Email: drabat@cerede.es

[1]Sports Orthopedics Department, Cerede Sports Medicine Clinic, Barcelona, Spain
[2]Rehabilitation Department, Cerede Sports Medicine Clinic, Barcelona, Spain

Introduction

Patellar tendinopathy, with a prevalence rate that may reach 40% in high demand functional athletes[1,2], is a disease that is especially problematic for the patient as it is usually a chronic injury which can mean the end of a career in sports in severe cases[3].

Historically, patellar tendinopathy was considered an inflammatory process, but it is now known that this affectation is characterised as a degenerative process that may be associated with inflammation of the paratenon in some cases[4]. During the course of the tendon lesion, healing mechanisms are altered as a result of a faulty repair process that produces a degeneration of collagen fibres of the tendon as well as vascular changes[5,6]. There are multi-factor causes for the onset of patellar tendinitis[3], presenting repetitive microtraumatisms that bring about cyclical tendon overload as the common denominator. Secondarily, as a result of inadequate healing and insufficient recovery time, the tendon will initiate a degenerative process of the collagen fibres[3–6].

Many therapeutic techniques have been described in the literature. However, none has emerged as the gold standard[7] and that is probably due to lack of sufficient scientific evidence. Eccentric exercise has gained recognition within the scientific literature as first-line therapy[8], but when it fails or is ineffective there is no consensus as to which therapy to use.

Among the therapies most used currently, there are open or arthroscopic surgery[9,10], extracorporeal shockwave therapy (ESWT)[11], the intratissue percutaneous electrolysis technique (EPI®)[12] and the use of polidocanol injections[13] or platelet-rich plasma (PRP)[14].

This critical review, focused on patellar tendinopathy, studies these therapeutic methods by analysing the extent of scientific evidence.

Discussion

The authors have referenced some of their own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies.

The great difficulty that the treatment of patellar tendinopathy presents, given their high rate of chronicity and sport disability, has made this disease a great battlefield in traumatology and sports medicine today. At present, the literature does not present a clear treatment as the gold standard. The ones with the most widespread use are eccentric exercises and, if those should fail, the surgical option.

Establishing which should be the method of choice when treating patellar tendinopathy after failed conservative treatment is currently very

FOR CITATION PURPOSES: *Abat F, Sanchez-Ibañez JM.* Patellar tendinopathy: a critical review of current therapeutic options. OA Sports Medicine 2014 Jan 18;2(1):2.

Competing interests: none declared. Conflict of interests: none declared.
All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript.
All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.

OA Sports Medicine
Open Access

Review

difficult given the fact that there are very few randomised controlled trials (RCTs) or high quality studies, there mostly being prospective or retrospective studies of case series or low level of evidence comparative studies. Therefore, the present review aims to show the most relevant studies within each therapeutic option.

Historically, eccentric exercises have been considered a good treatment for tendinopathy although some authors argue that their strength is founded more in prevention than in the treatment of fully established lesions[2]. While some authors have argued for this therapeutic means[15,16], others indicate that there are no significant differences upon comparing them with control groups[17,18].

Although eccentric exercise is a good therapeutic tool, the type of exercises to use, the frequency, the load and the dosage of the same require further research so as to establish a clear protocol to follow.

Surgery has been positioned as the option of choice when other less invasive treatments have no effect[10]. A recent meta-analysis[19] reported that open surgery obtains results comparable to those obtained with arthroscopic surgery, being therefore up to the surgeon as to what must be the most suitable approach to treating this condition while producing the least comorbidity.

Analysing the works on the treatment of patellar tendinopathy with surgery is very difficult given the great heterogeneity of the samples studied, the various types of functional analysis and the fact that the postoperative rehabilitation protocol is detailed in few studies. This might clearly influence the clinical and functional outcomes[19].

Authors such as Pascarella et al.[9] or Willberg et al.[19] who advocate the use of arthroscopy or others such as Cucurulo et al.[10] or Shelbourne et al.[20] who advocate open surgery can be found in the current literature. Despite these results, authors such as Bahr et al.[15], in their RCT, showed that there was no advantage to patellar tenotomy versus eccentric exercise, opening a big question about the potential benefit of putting the patient through a surgical procedure.

These findings along with the low prediction of the results obtained with the surgical option for patellar tendinopathy[10] emphasise the importance of reserving surgery for those carefully selected patients who have undergone very controlled conservative treatment. It must be remembered that in any of these cases, it would result in a significant delay in the return to sporting activities.

Some authors have presented the ESWT as a valid option in cases in which conventional therapies have proven ineffective in the treatment of tendinopathy[11]. It supposedly provides benefits in reducing pain by suppressing the substance P neurotransmitters and the calcitonin gene-related peptide as well as by destroying unmyelinated nerve fibres[11].

An important multi-centre RCT showed that shock waves obtained the same results as the application of a placebo in a population of active broad-jump athletes with patellar tendinopathy[21]. In parallel, other studies such as the Wang et al.[22] study showed positive results with the use of ESWT. Notably, the participants continued their high level of physical activity throughout the study process in the study of Zwerver et al.[21]. This may have interfered in the results, while the Wang et al.[22] group did not allow patients to perform heavy activities.

A major weakness of the technique is the lack of consensus as to what the protocol for the application of ESWT should be in terms of dose, time or mode of application[23].

Intratissue percutaneous electrolysis (EPI®) is a technique that is performed under ultrasound guidance by which a non-thermal electrolytic ablation induces a controlled inflammatory response of injured tissue. Experimental studies have shown that the EPI® technique permits the activation of the cellular mechanisms involved in phagocytosis and the regeneration of damaged soft tissue[24].

This technique, created by Sanchez-Ibañez et al.[12,24] and who have over 10 years experience in its use[12], uses a flow of cathodic current directed exclusively to the area of degenerated tendon through an ultrasound guided needle that brings about an organic reaction that leads to rapid regeneration of the degenerated tendon. The EPI® technique combined with eccentric exercises has shown excellent results in the treatment of refractory tendinopathies over conventional treatment[12,25].

Despite being one of the few studies that follows the rules of the functional assessment of patellar tendinopathy by means of the validated Victorian Institute of Sport Assessment-Patella questionnaire and providing a follow-up of 10 years, the study has some important limitations for being a prospective study of a case series[12,25].

The combination of different techniques with eccentric exercise is a common practice in studies of tendinopathy as eccentric exercises provide physical support for the proper maturation of collagen fibres. Recent work by authors such as de Vos et al.[26] and Filardo et al.[27] reported so, therefore, the fact of using eccentric exercises in combination with other techniques when exercise alone has failed does not limit the results obtained in these studies.

If the aetiological hypothesis of tendinopathies that defends hypervacularisation as the cause of the pain is accepted as valid, the use of sclerosis of neovessels using polidocanol may be justified[13]. Some authors such as Hoksrud et al. advocate this technique[13], whereas authors such as Willberg et al.[28], in a randomised controlled study, demonstrated that patients treated with polidocanol in-

FOR CITATION PURPOSES: *Abat F, Sanchez-Ibañez JM.* Patellar tendinopathy: a critical review of current therapeutic options. OA Sports Medicine 2014 Jan 18;2(1):2.

Competing interests: none declared. Conflict of interests: none declared.
All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript.
All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.

OA Sports Medicine
Open Access

jections showed no better functional outcomes than those treated with arthroscopic surgery.

The use of PRP is based on the hypothesis that it has the potential to cause changes in the production and degradation of collagen fibres by acting at the level of matrix regulating enzymes[14]. In spite of the many laboratory studies that suggest the great potential of this technique[29], the fact that healthy or surgically injured tendons are used represents a difficulty in extrapolating clinical data.

There are studies that show significant improvements in both pain and function when using PRP. Nevertheless, most of them are without significant differences when compared with controls groups[30].

Regardless of the great potential of this technique, the main limitation is currently in the lack of conclusive studies on the quantity of growth factors that are obtained with different systems of cell separation, what the optimal mixture is, which conditions the patient must meet prior to blood collection or what the volume and frequency of injections should be[14]. Similarly, it remains unclear as to whether the activation of platelets prior to infiltration is required[14,30].

Conclusion

Larger RCTs on the various treatment options and even comparative studies between them are needed to determine what the treatment of choice for patellar tendinopathy should be.

Abbreviations list

ESWT, extracorporeal shockwave therapy; PRP, platelet-rich plasma; RCT, randomised controlled trial.

References

1. Lian OB, Engebretsen L, Bahr R. Prevalence of jumper's knee among elite athletes from different sports: a cross-sectional study. Am J Sports Med. 2005 Apr;33(4):561–7.
2. Fredberg U, Bolvig L, Andersen NT. Prophylactic training in asymptomatic soccer players with ultrasonographic abnormalities in Achilles and patellar tendons: the Danish Super League Study. Am J Sports Med. 2008 Mar;36(3):451–60.
3. Peers KH, Lysens RJ. Patellar tendinopathy in athletes: current diagnostic and therapeutic recommendations. Sports Med. 2005;35(1):71–87.
4. Maffulli N, Khan KM, Puddu G. Overuse tendon conditions: time to change a confusing terminology. Arthroscopy. 1998 Nov–Dec;14(8):840–3.
5. Rees JD, Maffulli N, Cook J. Management of tendinopathy. Am J Sports Med. 2009 Sep;37(9):1855–67.
6. Danielson P, Andersson G, Alfredson H, Forsgren S. Marked sympathetic component in the perivascular innervation of the dorsal paratendinous tissue of the patellar tendon in arthroscopically treated tendinosis patients. Knee Surg Sports Traumatol Arthrosc. 2008 Jun;16(6):621–6.
7. Andres BM, Murrell GA. Treatment of tendinopathy: what works, what does not, and what is on the horizon. Clin Orthop Relat Res. 2008 Jul;466(7):1539–54.
8. Larsson ME, Käll I, Nilsson-Helander K. Treatment of patellar tendinopathy a systematic review of randomized controlled trials. Knee Surg Sports Traumatol Arthrosc. 2012 Aug;20(8):1632–46.
9. Pascarella A, Alam M, Pascarella F, Latte C, Di Salvatore MG, Maffulli N. Arthroscopic management of chronic patellar tendinopathy. Am J Sports Med. 2011 Sep;39(9):1975–83.
10. Cucurulo T, Louis ML, Thaunat M, Franceschi JP. Surgical treatment of patellar tendinopathy in athletes. A retrospective multicentric study. Orthop Traumatol Surg Res. 2009 Dec;95(8 Suppl 1):S78–84.
11. Wang CJ, Ko JY, Chan YS, Weng LH, Hsu SL. Extracorporeal shockwave for chronic patellar tendinopathy. Am J Sports Med. 2007 Jun;35(6):972–8.
12. Abat F, Gelber PE, Polidori F, Monllau JC, Sanchez-Ibañez JM. Clinical results after ultrasound-guided intratissue percutaneous electrolysis (EPI(®)) and eccentric exercise in the treatment of patellar tendinopathy. Knee Surg Sports Traumatol Arthrosc. 2014 Jan.
13. Hoksrud A, Ohberg L, Alfredson H, Bahr R. Ultrasound-guided sclerosis of neovessels in painful chronic patellar tendinopathy: a randomized controlled trial. Am J Sports Med. 2006 Nov;34(11):1738–46.
14. Mishra A, Woodall J Jr, Vieira A. Treatment of tendon and muscle using platelet-rich plasma. Clin Sports Med. 2009 Jan;28(1):113–25.
15. Bahr R, Fossan B, Løken S, Engebretsen L. Surgical treatment compared with eccentric training for patellar tendinopathy (Jumper's Knee). A randomized, controlled trial. J Bone Joint Surg Am. 2006 Aug;88(8):1689–98.
16. Visnes H, Hoksrud A, Cook J, Bahr R. No effect of eccentric training on jumper's knee in volleyball players during the competitive season: a randomized clinical trial. Clin J Sport Med. 2005 Jul;15(4):227–34.
17. Frohm A, Saartok T, Halvorsen K, Renström P. Eccentric treatment for patellar tendinopathy: a prospective randomised short-term pilot study of two rehabilitation protocols. Br J Sports Med. 2007 Jul;41(7):e7.
18. Marcheggiani Muccioli GM, Zaffagnini S, Tsapralis K, Alessandrini E, Bonanzinga T, Grassi A, Bragonzoni L, Della Villa S, Marcacci M. Open versus arthroscopic surgical treatment of chronic proximal patellar tendinopathy. A systematic review. Knee Surg Sports Traumatol Arthrosc. 2013 Feb;21(2):351–7.
19. Willberg L, Sunding K, Ohberg L, Forssblad M, Alfredson H. Treatment of Jumper's knee: promising short-term results in a pilot study using a new arthroscopic approach based on imaging findings. Knee Surg Sports Traumatol Arthrosc. 2007 May;15(5):676–81.
20. Shelbourne KD, Henne TD, Gray T. Recalcitrant patellar tendinosis in elite athletes: surgical treatment in conjunction with aggressive postoperative rehabilitation. Am J Sports Med. 2006 Jul;34(7):1141–6.
21. Zwerver J, Hartgens F, Verhagen E, van der Worp H, van den Akker-Scheek I, Diercks RL. No effect of extracorporeal shockwave therapy on patellar tendinopathy in jumping athletes during the competitive season: a randomized clinical trial. Am J Sports Med. 2011 Jun;39(6):1191–9.
22. Wang CJ, Ko JY, Chan YS, Weng LH, Hsu SL. Extracorporeal shockwave for chronic patellar tendinopathy. Am J Sports Med. 2007 Jun;35(6):972–8.
23. vanLeeuwen MT, Zwerver J, van den Akker-Scheek I. Extracorporeal

FOR CITATION PURPOSES: *Abat F, Sanchez-Ibañez JM.* Patellar tendinopathy: a critical review of current therapeutic options. OA Sports Medicine 2014 Jan 18;2(1):2.

Competing interests: none declared. Conflict of interests: none declared.
All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript.
All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.

OA Sports Medicine
Open Access

shockwave therapy for patellar tendinopathy: a review of the literature. Br J Sports Med. 2009 Mar;43(3):163–8.
24. Abat F, Valles S, Gelber PE, Polidori F, Stitik TP, García-Herreros S, Monllau JC, Sanchez-Ibañez JM. Mecanismosmoleculares de reparaciónmediante la técnicaElectrólisisPercutáneaIntratisular en la tendinosisrotuliana. Rev Esp Cir OrtopTraumatol. 2014 (in Spanish), http://dx.doi.org/10.1016/j.recot.2014.01.002.
25. Abat F, Diesel WJ, Gelber PE, Polidori F, Monllau JC, Sanchez-Ibañez JM. Effectiveness of the Intratissue Percutaneous Electrolysis (EPI®) technique and isoinertial eccentric exercise in the treatment of patellar tendinopathy at two years follow-up. Muscles Ligaments Tendons J. 2014.
26. de Vos RJ, Weir A, van Schie HT, Bierma-Zeinstra SM, Verhaar JA, Weinans H, Tol JL. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA. 2010 Jan 13;303(2):144–9.
27. Filardo G, Kon E, Della Villa S, Vincentelli F, Fornasari PM, Marcacci M. Use of platelet-rich plasma for the treatment of refractory jumper's knee. Int Orthop. 2010 Aug;34(6):909–15.
28. Willberg L, Sunding K, Forssblad M, Fahlström M, Alfredson H. Sclerosing polidocanol injections or arthroscopic shaving to treat patellar tendinopathy/jumper's knee? A randomised controlled study. Br J Sports Med. 2011 Apr;45(5):411–5.
29. deMos M, van der Windt AE, Jahr H, van Schie HT, Weinans H, Verhaar JA, van Osch GJ. Can platelet-rich plasma enhance tendon repair? A cell culture study. Am J Sports Med. 2008 Jun;36(6):1171–8.
30. de Vos RJ, van Veldhoven PL, Moen MH, Weir A, Tol JL, Maffulli N. Autologous growth factor injections in chronic tendinopathy: a systematic review. Br Med Bull. 2010;95:63–77.

FOR CITATION PURPOSES: *Abat F, Sanchez-Ibañez JM.* Patellar tendinopathy: a critical review of current therapeutic options. OA Sports Medicine 2014 Jan 18;2(1):2.

Competing interests: none declared. Conflict of interests: none declared.
All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript.
All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.

International Journal of
Clinical & Medical Imaging

ISSN : IJCMI
Volume 1 • Issue 3 • 1000160
January, 2014
http://dx.doi.org/10.4172/ijcmi.1000160

Clinical Image

Title: Intratissue Percutaneous Electrolysis (Epi®) in the Treatment of Patellar Tendinopathy

Ferran Abat and Jose Manuel Sanchez-Ibanez
Cerede Sports Medicine Clinic, Barcelona, Spain



Intratissue percutaneous electrolysis (EPI®) treatment is an actual ultrasound-guided technique that leads to a non-thermal electro chemical ablation through a cathodic fl w directly at the clinical focus of degeneration. EPI® causes an organic reaction leading to a highly localized inflammation, exclusively at the region of treatment that conduces to a rapid regeneration of the injured tendon.

Figure Legends

a) High-resolution colour Doppler ultrasound images of patellar tendinopathy using linear multi-frequency probe (ML 6-15MHz.). Longitudinal view of the involved tendon showing a high degree of neovascularization, thickness and hipoecogenic zones.

b) Shows the GAP of 7 mm in the proximal part of the tendon.

c) Intratissue Percutaneous Electrolysis (EPI®) technique.

d) Precise 0.3 mm ultrasound guided EPI® punctures on the injured region of the patellar tendon.

e,f) High-resolution gray-scale ultrasound of the same patient two months after initiation of the EPI® procedures. Note the remarkable decrease in the vascularization and hypoechogenicity clearly seen in the longitudinal view.

***Corresponding author:** *Ferran Abat, Cerede Sports Medicine Clinic, Cerede Sports Medicine Clinic, Barcelona, Spain, Tel: 18-10b. 08017; E-Mail: fabat@epiadvanced.com*

Abat et al. BMC Sports Science, Medicine, and Rehabilitation (2015) 7:7
DOI 10.1186/s13102-015-0002-0

BMC Sports Science, Medicine & Rehabilitation

RESEARCH ARTICLE Open Access

An experimental study of muscular injury repair in a mouse model of notexin-induced lesion with EPI® technique

Ferran Abat[1], Soraya-L Valles[2], Pablo-Eduardo Gelber[3,4], Fernando Polidori[5], Adrian Jorda[2], Sergio García-Herreros[2], Joan-Carles Monllau[3,6,7] and Jose-Manuel Sanchez-Ibáñez[5*]

Abstract

Background: The mechanisms of muscle injury repair after EPI® technique, a treatment based on electrical stimulation, have not been described. This study determines whether EPI® therapy could improve muscle damage.

Methods: Twenty-four rats were divided into a control group, Notexin group (7 and 14 days) and a Notexin + EPI group. To induce muscle injury, Notexin was injected in the quadriceps of the left extremity of rats. Pro-inflammatory interleukin 1-beta (IL-1beta) and tumoral necrosis factor-alpha (TNF-alpha) were determined by ELISA. The expression of receptor peroxisome gamma proliferator activator (PPAR-gamma), vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor-1 (VEGF-R1) were determined by western-blot.

Results: The plasma levels of TNF-alpha and IL-1beta in Notexin-injured rats showed a significant increase compared with the control group. EPI® produced a return of TNF-alpha and IL-1beta values to control levels. PPAR-gamma expression diminished injured quadriceps muscle in rats. EPI® increased PPAR-gamma, VEGF and VEGF-R1 expressions. EPI® decreased plasma levels of pro-inflammatory TNF-alpha and IL-1beta and increased anti-inflammatory PPAR-gamma and proangiogenic factors as well as VEGF and VEGF-R1 expressions.

Conclusion: The EPI® technique may affect inflammatory mediators in damaged muscle tissue and influences the new vascularization of the injured area. These results suggest that EPI® might represent a useful new therapy for the treatment of muscle injuries. Although our study in rats may represent a valid approach to evaluate EPI® treatment, studies designed to determine how the EPI® treatment may affect recovery of injury in humans are needed.

Keywords: EPI, Technique, Notexin-induced, Muscle, Injury

Background

Soft tissue injuries are recurrent in sports and have an incidence rate of some 30% [1]. An overly conservative therapeutic approach conflicts with patients' economics interests and the ability to practice their chosen sport. Some authors have proposed qualitative and histopathological classifications of muscle injuries directly related to the appearance of the lesion and its evolution [2].

The inflammatory process is one of the most important parts of the immune system's response to injury. It is due to the fact that the biochemical mechanism and the signal cascade are consistent and durable, independent of the underlying cause of the wound [3]. Non-muscle cells such as leukocytes, phagocytes, macrophages, cytokines or growth factors play an important role in the inflammatory process in terms of recovery and regeneration following injury to the muscle as well as in the secondary damage that occurs during the inflammatory process. Certain substances, such as interleukin 1-β (IL-1β), released from the muscle injury act as intercellular messengers, start the process of inflammation and repair [4]. Moreover, tumor necrosis factor-alpha (TNF-α) is an important mediator of the inflammatory response after injury [5] whereas activation of PPAR, an anti-inflammatory protein, suppresses pro-inflammatory processes [6,7]. As a result of muscle injury, localized

* Correspondence: drsanchez@cerede.es
[5]Department of Sports Rehabilitation, Cerede Sports Medicine, Barcelona, Spain
Full list of author information is available at the end of the article

vasodilatation induced by two mechanisms comes about through the release of histamines from the cells present within the damaged area and by activating the route of the vascular endothelial growth factor and nitric oxide (VEGF-NO) [8]. VEGF is the most important capillary growth factor in skeletal muscle [7] and is essential to basal capillarization in the tissue and increased capillary growth in response to different mechanical stimuli [9].

Electrical stimulations are likely to serve as an integrator to organize cells into structured tissues in wound healing, development and tissues regeneration. Because cells possess signaling systems that make for electric stimulation, the exogenous application of therapeutic currents for wound healing is considered to have effects as well. The difficulties lie in the technical details such as types of electrodes, stimulation parameters, stimulation position, and the variability of intrinsic resistance [10].

The EPI® technique is an ultrasound guided physiotherapeutic and medical technique that consists in causing, by means of a galvanic current transmitted through an acupuncture needle, localized lysis in the damaged and/or degenerated tissue [11-13]. The application of a galvanic current brings about a chemical reaction, which causes the dissociation of molecules of sodium chloride and water. This process results in the formation of molecules of sodium hydroxide, which cause the destruction of the damaged tissue and activate the inflammatory repair response. The application of EPI® can stimulate the inflammatory response and promote wound healing in degenerated patellar tendon in rats [11] and has proven effective in the treatment of chronic patellar tendinopathy [12,13].

Currently there is no published basic research relative to the effect on muscle tissue injury upon applying this treatment. Accordingly, the objective of this study was to determine whether the application of EPI® therapy could have a beneficial effect on damaged muscle. An experimental design was carried out with the EPI® treatment after 7 days of Notexin-induced injury. Notexin has been described as inducing necrosis of skeletal muscle fibers in experimental inflammation models. Notexin, a presynaptic phospholipase A_2 neurotoxin isolated from snake venom, produced inflammatory events associated with enzymatic activity and the release of arachidonic acid metabolites or mechanism related to phospholipid hydrolysis [14].

The experimental hypothesis is that the application of intratissue percutaneous electrolysis therapy after Notexina induced muscle damage causes muscular effects that may be conducive to the recovery of injured muscle tissue.

Methods

Twenty-four Sprague-Dawley rats weighing 250-300g were divided into four groups. To induce muscle injury, 200 μl of Notexin was injected intramuscularly at a concentration of 10 μg/ml in the quadriceps of the left extremity, causing total degeneration of the muscle. As control, a group of rats (n = 6) were injected with 200 μl of saline solution. At seven days, rats were sacrificed and samples were obtained to determine the effects of Notexin-induced muscle injury. To study the effects of EPI® treatment on tissue injury, a specific approved EPI® device (EPI Advanced Medicine, Barcelona, Spain) was used. The following protocol was performed: on day seven of Notexin-induced muscle injury, one group of rats (n = 6) were treated with EPI®. This treatment consists in the application of a continuous current of 4 pulses at an intensity of 3 mA for 5 seconds conveyed to the muscle. As an electrode, an acupuncture needle with a diameter of 0.32 mm was used. To study how the injury evolves without receiving EPI® treatment, another group of rats (n = 6) was maintained dover 14 days after Notexin-induced injury. Previous to each treatment, rats were anesthetized intraperitoneally with sodium pentobarbital (90 mg/kg). The evolution of the muscle tissue injury was assessed by means of ultrasound images. The same evaluations were carried out after seven days of EPI® treatment. After the protocol, rats were sacrificed and muscle tissue was removed from the treatment area and samples were analyzed by using Western blot. Additionally blood samples were collected to detect TNF-α and IL-1β cytokines plasma levels with ELISA. The Ethical Committee of the University of Medicine of Valencia, Spain (A1301314899794) approved the study. All animal procedures were carried out in accordance with the European legislation on the use and care of laboratory animals (CEE 86/609).

Ultrasonography was performed before and after EPI® treatment to follow up on the muscle tissue injury induced by Notexin (Figure 1). This examination was performed according to the protocol previously described [15].

Plasma levels of cytokines IL-1β and tumor necrosis factor-α (TNF-α) were determined with ELISA kits (Thermo Scientific Laboratories, Rockford, USA) following manufactorer's recommendations.

Muscle tissues were homogenized in a lysis buffer of (in mM) 50 Tris-HCl, 125 NaCl, 1 EDTA, 1 EGTA and 1% Nonidet (NP-40 containing 5% Complete Mini-tab cocktail proteinase inhibitor (Roche Biochemicals). It was then centrifuged at 10000 rpm for 15 min at 4°C. The protein concentration was determined using a modified Lowry method. Protein was resolved in 12% SDS-PAGE and electrophoretically transferred onto a PVDF-membrane using a Mini Trans-Blot cell (BioRad laboratories, California). Membranes were put in blocks in 5% skim milk for 1 hour at room temperature and then incubated with the corresponding antibodies following the



Figure 1 Comparison control tissue **(A)**, muscle tissue 21 days after injury induction with Notexina **(B)** and the effect of the application of EPI® from7 days of the induced lesion **(C)** in ultrasound imaging (US). It is possible to observe the area of disruption in the middle portion of the quadriceps muscle of rats from 21 days of the induced lesion (surrounded area), compared to normal tissue from the same area **(B)**. Image **(C)** shows an area of less disruption in the same muscle portion treated with EPI® from 21 days after induction of injury (surrounded area).

manufacturer's recommendations. After washing, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody (Sigma Aldrich). The blots were then visualized using a InmunostarTM HRP Substrate Kit (BioRad), again, in accordance with manufacturer's instructions. The relative densities of the bands were analyzed using Image Gauge v4.0, Fujifilm. The proteins were normalized with tubulin. Monoclonal anti-vascular endothelial growth factor (VEGF) (1:500), anti-vascular endothelial growth factor receptor 1 (VEGF-R1) (1:500), anti-PPAR-γ (1:500) and anti-tubulin (1:1000) were used.

For statistical analysis, data are expressed as mean ± standard deviation (SD). An analysis of variance (ANOVA factor) was performed to analyze the relationships within and between variables. Post-Hoc and Dunnet tests were also done to compare the different groups with the control group and the Scheffe test was used to compare all groups. A probability value of less than 0.05 was considered significant.

Results

Notexin produced tissue injury characterized as an anechoic ultrasound image with fluid collection corresponding to a muscle lesion (Figure 2A). Treatment with EPI® produced resorption of the fluid and repair without scar tissue thickening (Figure 2B).

The levels of TNF-α and IL-1β pro-inflammatory factors in Notexin injured rats showed a significant increase ($p < 0.05$) in plasma concentration relative to the control. In addition, a significant decrease in the concentration of TNF-α and IL-1β was observed when the Notexin + EPI group and the Notexin group ($p < 0.05$) were compared. So, the application of the EPI® treatment after Notexin provoked the decrease of both TNF-α and IL-1β to control levels (Figure 3A and B). After 14 days of Notexin treatment without EPI® application, the values of cytokines continued increased (Figure 3A and B). These results rule out spontaneous recovery of the muscle damage.

Similarly, Notexin-induced injury decreases PPAR-γ expression values ($p < 0.05$) in rat quadriceps muscle. The application of EPI® increased PPAR-γ expression and were returned to the values of the control, showing that EPI® treatment produces an improvement in anti-inflammatory PPAR-γ protein (Figure 4). Furthermore, at 14 days of Notexin treatment without EPI® application, PPAR-γ protein expression remains decreased, thus indicating that an increase in PPAR-γ protein expression is not spontaneous but due to the EPI® treatment.



Figure 2 Longitudinal ultrasound images of left rat quadriceps. After 7 days treated with Notexin **(A)**, an anechoic image with fluid collection (arrow) indicating muscle lesion was observed. After EPI® treatment **(B)** a complete resorption of the haematoma with muscle repair (arrow) can be seen.



Figure 3 Plasma levels of IL-1β **(A)** and TNF-α **(B)** in control (C), Notexin (N7d, N14 d) and Notexin + EPI (N + E) groups. Values were measured by ELISA assay as indicated in methods. Data are mean ± SD of six independent experiments. *$p < 0.05$ *vs* control group; # $p < 0.05$ vs both Notexin groups.

Notexin (7 and 14 days) treatment produced an increase in both VEGF and VEGF-R1 protein expression compared with the control ($p < 0.05$). Furthermore, EPI® treatment significantly potentiated the increase in VEGF and VEGF-R1 protein expression induced by Notexin (Figure 5).

No adverse events were presented during the study.

Discussion

The main findings of this study is that EPI® applied after Notexin-induced muscle injury in rats decreases the production of the inflammatory mediators TNF-α and IL-1β, increases the protein expression of anti-inflammatory factor PPAR-γ and the angiogenic involved proteins VEGF and VEGF-R1.

An increase in the TNF-α plasma levels was described in the first days of tissular injury [16,17] and remained elevated due to its action on cellular necrosis [18]. TNF-α disrupts the differentiation process and can promote cell catabolism thereby accelerating protein degradation [5]. Furthermore, TNF-α inhibits myogenesis through redox-dependent and independent pathways [19]. One potential mechanism by which TNF-α might directly stimulate catabolism is by inhibiting myoblast differentiation, an action that might limit the regenerative response of satellite cells to muscle injury [5]. A second mechanism, apoptosis, appears less important. The third mechanism consists in a direct catabolic effect on muscle tissue. In a muscular cell culture, TNF-α directly decreases total muscle protein and the loss of muscle-specific proteins, including adult fast-type myosin heavy chain [5,19].

Our data shows an increase in the plasma level of TNF-α due to Notexin-induced injury. EPI® treatment normalized the levels of TNF-α to reach control group values. By contrast, in the group of rats without EPI® treatment, the TNF-α levels remained elevated with respect to the control group at 14 days after application.

TNF-α action is also sensitive to other ligand/receptor interactions (e.g. interleukin-1 and interleukin-6). Notexin caused a significant increase of IL-1β compared to the control group. The maintenance of IL-1β over time has been associated with its condition as a pro-inflammatory cytokine more than for its action on tissue necrosis [16].



Figure 4 PPAR-γ protein expression (relative densitometric units) in control (C), Notexin (N7d, N14 d) and Notexin + EPI (N + E) groups. Values were determined in left rat quadriceps muscles by Western blot. A representative inmunoblot is shown and tubulin was used as control amount of protein. Data are mean ± SD of six independent experiments. *$p < 0.05$ *vs* control group; # $p < 0.05$ vs both Notexin groups.



Figure 5 Analysis of VEGF and VEGF-R1 proteins. VEGF **(A)** and VEGF-R1 **(B)** protein expression in control (C), Notexin (N7d, N14 d) and Notexin + EPI (N + E) groups were determined by Western blot. Values were determined in left rat quadriceps muscles. In each panel, a representative inmunoblot is shown and tubulin was used as control amount of protein. Data are mean ± SD of six independent experiments. *$p < 0.05$ *vs* control group; # $p < 0.05$ vs both Notexin groups.

Furthermore, IL-1β induces inhibition of protein synthesis in skeletal muscle [20]. EPI® treatment returns IL-1β plasma levels to normal values. On the contrary, after 14 days of application without EPI®, the levels of IL-1β remain significantly high compared to control values. Taken together, the results indicate that EPI® treatment is effective in diminishing pro-inflammatory mediators. Further studies are needs to determine the mechanisms involved in the inflammatory effects of EPI® treatment. Besides that, EPI® decreases pro-inflammatory mediators and anti-inflammatory proteins may also be activated. PPAR-γ has been recognized as playing a fundamental role in the immune response through its ability to decrease the expression of pro-inflammatory genes [21]. It also increases the expression levels of genes that are involved in anti-inflammatory effects and tissue repair [22,23]. Furthermore, PPAR-γ induces the expression of VEGF and its receptors in cultured cardiac myofibroblasts [24]. Our data indicated that Notexin produced a significant decrease in PPAR-γ protein expression, similar at 7 and 14 days, compared with control. EPI® treatment significantly increases PPAR-γ protein expression reduced by Notexin and returns levels to control values. In addition, PPAR-γ promotes the myocellular storage of energy by increasing fatty acid uptake and esterification while simultaneously enhancing insulin signaling and glycogen formation, which have beneficial effects on metabolic health and therefore on tissue repair [25].

Electrical stimulation has multiple effects in directing cell division, vascular endothelial cells, angiogenesis and endothelial migration, all of which are important elements in wound healing [10]. Vascular endothelial growth factor (VEGF) is a paracrine factor. Its main function is to promote angiogenesis by improving cellular survival, inducing proliferation and enhancing the migration and invasion of endothelial cells. Skeletal muscle fibers can control capillary growth by releasing VEGF from intracellular vesicles during contraction [26]. Recent evidence suggests that VEGF has effects on skeletal muscle regeneration by stimulating the myogenic differentiation of muscle-derived stem cells [27,28].

Our results indicate a clear induction of VEGF protein expression after Notexin-induced damage. These results are in accordance with a greater production of VEGF in damaged tissue than in normal tissue [29]. Furthermore, VEGF-R1, the more actively induced receptor by tissue injury, is also increased as has been described in trauma patients [30]. EPI® treatment further significantly increases both VEGF and VEGF-R1 thus suggesting an active role in maintaining blood flow in the microcirculation and also may increase the systemic level of soluble anti-inflammatory and cytoprotective mediator events that can improve the recovery from injury [30].

Despite the many treatments proposed to treat muscle injuries, the rate of re-injury is still very high. This is probably due to the fact that a greater understanding and analysis of the type, size and location of the lesion in each case [31] is required.

Some authors argue that the size of the lesion correlates with the time the patient will need to return to competition [32]. By contrast, other study groups suggest that neither the presence of ultrasound findings nor the size of them correlate with the time needed to return

to competition. Thus, the prognosis for muscular injuries should not be guided by these results alone [33,34].

Although the number of cases may be considered low, the difference between the variables studied was very high. Therefore, sufficient power was obtained so as to detect differences with a significance ranging from 55 to 58% for VEGF and VEGF-R1 variables as well as from 88% to 100% in TNF and IL-1B variables.

The work has some limitations such as the use of rats. As such, it might not be possible to extrapolate the result to humans. In spite of that possibility, rats have been used in many valid experimental studies [14-17,20,27]. Another limitation is the lack of a histological or functional evaluation, which could give physiological relevance to the interpretation of the data presented [35]. The electrolysis and/or sodium hydroxide produced by the EPI® technique may interfere with IL-1beta and TNF-alpha values, affecting the existing cytokines. Therefore, we wait 7 days after the EPI® technique application to see its beneficial effects. Cytokines from the cells at the local position will be produced chronically and maintained over time when inflammation and damage is present. We detect a reduction of pro-inflammatory cytokines after EPI® induction. Thus, cells are probably in a state of less inflammation with less cytokine production in comparison to cells without the EPI® technique.

Despite the limitations exposed, the present work is the first investigation on the effect of EPI® on muscle tissue that shows the biomolecular mechanisms triggered by the application of the same. This experimental work is the basis upon which clinical trials to confirm the effectiveness of the EPI® in humans should be developed.

Conclusion

The application of EPI® on rat muscle previously injured with Notexin causes a significant decrease in pro-inflammatory mediators like TNF-α as well as IL-1β levels. On the other hand, the application of EPI® produced an increase in the expression of anti-inflammatory proteins (PPAR-γ) and also increases VEGF and VEGF-R1 expression. Therefore, the use of EPI® may affect inflammatory mediators in damaged muscle tissue and influence the new vascularization of the injured area. These results suggest that EPI® might represent a useful new therapy for the treatment of muscle injuries.

Although our study in rats may represent a valid approach to evaluate EPI® treatment, studies designed to determine how EPI® treatment may affect recovery of injury in humans are needed.

Competing interests

The authors declare that one of the author (SIJM) have the patent for the EPI® devices. This author has participated in the intervention process, but not in data acquisition and/or the analysis of this study. All authors have made substantial contributions to the conception and design of the study, acquisition of data, the analysis and interpretation of data, drafting the article, revising it critically for important intellectual content and final approval of the version submitted. No fundings was obtained for this study.

Authors' contributions

AF, SLV, SIJM, PEG and MJC conceived of the study, and participated in its design and coordination and drafted the manuscript. AF, SLV, SIJM and GHS carried out the immunoassays and helped to draft the manuscript. PF, JA, SLV and GHS carried out the molecular studies helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We are grateful to E. Goode for his help in editing the manuscript. We also thank G. Gich for assisting in the statistical analysis.

Author details

[1]Department of Sports Orthopedics, ReSport Clinic, Barcelona, Spain. [2]Department of Physiology, Faculty of Medicine, University of Valencia, Valencia, Spain. [3]Catalan Institut of Traumatology and Sports Medicine (ICATME), Hospital Universitari Dexeus, Universitat Autónoma de Barcelona, Barcelona, Spain. [4]Department of Orthopedic Surgery, Hospital de la Santa Creu i Sant Pau, University Autonoma of Barcelona, Barcelona, Spain. [5]Department of Sports Rehabilitation, Cerede Sports Medicine, Barcelona, Spain. [6]Universitat Autónoma de Barcelona, Barcelona, Spain. [7]Department of Orthopedic Surgery and Traumatology, Hospital del Mar, Universitat Autónoma de Barcelona, Barcelona, Spain.

Received: 2 September 2014 Accepted: 26 March 2015
Published online: 17 April 2015

References

1. Ekstrand J, Hägglund M, Waldén M. Epidemiology of muscle injuries in professional football (soccer). Am J Sports Med. 2011;39(6):1226–32.
2. Verrall GM, Slavotinek JP, Barnes PG. The effect of sports specific training on reducing the incidence of hamstring injuries in professional Australian rules football players. Br J Sports Med. 2005;39(6):363–8.
3. Li Y, Foster W, Deasy BM, Chan Y, Prisk V, Tang Y, et al. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am J Pathol. 2004;164(3):1007–19.
4. Tidball JG. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol. 2005;288(2):R345–53.
5. Moresi V, Pristerà A, Scicchitano BM, Molinaro M, Teodori L, Sassoon D, et al. Tumor necrosis factor-alpha inhibition of skeletal muscle regeneration is mediated by a caspase-dependent stem cell response. Stem Cells. 2008;26(4):997–1008.
6. Liu CS, Chang CC, Du YC, Chang FR, Wu YC, Chang WC, et al. 2-hydroxy-4'-methoxychalcone inhibits proliferation and inflammation of human aortic smooth muscle cells by increasing the expression of peroxisome proliferator-activated receptor gamma. J Cardiovasc Pharmacol. 2012;59(4):339–51.
7. Thom R, Rowe GC, Jang C, Safdar A, Arany Z. Hypoxic induction of vascular endothelial growth factor (VEGF) and angiogenesis in muscle by truncated peroxisome proliferator-activated receptor γ coactivator (PGC)-1α. J Biol Chem. 2014;289(13):8810–7.
8. Hudlicka O, Brown MD. Adaptation of skeletal muscle microvasculature to increased or decreased blood flow: role of shear stress, nitric oxide and vascular endothelial growth factor. J Vasc Res. 2009;46(5):504–12.
9. Olfert IM, Howlett RA, Wagner PD, Breen EC. Myocyte vascular endotelial growth factor is required for exercise-induced skeletal muscle angiogenesis. Am J Physiol Regul Integr Comp Physiol. 2010;299(4):R1059–67.
10. Zhao M. Electrical fields in wound healing-An overriding signal that directs cell migration. Semin Cell Dev Biol. 2009;20(6):674–82.
11. Abat F, Valles SL, Gelber PE, Polidori F, Stitik TP, García-Herreros S, et al. Molecular repair mechanisms using the Intratissue Percutaneous Electrolysis technique in patellar tendonitis. Rev Esp Cir Ortop Traumatol. 2014;58(4):201–5.
12. Abat F, Gelber PE, Polidori F, Monllau JC, Sanchez-Ibañez JM. Clinical results after ultrasound-guided intratissue percutaneous electrolysis (EPI®) and eccentric exercise in the treatment of patellar tendinopathy. Knee Surg Sports Traumatol Arthrosc. 2014;23(4):1046–52.

13. Abat F, Diesel WJ, Gelber PE, Polidori F, Monllau JC, Sanchez-Ibañez JM. Effectiveness of the Intratissue Percutaneous Electrolysis (EPI®) technique and isoinertial eccentric exercise in the treatment of patellar tendinopathy at two years follow-up. Muscles Ligaments Tendons J. 2014;4(2):188–93.
14. Head SI, Houweling PJ, Chan S, Chen G, Hardeman EC. Properties of regenerated mouse extensor digitorum longus muscle following notexin injury. Exp Physiol. 2014;99(4):664–74.
15. Joensen J, Gjerdet NR, Hummelsund S, Iversen V, Lopes-Martins RA, Bjordal JM. An experimental study of low-level laser therapy in rat Achilles tendon injury. Lasers Med Sci. 2012;27(1):103–11.
16. Meador BM, Krzyszton CP, Johnson RW, Huey KA. Effects of IL-10 and age on IL-6, IL-1beta, and TNF-alpha responses in mouse skeletal and cardiac muscle to an acute inflammatory insult. J Appl Physiol. 2008;104(4):991–7.
17. Crassous B, Richard-Bulteau H, Deldicque L, Serrurier B, Pasdeloup M, Francaux M, et al. Lack of effects of creatine on the regeneration of soleus muscle after injury in rats. Med Sci Sports Exerc. 2009;41(9):1761–9.
18. Bhatnagar S, Panguluri SK, Gupta SK, Dahiya S, Lundy RF, Kumar A. Tumor necrosis factor-α regulates distinct molecular pathways and gene networks in cultured skeletal muscle cells. PLoS One. 2010;12;5(10):e13262.
19. Langen RC, Schols AM, Kelders MC, Van Der Velden JL, Wouters EF, Janssen-Heininger YM. Tumor necrosis factor-alpha inhibits myogenesis through redox-dependent and -independent pathways. Am J Physiol Cell Physiol. 2002;283(3):C714–21.
20. Borghi SM, Zarpelon AC, Pinho-Ribeiro FA, Cardoso RD, Cunha TM, Alves-Filho JC, et al. Targeting interleukin-1β reduces intense acute swimming-induced muscle mechanical hyperalgesia in mice. J Pharm Pharmacol. 2014;66(7):1009–20.
21. Bertin B, Dubuquoy L, Colombel JF, Desreumaux P. PPAR-gamma in ulcerative colitis: a novel target for intervention. Curr Drug Targets. 2013;14(12):1501–7.
22. von Knethen A, Neb H, Morbitzer V, Schmidt MV, Kuhn AM, Kuchler L, et al. PPARγ stabilizes HO-1 mRNA in monocytes/macrophages which affects IFN-β expression. Free Radic Biol Med. 2011;51(2):396–405.
23. Lea S, Plumb J, Metcalfe H, Spicer D, Woodman P, Fox JC, et al. The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD. Eur Respir J. 2014;43(2):409–20.
24. Chintalgattu V, Harris GS, Akula SM, Katwa LC. PPAR-gamma agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts. Cardiovasc Res. 2007;74(1):140–50.
25. Hu S, Yao J, Howe AA, Menke BM, Sivitz WI, Spector AA, et al. Peroxisome proliferator-activated receptor γ decouples fatty acid uptake from lipid inhibition of insulin signaling in skeletal muscle. Mol Endocrinol. 2012;26(6):977–88.
26. Hoier B, Prats C, Qvortrup K, Pilegaard H, Bangsbo J, Hellsten Y. Subcellular localization and mechanism of secretion of vascular endothelial growth factor in human skeletal muscle. FASEB J. 2013;27(9):3496–504.
27. Bouchentouf M, Benabdallah BF, Bigey P, Yau TM, Scherman D, Tremblay JP. Vascular endothelial growth factor reduced hypoxia-induced death of human myoblasts and improved their engraftment in mouse muscles. Gene Ther. 2008;15(6):404–14.
28. Beckman SA, Chen WC, Tang Y, Proto JD, Mlakar L, Wang B, et al. Beneficial effect of mechanical stimulation on the regenerative potential of muscle-derived stem cells is lost by inhibiting vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2013;33(8):2004–12.
29. Rignault-Clerc S, Bielmann C, Delodder F, Raffoul W, Waeber B, Liaudet L, et al. Functional late outgrowth endotelial progenitors isolated from peripheral blood of burned patients. Burns. 2013;39(4):694–704.
30. Ostrowski SR, Sørensen AM, Windeløv NA, Perner A, Welling KL, Wanscher M, et al. High levels of soluble VEGF receptor 1 early after trauma are associated with shock, sympathoadrenal activation, glycocalyx degradation and inflammation in severely injured patients: a prospective study. Scand J Trauma Resusc Emerg Med. 2012;10:20–7.
31. Askling CM, Tengvar M, Tarassova O, Thorstensson A. Acute hamstring injuries in Swedish elite sprinters and jumpers: a prospective randomised controlled clinical trial comparing two rehabilitation protocols. Br J Sports Med. 2014;48(7):532–9.
32. Connell DA, Schneider-Kolsky ME, Hoving JL, Malara F, Buchbinder R, Koulouris G, et al. Longitudinal study comparing sonographic and MRI assessments of acute and healing hamstring injuries. AJR Am J Roentgenol. 2004;183(4):975–84.
33. Petersen J, Thorborg K, Nielsen MB, Skjødt T, Bolvig L, Bang N, et al. The diagnostic and prognostic value of ultrasonography in soccer players with acute hamstring injuries. Am J Sports Med. 2014;42(2):399–404.
34. Prior M, Guerin M, Grimmer K. An evidence-based approach to hamstring strain injury: a systematic review of the literature. Sports Health. 2009;1(2):154–64.
35. Delos D, Leineweber MJ, Chaudhury S, Alzoobaee S, Gao Y, Rodeo SA. The effect of platelet-rich plasma on muscle contusion healing in a rat model. Am J Sports Med. 2014;42(9):2067–74.

Sànchez-Ibàñez et al., Orthop Muscular Syst 2015, 4:4
http://dx.doi.org/10.4172/2161-0533.1000200

Orthopedic & Muscular System: Current Research

Research Article Open Access

Ultrasound-Guided EPI® Technique and Eccentric Exercise, New Treatment for Achilles and Patellar Tendinopathy Focused on the Region-Specific of the Tendon

Jose Manuel Sànchez-Ibàñez[1*], Maria Elisa Fernàndez[1], Carlos Moreno[2], Daniel Marti[3] and Pedro Belón[4]

[1]Department of Sports Rehabilitation, CEREDE Sports Orthopaedics Medicine & Rehabilitation Clinic, Barcelona, Spain
[2]Department of Sports Medicine and Rehabilitation, Udinese Calcio FC, Udine, Italy
[3]Department of Sports Medicine and Rehabilitation, Tottenham Hotspur FC, Hotspur Way, Enfield, Middlesex, UK
[4]Department of Physical Therapy, Clínica CEMTRO, Madrid, Spain

Abstract

Treatment of tendon injuries is a subject of frequent debate in sports medicine and physiotherapy. Achilles and patellar tendinopathy is a common, painful, overuse disorder, and is associated with a failure of the tendon repair process they have a low potential for healing with the usual techniques.

Therefore, new treatments for tendinopaties drawn from the existing literature as well as from their own experience dealing with this condition to deal with this delicate pathology have been developed over recent past decades.

This brief review aims to update recent information on the treatment with the ultrasound-guided EPI® technique and eccentric exercise in Achilles and patellar tendinopathy resulted in a great improvement in function and a rapid return to the previous level of activity.

Keywords: Tendinopathy; EPI® technique; Eccentric exercise therapy

Introduction

The Achilles tendon and patellar tendon are most affected, in both elite and recreational athletes, in sports that heavily load the lower extremities [1]. It is tendons play an essential role in the musculoskeletal system by transferring the tensile loads from muscle to bone so as to enable joint motion and stabilization [2]. Despite this ability to adapt to physiological loads tendinopathies it represents a clinical problem which affects both professional and recreational athletes as well as people involved in repetitive work [3,4]. Tendinopathies overuse represents 30 to 50 % of all sports injuries and result in a signifi ant amount of morbidity and spending health care [5], it is estimated that they could cost the United States health system some 30 billion dollars, annually [6].

The etiology de la Achilles and patellar tendinopathy includes lifestyle, loading pattern, biological variables (genetics, age, sex) as well as different pharmacological agents [7].

Achilles tendinopathy is more prevalent in the lower extremity, with a frequency of 5.9% in sedentary and about 50 % for endurance athletes [8,9]. Patellar tendinopathy is most common involvement in the knee and its prevalence has been reported to be 44.6% in elite volleyball players [10] and 31.9 % in elite basketball players [11] and also represents two thirds of all pathologies of the knee between these two sports [8].

The traditional model of "tendonitis" as an inflammatory process is now obsolete since the appearance of several publications, which have described the pathological process of the tendon as mainly degenerative (tendinosis) [12,13]. Th s is justifi d due to the absence of inflammatory cells, the presence of areas of collagen degeneration, myxoid degeneration and an increase in fundamental substance and is associated with a failure of the tendon repair process [12,13].

Achilles and patellar tendinopathy is a clinical diagnosis and typically is based on medical history and clinical fi dings. Imaging techniques: such as Color Doppler Sonography (CDS) and Magnetic Resonance Imaging (MRI) are valuable tools to confi m the diagnosis and provide guidance for treatment [14].

The tendon injury can occur in the tenotendinous region, as in the Achilles tendon. However, most of the tendon pathology and pain is located in the osteotendinous, such as elbow lateral epicondyle, patellar tendon and the medial epicondyle tendons and tendons in the groin [15]. While osteotendinous and tenotendinous and are morphologically different region in normal state, the occurrence of extracellular matrix pathology induced cellular changes are indistinguishable [16].

Achilles and patellar tendinopathy this is accompanied by an excessive nociceptive signalling from the tendon, causing pain and restricted mobility [17] he mechanisms behind these structural and neurological changes are not fully understood. A more recent theory ascribes part of the tendinosis changes to an increased production of biochemical agents, such as substance P (SP) [18] and NMDAR1 glutamate receptor [19,20].

Overall tendinopathies are characterized by prolonged, localized pain, associated with physical activity requiring cyclic mechanical stimuli. Patients respond poorly to most conservative treatments, however, a broad spectrum of disorders of the tendon within the concept of tendinopathy that share some common characteristics (paratendinitis, tendinitis, tendon overuse injuries, spontaneous tendon rupture, calcifying tendinitis) or gaps, often converge in the same tendon (Figure 1). In this sense, there is no single etiology and pathogenesis that can explain all these processes [15].

Treatment options have changed over the last decade in parallel to

***Corresponding author:** Jose Manuel Sànchez-Ibàñez, CEREDE Sports Orthopaedics Medicine and Rehabilitation, C/ Doctor Roux nº 8-10 bajos, Barcelona 08017, Spain, Tel: +34934523510; E-mail: drsanchez@cerede.es

Received September 11 2015; **Accepted** September 25 2015; **Published** October 06 2015

Citation: Sànchez-Ibàñez JM, Fernàndez ME, Moreno C, Marti D, Belón P (2015) Ultrasound-Guided EPI® Technique and Eccentric Exercise, New Treatment for Achilles and Patellar Tendinopathy Focused on the Region-Specific of the Tendon. Orthop Muscular Syst 4: 200. doi:10.4172/2161-0533.1000200



Figure 1: Longitudinal ultrasound view of Achilles tendinopathy. Gray-scale and power-doppler ultrasound showing the sonographic findings characteristic of Achilles tendinopathy. The sonogram reveals the hypoechoic, darken area of the Achilles tendon, tendon thickening and neovascularization.

the pathophysiological and histopathological fi dings in tendinopathy. Since the underlying pathology of chronic tendinopathy can be defi ed as a "defective healing response", treatment should aim to encourage regeneration of the tendon, pain modulation and the restoration of the biomechanical properties [21].

Current treatment options include eccentric training, open or arthroscopic surgery, extracorporeal shockwave therapy, non-steroidal anti-inflammatory drugs, platelet-rich plasma injection and aprotinin. These studies have also suggested that, in general, patients with a worse functional status before treatment obtain inferior fi al outcomes. However, due to the limited evidence-based therapies, there are still several controversies regarding the real efficacy of these treatment modalities [22].

In this paper the authors will update the knowledge about Achilles an patellar tendinopathy and current treatments with EPI® technique and eccentric exercise focused on the region-specific of the tendon drawn from the existing literature as well as from their own experience dealing with this condition.

Eccentric exercise therapy

Eccentric exercise therapy has shown to cause an upregulation of Insulin-like Growth Factor (IGF-I). Th s upregulation of IGF-I is associated with cellular proliferation and matrix remodelling within the tendon [23].

Programs of eccentric exercise have been proposed as a key element in strength training in rehabilitation because they can supposedly counteract the response of defective healing that apparently underlies tendinopathy by promoting the creation of collagen fibers within the tendon [24,25]. The literature places increasing emphasis on the importance of a proper choice of the load used [26].

The continuum model in tendinopathy (reactive tendinopathy, tendon dysrepair and degenerative tendinopathy) provides a reasoned basis for believing that the protocol to be performed depends on the current clinical presentation [15]. The protocol proposed by Alfredson et al. is generally used [24] it consists of three sets of 15 repetitions, performed twice a day, seven days a week for 12 weeks.

Ohberg et al. [27] examined tendon structure by grey-scale ultrasound in 26 tendons with Achilles tendinosis, which had been treated with eccentric exercise. Remarkably, after a mean follow up of 3.8 years, 19 of 26 tendons had a more normalised structure, as gauged by their thickness and by the reduction of hypoechoic áreas.

Visnes et al. [28] suggested that eccentric training had a positive effect on patellar tendinopathy and recommended that athletes suspend sports activity during rehabilitation.

The gradual progression from eccentric- concentric to eccentric followed by a faster loading can benefit patients with Achilles tendinopathy can not start with a program proposed by eccentric Alfredson et al [24] due to pain or weakness of the sural triceps muscle [29].

Isoinertial eccentric training (YoYoTechnology AB, Stockholm, Sweden) resulted in an improvement of muscle function and reduced pain in patients with patellar tendinopathy [30]. The combination of EPI® technique and isoinertial eccentric exercise offers good results in the treatment patellar tendinopathy [31].

Ultrasound-guided EPI® technique

In recent years, the intratissue percutaneous electrolysis (EPI®) technique has become more relevant in the scientific literature [31-33] given the good results yielded in the treatment of degenerative tendinopathy in comparison to other previous conservative treatments.

Th s technique, created by Sánchez-Ibáñez JM [34,35] and who have over 15 years experience in its use, uses a fl w of cathodic current directed exclusively to the area of degenerated tendon through an ultrasound guided needle that brings about an organic reaction that leads to rapid regeneration of the degenerated tendon.

The application of EPI® technique produces a non-thermal electrochemical reaction centered on degenerated tissue (tendinosis). Th s leads to a controlled local inflammatory reaction that leads to the regeneration of damaged tissue [33,36].

The EPI® technique (Figure 2) achieves a very localized organic reaction in the clinical focus by using a specially designed EPI® device for this purpose (EPI Advanced Medicine®, Barcelona, Spain. EPI® technique videos online: www.epiadvanced.com), which leads to the rapid regeneration of degenerated tissue. Th s leads to the production of new immature collagen fibers that become mature by means of eccentric stimulus [32], thereby obtaining good results in the short and



Figure 2A: Treatment of Achilles tendinopathy with ultrasound-guided EPI® technique (EPI Advanced Medicine®, Barcelona, Spain).



Figure 2B: Longitudinal ultrasound view of Achilles tendinopathy. Treatment is directed exclusively to the area of tendon injury. Note the non-thermal electrochemical reaction (white area) produced on the tip of the needle, just in the area of damaged tissue.

long-term in terms of pain and function.

In experimental studies with human tendon injury, there has been a disproportionate expression of certain cytokines and matrix metalloproteinase (MMPs), prostaglandin E2 (PGE2), interleukin -6 (IL-6) and interleukin -1b (IL-1b) [37,38]. IL- 1b in turn increases the production of matrix metalloproteinase -1 (MMP-1), matrix metalloproteinase -3 (MMP-3) and prostaglandin E2 (PGE-2) [39].

A recent experimental study [33] showed that with the use of ultrasound-guided EPI® technique in patellar tendinopathy increase of anti-inflammatory proteins, like peroxisome proliferator-activated receptor gamma (PPAR-γ). These proteins play a key role in the inhibition of expression of proinflammatory molecules secreted by macrophages, such as tumor necrosis factor alpha (TNF-α), IL-6 and IL-1β, thus producing in the treated tissue a highly benefic al molecular response during degenerative tendinopathy. Th s, in turn, results in an increase of the expression of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor 2 (VEGFR-2), mediators responsible for angiogenesis anti-inflammatory response. The EPI® technique makes for the activation of molecular and cellular mechanisms of the tendon responsible for phagocytosis and the regeneration of degenerated tissue [33,36].

In recent research [31] to evaluate the therapeutic effects EPI® technique and eccentric exercise on the patellar tendinopathy. The primary outcome measure was knee function using the Victorian Institute of Sport Assessment–Patella (VISA-P) score, a specific validated questionnaire to quantify pain and knee function and ability to play sport in patients with patellar tendinopathy [40,41]. The VISA-P score ranged from a maximum of 100 in asymptomatic patients to the theoretical minimum of 0. The authors of the score suggested that a score between 80 and 100 points might be considered as the optimal outcome category. Functional evaluation was further assessed with Blazina's classifi ation [42]. Th s classifi ation categorizes the symptomatic patients as in phase I (pain only after activity), phase II (discomfort during activity), phase III (pain during activity that interferes with participation) and phase IV (complete tendon disruption). The Tegner score was also used to assess the influence of the treatment in terms of restoring the previous sports activity level. All the written questionnaires were personally filled out by all patient before treatment, at the end of the treatment (at 3-month) and at the 2-year follow-up. The questionnaires corresponding to the 5 and 10 year follow-up evaluations were all filled out through a telephone interview. Patient satisfaction was measured according to the Roles and Maudsley score [43]. In this score, patients are classifi d as Excellent (no pain, full movement and full activity), Good (occasional discomfort, full movement and full activity), Fair (some discomfort after prolonged activity) or Poor (pain limiting activities). The results documented were good and stable with the VISA-P score, Tegner scores and Roles and Maudsley score, and terms of clinical and functional improvement in patellar tendinopathy and providing a follow-up of 10 year.

In recent research [44] to evaluate the therapeutic effects EPI® technique and eccentric exercises on the Achilles tendinopathy. A prospective study of 39 patients with Achilles tendinopathy was carried out. The patients were evaluated using the Victoria Institute of Sports Assessment - Achilles (VISA-A) score and the Foot and Ankle Disability Index for Sport scale (FADI); at the beginning of the study and after being monitored for 3 months. At the beginning of the study, the VISA-A score was an average of 47 ± 19.8 (mean ± SD ;) and after being monitored for 3 months the score was an average of 90.8 ± 5.5 (mean ± SD), showing statistically signifi ant differences ($p<0.001$). The results of the FADI showed that the average score at the beginning was 64.5 ± 26.9 (mean ± SD) and after 3 months it was 123 ± 1.5 (mean ± SD). Statistically signifi ant differences were identifi d ($p<0.001$). The use of the EPI® technique in combination with eccentric exercise in Achilles tendinopathy has shown evidence of a signifi ant improvement in terms of pain and function. Not many sessions are required and the treatment time is short. The procedure has proven to be safe.

Discussion

Treatment of Achilles and patellar tendinopathy is a subject of frequent debate in sports medicine and physiotherapy. Multiple techniques have been described for their treatment and although some of them [31,45-48].

To date, there is no consensus on the optimal treatment of Achilles and patellar tendinopathy. It has been suggested that the incomplete understanding of the underlying mechanisms (etiology of the condition) limits the ability to develop effective treatment strategies [49].

Doubts have mainly centered on the fact that there are few controlled prospective studies that analyze all aspects of tendinosis, and few studies that investigate the early stages of these processes and their healing mechanisms. The exact mechanism by which tendinopathy develops in humans remains the target of numerous investigations. A variety of degenerative characteristics associated tendinopathies, including accumulation glycosaminoglycan (GAG), calcifi ation and lipid accumulation nerve damage and hyperinnervation, is one of the theories whose publications are scarce, despite its special interest in explaining the possible pathophysiological mechanisms of pain in tendinopathy [50].

In several studies it has been shown that there is a correlation between tendinopathy and hyperinnervation, citing that the production of Nerve Growth Factor (NGF) and the corresponding hyperinnervation could be induced by repetitive ischemic crisis in osteotendinous union [51,52]. Th s growth of nerve fibers, which causes chronic pain, could be part of a process of abnormal tissue repair, preceded by repetitive microtrauma [53].

Despite its prevalence, the precise pathogenic mechanisms of tendinopathy are not clear and, as a result, current treatments of tendinopathies are largely empirical and not always effici t [15,54]. The continuum model of tendon pathology was proposed to provide a model for the staging of tendon pathology and to assist clinicians in managing this often complex condition. The model presents clinical, histological and imaging evidence for the progression of tendon

pathology as a three-stage continuum: reactive tendinopathy, tendon disrepair and degenerative tendinopathy [15].

One of the clinical effects that eccentric exercises might have in tendinopathy is in pain modulation due to changes in glutamate content or in the central nervous system with increased activation of inhibitory neurons and cortical reorganization [48,55]. There is little evidence that isolated eccentric exercise reduces pain in tendinopathy compared with concentric exercise [56].

It is considered that hypoxia could be responsible for neovascularization in tendinopathies, capillary fl w and post-capillary pressure decreased following 12 weeks of eccentric loading [57].

In the treatment of tendinopathy, there is confli ting evidence that eccentric exercises are superior to other load programs [56]. Eccentric work on an inclined plane did not improve functional outcomes when it was done during a competitive season in volleyball [58]. In another study, continuous sporting activity did not compromise clinical outcomes at 12 months, as long as the sport was introduced incrementally ensuring minimal pain during and after loading [59]. Eccentric decline squat training and heavy slow resistance training showed good long-term clinical results, and heavy slow resistance training also resulted in advantages in pathological improvement and increased collagen turnove [60].

Some authors have demonstrated better results with eccentric exercise on corporeal tendinopathies in comparison with enthesopathies [22].

On the other hand, maximal eccentric loading may be best for some groups of patients and permit adaptive changes in the tendon [30].

Despite the fact that the eccentric muscle workout has become the dominant conservative strategy in treating Achilles and patellar tendinopathy, up to 45% of patients do not respond to this treatment [61].

A recent study suggests that sedentary subjects with Achilles tendinopathy may show less promising results with eccentric exercise therapy compared to athletic subjects [62].

Despite some good results reported with eccentric programmes [61,63], it is still unclear as to the more effective exercise protocol, its frequency, load and dosage.

Despite over 15 years of experience in the use of the EPI® technique and its widespread deployment in sporting clubs around the world, this technique has grown in relative to scientific dissemination in recent years [31-33].

The EPI® technique is contraindicated mainly in patients with tumors, articular or systemic infection and bleeding disorders [34].

An experimental study showed that after application of the degenerated tendon EPI® technique, an increase in anti -inflammatory proteins, like PPAR-γ has been observed after treatment with the EPI® technique. These proteins play a key role in the inhibition of expression of proinflammatory molecules secreted by macrophages, such as TNF-α, IL-6 and IL-1β [64] thus producing in the treated tissue a highly benefic al molecular response during tendinopathy. Th s, in turn, results in an increase of the expression of VEGF and VEGFR-2, mediators responsible for angiogenesis anti-inflammatory response [65,66].

In another recent study by Sánchez-Ibàñez and co-workers [31] reported that treatment with the ultrasound-guided EPI® technique and eccentric exercises in patellar tendinopathy resulted in a great improvement in knee function and a rapid return to the previous level of activity after few sessions. The limitations of this study are the absence of a control group.

References to the use of the EPI® technique in combination with eccentric exercise can be found in the literature. In those cases the EPI® technique focuses on biological tissue recovery, leaving the functional recovery of tissue biomechanics to eccentric exercise [31].

Conclusions

Achilles and patellar tendinopathy is a condition that causes many patients signifi ant pain and disability. Currently, the aetiology of tendinopathy is still unclear, it is multifactorial, and influenced by intrinsic and extrinsic factors. Tendinopathy often becomes chronic because the exact pathogenesis remains largely unknown. Physicians and physiotherapist have a variety of therapeutic options available to treat tendinopathies but, in each case, there is a lack of evidence supporting their use as the gold standard treatment.

The combination of EPI® technique and eccentric exercise offers good results in terms of clinical and functional improvement in Achilles and patellar tendinopathy with low morbidity in a half study period.

Acknowledgements

We are grateful to Julita Cuquerella and David MacManus for your help in editing the manuscript.

Author Contributions

Wrote the first draft of the manuscript: JMS, MEF, CM, DM, PB. Contributed to the writing of the manuscript: JMS, MEF, CM, DM, PB. Agree with manuscript results and conclusions: JMS, MEF, CM, DM, PB. Jointly developed the structure and arguments for the paper: JMS, MEF, CM, DM, PB. Made critical revisions and approved final version: JMS, MEF, CM, DM, PB. All authors reviewed and approved the final manuscript.

Disclosures and Ethics

The authors declare that one author has the patent for the EPI devices® and one author are the creators of the EPI® Technique.

References

1. Scott A, Ashe MC (2006) Common tendinopathies in the upper and lower extremities. Curr Sports Med Rep 5: 233-241.
2. Tresoldi I, Oliva F, Benvenuto M, Fantini M, Masuelli L, et al. (2013) Tendon's ultrastructure. Muscles Ligaments Tendons J 3: 2-6.
3. Kannus P (1997) Etiology and pathophysiology of chronic tendon disorders in sports. Scand J Med Sci Sports 7: 78-85.
4. Kvist M (1994) Achilles tendon injuries in athletes. Sports Med 18: 173-201.
5. Maffulli N, Wong J, Almekinders LC (2003) Types and epidemiology of tendinopathy. Clin Sports Med 22: 675-692.
6. Butler DL, Gooch C, Kinneberg KR, Boivin GP, Galloway MT, et al. (2010) The use of mesenchymal stem cells in collagen-based scaffolds for tissue-engineered repair of tendons. Nat Protoc 5: 849-863.
7. Hess GW (2010) Achilles tendon rupture: a review of etiology, population, anatomy, risk factors, and injury prevention. Foot Ankle Spec 3: 29-32.
8. Scott A, Ashe MC (2006) Common tendinopathies in the upper and lower extremities. Curr Sports Med Rep 5: 233-241.
9. Fredberg U and Stengaard-Pedersen K (2008) Chronic tendinopathy tissue pathology, pain mechanisms, and etiology with a special focus on inflammation. Scandinavian Journal of Medicine & Science in Sports 18; 3-15.
10. Ferretti A, Papandrea P, Conteduca F (1990) Knee injuries in volleyball. Sports Med 10: 132-138.
11. Lian OB, Engebretsen L, Bahr R (2005) Prevalence of jumper's knee among

elite athletes from different sports: a cross-sectional study. Am J Sports Med 33: 561-567.

12. Alfredson H, Lorentzon R (2002) Chronic tendon pain: no signs of chemical inflammation but high concentrations of the neurotransmitter glutamate. Implications for treatment? Curr Drug Targets 3: 43-54.
13. Cook JL, Khan KM, Maffulli N, Purdam C (2000) Overuse tendinosis, not tendinitis part 2: applying the new approach to patellar tendinopathy. Phys Sportsmed 28: 31-46.
14. Warden SJ, Kiss ZS, Malara FA, Ooi AB, Cook JL, et al. (2007) Comparative accuracy of magnetic resonance imaging and ultrasonography in confirming clinically diagnosed patellar tendinopathy. Am J Sports Med 35: 427-436.
15. Cook JL, Purdam CR (2009) Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy. Br J Sports Med 43: 409-416.
16. Maffulli N, Testa V, Capasso G, Ewen SW, Sullo A, et al. (2004) Similar histopathological picture in males with Achilles and patellar tendinopathy. Med Sci Sports Exerc 36: 1470-1475.
17. Kader D, Saxena A, Movin T, Maffulli N (2002) Achilles tendinopathy: some aspects of basic science and clinical management. Br J Sports Med 36: 239-249.
18. Backman LJ, Andersson G, Wennstig G, Forsgren S, Danielson P (2011) Endogenous substance P production in the Achilles tendon increases with loading in an in vivo model of tendinopathy-peptidergic elevation preceding tendinosis-like tissue changes. J Musculoskelet Neuronal Interact 11: 133-140.
19. Alfredson H, Forsgren S, Thorsen K, Fahlström M, Johansson H, et al. (2001) Glutamate NMDAR1 receptors localised to nerves in human Achilles tendons. Implications for treatment? Knee Surg Sports Traumatol Arthrosc 9: 123-126.
20. Molloy TJ, Kemp MW, Wang Y, Murrell GA (2006) Microarray analysis of the tendinopathic rat supraspinatus tendon: glutamate signaling and its potential role in tendon degeneration. J Appl Physiol (1985) 101: 1702-1709.
21. Cook JL, Khan KM (2001) What is the most appropriate treatment for patellar tendinopathy? Br J Sports Med 35: 291-294.
22. Andres BM, Murrell GA (2008) Treatment of tendinopathy: what works, what does not, and what is on the horizon. Clin Orthop Relat Res 466: 1539-1554.
23. Olesen JL, Heinemeier KM, Gemmer C, Kjaer M, Flyvbjerg A, et al. (2007) Exercise-dependent IGF-I, IGFBPs, and type I collagen changes in human peritendinous connective tissue determined by microdialysis. J Appl Physiol (1985) 102: 214-220.
24. Alfredson H, Pietilä T, Jonsson P, Lorentzon R (1998) Heavy-load eccentric calf muscle training for the treatment of chronic Achilles tendinosis. Am J Sports Med 26: 360-366.
25. Mafi N, Lorentzon R, Alfredson H (2001) Superior short-term results with eccentric calf ?muscle training compared to concentric training in a randomized prospective multicenter study on patients with chronic Achilles tendinosis. Knee Surg Sports Traumatol Arthrosc 9: 42-47.
26. Magnusson SP, Langberg H, Kjaer M (2010) The pathogenesis of tendinopathy: balancing the response to loading. Nat Rev Rheumatol 6: 262-268.
27. Ohberg L, Lorentzon R, Alfredson H (2004) Eccentric training in patients with chronic Achilles tendinosis: normalised tendon structure and decreased thickness at follow up. Br J Sports Med 38: 8-11.
28. Visnes H, Bahr R (2007) The evolution of eccentric training as treatment for patellar tendinopathy (jumper's knee): a critical review of exercise programmes. Br J Sports Med 41: 217-223.
29. Silbernagel KG, Thomeé R, Thomeé P, Karlsson J (2001) Eccentric overload training for patients with chronic Achilles tendon pain--a randomised controlled study with reliability testing of the evaluation methods. Scand J Med Sci Sports 11: 197-206.
30. Romero-Rodriguez D, Gual G, Tesch PA (2011) Efficacy of an inertial resistance training paradigm in the treatment of patellar tendinopathy in athletes: a case-series study. Phys Ther Sport 12: 43-48.
31. Abat F, Gelber P, Polidori F, Monllau JC, Sánchez-Ibáñez JM (2014) Clinical results after ultrasound-guided intratissue percutaneous electrolysis (EPI®) and eccentric exercise in the treatment of patellar tendinopathy over a 10-year follow- up. Knee Surgery, Sports Traumatology, Arthroscopy 23:1046-1052.
32. Abat F, Diesel WJ, Gelber P, Polidori F Monllau JC, et al. (2014) Effectiveness of the Intratissue Percutaneous Electrolysis (EPI®) technique and isoinertial eccentric exercise in the treatment of patellar tendinopathy at two years follow-up. Muscles, Ligaments and Tendons Journal 4: 188-193.
33. Abat F, Valles SL, Paredes-Brunet P, Polidori F, Gelber PE, et al. (2014) Molecular repair mechanisms using the Intratissue Percutaneous Electrolysis technique in patellar tendonitis. Rev Esp Cir Ortop Traumatol 58: 201-205.
34. Sánchez-Ibáñez JM (2013) Clinical evolution in the chronic pattellar enthesopathy treatment by EPI® Technique guided-ultrasound - Study of several cases in sports population. [PhD. Thesis], Universidad de León. León. Spain.
35. Sánchez-Ibáñez JM, Colmena C, Benabent J, Garcia-Herreros S, Valles SL (2013) New Technique in Tendon Sport Recovery. Percutaneous Electrolysis Intratissue (EPI®). Int J Phys Med Rehabil 1: 113.
36. Abat F, Valles SL, Gelber PE, Polidori F, Jorda A, García-Herreros S, et al. (2015) An experimental study of muscular injury repair in a mouse model of notexin-induced lesion with EPI® technique. BMC Sports Science, Medicine and Rehabilitation 7: 7.
37. Skutek M, van Griensven M, Zeichen J, Brauer N, Bosch U (2001) Cyclic mechanical stretching enhances secretion of Interleukin 6 in human tendon fibroblasts. Knee Surg Sports Traumatol Arthrosc 9: 322-326.
38. Tsuzaki M, Bynum D, Almekinders L, Yang X, Faber J, et al. (2003) ATP modulates load-inducible IL-1beta, COX 2, and MMP-3 gene expression in human tendon cells. J Cell Biochem 89: 556-562.
39. Tsuzaki M, Guyton G, Garrett W, Archambault JM, Herzog W, et al. (2003) IL-1 beta induces COX2, MMP-1, -3 and -13, ADAMTS-4, IL-1 beta and IL-6 in human tendon cells. J Orthop Res 21: 256-264.
40. Hernandez-Sanchez S, Hidalgo MD, Gomez A (2011) Cross-cultural adaptation of VISA-P score for patellar tendinopathy in Spanish population. J Orthop Sports Phys Ther 41: 581-591.
41. Visentini PJ, Khan KM, Cook JL, Kiss ZS, Harcourt PR, et al. (1998) The VISA score: an index of severity of symptoms in patients with jumper's knee (patellar tendinosis). Victorian Institute of Sport Tendon Study Group. J Sci Med Sport 1: 22-28.
42. Roels J, Martens M, Mulier JC, Burssens A (1978) Patellar tendinitis (jumper's knee). Am J Sports Med 6: 362-368.
43. Roles NC, Maudsley RH (1972) Radial tunnel syndrome: resistant tennis elbow as a nerve entrapment. J Bone Joint Surg Br 54: 499-508.
44. Sanchez-Ibañez JM, Fernández ME, Segarra V, Marco J, Monllau JC, et al. (2014) Clinical results after ultrasound-guided intratissue percutaneous electrolysis (EPI®) and isoinertial exercise in the treatment of Achilles tendinopathy: 23.
45. Abat F, Sánchez-Ibáñez JM (2014) Patellar tendinopathy: A critical review of current therapeutic options. OA Sports Medicine 18; 2.
46. Rompe JD, Maffulli N (2007) Repetitive shock wave therapy for lateral elbow tendinopathy (tennis elbow): a systematic and qualitative analysis. Br Med Bull 83: 355-378.
47. Andia I, Abate M (2012) Platelet rich plasma injections for tendinopathy and osteoarthritis. Int J Clin Rheumatol 7: 397-412.
48. Alfredson H, Ohberg L, Forsgren S (2003) Is vasculo-neural ingrowth the cause of pain in chronic Achilles tendinosis? An investigation using ultrasonography and colour Doppler, immunohistochemis- try, and diagnostic injections. Knee Surg Sports Traumatol Arthrosc 11: 334-338.
49. Cannell LJ, Taunton JE, Clement DB, Smith C, Khan KM (2001) A randomised clinical trial of the efficacy of drop squats or leg extension/leg curl exercises to treat clinically diagnosed jumper's knee in athletes: pilot study. Br J Sports Med 35: 60-64.
50. Riley G (2004) The pathogenesis of tendinopathy. A molecular perspective. Rheumatology (Oxford) 43: 131-142.
51. Danielson P, Andersson G, Alfredson H, Forsgren S (2008) Marked sympathetic component in the perivascular innervation of the dorsal paratendinous tissue of the patellar tendon in arthroscopically treated tendinosis patients. Knee Surg Sports Traumatol Arthrosc 16: 621-626.
52. Bagge J, Lorentzon R, Alfredson H, Forsgren S (2009) Unexpected presence of the neurotrophins NGF and BDNF and the neurotrophin receptor p75 in the

tendon cells of the human Achilles tendon. Histol Histopathol 24: 839-848.

53. Danielson P, Alfredson H, Forsgren S (2007) In situ hybridization studies confirming recent findings of the existence of a local nonneuronal catecholamine production in human patellar tendinosis. Microsc Res Tech 70: 908-911.

54. Wang JH, Iosifidis MI, Fu FH (2006) Biomechanical basis for tendinopathy. Clin Orthop Relat Res 443: 320-332.

55. Wand BM, O'Connell NE (2008) Chronic non-specific low back pain - sub-groups or a single mechanism? BMC Musculoskelet Disord 9: 11.

56. Jonsson P, Alfredson H (2005) Superior results with eccentric compared to concentric quadriceps training in patients with jumper's knee: a prospective randomised study. Br J Sports Med 39: 847-850.

57. Knobloch K, Kraemer R, Jagodzinski M, Zeichen J, Meller R, et al. (2007) Eccentric training decreases paratendon capillary blood flow and preserves paratendon oxygen saturation in chronic achilles tendinopathy. J Orthop Sports Phys Ther 37: 269-276.

58. Visnes H, Hoksrud A, Cook J, Bahr R (2005) No effect of eccentric training on jumper's knee in volleyball players during the competitive season: a randomized clinical trial. Clin J Sport Med 15: 227-234.

59. Silbernagel KG, Thomee R, Eriksson BI, et al. (2007) Continued sports activity, using a pain-monitoring model, during rehabilitation in patients with Achilles tendinopathy: a randomized controlled study. Am J Sports Med 35: 897-906.

60. Kongsgaard M, Kovanen V, Aagaard P, Doessing S, Hansen P, et al. (2009) Corticosteroid injections, eccentric decline squat training and heavy slow resistance training in patellar tendinopathy. Scand J Med Sci Sports 19: 790-802.

61. Malliaras P, Barton CJ, Reeves ND, Langberg H (2013) Achilles and patellar tendinopathy loading programmes: a systematic review comparing clinical outcomes and identifying potential mechanisms for effectiveness. Sports Med 43: 267-286.

62. Sayana MK, Maffulli N (2007) Eccentric calf muscle training in non-athletic patients with Achilles tendinopathy. J Sci Med Sport 10: 52-58.

63. Silbernagel KG, Brorsson A, Lundberg M (2011) The majority of patients with Achilles tendinopathy recover fully when treated with exercise alone: a 5-year follow-up. Am J Sports Med 39: 607-613.

64. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86.

65. Sahin H, Tholema N, Petersen W, Raschke MJ, Stange R (2012) Impaired biomechanical properties correlate with neoangiogenesis as well as VEGF and MMP-3 expression during rat patellar tendon healing. J Orthop Res 30: 1952-1957.

66. Nakama LH, King KB, Abrahamsson S, Rempel DM (2006) VEGF, VEGFR-1, and CTGF cell densities in tendon are increased with cyclical loading: An in vivo tendinopathy model. J Orthop Res 24: 393-400.

Citation: Sànchez-Ibàñez JM, Fernàndez ME, Moreno C, Marti D, Belón P (2015) Ultrasound-Guided EPI® Technique and Eccentric Exercise, New Treatment for Achilles and Patellar Tendinopathy Focused on the Region-Specific of the Tendon. Orthop Muscular Syst 4: 200. doi:10.4172/2161-0533.1000200

Rheumatology: Current Research

Sànchez-Ibàñez, et al., Rheumatology (Sunnyvale)
2015, 5:4
http://dx.doi.org/10.4172/2161-1149.1000173

Review Article Open Access

New Treatments for Degenerative Tendinopathy, focused on the Region-Specific of the Tendon

Jose Manuel Sànchez-Ibàñez[1,2*], Maria Elisa Fernández[1], Joan Carles Monllau[3,4], Ángel Alonso-Díez[2], Jesús Sánchez-García[2] and Jose Luis Sánchez-Sánchez[5]

[1]*Department of Sports Rehabilitation, CEREDE Sports Medicine and Rehabilitation Clinic, Barcelona, Spain*

[2]*Department of Medicine, Surgery and Anatomy, University of León, León, Spain*

[3]*Department of Orthopaedic Surgery and Traumatology, Parc de Salut Mar, Universitat Autónoma de Barcelona, Barcelona, Spain*

[4]*Catalan Institute of Traumatology and Sports Medicine (ICATME), Hospital Universitari Dexeus, Universitat Autónoma de Barcelona, Barcelona, Spain*

[5]*Department of Physical Therapy, University of Salamanca, Salamanca, Spain*

[*]**Corresponding author:** Jose Manuel Sánchez-Ibàñez, CEREDE Sports Medicine and Rehabilitation Clinic, C/ Doctor Roux nº 8-10 bajos, Barcelona 08017, Spain, Tel: +34934523510; E-mail: drsanchez@cerede.es

Received date: September 09, 2015; **Accepted date:** October 20, 2015; **Published date:** October 26, 2015

Abstract

Tendinopathy is a common, painful, overuse disorder associated with a failure of the tendon repair process and has a low potential for healing with the usual techniques. Although many different treatment methods have been described, there is no consensus regarding the optimal treatment for this condition.

Therefore, new treatments for tendinopathies drawn from the existing literature as well as from their own experience dealing with this condition to deal with this delicate pathology have been developed over last few decades. Although some treatments like eccentric training, the EPI® technique, extra-corporeal shock wave therapy (ESWT), hyaluronic acid (HA), platelet-rich plasma (PRP) are being established as the main therapeutic models, there are still questions to be answered as well as the need for a clear treatment protocol to be established.

This brief review aims to update recent information on the treatment approaches of tendinopathy focused on the specific area of the tendon.

Keywords: Tendinopathy; EPI® technique; Treatment approaches

Introduction

Th tendons play an essential role in the musculoskeletal system by transferring the tensile loads from muscle to bone so as to enable joint motion and stabilization [1]. Tendons have the ability to adapt to load changes, increasing collagen synthesis as a result of acute and prolonged physical exercise training [2,3]. Despite this ability to adapt physiological loads, tendinopathies represent a clinical problem which affect both professional and recreational athletes as well as people involved in repetitive work [4,5]. Tendinopathies overuse represents 30% to 50% of all sports injuries and result in a significan amount of morbidity and spending health cost [6]. More than 28 million patients in the United States have tendon damage annually [7]; it is estimated that they could cost the United States health system some $30 billion per annum [8].

Th etiology includes lifestyle, loading pattern, biological variables (genetics, age, sex) as well as differen pharmacological agents [9].

Th Achilles tendon and patellar tendon are most affected in both elite and recreational athletes, in sports that heavily load the lower extremities [10]. Achilles tendinopathy is more prevalent in the lower extremity, with a frequency of 5.9% in sedentary and about 50% for endurance athletes [10,11]. Patellar tendinopathy is most common involvement in the knee and its prevalence has been reported to be 44.6% in elite volleyball players [12] and 31.9% in elite basketball players [13] and also represents two thirds of all pathologies of the knee between these two sports [10].

Th traditional model of "tendonitis" as an inflammator process is now obsolete since the appearance of several publications, which have described the pathological process of the tendon as mainly degenerative (tendinosis) [14,15]. Thi is justifie due to the absence of inflammator cells, the presence of areas of collagen degeneration, myxoid degeneration and an increase in fundamental substance and is associated with a failure of the tendon repair process [14,15].

Tendinopathy is a clinical diagnosis and typically is based on medical history and clinical findings Imaging techniques: such as color doppler sonography (CDS) and magnetic resonance imaging (MRI) are valuable tools to confir the diagnosis and provide guidance for treatment [16].

Th tendon injury can occur in the tenotendinous region, as in the Achilles tendon. However, most of the tendon pathology and pain is located in the osteotendinous, such as elbow lateral patellar tendon and the medial epicondyle tendons and tendons in the groin [17]. While osteotendinous and tenotendinous and are morphologically differen region in normal state, the occurrence of extracellular matrix pathology induced cellular changes are indistinguishable [18].

Tendinopathies are in the main accompanied by an excessive nociceptive signalling from the tendon, causing pain and restricted mobility [19]. Mechanisms driving these structural and neurological changes are not fully understood. A more recent theory ascribes part of

the tendinosis changes to an increased production of biochemical agents, such as substance P (SP) [20] and NMDAR1 glutamate receptor [20-22].

Overall tendinopathies are characterized by prolonged, localized pain, associated with physical activity requiring cyclic mechanical stimuli. Patients respond poorly to most conservative treatments, however, a broad spectrum of disorders of the tendon within the concept of tendinopathy that share some common characteristics (paratendinitis, tendinitis, tendon overuse injuries, spontaneous tendon rupture, calcifying tendinitis) or gaps, ofte converge in the same tendon (Figure 1). In this sense, there is no single etiology and pathogenesis that can explain all these processes [17].



Figure 1: Transverse ultrasound of patellar tendinopathy with area of fibrilla rupture (hypoechogenic foci surrounded by connective reinforcement). Tendon degeneration in its most proximal and deep portion (critical area to receive higher tensile strength during tissue stress).

Treatment options have changed over the last decade in parallel to the pathophysiological and histopathological finding in tendinopathies. Since the underlying pathology of chronic tendinopathy can be define as a "defective healing response", treatment should aim to encourage regeneration of the tendon, pain modulation and the restoration of the biomechanical properties [23,24].

In this paper the authors will update the knowledge about tendinopathy and current treatments focused on the region-specifi of the tendon drawn from the existing literature as well as from their own experience dealing with this condition. Some of these treatments are eccentric training, the EPI® technique, extra-corporeal shock wave therapy (ESWT), hyaluronic acid (HA), platelet-rich plasma (PRP) are other treatment options [25].

Anti-inflammatory therapy

Conventional conservative treatments have generally been used empirically to reduce pain and inflammation Thes treatments include relative repose or activity modification cold, stretching, orthopedic supports, physiotherapy and biomechanical correction. The are usually employed initially in acute and the more hyperalgesic phase of tendinopathy but fail to modify the histological structure of the tendon [26,27].

Th aim of non-steroidal anti-inflammator drugs (NSAIDs) is to reduce inflammatio by inhibiting the synthesis of inflammator factors (inflammator cells, prostaglandins, interleukins, etc.) and their use has been popular in the management of tendinopathy for years [28]. NSAIDs affec the activity of tenocytes and glycosaminoglycan synthesis [29,30]. While their use can be justifie on a reactive tendinopathy, the tendon's response upon loading can be affecte by a potential inhibition of collagen synthesis [31] as well as have a detrimental effec on muscle adaptation [32].

Possible mechanisms of action of corticosteroid injection include a reduction in extrinsic or intrinsic inflammation reduction in the proliferation of tenocytes, anti-angiogenic activity, and the inhibition of scar formation, some anti-nociceptive action or a combination of these mechanisms [33].

Th literature suggests that the majority of patients may experience a short-term improvement in terms of pain and/or function but in exchange for a high risk of relapse in the medium term and with side effect that may even lead to a rupture of the tendon [34]. Two recent systematic reviews showed worse results from the use of glucocorticoids in comparison to other treatments and the placebo group in the medium and long-term [35,36].

Konsgaard et al. [37] reported that heavy slow resistance training also resulted in significan improvement compared with corticosteroid injections.

Eccentric exercises

Eccentric exercise has shown to cause an upregulation of insulin-like growth factor (IGF-I). Thi upregulation of IGF-I is associated with cellular proliferation and matrix remodelling within the tendon [38].

Programs of eccentric exercise have been proposed as a key element in strength training in rehabilitation because they can supposedly counteract the response of defective healing that apparently underlies tendinopathy by promoting the creation of collagen fiber within the tendon [39,40]. Th literature places increasing emphasis on the importance of a proper choice of the load used [41].

Th continuum model in tendinopathy (reactive tendinopathy, tendon dysrepair and degenerative tendinopathy) provides a reasoned basis for believing that the protocol to be performed depends on the current clinical presentation [17]. Th protocol proposed by Alfredson et al. is generally used [39]. It consists of three sets of 15 repetitions, performed twice a day, seven days a week for 12 weeks.

Ohberg et al. [42] examined tendon structure by grey-scale ultrasound in 26 tendons with Achilles tendinosis, which had been treated with eccentric exercise. Remarkably, afte a mean follow up of 3.8 years, 19 of 26 tendons had a more normalised structure, as gauged by their thickness and by the reduction of hypoechoic areas.

Visnes et al. [43] suggested that eccentric training had a positive effec on patellar tendinopathy and recommended that athletes suspend sports activity during rehabilitation.

Th gradual progression from eccentric-concentric to eccentric followed by a faster loading can benefi patients with Achilles tendinopathy cannot start with a program proposed by eccentric

Alfredson et al. [39] due to pain or weakness of the sural triceps muscle [44].

Isoinertial eccentric training (YoYoTechnology AB, Stockholm, Sweden) resulted in an improvement of muscle function and reduced pain in patients with patellar tendinopathy [45]. Th combination of EPI® technique and isoinertial eccentric exercise offer good results in the treatment patellar tendinopathy [46].

EPI® technique

In recent years, the intratissue percutaneous electrolysis (EPI®) technique has become more relevant in the scientifi literature [46-48] given the good results yielded in the treatment of patellar degenerative tendinopathy in comparison to other previous conservative treatments.

Thi technique, created by Sánchez-Ibáñez [49,50] and who have over 15 years' experience in its use, uses a flo of cathodic current directed exclusively to the area of degenerated tendon through an ultrasound-guided needle that brings about an organic reaction that leads to rapid regeneration of the degenerated tendon.

Th application of ultrasound-guided EPI® technique produces a non-thermal electrochemical reaction centered on degenerated tissue (tendinosis). Thi leads to a controlled local inflammator reaction that leads to the regeneration of damaged tissue [48,51].

In experimental studies with human tendon injury, there has been a disproportionate expression of certain cytokines and matrix metalloproteinase (MMPs), prostaglandin E2 (PGE2), interleukin-6 (IL-6) and interleukin-1b (IL-1b) [52,53]. IL-1b in turn increases the production of matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-3 (MMP-3) and prostaglandin E2 (PGE-2) [53].

A recent experimental study [48] showed that with the use of EPI® technique in patellar tendinopathy increase of anti-inflammator proteins, like peroxisome proliferator-activated receptor gamma (PPAR-γ). Thes proteins play a key role in the inhibition of expression of proinflammator molecules secreted by macrophages, such as tumor necrosis factor alpha (TNF-α), IL-6 and IL-1β, thus producing in the treated tissue a highly beneficia molecular response during degenerative tendinopathy. This in turn, results in an increase of the expression of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor 2 (VEGFR-2), mediators responsible for angiogenesis anti-inflammator response. Th EPI® technique makes for the activation of molecular and cellular mechanisms of the tendon responsible for phagocytosis and the regeneration of degenerated tissue.

In recent research to evaluate the therapeutic effect EPI® technique on the patellar tendinopathy [46]. Th results documented were good and stable with the Victorian Institute of Sport Assessment-Patella (VISA-P) score, Tegner scores and Roles and Maudsley score, and terms of clinical and functional improvement in patellar tendinopathy and providing a follow-up of 10 year.

Th EPI® technique (Figure 2) achieves a much localized organic reaction in the clinical focus by using a specially designed device for this purpose (EPI Advanced Medicine®, Barcelona, Spain. EPI® technique videos online: www.epiadvanced.com), which leads to the rapid regeneration of degenerated tissue. Thi leads to the production of new immature collagen fiber that become mature by means of eccentric stimulus [47], thereby obtaining good results in the short and long-term in terms of pain and function.



Figure 2: A) Treatment of patellar tendinopathy with ultrasound-guided EPI®- MTR device (EPI Advanced Medicine®, Barcelona, Spain). B) Ultrasound longitudinal view of patellar tendinopathy with area of fibrilla rupture. C) Treatment is directed exclusively to the area of tendon injury. Note the electrochemical reaction (white area) produced on the tip of the needle, just in the area of damaged tissue. D) Longitudinal ultrasound view of patellar tendinopathy, three weeks post-treatment with EPI® technique. Note that the area of fibrillar rupture has been replaced by new connective tissue.

Extra-corporeal shock wave therapy (ESWT)

Several clinical trials have evaluated the use of extra-corporeal shock waves therapy (ESWT) for the treatment of patients with chronic tendinopathy with divergent results [28,54,55]. Multiple variables are associated with this therapy, the type of shock wave generator (electrohydraulic, electromagnetic or piezoelectric), the wave type (radial or focal), the intensity (total energy per shock waves/session), the frequency and the protocol of application and repetitions [56].

Some of the effect of ESWT on tendinopathies like the inhibition of nociception with the release of substances which inhibit pain (endorphins), the increase in the permeability of cell membranes of neurons and cellular damage that could create immediate analgesia have been described [25].

Other biological effect of ESWT described, are the induction of specifi growth factors (TGF-β1 and IGF-1) which play an important anabolic and mitogen role, increased blood flow mediators of the inflammator process, and increased release of hydroxyproline tenocytes of proliferation and collagen synthesis [57].

However, evidence of the effectivenes of ESWT in the treatment of tendinopathy is inconsistent, still so, it is widely used in sports medicine and physiotherapy [58]. It appears that the combination of treatments may have a synergistic effec and lead to better results. In this sense, a study showed better results by combining the ESWT and eccentric exercises than by performing eccentric exercises alone [59, 60].

Platelet-rich plasma (PRP)

Platelets are nonnucleated cytoplasmic bodies derived from megakaryocyte precursors. The play a pivotal role in hemostasis and wound healing via the formation of fibri clots. Therefore increasing platelet concentration in injured tissue and may result in an exponential release of diverse bioactive factors and, subsequently, enhance the healing process [61].

Injections with platelet rich plasma (PRP) has been used for the treatment of tendinopathy with the aim of providing cellular and humoral mediators to induce healing in areas of degeneration. Despite the long road ahead toward establishing an agreed protocol on the use of PRP [62,63], it is a widespread treatment option for the treatment of chronic tendon injuries and its beneficia effect have been demonstrated in several studies [70].

A recent experimental study showed that with the use of PRP in patellar tendinopathy, there was an increase in fibroblast and bone marrow stem cells inside of and around the injury. Cell proliferation was twice as high and the PRP-treated group also showed a significan increase in type I and III collagen when compared to the control group [64]. Another in vitro study in humans showed that following the application of PRP, there was increased cellular proliferation, collagen production in tenocytes, an overexpression of the receptor of vascular endothelial growth factor-A (VEGF-A) and an increase in the concentration of transforming growth factor beta (TGF-B), indicating an increase in the production of type I and III collagen [65]. Despite everything described, it should be noted that there are differen techniques for the preparation of PRP, thus obtaining differen volumes and concentrations of platelets [66,67].

Filardo et al. [68] evaluate the therapeutic effect of multiple PRP injections on the healing of chronic refractory patellar tendinopathy. Th results documented were good and stable with the VISA-P score. Th ultrasound measurements showed that tendon thickness and neovascularization level gradually decrease over time, despite an initial increase afte the injection cycle.

Dallaudiére et al. [69] also aimed to assess the effica and tolerance of intratendinous injection of PRP to treat tendinopathy. Thi study included 41 patients had patellar tendinopathy. Th average WOMAC scores of 41 patients with patellar tendinopathy improved from 38 to 16 at the 6-week follow-up and more improved (6 scores) at 32-month follow-up. No clinical complication was reported during follow-up. Thi study demonstrates that the ultrasound-guided injection of PRP allows rapid healing of tendon with good tolerance.

Another study of randomised control trials (RCT) by Dragoo et al. [70] compared a regimen of eccentric exercises combined with either ultrasound-guided PRP injection or ultrasound-guided dry needling alone in the treatment of patellar tendinopathy. Th PRP group showed significantl better improvement than the dry needling group in VISA-P score at 12 weeks. However, at 26-week follow-up, the differenc between the PRP and dry needling groups dissipated in all assessed scores, such as VISA-P, Tegner, VAS, and short form-12 (SF-12) scores.

Sclerosant injections (polidocanol)

Based on the theory that neovascularization are associated with an underlying mechanism due to overuse in tendinopathies. Th randomized, double-blind trial by Alfredson and Öhberg focused on the potential benefi of the sclerosing substance polidocanol on chronic tendinopathies. Th VAS pain and the patient's satisfaction at 3 months of those who were injected, compared with those of whom received injections of local anesthetics only, supported the superiority of the tested treatment, with significan difference in the values recorded ($p<0.005$) [71].

Th use of polidocanol (a vascular sclerosing agent) has been put forth for the treatment of the same [72]. Polidocanol is used to sclerose areas of high intratendinous blood flow which is sometimes called "neovascularization", visible histopathologically [73] and in vivo by means of high-resolution ultrasound with color doppler.

Some studies have reported effect using polidocanol for patellar tendinopathy, tennis elbow or Achilles tendinopathy [72,74,75].

Studies that associate sclerosing injections and eccentric training have shown a decrease in pain during eccentric training, resulting in complete resolution of pain in the short term Achilles tendinopathy [26].

Zeisig et al. [76] they reported that maintained sclerosis neovascularization in lateral elbow epicondylitis was a good predictor of positive clinical effec at 2 years follow-up.

High-volume image guided injection (HVIGI)

Differen methodologies have been described when applying HVIGI. In one study in athletes with achilles tendinopathy, patients were treated with 10 ml of 0.5% bupivacaine hydrochloride injection plus 40 ml saline solution and 25 mg of aprotinin. Th HVIGI with aprotinin showed a significan improvement in pain and function in both the short and long term follow up of 12 months [77].

Study groups like those of Chan et al. [78] reported good results with the use of high volume image-guided injections (HVIGI) in the treatment of tendinopathy mainly of the Achilles and patellar tendon, claiming that they significantl reduce pain and improve function.

Thi intervention uses large volume injections of saline solution, corticosteroids or an anesthetic that make the neovessels stretch, break or occlude. Occlusion or interruption of neovessels supposedly also affect the innervation that it accompanies [79].

Hyaluronic acid (HA)

Possible biological effect of hyaluronic acid (HA) in tendinopathies be related with an anti-inflammator activity, enhanced cell proliferation, and collagen deposition, besides the lubricating action on the sliding surface of the tendon.

Study groups like those of Petrella et al. [80] determined the effica of periarticular HA injections in patients with chronic lateral epicondylosis. Pain, both at rest and afte grip testing, was significantl reduced in the study group compared to controls.

Muneta et al. [81] reported good results with the use of HA in the treatment of patellar tendinopathy. Afte treatment, 94% of patients were rated in excellent in good conditions complained of some degree of limitation.

Injections of the MMP-inhibitor (Aprotinin)

Tendinopathies, are characterized by changes in expression and activity of various metalloproteinase enzymes that degrade the matrix which are consistent with increased proteolytic activity in the degenerate tendons [25].

Aprotinin is a broad spectrum inhibitor of matrix metalloproteinase (MMPs) [82]. It is suggested that by inhibiting the enzymes that break down or degrade tendons, the healing response may be promoted.

In a study by Orchard et al. [83] with 430 patients sufferin from patellar and Achilles tendinopathy treated with local injections of aprotinin, the results showed that, at a minimum follow-up of 3 months (range 3-54 months), 76% of patients improved clinically and functionally.

Brown et al. [84] conducted a randomized control trial study (RCT) the use of aprotinin in the treatment of Achilles tendinopathy, 26 patients divided into 2 groups, one group with aprotinin injection and another group with saline (placebo). Ther were no significan differenc scores in VISA-A (p=0.946) at 52 weeks of follow-up.

Stem cells

In the last few decades, several emerging strategies including with mesenchymal stem cells (MSC) have been proposed to enhance tendon healing. Stem cells are undifferentiate cells with ability of self-renewing and differentiatin in progenitor or precursor cells. Th latter are committed cells for a specifi cell lineage, but are not able to self-renew [85].

Human MSCs have been isolated from adipose tissue, umbilical cord, placenta, peripheral blood, connective tissues of the dermis and skeletal muscle [86-91].

A stem cell population has been recently identifie in human tendons, residing in a unique tendon extracellular matrix (ECM) niche [92].

Tendon stem cells (TSCs) have been described in 2007 by Bi et al. [92]. Thes stem cells present in mature tendon have multi-differentiatio and self-renewal potential [92]. The can differentiat into other cell types, like muscle or fat cells. Thes cells have been implicated as possible cause of chronic tendinopathy because of the erroneous differentiatio into abnormal matrix components causing fatty degeneration and calcification Thes cells are still in the preclinical experimentation stage but have great potential for tendon therapy in the future [93].

TCSs could be involved in tendon homeostasis, remodelling, and repair, by ensuring replacement of mature cells lost, or in the pathogenesis of tendinopathy, as this tendon disorder is associated with chondroid and fatty degeneration, and ossificatio [94].

Since the tendon cell rate is low like its biological turnover, it has recently been proposed that adult stem cells would be good candidates for the regeneration of the tendon [95]. However, the exact role in the healing process of stem cells implanted into the tendon remains uncertain. One possibility is that they differentiat into tenocytes and are involved in healing by producing collagen and remodeling. It has also been suggested that the mononuclear bone marrow stem cells (BM-MNC) can aid in healing by acting as "growth factor pumps" rather than through terminal differentiatio [96].

In vitro research has shown encouraging results with the use of stem cells for the treatment of degenerative diseases, like tendinopathy, of the musculoskeletal system [97].

Bone marrow mesenchymal cells (BMSCs) have been shown effectiv in the management of superficia digital flexo tendon injuries in horses; BMSCs were inoculated in the injured tendons leading to lower of re-injury rate compared with the re-injury rate obtained with the conventional non cellular based management [98,99].

An experimental study conducted by Lacitignola et al. [100] showed in an in vivo collagenase-induced superficia digital flexo tendinopathy study of horses, that when injected with autologous BMSCs intratendinous it produced a regeneration effec on the tendon.

Also adipose derived stem cells were showed to be effectiv in the treatment of equine tendinopathies leading to normal horse activity recovery [101].

Obaid et al. [102] perform a RCT study of 40 human patients diagnosed with Achilles tendinosis, a group that was treated with autologous stem cells derived from skin and other serum group saline (placebo). Clinical outcomes were assessed with VAS and VISA-A questionnaire at 3 and 6 months follow-up. Significan improvements in the experimental group compared to the placebo group in VISA-A (p=0.02) and VAS (p<0.001) scores were found.

In theory, pluripotent stem cells can be isolated and then be integrated into an area of need of the tendon. Once stem cells are at the desired location, either by local signaling or by the addition of exogenous factors, they can lead pluripotent cells to differentiatin into the desired cell line [25].

Surgery

Historically, surgery has been proposed as a salvage technique if other treatments fail [103,104], showing similar functional results using an open or arthroscopic technique [105], and the latter with less comorbidity. With surgery, the removal of the degenerated tissue or calcification in order to promote the tissue response is generally sought.

Lorbach et al. [106] performed a prospective study to evaluate the clinical results of arthroscopic resection of the lower patellar pole in patients with patellar tendinopathy. Th main conclusion was that arthroscopic resection of the lower patellar pole as a minimal invasive method to treat patellar tendinopathy provides satisfactory clinical results in knee function and pain reduction with fast recovery and return to sport activities.

Kelly examined the results of arthroscopic tendon debridement with excision of the distal pole of the patella for refractory patellar tendinopathy [107]. He concluded that arthroscopic excision of the distal patellar pole with tendon debridement holds promise for the treatment of refractory patellar tendinopathy.

Shelbourne et al. [108] reported that surgical removal of necrotic tissue, surgical stimulation of remaining tendon, and aggressive rehabilitation afte patellar tendonectomy could allow athletes to return to sports. Overall, tendonectomy, surgical tendon stimulation, and aggressive post-operative rehabilitation were found to be a safe, effectiv way to return high-level athletes to their sports.

Analysis of the surgical treatments is complicated given the difference between both techniques, as well as the heterogeneity of the samples and the differen protocols used postoperatively [105].

Discussion

Treatment of tendon injuries is a subject of frequent debate in sports medicine and physiotherapy. Multiple techniques have been described for their treatment and although some of them [46,56,71,106,107].

To date, there is no consensus on the optimal treatment of tendinopathies. It has been suggested that the incomplete understanding of the underlying mechanisms (etiology of the condition), limits the ability to develop effectiv treatment strategies [108]. Are emerging as the most accepted treatment option, more RCT's are still needed to clearly establish what the therapeutic protocol therapeutic to follow should be.

Doubts have mainly centered on the fact that there are few controlled prospective studies that analyze all aspects of tendinosis, and few studies that investigate the early stages of these processes and their healing mechanisms. Th exact mechanism by which tendinopathy develops in humans remains the target of numerous investigations. A variety of degenerative characteristics associated tendinopathies, including accumulation glycosaminoglycan (GAG), calcificatio and lipid accumulation nerve damage and hyperinnervation, is one of the theories whose publications are scarce, despite its special interest in explaining the possible pathophysiological mechanisms of pain in tendinopathy [109].

In several studies it has been shown that there is a correlation between tendinopathy and hyperinnervation, citing that the production of nerve growth factor (NGF) and the corresponding hyperinnervation could be induced by repetitive ischemic crisis in osteotendinous union [110,111]. Thi growth of nerve fibers which causes chronic pain, could be part of a process of abnormal tissue repair, preceded by repetitive micro trauma [112].

Despite its prevalence, the precise pathogenic mechanisms of tendinopathy are not clear and, as a result, current treatments of tendinopathies are largely empirical and not always efficie [17,113]. Th continuum model of tendon pathology was proposed to provide a model for the staging of tendon pathology and to assist clinicians in managing this ofte complex condition. Th model presents clinical, histological and imaging evidence for the progression of tendon pathology as a three-stage continuum: reactive tendinopathy, tendon disrepair and degenerative tendinopathy [17].

Th use corticosteroids are by far the most utilized treatment in all painful tendinopathy. Da Cruz et al. [114] investigated the role of corticosteroid injections in Achilles tendinopathy, at fina follow-up (12 weeks), they were not able to fin a significan higher improvement within the intervention group in any of the primary outcomes measured.

Others authors [115] consider that in the absence of an inflammator process, there is no rational basis for the use of NSAIDs in chronic tendinopathy.

Chen et al. [116] believe that local infiltratio of corticosteroids is associated with an increased risk of spontaneous tendon rupture.

A review study conducted by Dean et al. [117] reported that the effect of corticosteroid injection, reduce cell viability, cell proliferation is reduced, degrades collagen, produces higher tendon necrosis, decreases the mechanical properties of the tendon, and it produces significan long-term tissue damage and tendon cells.

One of the clinical effect that eccentric exercises might have in tendinopathy is in pain modulation due to changes in glutamate content or in the central nervous system with increased activation of inhibitory neurons and cortical reorganization [71,118]. Ther is little evidence that isolated eccentric exercise reduces pain in tendinopathy compared with concentric exercise [119].

It is considered that hypoxia could be responsible for neovascularization in tendinopathies, capillary flo and post-capillary pressure decreased following 12 weeks of eccentric loading [120].

In the treatment of tendinopathy, there is conflictin evidence that eccentric exercises are superior to other load programs [119]. Eccentric work on an inclined plane did not improve functional outcomes when it was done during a competitive season in volleyball [121]. In another study, continuous sporting activity did not compromise clinical outcomes at 12 months, as long as the sport was introduced incrementally ensuring minimal pain during and afte loading [122]. Eccentric decline squat training and heavy slow resistance training showed good long-term clinical results, and heavy slow resistance training also resulted in advantages in pathological improvement and increased collagen turnover [37].

Some authors have demonstrated better results with eccentric exercise on corporeal tendinopathies in comparison with enthesopathies [35].

Further studies are needed to assess the unique effect of an eccentric strengthening program. Eccentric loading should be considered in conjunction with the concentric rather than just eccentric loading in Achilles and patellar tendinopathy. Patients with marked muscle weakness may benefi from a program of progressive eccentric-concentric loading [122]. On the other hand, maximal eccentric loading may be best for some groups of patients and permit adaptive changes in the tendon [45].

Despite the fact that the eccentric muscle workout has become the dominant conservative strategy in treating Achilles and patellar tendinopathy, up to 45% of patients do not respond to this treatment [123].

A recent study suggests that sedentary subjects with Achilles tendinopathy may show less promising results with eccentric exercise therapy compared to athletic subjects [124].

In the treatment of chronic lateral epicondylalgia where they were randomly assigned to three groups, one assigned to a stretching program, another to eccentric strengthening and the last to eccentric strengthening with stretching, no significan differenc was observed either in the evaluation of strength or the visual analog pain scale [125].

Despite some good results reported with eccentric programmes [123,126], it is still unclear as to the more effectiv exercise protocol, its frequency, load and dosage.

Despite over 15 years of experience in the use of the EPI® technique and its widespread deployment in sporting clubs around the world, this technique has grown in relative to scientifi dissemination in recent years [46].

An experimental study showed that afte application of the degenerated tendon EPI® technique, an increase in anti-inflammator proteins, like PPAR-γ has been observed afte treatment with the EPI® technique. Thes proteins play a key role in the inhibition of expression of proinflammator molecules secreted by macrophages, such as TNF-α, IL-6 and IL-1β [127] thus producing in the treated tissue a highly beneficia molecular response during tendinopathy. This in turn, results in an increase of the expression of VEGF and VEGFR-2, mediators responsible for angiogenesis anti-inflammator response [128,129].

In another recent study by Sánchez-Ibàñez and co-workers [46] it has been illustrated that when treatment with the US-guided EPI® technique and eccentric exercises in patellar tendinopathy it resulted in extensive improvement in the knee function and a rapid return to the previous level of activity afte few sessions. Th limitation of this study is the absence of a control group of subjects.

References to the use of the EPI® technique in combination with eccentric exercise can be found in the literature. In those cases the EPI® technique focuses on biological tissue recovery, leaving the functional recovery of tissue biomechanics to eccentric exercise.

Th EPI® technique is mainly contraindicated in patients with tumors, articular or systemic infection and bleeding disorders [49].

Regarding the effectivenes of extra-corporeal shock waves therapy (ESWT) for tendinopathy, according to published studies, conclusive results cannot be drawn because the clinical effect are unclear [130,131]. Th effectivenes of ESWT may depend on the stage of tendinopathy, it seems more appropriate in degenerative tendinopathy and where conservative treatment has little or no effec [17].

Th mechanisms of the therapeutic effec of ESWT in tendinopathy with calcificatio are also uncertain. It has been proposed that the increased pressure within the therapeutic focus produces a fragmentation and cavitation effec within calcification and leads to the disruption and disintegration of calcium deposit [132].

Some studies have shown that ESWT is as effectiv as surgery, but cheaper, and this treatment seems to be a supplement for the treatment of those tendinopathies who are refractory to conventional therapies [133]. In this sense, studies using high-energy ESWT do better in the tendinopathies than those using low-energy ESWT [54]. Thi is consistent with a recent study that showed ESWT had no effec in athletes with patellar tendinopathy who actively compete [130]. Currently, there is a controversy relative to the utilization of ESWT in the treatment of patellar tendinopathy [134] as well as in Achilles tendinopathy [54].

With the use of the platelet-rich plasma (PRP), the intention is to enhance the natural healing process at the site of injury through the action of growth factors (PDGF, IGF-1, VEGF, bFGF, TGF-β1, EGF, etc.) to promote matrix synthesis and the healing of injured tissue [135]. It should be noted that the delicate balance between these growth factors may have important implications in the control of angiogenesis and fibrosi [135].

Although many studies have been reported positive results using PRP [136,137], others have shown the same effec in comparison with a placebo [138,139]. De Vos et al. [139] found no significan difference between the group of patients with Achilles tendinopathy treated with PRP and the group treated with saline (placebo) to kept under review 24 weeks; these results agree with de Jonge et al. [138].

At the same time, many questions are raised about what the optimal concentration of platelets should be, in which phase of the injury is it better to do infiltratio or how it should be prepared [66]. Caution is warranted when comparing differen PRP studies, differen types of PRP or PRP-derived products have been used, with a variety of platelet concentrations, inclusion of leucocytes, the use of anticoagulant and the use of activating agents.

Throug the present research, it is hard to draw a clear conclusion for the effectivenes of PRP treatment on tendinopathy.

PRP injections should be avoided in patients sufferin from infection, tumoral disease, coagulation disorders and changes in the number of platelets [135].

Th use of polidocanol injection is based on the belief that neovascularizations are associated with the mechanism underlying tendinopathy due to overuse. Although it is unclear whether this is a causal agent in the pathophysiology of tendinopathy [140]. In fact, these "neovessels" may be associated with the ingrowth of nerves in the areas of pathological tendons [141] and it is possible that nerve fiber are the pain generators in chronic tendinopathy [142]. A priori, polidocanol injections may not only sclerose the veins, but may also eliminate the pain nerve fiber [25]. Although polidocanol injections appear to provide pain relief, it is unclear what role they can play in tendon healing in tendinopathy.

Hoksrud et al. [74] reported reduced pain afte ultrasound-guided sclerosing in patients with patellar tendinopathy, contradictory results were recently presented in a retrospective study [143] in which sclerosing injections in 48 patients with chronic Achilles tendinopathy revealed less promising results than expected [143]. Even though capilliary blood flo may decrease by around 25% [144] some authors say that there is no relationship between changes shown in ultrasound and tendon function afte sclerosing treatment.

Willberg et al. [145] compared the clinical effect in patellar tendinopathy afte treatment with sclerosing polidocanol injections and arthroscopic shaving. Afte treatment, the patients treated with arthroscopic shaving had a significantl lower visual analogue score (VAS) score at rest and during activity, and were significantl more satisfie compared with the patients in the sclerosing injection group.

Prospective comparative studies involved small numbers of patients: polidocanol injections were superior to lidocaine injections [75], and similar results were found when compared with patients undergoing mini-open surgery [146].

Although some studies that associate sclerosing injections with eccentric training have shown a decrease in pain [26], further studies to evaluate its safety (possible nerve damage) and effectiveness to determine the injection protocol (volume/concentration) and its combination with other therapies are needed [141].

Avoid injection of polidocanol in patients who previously had an allergic reaction to polidocanol or diagnosed with a blood clotting disorder. Nor it is recommended in pregnant or latency [141].

While some authors advocate the use of high-volume image guided injection (HVIGI) in treating refractory tendinopathy [77,147]. Preliminary studies have shown that a HVIGI with normal saline, local anaesthetic and corticosteroid can significantl reduce pain and improve short- and long-term function in patients with Achilles tendinopathy [77,78,147] reported results are not conclusive nor homogeneous enough to establish a protocol for use.

HVIGI adverse effect are similar to those of other injection techniques. Caution must be exercised with the administration of the diluted corticosteroid, for possible risk of tendon rupture and should not be injected into the ducts inside and outside the tendon [77].

Hyaluronic acid (HA) is actively secreted by the tendon sheath it is an important component of the synovial fluid which allows a smooth tendon gliding, and provides nutrition to tendon itself [148]. Moreover, it is an important component of tendon structure, being largely present in extracellular space.

Several studies have been performed to evaluate the effica of HA on adhesions, gliding resistance, and tendon healing [149-152].

Despite the promising results of HA injections for treating tendinopathy in most of the studies the joint space has been injected and not into the tendon, and it could be that the modificatio of the synovial flui exerts a positive effec on the tendon [153].

Avoid introduction of HA into the tendon and the peritendinous fat to avoid delete rating effect [81].

Aprotinin injections have been shown to provide clinical improvement in tendinopathies, most successful in patients with Achilles tendinopathy or with patellar tendinopathy [55,82]. Also better results have been obtained with aprotinin injections with corticosteroid injections or saline [82].

Moreover, in 7% of cases systemic allergic reactions occurred when aprotinin injections were applied at intervals of 2 to 4 weeks, but if applied every 6 weeks the reactions of systemic allergy was reduced significantl to 0-9%. Positive IgG antibodies against aprotinin patients most at risk of an anaphylactic reaction during treatment with this; therefore the authors recommend that if this type of technique is to be used the necessary equipment to treat anaphylaxis should be present [152].

Brown et al. [84] investigated whether aprotinin could achieve better improvement than the usual rehabilitation protocol adopted to treat Achilles tendinopathy in their RCT. The recorded VISA-A scores, tenderness, satisfaction and other clinical parameters and demonstrated no significan statistical differences

It has been suggested that the effica of stem cells is related to its state of differentiation i.e., the greater the state of differentiatio the more effectiv will the effec be in the healing of the tissues in which they are implanted [154]. Keeping this statement in mind, it should be remembered that the cells that are better able to differentiat have lower telomere length and therefore a greater degree of aging during wound healing and therefore may not be able to complete the necessary steps in the process of regeneration and produce a useful and sufficie cellular matrix [155].

Another important aspect concerning the use of stem cells is their viability during the inflammator phase of the tendon [154]. During the inflammator phase, differen types of cytokines, cytotoxic proteins and inflammator factors are released by necrotic tissue and inflammator cells reduce the possibilities of viability of stem cells in the host [97,154].

Stem cells are promising candidate for the management of tendinopathies and tendon rupture. However, these cell-based strategies have been investigated only in preclinical studies and the role of stem cells needs to be confirmed Tendon stem cells have been hypothesized to have a crucial role in the development of calcifying tendinopathy due to the erroneous differentiatio of tendon stem cells (TSCs) to chondrocytes or osteoblasts. For this reason it was hypothesized that the re-direction of the differentiatio of resident TSCs or supplementation of mesenchymal stem cells (MSCs) programmed for tenogenic differentiatio may be appealing targets for the treatment of tendinopathy in the future [156].

Th use of stem cells is in the early stage of clinical application in humans. Ther is only one clinical study performed on human subjects showing that inoculation of bone marrow mononuclear cells (BMMNC) in tendinopathy patellar has good mid-term clinically and ultrasound results [155]. As demonstrated by these preliminary studies, management of tendinopathies with stem cells is promising even though more clinical studies are needed to validate this treatment approach.

Despite the growing interest in this type of therapy and its expected potential, there are still many open questions to answer in order to implement these techniques in the tendinopathy treatment protocol. Further research is required to identify mechanisms involved in tendon regeneration and in survival, proliferation, and differentiatio of stem cells.

Although the results shown by some authors with the surgical treatment of tendinopathy [157-159] showed that surgery did not show advantages over eccentric exercise in their RCT. In addition, the low predictability of the results obtainable through surgery make it such that this technique should be put forward only in selected cases and afte other conservative options fail.

It is commonly accepted that surgical treatment must be indicated in motivated patients if carefully followed conservative treatment is unsuccessful afte 3-6 months [103,104]. Th literature, however, does not clarify which surgical technique is more effective

Conclusion

In this report, a brief review of treatment approaches of tendinopathy was conducted. Tendinopathy is a condition that causes significan pain and disability in many patients. Currently, the etiology of tendinopathy is still unclear, it is multifactorial, and influence by intrinsic and extrinsic factors. Tendinopathy ofte becomes chronic because the exact pathogenesis remains largely unknown. Th continuum model of tendon pathology was proposed to provide a model for the staging of tendon pathology. Physicians and physiotherapist have a variety of therapeutic options available to treat tendinopathies but, in each case, there is a lack of evidence supporting their use as the gold standard treatment. Larger randomized controlled trials on the various treatment options and even comparative studies between them are needed to determine the treatment of choice (Gold Standard) for tendinopathies.

Acknowledgement

We are grateful to Julita Cuquerella and David MacManus for your help in editing the manuscript.

Author Contributions

Wrote the firs draft of the manuscript: JMS, MEF, JCM, AAD, JSG, JSS. Contributed to the writing of the manuscript: JMS, MEF, JCM, AAD, JSG, JSS. Agree with manuscript results and conclusions: JMS, MEF, JCM, AAD, JSG, JSS. Jointly developed the structure and arguments for the paper: JMS, MEF, JCM, AAD, JSG, JSS. Made critical revisions and approved fina version: JMS, MEF, JCM, AAD, JSG, JSS. All authors reviewed and approved the fina manuscript.

Disclosures and Ethics

Th authors declare that one author has the patent for the EPI devices® and one author is the creator of the EPI® technique.

References

1. Tresoldi I, Oliva F, Benvenuto M, Fantini M, Masuelli L, et al. (2013) Tendon's ultrastructure. Muscles Ligaments Tendons J 3: 2-6.
2. Couppé C, Kongsgaard M, Aagaard P, Hansen P, Bojsen-Moller J, et al. (2008) Habitual loading results in tendon hypertrophy and increased stiffnes of the human patellar tendon. J Appl Physiol (1985) 105: 805-810.
3. Langberg H, Skovgaard D, Asp S, Kjaer M (2000) Time pattern of exercise-induced changes in type I collagen turnover afte prolonged endurance exercise in humans. Calcif Tissue Int 67: 41-44.
4. Kannus P (1997) Etiology and pathophysiology of chronic tendon disorders in sports. Scand J Med Sci Sports 7: 78-85.
5. Kvist M (1994) Achilles tendon injuries in athletes. Sports Med 18: 173-201.
6. Maffull N, Wong J, Almekinders LC (2003) Types and epidemiology of tendinopathy. Clin Sports Med 22: 675-692.
7. Edelstein L, Thoma SJ, Soslowsky LJ (2011) Rotator cuff tears: what have we learned from animal models? J Musculoskelet Neuronal Interact 11: 150-162.
8. Butler DL, Gooch C, Kinneberg KR, Boivin GP, Galloway MT, et al. (2010) Th use of mesenchymal stem cells in collagen-based scaffold for tissue-engineered repair of tendons. Nat Protoc 5: 849-863.
9. Hess GW (2010) Achilles tendon rupture: a review of etiology, population, anatomy, risk factors, and injury prevention. Foot Ankle Spec 3: 29-32.
10. Scott A, Ashe MC (2006) Common tendinopathies in the upper and lower extremities. Curr Sports Med Rep 5: 233-241.
11. Fredberg U, Stengaard-Pedersen K (2008) Chronic tendinopathy tissue pathology, pain mechanisms, and etiology with a special focus on inflammation Scand J Med Sci Sports 18: 3-15.
12. Ferretti A, Papandrea P, Conteduca F (1990) Knee injuries in volleyball. Sports Med 10: 132-138.
13. Lian OB, Engebretsen L, Bahr R (2005) Prevalence of jumper's knee among elite athletes from differen sports: a cross-sectional study. Am J Sports Med 33: 561-567.
14. Alfredson H, Lorentzon R (2002) Chronic tendon pain: no signs of chemical inflammatio but high concentrations of the neurotransmitter glutamate. Implications for treatment? Curr Drug Targets 3: 43-54.
15. Cook JL, Khan KM, Maffull N, Purdam C (2000) Overuse tendinosis, not tendinitis part 2: applying the new approach to patellar tendinopathy. Phys Sportsmed 28: 31-46.
16. Warden SJ, Kiss ZS, Malara FA, Ooi AB, Cook JL, et al. (2007) Comparative accuracy of magnetic resonance imaging and ultrasonography in confirmin clinically diagnosed patellar tendinopathy. Am J Sports Med 35: 427-436.
17. Cook JL, Purdam CR (2009) Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy. Br J Sports Med 43: 409-416.
18. Maffull N, Testa V, Capasso G, Ewen SW, Sullo A, et al. (2004) Similar histopathological picture in males with Achilles and patellar tendinopathy. Med Sci Sports Exerc 36: 1470-1475.
19. Kader D, Saxena A, Movin T, Maffull N (2002) Achilles tendinopathy: some aspects of basic science and clinical management. Br J Sports Med 36: 239-249.
20. Backman LJ, Andersson G, Wennstig G, Forsgren S, Danielson P (2011) Endogenous substance P production in the Achilles tendon increases with loading in an in vivo model of tendinopathy-peptidergic elevation preceding tendinosis-like tissue changes. J Musculoskelet Neuronal Interact 11: 133-140.
21. Alfredson H, Forsgren S, Thorse K, Fahlstrom M, Johansson H, et al. (2001) Glutamate NMDAR1 receptors localised to nerves in human Achilles tendons: Implications for treatment? Knee Surg Sports Traumatol Arthrosc 9: 123-126.
22. Molloy TJ, Kemp MW, Wang Y, Murrell GA (2006) Microarray analysis of the tendinopathic rat supraspinatus tendon: glutamate signaling and its potential role in tendon degeneration. J Appl Physiol (1985) 101: 1702-1709.
23. Cook JL, Khan KM (2001) What is the most appropriate treatment for patellar tendinopathy? Br J Sports Med 35: 291-294.
24. Peers KH, Lysens RJ (2005) Patellar tendinopathy in athletes: current diagnostic and therapeutic recommendations. Sports Med 35: 71-87.
25. Andres BM, Murrell GA (2008) Treatment of tendinopathy: what works, what does not, and what is on the horizon. Clin Orthop Relat Res 466: 1539-1554.
26. Alfredson H (2005) Conservative management of Achilles tendinopathy: new ideas. Foot Ankle Clin 10: 321-329.
27. Fournier PE, Rappoport G (2005) [Tendinopathy: physiopathology and conservative treatment]. Rev Med Suisse 1: 1840-1842, 1845-1846.
28. Glaser T, Poddar S, Tweed B, Webb CW (2008) Clinical inquiries. What's the best way to treat Achilles tendonopathy? J Fam Pract 57: 261-263.
29. Tsai WC, Hsu CC, Chou SW, Chung CY, Chen J, et al. (2007) Effect of celecoxib on migration, proliferation and collagen expression of tendon cells. Connect Tissue Res 48: 46-51.
30. Riley GP, Cox M, Harrall RL, Clements S, Hazleman BL (2001) Inhibition of tendon cell proliferation and matrix glycosaminoglycan synthesis by non-steroidal anti-inflammator drugs in vitro. J Hand Surg Br 26: 224-228.
31. Christensen B, Dandanell S, Kjaer M, Langberg H (2011) Effec of anti-inflammator medication on the running-induced rise in patella tendon collagen synthesis in humans. J Appl Physiol (1985) 110: 137-141.
32. Järvinen TA, Järvinen TL, Kääriäinen M, Äärimaa V, Vaittinen S, et al. (2007) Muscle injuries: optimising recovery. Best Pract Res Clin Rheumatol 21: 317-331.
33. Coombes BK, Bisset L, Brooks P, Khan A, Vicenzino B (2013) Effec of corticosteroid injection, physiotherapy, or both on clinical outcomes in patients with unilateral lateral epicondylalgia: a randomized controlled trial. JAMA 309: 461-469.
34. Maffull N, Papalia R, D'Adamio S, Diaz Balzani L, Denaro V (2015) Pharmacological interventions for the treatment of Achilles tendinopathy: a systematic review of randomized controlled trials. Br Med Bull 113: 101-115.
35. Magnussen RA, Dunn WR, Thomso AB (2009) Nonoperative treatment of midportion Achilles tendinopathy: a systematic review. Clin J Sport Med 19: 54-64.
36. Coombes BK, Bisset L, Vicenzino B (2010) Effica and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet 376: 1751-1767.
37. Kongsgaard M, Kovanen V, Aagaard P, Doessing S, Hansen P, et al. (2009) Corticosteroid injections, eccentric decline squat training and heavy slow resistance training in patellar tendinopathy. Scand J Med Sci Sports 19: 790-802.
38. Olesen JL, Heinemeier KM, Gemmer C, Kjaer M, Flyvbjerg A, et al. (2007) Exercise-dependent IGF-I, IGFBPs, and type I collagen changes in human peritendinous connective tissue determined by microdialysis. J Appl Physiol (1985) 102: 214-220.
39. Alfredson H, Pietilä T, Jonsson P, Lorentzon R (1998) Heavy-load eccentric calf muscle training for the treatment of chronic Achilles tendinosis. Am J Sports Med 26: 360-366.
40. Mafi N, Lorentzon R, Alfredson H (2001) Superior short-term results with eccentric calf muscle training compared to concentric training in a randomized prospective multicenter study on patients with chronic Achilles tendinosis. Knee Surg Sports Traumatol Arthrosc 9: 42-47.
41. Magnusson SP, Langberg H, Kjaer M (2010) Th pathogenesis of tendinopathy: balancing the response to loading. Nat Rev Rheumatol 6: 262-268.

42. Ohberg L, Lorentzon R, Alfredson H (2004) Eccentric training in patients with chronic achilles tendinosis: normalised tendon structure and decreased thickness at follow up. Br J Sports Med 38: 8-11.
43. Visnes H, Bahr R (2007) Th evolution of eccentric training as treatment for patellar tendinopathy (jumper's knee): a critical review of exercise programmes. Br J Sports Med 41: 217-223.
44. Silbernagel KG, Thome R, Thome P, Karlsson J (2001) Eccentric overload training for patients with chronic Achilles tendon pain--a randomised controlled study with reliability testing of the evaluation methods. Scand J Med Sci Sports 11: 197-206.
45. Romero-Rodriguez D, Gual G, Tesch PA (2011) Effica of an inertial resistance training paradigm in the treatment of patellar tendinopathy in athletes: a case-series study. Phys The Sport 12: 43-48.
46. Abat F, Gelber P, Polidori F, Monllau JC, Sánchez-Ibáñez JM (2015) Clinical results afte ultrasound-guided intratissue percutaneous electrolysis (EPI®) and eccentric exercise in the treatment of patellar tendinopathy. Knee Surg Sports Traumatol Arthrosc 23: 1046-1052.
47. Abat F, Diesel WJ, Gelber PE, Polidori F, Monllau JC, et al. (2014) Effectivenes of the Intratissue Percutaneous Electrolysis (EPI®) technique and isoinertial eccentric exercise in the treatment of patellar tendinopathy at two years follow-up. Muscles Ligaments Tendons J 4: 188-193.
48. Abat F, Valles SL, Gelber PE, Polidori F, Stitik TP, et al. (2014) Molecular repair mechanisms using the Intratissue Percutaneous Electrolysis technique in patellar tendonitis. Rev Esp Cir Ortop Traumatol 58: 201-205.
49. Sánchez-Ibáñez JM. Clinical evolution in the chronic pattellar enthesopathy treatment by EPI® Technique guided-ultrasound - Study of several cases in sports population. [PhD. Thesis] Universidad de León. León. Spain. 2013.
50. Sanchez-Ibañez JM, Colmena C, Benabent J, Garcia-Herreros S, Valles SL (2013) New Technique in Tendon Sport Recovery. Percutaneous Electrolysis Intratissue (EPI®). Int J Phys Med Rehabil 1: 113.
51. Abat F, Valles SL, Gelber PE, Polidori F, Jorda A, et al. (2015) An experimental study of muscular injury repair in a mouse model of notexin-induced lesion with EPI® technique. BMC Sports Sci Med Rehabil 7: 7.
52. Skutek M, van Griensven M, Zeichen J, Brauer N, Bosch U (2001) Cyclic mechanical stretching enhances secretion of Interleukin 6 in human tendon fibroblasts Knee Surg Sports Traumatol Arthrosc 9: 322-326.
53. Tsuzaki M, Bynum D, Almekinders L, Yang X, Faber J, et al. (2003) ATP modulates load-inducible IL-1beta, COX 2, and MMP-3 gene expression in human tendon cells. J Cell Biochem 89: 556-562.
54. Furia JP (2006) High-energy extracorporeal shock wave therapy as a treatment for insertional Achilles tendinopathy. Am J Sports Med 34: 733-740.
55. Hennessy MS, Molloy AP, Sturdee SW (2007) Noninsertional Achilles tendinopathy. Foot Ankle Clin 12: 617-641, vi-vii.
56. Rompe JD, Maffull N (2007) Repetitive shock wave therapy for lateral elbow tendinopathy (tennis elbow): a systematic and qualitative analysis. Br Med Bull 83: 355-378.
57. Chao YH, Tsuang YH, Sun JS, Chen LT, Chiang YF, et al. (2008) Effect of shock waves on tenocyte proliferation and extracellular matrix metabolism. Ultrasound Med Biol 34: 841-852.
58. van der Worp H, van den Akker-Scheek I, van Schie H, Zwerver J (2013) ESWT for tendinopathy: technology and clinical implications. Knee Surg Sports Traumatol Arthrosc 21: 1451-1458.
59. Peers KHE (2003) Extracorporeal shock wave therapy in chronic achilles and patellar tendinopathy. Thesis KU Leuven (ISBN: 9058673049).
60. Rompe JD, Furia J, Maffull N (2009) Eccentric loading versus eccentric loading plus shock-wave treatment for midportion achilles tendinopathy: a randomized controlled trial. Am J Sports Med 37: 463-470.
61. Middleton KK, Barro V, Muller B, Terada S, Fu FH (2012) Evaluation of the effect of platelet-rich plasma (PRP) therapy involved in the healing of sports-related soft tissue injuries. Iowa Orthop J 32: 150-163.
62. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA (2009) Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med 37: 2259-2272.
63. Kaux JF, Degrave N, Crielaard JM (2007) Platelet rich plasma : traitement des tendinopathies chroniques? Revue de la litte´rature. Journal de Traumatologie du Sport 24: 99-102.
64. Kajikawa Y, Morihara T, Sakamoto H, Matsuda K, Oshima Y, et al. (2008) Platelet-rich plasma enhances the initial mobilization of circulation-derived cells for tendon healing. J Cell Physiol 215: 837-845.
65. Klein MB, Yalamanchi N, Pham H, Longaker MT, Chang J (2002) Flexor tendon healing in vitro: effect of TGF-beta on tendon cell collagen production. J Hand Surg Am 27: 615-620.
66. Leitner GC, Gruber R, Neumüller J, Wagner A, Kloimstein P, et al. (2006) Platelet content and growth factor release in platelet-rich plasma: a comparison of four differen systems. Vox Sang 91: 135-139.
67. Kaux JF, Le Goff C, Seidel L, Péters P, Gothot A, et al. (2011) [Comparative study of fiv techniques of preparation of platelet-rich plasma]. Pathol Biol (Paris) 59: 157-160.
68. Filardo G, Kon E, Di Matteo B, Pelotti P, Di Martino A, et al. (2013) Platelet-rich plasma for the treatment of patellar tendinopathy: clinical and imaging finding at medium-term follow-up. Int Orthop 37: 1583-1589.
69. Dallaudière B, Pesquer L, Meyer P, Silvestre A, Perozziello A, et al. (2014) Intratendinous injection of platelet-rich plasma under US guidance to treat tendinopathy: a long-term pilot study. J Vasc Interv Radiol 25: 717-723.
70. Dragoo JL, Wasterlain AS, Braun HJ, Nead KT (2014) Platelet-rich plasma as a treatment for patellar tendinopathy: a double-blind, randomized controlled trial. Am J Sports Med 42: 610-618.
71. Alfredson H, Ohberg L, Forsgren S (2003) Is vasculo-neural ingrowth the cause of pain in chronic Achilles tendinosis? An investigation using ultrasonography and colour Doppler, immunohistochemistry, and diagnostic injections. Knee Surg Sports Traumatol Arthrosc 11: 334-338.
72. Kraushaar BS, Nirschl RP (1999) Tendinosis of the elbow (tennis elbow). Clinical features and finding of histological, immunohistochemical, and electron microscopy studies. J Bone Joint Surg Am 81: 259-278.
73. Alfredson H, Ohberg L (2005) Neovascularisation in chronic painful patellar tendinosis-promising results afte sclerosing neovessels outside the tendon challenge the need for surgery. Knee Surg Sports Traumatol Arthrosc 13: 74-80.
74. Hoksrud A, Ohberg L, Alfredson H, Bahr R (2006) Ultrasound-guided sclerosis of neovessels in painful chronic patellar tendinopathy: a randomized controlled trial. Am J Sports Med 34: 1738-1746.
75. Alfredson H, Ohberg L (2015) Sclerosing injections to areas of neovascularization reduces pain in chronic Achilles tendinopathy: a double-blind randomised trial. Knee Surg Sports Traumatol Arthrosc 13: 338-344.
76. Zeisig E, Fahlström M, Ohberg L, Alfredson H (2010) A two-year sonographic follow-up afte intratendinous injection therapy in patients with tennis elbow. Br J Sports Med 44: 584-587.
77. Maffull N, Spiezia F, Longo UG, Denaro V, Maffull GD (2013) High volume image guided injections for the management of chronic tendinopathy of the main body of the Achilles tendon. Phys The Sport 14: 163-167.
78. Chan O, O'Dowd D, Padhiar N, Morrissey D, King J, et al. (2008) High volume image guided injections in chronic Achilles tendinopathy. Disabil Rehabil 30: 1697-1708.
79. Loppini M, Maffull N (2012) Conservative management of tendinopathy: an evidence-based approach. Muscles Ligaments Tendons J 1: 134-137.
80. Petrella RJ, Cogliano A, Decaria J, Mohamed N, Lee R (2010) Management of Tennis Elbow with sodium hyaluronate periarticular injections. Sports Med Arthrosc Rehabil The Technol 2: 4.

81. Muneta T, Koga H, Ju YJ, Mochizuki T, Sekiya I (2012) Hyaluronan injection therapy for athletic patients with patellar tendinopathy. J Orthop Sci 17: 425-431.
82. Orchard J, Massey A, Brown R, Cardon-Dunbar A, Hofmann J (2008) Successful management of tendinopathy with injections of the MMP-inhibitor aprotinin. Clin Orthop Relat Res 466: 1625-1632.
83. Orchard J, Massey A, Brown R, Cardon-Dunbar A, Hofmann J (2008) Successful management of tendinopathy with injections of the MMP-inhibitor aprotinin. Clin Orthop Relat Res 466: 1625-1632.
84. Brown R, Orchard J, Kinchington M, Hooper A, Nalder G (2006) Aprotinin in the management of Achilles tendinopathy: a randomised controlled trial. Br J Sports Med 40: 275-279.
85. Zipori D (2005) Th stem state: plasticity is essential, whereas self-renewal and hierarchy are optional. Stem Cells 23: 719-726.
86. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, et al. (2001) Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7: 211-228.
87. Bieback K, Kern S, Klüter H, Eichler H (2004) Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 22: 625-634.
88. Goodwin HS, Bicknese AR, Chien SN, Bogucki BD, Quinn CO, et al. (2001) Multilineage differentiatio activ- ity by cells isolated from umbilical cord blood: expres- sion of bone, fat, and neural markers. Biol Blood Marrow Transplant 7: 581-588.
89. Rus Ciucă D, Soriţău O, Suşman S, Pop VI, Mihu CM (2011) Isolation and characterization of chorionic mesenchyal stem cells from the placenta. Rom J Morphol Embryol 52: 803-808.
90. Kuznetsov SA, Mankani MH, Gronthos S, Satomura K, Bianco P, et al. (2001) Circulating skeletal stem cells. J Cell Biol 153: 1133-1140.
91. Jiang Y, Vaessen B, Lenvik T, Blackstad M, Reyes M, et al. (2002) Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol 30: 896-904.
92. Bi Y, Ehirchiou D, Kilts TM, Inkson CA, Embree MC, et al. (2007) Identificatio of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med 13: 1219-1227.
93. Zhang J, Wang JH (2010) Mechanobiological response of tendon stem cells: implications of tendon homeostasis and pathogenesis of tendinopathy. J Orthop Res 28: 639-643.
94. Longo UG, Franceschi F, Ruzzini L, Rabitti C, Morini S, et al. (2007) Light microscopic histology of supraspinatus tendon ruptures. Knee Surg Sports Traumatol Arthrosc 15: 1390-1394.
95. Chong AK, Ang AD, Gohetal JC (2007) Bone marrow-derived mesenchymal stem cells influenc early tendon-healing in a rabbit achilles tendon model. J Bone Joint Surg Am 89: 74-81.
96. Ouyang HW, Goh JC, Lee EH (2004) Viability of allogeneic bone marrow stromal cells following local delivery into patella tendon in rabbit model. Cell Transplant 13: 649-657.
97. Sharma P, Maffull N (2008) Tendinopathy and tendon injury: the future. Disabil Rehabil 30: 1733-1745.
98. Smith RK (2008) Mesenchymal stem cell therapy for equine tendinopathy. Disabil Rehabil 30: 1752-1758.
99. Godwin EE, Young NJ, Dudhia J, Beamish IC, Smith RK (2012) Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficia digital flexo tendon. Equine Vet J 44: 25-32.
100. Lacitignola L, Crovace A, Rossi G, Francioso E (2008) Cell therapy for tendinitis, experimental and clinical report. Vet Res Commun 32: S33-38.
101. Del Bue M, Riccò S, Ramoni R, Conti V, Gnudi G, et al. (2008) Equine adipose-tissue derived mesenchymal stem cells and platelet concentrates: their association in vitro and in vivo. Vet Res Commun 32: S51-55.
102. Obaid H, Clarke A, Rosenfeld P, Leach C, Connell D (2012) Skin-derived fibroblast for the treatment of refractory Achilles tendinosis: preliminary short-term results. J Bone Joint Surg 94: 193-200.
103. Ferretti A, Conteduca F, Camerucci E, Morelli F (2002) Patellar tendinosis: a follow-up study of surgical treatment. J Bone Joint Surg Am 84A: 2179-85.
104. Pascarella A, Alam M, Pascarella F, Latte C, Di Salvatore MG, et al. (2011) Arthroscopic management of chronic patellar tendinopathy. Am J Sports Med 39: 1975-1983.
105. Rodriguez-Merchan EC (2013) Th treatment of patellar tendinopathy. J Orthop Traumatol 14: 77-81.
106. Lorbach O, Diamantopoulos A, Paessler HH (2008) Arthroscopic resection of the lower patellar pole in patients with chronic patellar tendinosis. Arthroscopy 24: 167-173.
107. Kelly JD 4th (2009) Arthroscopic excision of distal pole of patella for refractory patellar tendinitis. Orthopedics 32: 504.
108. Shelbourne KD, Henne TD, Gray T (2006) Recalcitrant patellar tendinosis in elite athletes: surgical treatment in conjunction with aggressive postoperative rehabilitation. Am J Sports Med 34: 1141-1146.
109. Riley G (2004) Th pathogenesis of tendinopathy. A molecular perspective. Rheumatology (Oxford) 43: 131-142.
110. Danielson P, Andersson G, Alfredson H, Forsgren S (2008) Marked sympathetic component in the perivascular innervation of the dorsal paratendinous tissue of the patellar tendon in arthroscopically treated tendinosis patients. Knee Surg Sports Traumatol Arthrosc 16: 621-626.
111. Bagge J, Lorentzon R, Alfredson H, Forsgren S (2009) Unexpected presence of the neurotrophins NGF and BDNF and the neurotrophin receptor p75 in the tendon cells of the human Achilles tendon. Histol Histopathol 24: 839-848.
112. Danielson P, Alfredson H, Forsgren S (2007) In situ hybridization studies confirmin recent finding of the existence of a local nonneuronal catecholamine production in human patellar tendinosis. Microsc Res Tech 70: 908-911.
113. Wang JH, Iosifidi MI, Fu FH (2006) Biomechanical basis for tendinopathy. Clin Orthop Relat Res 443: 320-332.
114. DaCruz DJ, Geeson M, Allen MJ, Phair I (1988) Achilles paratendonitis: an evaluation of steroid injection. Br J Sports Med 22: 64-65.
115. Magra M, Maffull N (2006) Nonsteroidal antiinflammator drugs in tendinopathy: friend or foe. Clin J Sport Med 16: 1-3.
116. Chen SK, Lu CC, Chou PH, Guo LY, Wu WL (2009) Patellar tendon ruptures in weight lifter afte local steroid injections. Arch Orthop Trauma Surg 129: 369-372.
117. Dean BJ, Lostis E, Oakley T, Rombach I, Morrey ME, et al. (2014) Th risks and benefit of glucocorticoid treatment for tendinopathy: a systematic review of the effect of local glucocorticoid on tendon. Semin Arthritis Rheum 43: 570-576.
118. Wand BM, O'Connell NE (2008) Chronic non-specifi low back pain - sub-groups or a single mechanism? BMC Musculoskelet Disord 9: 11.
119. Jonsson P, Alfredson H (2005) Superior results with eccentric compared to concentric quadriceps training in patients with jumper's knee: a prospective randomised study. Br J Sports Med 39: 847-850.
120. Knobloch K, Kraemer R, Jagodzinski M, Zeichen J, Meller R, et al. (2007) Eccentric training decreases paratendon capillary blood flo and preserves paratendon oxygen saturation in chronic achilles tendinopathy. J Orthop Sports Phys The 37: 269-276.
121. Visnes H, Hoksrud A, Cook J, Bahr R (2005) No effec of eccentric training on jumper's knee in volleyball players during the competitive season: a randomized clinical trial. Clin J Sport Med 15: 227-234.
122. Silbernagel KG, Thome R, Eriksson BI, Karlsson J (2007) Continued sports activity, using a pain-monitoring model, during rehabilitation in patients with Achilles tendinopathy: a randomized controlled study. Am J Sports Med 35: 897-906.
123. Malliaras P, Barton CJ, Reeves ND, Langberg H (2013) Achilles and patellar tendinopathy loading programmes : a systematic review comparing clinical outcomes and identifying potential mechanisms for effectiveness Sports Med 43: 267-286.
124. Sayana MK, Maffull N (2007) Eccentric calf muscle training in non-athletic patients with Achilles tendinopathy. J Sci Med Sport 10: 52-58.

125. Martinez-Silvestrini JA, Newcomer KL, Gay RE, Schaefer MP, Kortebein P, et al. (2005) Chronic lateral epicondylitis: comparative effectivenes of a home exercise program including stretching alone versus stretching supplemented with eccentric or concentric strengthening. J Hand The 18: 411-419.

126. Silbernagel KG, Brorsson A, Lundberg M (2011) Th majority of patients with Achilles tendinopathy recover fully when treated with exercise alone: a 5-year follow-up. Am J Sports Med 39: 607-613.

127. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammator cytokines. Nature 391: 82-86.

128. Sahin H, Tholem N, Petersen W, Raschke MJ, Stange R (2012) Impaired biomechanical properties correlate with neoangiogenesis as well as VEGF and MMP-3 expression during rat patellar tendon healing. J Orthop Res 30: 1952-1957.

129. Nakama LH, King KB, Abrahamsson S, Rempel DM (2006) VEGF, VEGFR-1, and CTGF cell densities in tendon are increased with cyclical loading: An in vivo tendinopathy model. J Orthop Res 24: 393-400.

130. Zwerver J, Hartgens F, Verhagen E, van der Worp H, van den Akker-Scheek I, et al. (2011) No effec of extracorporeal shockwave therapy on patellar tendinopathy in jumping athletes during the competitive season: a randomized clinical trial. Am J Sports Med 39: 1191-1199.

131. Rees JD, Maffull N, Cook J (2009) Management of tendinopathy. Am J Sports Med 37: 1855-1867.

132. Mouzopoulos G, Stamatakos M, Mouzopoulos D, Tzurbakis M (2007) Extracorporeal shock wave treatment for shoulder calcifi tendonitis: a systematic review. Skeletal Radiol 36: 803-811.

133. Rasmussen S, Christensen M, Mathiesen I, Simonson O (2008) Shockwave therapy for chronic Achilles tendinopathy: a double-blind, randomized clinical trial of efficac Acta Orthop 79: 249-256.

134. Vulpiani MC, Vetrano M, Savoia V, Di Pangrazio E, Trischitta D, et al. (2007) Jumper's knee treatment with extracorporeal shock wave therapy: a long-term follow-up observational study. J Sports Med Phys Fitness 47: 323-328.

135. Anitua E, Sanchez M, Nurden AT, Zalduendo M, de la Fuente M, et al. (2007) Reciprocal actions of platelet-secreted TGF-beta1 on the production of VEGF and HGF by human tendon cells. Plast Reconstr Surg 119: 950-959.

136. Filardo G, Kon E, Della Villa S, Vincentelli F, Fornasari PM, et al. (2010) Use of platelet-rich plasma for the treatment of refractory jumper's knee. Int Orthop 34: 909-915.

137. Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T (2010) Positive effec of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med 38: 255-262.

138. de Jonge S, de Vos RJ, Weir A, van Schie HT, Bierma-Zeinstra SM, et al. (2011) One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: a double-blind randomized placebo-controlled trial. Am J Sports Med 39: 1623-1629.

139. de Vos RJ, Weir A, van Schie HT, Bierma-Zeinstra SM, Verhaar JA, et al. (2010) Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA 303: 144-149.

140. Scott A, Cook JL, Hart DA, Walker DC, Duronio V, et al. (2007) Tenocyte responses to mechanical loading in vivo: a role for local insulin-like growth factor 1 signaling in early tendinosis in rats. Arthritis Rheum 56: 871-881.

141. Rabago D, Best TM, Zgierska AE, Zeisig E, Ryan M, et al. (2009) A systematic review of four injection therapies for lateral epicondylosis: prolotherapy, polidocanol, whole blood and platelet rich plasma. British Journal of Sports Medicine 43: 471-481.

142. Scott A, Lian Ø, Bahr R, Hart DA, Duronio V (2008) VEGF expression in patellar tendinopathy: a preliminary study. Clin Orthop Relat Res 466: 1598-1604.

143. van Sterkenburg MN, de Jonge MC, Sierevelt IN, van Dijk CN (2010) Less promising results with sclerosing ethoxysclerol injections for midportion achilles tendinopathy: a retrospective study. Am J Sports Med 38: 2226-2232.

144. Knobloch K, Spies M, Busch KH, Vogt PM (2007) Sclerosing therapy and eccentric training in flexo carpi radialis tendinopathy in a tennis player. Br J Sports Med 41: 920-921.

145. Willberg L, Sunding K, Forssblad M, Fahlström M, Alfredson H (2011) Sclerosing polidocanol injections or arthroscopic shaving to treat patellar tendinopathy/jumper's knee? A randomised controlled study. Br J Sports Med 45: 411-415.

146. Alfredson H, Ohberg L, Zeisig E, Lorentzon R (2007) Treatment of midportion Achilles tendinosis: similar clinical results with US and CD-guided surgery outside the tendon and scle- rosing polidocanol injections. Knee Surg Sports Traumatol Arthrosc 15: 1504-1509.

147. Humphrey J, Chan O, Crisp T, Padhiar N, Morrissey D, et al. (2010) Th short-term effect of high volume image guided injections in resistant non-insertional Achilles tendinopathy. J Sci Med Sport 13: 295-298.

148. Hagberg L, Heinegard D and K. Ohlsson K (1992) Th contents of macromolecule solutes in flexo tendon sheath flui and their relation to synovial fluid A quantitative analysis. J Hand Surg Br 17: 167-171.

149. Kolodzinskyi MN, Zhao C, Sun YL, An KN, Thoreso AR, et al. (2013) Th effect of hylan g-f 20 surface modificatio on gliding of extrasynovial canine tendon graft in vitro. J Hand Surg Am 38: 231-236.

150. Momose T, Amadio PC, Zobitz ME, Zhao C, An KN (2002) Effec of paratenon and repetitive motion on the gliding resistance of tendon of extrasynovial origin. Clin Anat 15: 199-205.

151. Işik S, Oztürk S, Gürses S, Yetmez M, Güler MM, et al. (1999) Prevention of restrictive adhesions in primary tendon repair by HA-membrane: experimental research in chickens. Br J Plast Surg 52: 373-379.

152. Liu Y, Skardal A, Shu XZ, Prestwich GD (2008) Prevention of peritendinous adhesions using a hyaluronan-derived hydrogel fil following partial-thickness flexo tendon injury. J Orthop Res 26: 562-569.

153. Abate M, Schiavone C1, Salini V1 (2014) Th use of hyaluronic acid afte tendon surgery and in tendinopathies. Biomed Res Int 2014: 783632.

154. Moshiri A, Oryan A, Meimandi-Parizi A (2013) Role of stem cell therapy in orthopaedic tissue engineering and regenerative medicine: a comprehensive review of the literature from basic to clinical application. Hard Tissue 2: 31.

155. Pascual-Garrido C, Rolón A, Makino A (2012) Treatment of chronic patellar tendinopathy with autologous bone marrow stem cells: a 5-year-followup. Stem Cells Int 2012: 953510.

156. Rui YF, Lui PP, Chan LS, Chan KM, Fu SC, et al. (2011) Does erroneous differentiatio of tendon-derived stem cells contribute to the pathogenesis of calcifying tendinopathy? Chin Med J (Engl) 124: 606-610.

157. Cucurulo T, Louis ML, Thauna M, Franceschi JP (2009) Surgical treatment of patellar tendinopathy in athletes. A retrospective multicentric study. Orthop Traumatol Surg Res 95: S78-84.

158. Bahr R, Fossan B, Løken S, Engebretsen L (2006) Surgical treatment compared with eccentric training for patellar tendinopathy (Jumper's Knee). A randomized, controlled trial. J Bone Joint Surg Am 88: 1689-1698.

159. Santander J, Zarba E, Iraporda H, Puleo S (2012) Can arthroscopically assisted treatment of chronic patellar tendinopathy reduce pain and restore function? Clin Orthop Relat Res 470: 993-997.

Journal of Novel Physiotherapies

Sánchez-Ibáñez, J Nov Physiother 2016, 7:1
DOI: 10.4172/2165-7025.1000i101

Clinical Image OMICS International

Intratissue Percutaneous Electrolysis (EPI®) in the Treatment of Achilles Tendinopathy

Jose Manuel Sánchez-Ibáñez*

Sports Rehabilitation Center (CEREDE), Barcelona, Spain

***Corresponding author**: Jose Manuel Sánchez-Ibáñez, Sports Rehabilitation Center (CEREDE), Barcelona Clinic, Spain, Tel: +34 934 523 510; E-mail: drsanchez@cerede.es

Received date: December 12, 2016; **Accepted date**: December 16, 2016; **Published date**: December 19, 2016

Intratissue Percutaneous Electrolysis

Intratissue percutaneous electrolysis (EPI®) ultrasound-guided treatment [1-5] is the application of a direct current (DC) whose catodic flow is transferred to the area of the degenerative tendon [6-8] using an acupuncture needle. This accumulated electrical charge (AEC) in the degenerative tissue will produce the activation of the molecular, cellular and biological processes necessary to restore the regeneration mechanisms of the tendon (Figures 1 and 2). In recent studies it has been demonstrated that EPI® technique is effective in tendinopathy and sport muscular injuries (Figures 3 and 4).



Figure 1: Ultrasound image with power Doppler. Longitudinal view of an Achilles neovascular tendinopathy with thickening of the tendon and hipoecoic image.



Figure 2: Achilles tendinopathy treatment using Intratissue Percutaneous Electrolysis (EPI®) technique.



Figure 3: Hiperecoic image produced by the EPI® needle of 0.30 mm in the degenerative area of the tendon. This hiperecoic image correspondence to a gas density produced by the electrochemical response of the catodic flow (CF) in the degenerative extracellular matrix.



Figure 4: Ultrasound image in longitudinal view and color Doppler two months after the EPI® technique treatment ultrasound-guided. It is observed the degenerated area of the tendon that is substituted by a new connective tissue and decrease the neovascular effect.

References

1. Sànchez-Ibàñez JM (2015) Ultrasound-Guided EPI® Technique: New Treatment for for Degenerative Tendinopathy. J Nurs Care 4: 310.
2. Sànchez-Ibàñez JM, Fernández ME, Monllau JC, Alonso-Díez A, Jesús Sánchez-García J, et al. (2015) New Treatments for Degenerative

Tendinopathy, focused on the Region-Specific of the Tendon. Rheumatology (Sunnyvale) 5: 173.

3. Sànchez-Ibàñez JM, Fernàndez ME, Moreno C, Marti D, Belón P (2015) Ultrasound-Guided EPI® technique and eccentric exercise, new treatment for Achilles and Patellar tendinopathy focused on the region-specific of the tendon. Orthop Muscular Syst 4: 200.
4. Abat F, Valles SL, Gelber PE, Polidori F, Sanchez-Ibáñez JM, et al. (2015) An experimental study of muscular injury repair in a mouse model of notexin-induced lesion with EPI® technique. BMC Sports Sci Med Rehabil 7: 7.
5. Sanchez-Ibañez JM, Colmena C, Benabent J, Garcia-Herreros S, Valles SL (2013) New Technique in Tendon Sport Recovery. Percutaneous Electrolysis Intratissue (EPI®). Int J Phys Med Rehabil 1: 113.
6. Abat F, Gelber P, Polidori F, Monllau JC, Sánchez-Ibáñez JM (2014) Clinical results after ultrasound-guided intratissue percutaneous electrolysis (EPI®) and eccentric exercise in the treatment of patellar tendinopathy over a 10-year follow- up. Knee Surg Sports Traumatol Arthrosc 23: 1046-1052.
7. Sánchez-Ibáñez JM, Alves R, Polidori F, Valera F, Minaya F, et al. (2013) Effectiveness of ultrasound-guided EPI® technique in the treatment of insertional patellar tendinopathy in soccer players. Br J Sports Med 47: e2.
8. Sánchez-Ibáñez JM (2008) Ultrasound guided percutaneous electrolysis (EPI) in patients with chronic insertional patellar tendinophaty:a pilot study. Knee Surg Sports Traumatol Arthrosc 16: 220-221.

Distiquiasis canina

Tratamiento con la técnica EPI®

A. Alonso Díez [1]; **J. Sánchez García** [1]; **AE. Serrantes Gómez** [1]; **MB. García Rodríguez** [1]; **D. Bobis Villagrá** [2]; **JM. Sánchez Ibáñez** [3].

(1) Departamento de Medicina, Cirugía y Anatomía Veterinaria. Universidad de León.

(2) Hospital Veterinario Valencia Sur. Silla (Valencia).

(3) Cerede Sports Medicine Clinic. Barcelona.

El término distiquiasis hace referencia al **crecimiento ectópico de las pestañas** en zonas no habituales del borde palpebral, con una dirección anómala, asomando dichos pelos por el borde libre del párpado **a través del conducto excretor de las glándulas de Meibomio**, en un número variable, que puede ir de uno solo a múltiples pelos (Stades, 2007). El folículo suele estar a 4-6 mm de distancia del borde libre del párpado en el aspecto distal de la superficie posterior del tarso, o cerca de la base de las glándulas de Meibomio. Las glándulas de Meibomio son glándulas sebáceas constituidas por acinis holocrinos dispuestos verticalmente para abrirse en un conducto central; cuando crece uno o varios pelos en su interior resulta la distiquiasis (Raimond-Letron *et al*., 2012) (figura **1**).

La sintomatología depende del tipo de pelos y su dirección. Si van dirigidos el exterior del ojo pueden no tener ninguna repercusión clínica; sin embargo, si van dirigidos hacia la córnea pueden causar desde irritación (prurito ocular y epífora) hasta una lesión corneal (úlcera) (Gellatt, 2003).

No es un proceso frecuente y tiene mayor incidencia en la especie canina, en la que se han realizado estudios acerca de la heredabilidad del proceso (Kaufhold *et al*., 2007; Petersen *et al*., 2015). Aunque es raro en otras especies, también se ha descrito en gatos (Reinstein *et al*., 2011), hurones (Verboven *et al*., 2014) y caballos frisones (Hermans *et al*., 2014).

Las razas caninas en las que aparece este proceso con mayor frecuencia son: Staffordshire bull terrier, bulldog inglés, cocker spaniel, spaniel tibetano, shih-tzu y lhasa-apso, así como las braquiocefálicas (Gellatt, 2003); sin embargo, también se ha descrito en otras como el carlino (Krecny *et al*., 2015) y el Elo dog (Kaufhold *et al*., 2007).

La bibliografía consultada no refleja ningún tratamiento sencillo que garantice la resolución del proceso, siendo la recidiva habitual, por lo que debe informarse a los propietarios del pronóstico (Gellatt, 2003).

Tratamiento

El tratamiento más económico y simple de la distiquiasis consiste en la **depilación manual**, si bien con esta técnica el porcentaje de recidiva o reaparición de los cilios resulta inaceptablemente elevado, con el agravante de que los nuevos pelos ocasionarán una distiquiasis más grave, debido a que crecen más cortos y son menos flexibles que los iniciales. Por tanto, dicha técnica únicamente se recomienda en aquellos casos leves en que el animal tiene solamente dos o tres cilios problemáticos, o bien como técnica diagnóstica encaminada a confirmar o descartar que los pelos son la verdadera causa del problema ocular del paciente (Petersen-Jones, 2007).

En el pasado, se llegaron a desarrollar algunas **técnicas quirúrgicas** para la eliminación de los folículos desde los que se origina la distiquiasis, consistentes en la escisión palpebral, en la ablación tarsal parcial o plastias encaminadas a modificar la dirección de los cilios. Entre ellas se incluyen la escisión parcial de la meseta tarsal (Bedford, 1973), la eliminación de una tira tarsoconjuntival (Spreull, 1982) o la técnica de Hotz-Celsus para evertir el párpado y dirigir los pelos en dirección opuesta a la córnea. Estos métodos, que suponen una grave alteración anatómica y funcional del párpado, se encuentran en la actualidad prácticamente abandonados por sus múltiples inconvenientes. Entre los severos efectos secundarios, se describe la posibilidad de inducir cicatrices significativas, de provocar la distorsión de los párpados y de ocasionar lesiones en las glándulas de Meibomio incluso en pacientes con párpados gruesos, pudiendo causar, cualquiera de ellas, inestabilidad de la película lacrimal y dar lugar a problemas más



Figura 1
Distiquiasis de párpado superior.

serios aún que los causados por la propia distiquiasis (Peña *et al*., 1999; Petersen-Jones S, 2007).

En la actualidad, los tratamientos más utilizados son la criodepilación, la electrodepilación y la fotodepilación.

La **criodepilación** se lleva a cabo mediante la aplicación de una pequeña sonda de óxido nitroso o de nitrógeno líquido que se apoya sobre la conjuntiva en la zona en la que se sospecha que está el folículo del pelo ectópico. Al activar la sonda se congela la zona afectada del párpado durante algunos segundos, hasta que la bola de hielo que se forma alcanza el borde palpebral. Antes de retirar la sonda, es necesario esperar a la descongelación lenta de la misma para evitar arrancar el tejido congelado. El procedimiento se repite individualmente en cada pelo a tratar. Con esta técnica, los párpados sometidos al tratamiento se inflaman, lo que hace necesaria la administración sistémica de antinflamatorios no esteroideos, así como la aplicación, durante varios días, de diversos tratamientos locales que combinen antibióticos y corticoides. Tras la criodepilación, es común la despigmentación del párpado y del pelo, que puede llegar a ser permanente. La posibilidad de recidivas con esta técnica no es muy elevada, y los nuevos cilios no siempre precisan tratamiento, ya que suelen aparecer en un número reducido y ser más finos (Petersen-Jones S, 2007).

La **electrodepilación** se realiza, normalmente, con una unidad comercial de corriente continua diseñada al efecto, dotada de una placa ánodo, que debe sostenerse en la lengua de los pacientes, ganando así contacto eléctrico. Para llevarla a cabo, tras introducir el electrodo cátodo en forma de aguja en el párpado, a lo largo de la trayectoria del cilio y a varios milímetros de profundidad, se activa a una intensidad de 2-5 mA durante 5-10 segundos hasta que el pelo se suelte fácilmente. Se observa habitualmente la salida de secreción de las glándulas de Meibonio y burbujas de hidrógeno. Con este procedimiento, las recidivas son frecuentes, siendo necesario repetir la intervención. En cuanto a la utilización de corriente alterna de alta frecuencia, proporcionada por las unidades electroquirúrgicas, no está recomendada para la depilación, ya que puede producir necrosis y reacciones cicatriciales graves; además, se necesita de más tiempo y también suele ser necesario repetir la intervención (Petersen-Jones S, 2007). No obstante, Reinstein *et al*. (2011) documentan el tratamiento exitoso de la distiquiasis en un gato mediante la electrocauterización transconjuntival.

Figura 2
Equipo para técnica EPI®.

La **fotodepilación** o depilación por medio del láser, utilizada desde hace décadas en medicina humana, se ha introducido más recientemente en medicina veterinaria. Mediante un haz de luz monocromática, se transporta una gran cantidad de energía a través de la melanina del pelo, hasta su raíz. Cuando el haz de luz, con una determinada longitud de onda e intensidad, interacciona con el vello, la energía lumínica aplicada es absorbida por la melanina, transformándose en calor. Esto es lo que se conoce como fototermolisis selectiva, que provoca la destrucción del bulbo piloso sin afectar a los tejidos adyacentes. Entre las ventajas de esta técnica se encuentran la rapidez de actuación, realmente notable en las técnicas con escaneo (aplicadas generalmente en medicina humana) y menor en las técnicas de aplicación pelo a pelo (más utilizadas en veterinaria), su carácter indoloro y la larga duración de la depilación así obtenida. Como inconvenientes, se pueden citar el elevado coste de la técnica, la necesidad de varias sesiones para que resulte efectiva, la irradiación de toda la piel circundante en cada una de las sesiones, que puede dar lugar a efectos indeseados por la afectación de los melanocitos, y la considerable variabilidad de su eficacia en función de la pigmentación de los cilios del paciente, pues, al actuar el láser únicamente sobre las zonas ricas en melanina (oscuras), no resulta eficaz para el pelo blanco o muy claro (Campbell, 1990; Liew, 2002).

En el caso de la distiquiasis, el inconveniente más importante radica en el riesgo de daño ocular que podría generar su aplicación, ya que la retina tiene una gran concentración de melanocitos (Zaragoza, J.R, 1999; Parver, 2006; Spiess, 2012).

Los autores plantean una propuesta alternativa para el tratamiento de este proceso patológico mediante la **técnica EPI®** (electrólisis percutánea intratisular) aplicada a cada folículo piloso mal orientado.

Esta técnica, desarrollada en animales de experimentación y ampliamente aplicada, con éxito, en pacientes humanos para el tratamiento de lesiones musculoesqueléticas, aún no es muy conocida en veterinaria y, por lo tanto, no se está utilizando de manera rutinaria. Sin embargo, el equipo al que pertenecen los autores lleva tiempo trabajando en la adaptación de la técnica EPI® para su uso en la clíni-

ca veterinaria, considerando que es una técnica mínimamente invasiva con un gran futuro (Sánchez *et al*., 2011; 2015 Alonso *et al*., 2016).

La técnica EPI® produce la ablación electroquímica no térmica, por flujo catódico, de una determinada estructura orgánica en la que se ha insertado el electrodo cátodo. La EPI® produce una disociación del agua, las sales y los aminoácidos de la matriz extracelular, creando nuevas moléculas a través de una inestabilidad iónica. La reacción orgánica que se produce en la aguja catódica causa una inflamación aguda muy localizada, única y exclusivamente en el punto que se está tratando, lo que permite la activación inmediata de una respuesta inflamatoria breve, facilitando la fagocitosis de la zona (Sánchez-Ibáñez *et al*., 2005; 2008; 2010; 2013).

La depilación mediante la técnica EPI® consiste en la aplicación, auxiliados por la visión magnificada de un microscopio quirúrgico, de corriente continua a través de una aguja de acupuntura insertada en cada folículo piloso, que actúa como electrodo negativo (cátodo) y que va a provocar una reacción electroquímica en el folículo, facilitando su degeneración, su posterior reabsorción y, por lo tanto, su desaparición (figura **2**). Además, presenta la ventaja con respecto a otras técnicas que se utilizan actualmente del bajo coste del tratamiento (Alonso *et al*., 2015).

Estudio clínico

Se realiza un estudio con el objetivo de aumentar la eficacia del arsenal terapéutico actualmente empleado para el tratamiento de las distiquiasis y los cilios ectópicos en la clínica veterinaria, utilizando la técnica EPI®. Como segundo objetivo, se busca ajustar los protocolos y dosis de la dicha técnica para llegar a un tratamiento eficaz del citado proceso patológico.

Los casos estudiados corresponden a dos pacientes caninos con distiquiasis palpebral bilateral: el caso 1 es de raza shih-tzu, hembra, de 5 años de edad; el caso 2, un samoyedo de 2 años, macho. Ambos presentaban prurito ocular, blefaroespasmo notorio y epífora bilateral, así como úlcera corneal recurrente.

El caso 2, durante el año anterior y tras confirmar mediante depilación ordinaria que el origen del marcado blefarospasmo radicaba en la distiquiasis, había sido sometido a un tratamiento de electrodepilación con bisturí eléctrico monopolar mediado por pinza (10 meses antes) y, posteriormente, a electrodepilación ordinaria (4 meses antes), sin que ninguno de los procedimientos diera resultados positivos.

En ambos casos se realizó una exploración con biomicroscopio (figura **3**), observando los cilios a lo largo de toda la extensión de los bordes palpebrales superiores e inferiores de ambos ojos, que habían causado úlceras corneales de diversa consideración. En el caso 1 el proceso de distiquiasis, dado el número de cilios ectópicos, el grosor de los mismos y la magnitud de las lesiones corneales y conjuntivales, fue calificado de grave, mientras que en el caso 2, que tenía un muy elevado número de pelos y apenas era capaz de abrir los ojos, de muy grave (figura **4**).



Figura 3
Diagnóstico de distiquisis mediante biomicroscopía.



Figura 4: Aspecto de los ojos del perro del samoyedo, evaluado como muy grave, antes del inicio del tratamiento con EPI®.

Una vez iniciado el tratamiento de las úlceras corneales, se comenzó con las sesiones de EPI®, que se realizaron a intervalos aproximados de 30-60 días, en función de la recurrencia de los signos y las lesiones iniciales y de la gravedad de los mismos.

Para llevar a cabo el tratamiento de EPI®, los pacientes, en todas las ocasiones, fueron anestesiados mediante un protocolo convencional de anestesia general inhalatoria equilibrada, para evitar las molestias que ocasionan las punciones y las descargas en los párpados, así como los movimientos consecuentes que estas darían lugar, dificultando o imposibilitando su aplicación, o bien predisponiendo a la aparición de lesiones iatrogénicas en los ojos.



Figura 5
Durante las sesiones se empleó un microscopio quirúrgico.





Figuras 6 y 7: Aplicación de EPI®.
En la imagen inferior se observa la irrigación con suero salino fisiológico.

El **protocolo anestésico** utilizado en ambos casos fue el siguiente:

- Sedación: dexmedetomidina a 2,5 µg/kg y midazolam a 0,3 mg/kg, ambas por vía intramuscular (IM).
- Analgesia: butorfanol IM a 0,3 mg/kg.
- Inducción: propofol 4 mg/kg vía intravenosa (IV).
- Mantenimiento: anestesia inhalatoria con isofluorano mediante un circuito semicerrado circular con absorción de anhídrido carbónico en el caso 2, y mediante un circuito T de Ayre en el caso 1, mantenidos ambos pacientes siempre en respiración espontánea.

Para magnificar la visión y asegurar la correcta punción de los folículos ectópicos, se utilizó el microscopio quirúrgico modelo Wild Microscope®, con un objetivo Leica M690 y un ocular Leica 10445170 10X/21B, (figura **5**) con capacidad de conexión a cámara fotográfica, a monitor de visión y a grabadora informática.

La preparación del campo consistió en el lavado palpebral y ocular con suero salino fisiológico (SSF) estéril.

En ambos casos, se utilizó para el tratamiento un electroestimulador de cuatro salidas EPI® que constituye una fuente de corriente continua monopolar.

Las sesiones de técnica EPI® se realizaron colocando, en el polo cátodo del equipo, agujas de acupuntura estériles de acero inoxidable, que fueron variando a medida que aparecieron dificultades hasta dar con la más adecuada. En la primera ocasión, se utilizaron agujas de 0,18x13 mm y de 0,25x25 mm; en las dos siguientes de 0,25x25 mm; a partir de la tercera sesión, de acero recubiertas de oro de 0,40x15 mm.

El electrodo ánodo no modificado se ubicó en la región inguinal del paciente, envuelto en papel secante empapado con SSF, con el fin de aumentar la conductividad.

Para llevar a cabo la depilación, se insertó la aguja en el folículo piloso y se realizaron descargas en cada uno de ellos (figuras **6** y **7**). En las tres primeras ocasiones, se utilizó una dosis de 8 mA durante 2 segundos (a una media de 21,36 V y 0,339 J) y, a partir de la cuarta, dado que la extracción de los cilios con descargas de 2 segundos no siempre resultaba satisfactoria, de 8 mA durante 3 segundos (a una media de 14,04 V y 0,302 J). Durante las descargas, se observó la salida de secreción y burbujas, procediendo posteriormente a la extracción de los pelos mediante una pinza de mano. En el caso de que hubiera resistencia a la extracción manual o se rompiese el pelo como consecuencia de su desarrollo o grosor, se repetía una o dos veces más la descarga en el mismo folículo hasta que la extracción no ofreció dificultad alguna. Durante los impactos, se aplicaba, mediante goteo, SSF sobre el punto de entrada la aguja para facilitar la conducción eléctrica y, por lo tanto, activar la reacción química de la electrolisis.

Una vez finalizada la sesión, cuando se hubieron extraído todos los pelos visibles, se hizo un nuevo lavado ocular con SSF y se administraron dos gotas de colirio de diclofenaco sódico (Voltarén®) y pomada con gentamicina sulfato, metionina y retinol (Óculos epitelizante®) en cada ojo, cada 12 horas, durante los dos días posteriores a la intervención.

En las primeras ocasiones, para el postoperatorio inmediato, se colocó un collar isabelino como barrera física para evitar el rascado; no obstante, dado que los animales no mostraron apenas molestias y en ningún caso intentaron rascarse después de la intervención, en las siguientes sesiones no se aplicó dicha medida preventiva.

A la paciente del caso 1 se le realizaron tres sesiones de EPI® y en el caso 2, cinco sesiones.

Resultados y discusión

Uno de los principales problemas de la distiquiasis palpebral es el crecimiento de los cilios dirigidos hacia la córnea, ocasionando prurito ocular y úlcera corneal que, generalmente, se agrava con la automutilación por parte del animal al rascarse.

Según el conocimiento de los autores, no existe un tratamiento que, a la vez, sea eficaz y poco agresivo con los párpados y con otras estructuras del ojo y sus anejos.

La utilización de la técnica EPI® sobre los folículos pilosos ectópicos de los dos perros ha resultado muy satisfactoria, tanto en cuanto a la disminución de los cilios posteriormente a cada sesión, como en cuanto a los escasos efectos secundarios que se hallaron.

En ambos casos, la mejoría clínica fue muy ostensible ya a las pocas horas de cada tratamiento, pudiendo comprobarse que desaparece la fotofobia y el blefarospasmo.

• Caso 1

En la primera sesión, se comenzó con una única descarga eléctrica por folículo; sin embargo, se observó que los cilios más fuertes no se desprendían con facilidad o se quebraban al tirar de ellos con la pinza de mano. Por ello, se optó por aplicar dos descargas de 8 mA y 2 segundos por folículo, lo que resolvió el problema en la mayor parte de los pelos sin causar daños adicionales visibles en el canto palpebral.

Al utilizar para el electrodo cátodo las agujas de acupuntura de 0,18x13 mm, se encontró que se doblaban con facilidad y que no trasmitían adecuadamente la corriente eléctrica, por lo que se sustituyeron por otras de calibre 0,25x25 mm, que permitieron terminar la sesión (**tabla I**).

Tras 30 días, se realizó una revisión mediante biomicroscopía, hallando una reducción drástica del número de cilios sobre los cuatro párpados, cilios que además eran mucho más finos y aislados. El procedimiento de aplicación de la técnica EPI®, en esta segunda sesión, fue el mismo que para la primera.

Tabla I

Datos del caso 1 (shih-tzu)

	Día 0	Día 30	Día 60
Clínica	Prurito Blefarospasmo Epífora Fotofobia	Menos: Blefarospasmo Epífora Fotofobia	Apenas: Blefarospasmo Epífora Fotofobia
Test Schirmer	OD 20 OI 23	OD 23 OI 20	OD 26 OI 19
Exudado	Mucoso	Sin exudado	Sin exudado
Pelos	OD S: 3 OD I: 5 OI S: 5 OI I: 5 Gruesos	OD S: 2 OD I: 3 OI S: 3 OI I: 3 Más finos y aislados	OD S: 0 OD I: 2 OI S: 0 OI I: 2 Poco desarrollados
Hiperemia conjuntival	Palpebral + Bulbar +	Menos: Palpebral + Bulbar +	Menos aún: Palpebral + Bulbar +
Córnea	OD: queratitis; úlcera OI: NO	OD: NO OI: queratitis	OD: NO OI: NO
Borde palpebral	Normal	Normal	Normal
Valores EPI®	8 mA, 2 segundos	8 mA, 2 segundos	8 mA, 2 segundos
Aguja	0,25x25 mm	0,25x25 mm	0,25x25 mm
Descargas/pelo	2	2	2
Resultado inmediato (0-48 h)	Sin clínica	Sin clínica	Sin clínica

OI: Ojo izquierdo; OD: ojo derecho; S: párpado superior; I: párpado inferior.

Transcurridos dos meses, se realizó de nuevo una exploración ocular en la que, si bien aún se constató la presencia de algunos pelos ectópicos, resultaba obvia su disminución en cantidad y desarrollo. Se realizó un tercer tratamiento idéntico a los anteriores.

La presencia de estos cilios puede ser atribuida a que, en alguno de los folículos, la técnica EPI® no hubiera dado el resultado esperado con una o dos sesiones, o bien a que, en el momento del tratamiento, dichos cilios no fueran aún visibles.

En este primer caso, el resultado general fue sumamente satisfactorio, dada la marcada mejoría clínica que presentaba el paciente desde inmediatamente después de la primera intervención y en los días siguientes, ya que era capaz de abrir los ojos con normalidad, y no manifestaba fotofobia, blefaroespasmo, conjuntivitis ni cualquier otro efecto secundario. Sin embargo, debido a la imposibilidad de los clientes de continuar, el paciente no ha vuelto a revisión y no se ha podido completar el seguimiento del caso.

• Caso 2

Al perro de raza samoyedo del caso 2 se le habían realizado varios tratamientos médicos sintomáticos y dos quirúrgicos (uno mediante bisturí eléctrico monopolar y otro con electrodepilación convencional), ambos con resultados no satisfactorios.

Se le aplicaron cinco sesiones de EPI ®, consistentes en descargas de 8 mA durante 3 segundos, sin que en ninguna de ellas se presentara ningún tipo de problema, salvo que, dado que desde la primera

ocasión se constató que las agujas de 0,25x25 mm se doblaban con cierta facilidad, estas fueron sustituidas por otras de acero recubiertas de oro de 0,40x15 mm, cuya utilidad fue sumamente satisfactoria en todas las sesiones.

Tras las dos primeras sesiones, el número de pelos se redujo sensiblemente, pero, dado su ingente cantidad y su gran desarrollo, no fue hasta la tercera sesión cuando se constató una reducción drástica del número de pelos y de su grosor, evidenciándose una franca mejoría clínica (**tabla II**).

Durante la cuarta sesión, el tejido del borde palpebral, quizá por la proximidad temporal entre las anteriores sesiones, ofrecía una resistencia ligeramente mayor de lo habitual, lo que dificultó, en pequeña medida, la introducción de la aguja de acupuntura en el borde palpebral; aun así, el tratamiento se llevó a cabo sin mayores complicaciones.

En la revisión previa a la quinta sesión, la mejoría clínica fue ostensible en lo relativo a la conjuntivitis, la queratitis, la fotofobia y el blefarospasmo, que eran casi inapreciables, y los escasos pelos presentes eran mucho más finos. Durante la intervención, el tejido del borde palpebral no estaba indurado en absoluto ni ofrecía resistencia adicional a la penetración de la aguja y, después de cada impacto, los pelos se extrajeron con facilidad. Una vez desaparecidos los efectos de la anestesia, también desapareció el blefaroespasmo.

Dos meses después, en la última revisión oftalmológica del paciente, este apenas manifestaba sintomatología clínica, presentándose con ambos ojos completamente abiertos, sin epífora ni exudado, y sin conjuntivitis bulbar ni lesiones corneales, observándose únicamente dos pelos en un ojo, uno en cada párpado, y tres pelos en el otro ojo, dos en un párpado y uno en el otro, todos ellos muy finos y pequeños. Por esta razón, se decidió no realizar la intervención y proceder a una nueva valoración clínica más adelante (figura **8**).

A los 15 meses de la quita sesión, mediante la exploración con biomicroscopio, no se evidencia crecimiento de pelos ectópicos en los bordes palpebrales.

Conclusiones

El trabajo expuesto arroja las siguientes conclusiones:

❶ Para abordar con ciertas garantías de éxito el tratamiento de la distiquiasis palpebral y de sus consecuencias, haciendo uso de la técnica EPI®, es imprescindible un **diagnóstico oftalmológico** lo más certero y específico posible.

❷ El manejo clínico de la técnica EPI® a nivel palpebral es delicado, dado que es necesaria la punción exacta de los folículos y la aplicación de descargas sumamente precisas en los mismos, sin afectar al ojo ni a las estructuras altamente sensibles que lo rodean, por lo que se hace imprescindible un buen protocolo de anestesia general equilibrada.

❸ Los detalles aportados para la aplicación de la técnica EPI® en los párpados (microscopía quirúrgica, humectación del cilindro ánodo, irrigación de las agujas con SSF durante las descargas, valores de la longitud y grosor de las mismas, dosis y tiempos de aplicación, etc.) se han mostrado altamente eficaces a la hora de tratar los cilios ectópicos en oftalmología veterinaria.

Tabla II

Datos del caso 2 (samoyedo)

	Día 0	Día 30	Día 60	Día 90	Día 150	Día 210
Clínica	Prurito, blefarospasmo, epífora, fotofobia	Prurito, blefarospasmo, epífora, fotofobia	Clara mejoría, pero: prurito, blefarospasmo epífora, fotofobia	Clara mejoría menos: prurito, blefarospasmo epífora, fotofobia	Mejoría ostensible: blefarospasmo. Casi sin síntomas	Sín clínica
Test Schirmer	OD 23 OI 20	OD 23 OI 20	OD 21 OI 24	OD 25 OI 23	OD 18 OI 20	OD 18 OI 23
Exudado	Sin exudado	Sin exudado	Sin exudado	Sin exudado	Sin exudado	Sin exudado
Pelos	En ambos ojos y ambos párpados. Abundantes, gruesos y duros	Menos cantidad OD S: 6 OD I: 3 OI S: 8 OI I: 9	Menos gruesos OD S: 5 OD I: 2 OI S: 7 OI I: 8	Menos gruesos OD S: 4 OD I: 2 OI S: 6 OI I: 7	Muy finos OD S: 2 OD I: 2 OI S: 5 OI I: 3	Muy finos OD S: 1 OD I: 1 OI S: 2 OI I: 1
Hiperemia conjuntival	En ambos ojos Palpebral ++ Bulbar ++	En ambos ojos: Palpebral + Bulbar +	En ambos ojos: Palpebral ++ Bulbar ++	En ambos ojos Palpebral +	En ambos ojos Palpebral +	No
Córnea	Normal	Normal	Normal	Normal	Normal	Normal
Borde palpebral	Normal	Normal	Normal	Normal	Normal	Normal
Valores EPI®	8 mA, 3 segundos	8 mA, 3 segundos	8 mA, 3 segundos	8 mA, 3 segundos	8 mA, 3 segundos	-
Aguja	0,40x15 mm	0,40x15 mm	0,40x15 mm	0,40x15 mm	0,40x15 mm	-
Descargas/pelo	2-3	2-3	2-3	2-3	2-3	-
Resultado inmediato (0-48 h)	Sin clínica	Sin clínica	Sin clínica	Sin clínica	Sin clínica	-

OI: Ojo izquierdo; OD: ojo derecho; S: párpado superior; I: párpado inferior.

❹ La técnica EPI® es un procedimiento mínimamente invasivo que manifiesta una ausencia prácticamente absoluta de molestias y complicaciones secundarias para el paciente, lo que facilita enormemente su manejo postoperatorio; estos hechos sugieren una gran proyección de futuro para esta técnica en la clínica oftalmológica veterinaria.

❺ Dados los alentadores resultados de estas primeras experiencias con la aplicación de la técnica EPI® para la eliminación de folículos pilosos palpebrales y la ausencia de efectos secundarios de ningún tipo a corto, medio o largo plazo, comparada con otras técnicas de depilación existentes en el mercado y en la bibliografía revisada, consideramos que el procedimiento descrito podría hacerse extensivo a cualquier proceso que requiera eliminación definitiva del pelo para su solución.

Figura 8: Aspecto de los ojos de paciente del caso 2 tras la finalización del tratamiento.

Bibliografía

Abat F, Diessel, J, Gelber PE, Polidori F, Monllau JC, Sanchez-Ibañez JM. Mollecular repair mechanisms using the intratissue percutaneous electrolysis (EPI®) technique in patellar tendonitis. Revista Española de Cirugía Ortopédica y Traumatología. 2014; 58(4): 201-205.

Abat F, Gelber PE, Polidori F, Monllau JC, Sanchez-Ibañez JM. Clinical results after ultrasound-guided intratissue percutaneous electrolysis (EPI®) and eccentric exercise in the treatment of patellar tendinopathy. Knee Surg Sports Traumatol Arthrosc. 2014 Jan 30.

Abat F, Gelber PE, Monllau JC, Sanchez-Ibañez JM. Large tear of the pectoralis major muscle in an athlète. Results after treatment with intratissue percutaneous electrolysis (EPI®). Sports Medicine & Doping Studies. 2014. 4:2.

Abat F, Sanchez-Ibañez JM. Patellar tendinopathy: A critical review of current therapeutic options. OA Sports Medicine 2014;18;2(1):2

Abat, F., Sanchez Ibáñez, JM. Intratissue Percutaneous Electrolysis (EPI®) in the treatment of patellar tendinopaty. International Journal of Clinical & Medical Imaging. January 2014. 1 (3) 1000166.

Abat F, Valles SL, Gelber PE, Polidori F, Stitik TP, García-Herreros S, Monllau JC, Sanchez-Ibánez JM. Molecular repair mechanisms using the Intratissue ercutaneous Electrolysis technique in patellar tendonitis. Rev Esp Cir Ortop Traumatol. 2014 July-August; 58(4):201-205

Alonso Díez *et al.* (2015) La Técnica EPI® como alternativa para el tratamiento de la distiquiasis en caninos. En Actas del XX Congreso Internacional de Cirugía veterinaria (SECIVE). Coordinador: J.M.Gonzalo Orden. Área de Publicaciones. Universidad de León. ISBN: 978-84-9773-734-0. D.L. LE-289-2015. Pp.30-44.

Alonso, A.J.; Sánchez, J.; Sánchez-Valle, J.; García, M.B; Sánchez-Ibáñez, J.M. (2016) Técnica EPI®: alternativa para desmopatías y tenopatías en perros. Consulta Difus. Vet. Vol. 24, Nº 228. Marzo de 2016. Pp: 57-60.

Bedford, P.G.C., Distichiasis and its treatment by method of partial tarsal plate excision, Journal of Small Animal Practice, 1973; 14:1-7.

Campbell DC. Thermoablation treatment for trichiasis using the argon laser. Australian and New Zealand Journal of Ophthalmology. 1990; 18(4):427-30.

Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet. 2010 Nov 20; 376 (9754): 1751-67.

Dahlgren LA, van der Meulen MC, Bertram JE, Starrak GS, Nixon AJ. Insulin-like growth factor-I improves cellular and molecular aspects of healing in a collagenase-induced model of flexor tendinitis. J. Orthop. Res. 2002; 20: 910-919.

Dierickx, C.C., Laser Hair Removal: Scientific Principles and Practical Aspects, Wellman Laboratories of Photomedicine, Harvard Medical School, 1-8.

Gellatt, K.N., Enfermedades y cirugía de los párpados en el perro. En Fundamentos de Oftalmología Veterinaria, 2003, Ed. Masson, S.A. Barcelona (España) 47-72.

Hermans H1, Ensink JM. Treatment and long-term follow-up of distichiasis, with special reference to the Friesian horse: a case series. Equine Veterinary Journal. 2014 Jul;46(4):458-62.

Kaeding CC, Pedroza AD, Powers BC. Surgical treatment of chronic patellar tendinosis: a systematic review. Clin. Orthop. Relat. Res. 2007 Feb; 455: 102-6.

Kashiwagi *et al.* M. Effects of transforming growth factor-beta 1 on the early stages of healing of the Achilles tendon in a rat model. Scand. J. Plast. Reconstr. Surg. Hand Surg. 2004; 38: 193–197.

Kaufhold J *et al*. Analysis of the mode of inheritance for distichiasis in the Elo dog breed using complex segregation analyses. Berliner und Münchener tierärztliche Wochenschrift. 2007; 120(5-6):232-6.

Krecny M, Tichy A, Rushton J, Nell B. A retrospective survey of ocular abnormalities in pugs: 130 cases. Journal of Small Animal Practice, 2015, 56(2):96-102

Liew SH. Laser hair removal: guidelines for management. American Journal of Clinical Dermatology, 2002; 3(2):107-15.

Magra M, Maffulli N. Nonsteroidal antiinflammatory drugs in tendinopathy: friend or foe. Clin. J. Sport Med. 2006 16:1-3.

Maggs D J, Miller P E, Ofri R. Párpados. En: Fundamentos de Oftalomología Veterinaria. Editado por Slatter, 4ª Edición, 2009. Ed. Elsevier Saunders. Barcelona (España). 111-139.

Parver DL. Ocular phototoxicity In: Retinal Imaging (eds. Huang D, Kaiser PK, Lowder CY, Traboulsi EI). Mosby Elsevier: Philadelphia, 2006:421-426.

Peña TM, García FA. Reconstruction of the eyelids of a dog using grafts of oral mucosa. Veterinary Record. 1999, 10; 144(15):413-415.

Petersen-Jones S, Manual of Small Animal Ophthalmology (BSAVA), (2ª ed), 2007. Ediciones S, Barcelona (España). 119-156.

Petersen-Jones, S., Los párpados y la membrane nictitante. En Manual de Oftalmología en pequeños animales, 2ª Edición 2007. Ediciones S, Barcelona (España), 132-136

Richardson LE, Dudhia J, Clegg PD, Smith R. Stem cells in veterinary medicine-attempts at regenerating equine tendon after injury. Trends Biotechnol. 2007 25: 409-16.

Rodeo SA *et al*. Biologic augmentation of rotator cuff tendon healing with use of a mixture of osteoinductive growth factors. J. Bone Joint Surg. Am. 2007; 89: 2485-2497.

Sánchez García J. *et al*. Adaptación de la técnica Electrolisis Percutánea Intratisular (EPI®) para el tratamiento de las tenopatías y desmopatías en equinos. I Congreso Internacional de Electrolisis Percutánea Intratisular (EPI®): Tendón. Madrid. 2011.

Sánchez García, J *et al.* (2015) Primeros resultados de la utilización de la Técnica EPI® para el tratamiento de las desmopatías y tenopatías en equinos. En Actas del XX Congreso Internacional de Cirugía veterinaria (SECIVE). Coordinador: J.M. Gonzalo Orden. Area de Publicaciones. Universidad de León. ISBN: 978-84-9773-734-0. D.L. LE-289-2015. Pp. 78-92.

Sánchez Ibáñez, JM. Treatment of patellar tendinopathy in sportsmen through in Percutaneous Intratendon Electrolysis (EPI). Revista digital www.ephysiotherapy.net. 2005.

Sánchez-Ibáñez JM. Fisiopatología de la regeneración de los tejidos blandos. En: Vilar E, Sureda S, eds. Fisioterapia del aparato locomotor. Madrid: Mc Graw Hill, 2005. 69- 112.

Sánchez-Ibáñez JM. Ultrasound guided percutaneous electrolysis (EPI®) in patients with chronic insertional patellar tendinophaty: a pilot study. Knee Surg. Sports Traumatol. Arthrosc. 2008 May 16: 220-221.

Sánchez-Ibáñez, JM. Tratamiento mediante electrólisis percutánea intratisular (EPI®) ecoguiada de una tendinopatía de aquiles en un futbolista profesional. Podología Clínica, Julio: 2008 vol. 9 núm. 4:118-127.

Sánchez-Ibáñez, JM. Fascitis plantar: Tratamiento regenerativo mediante electrólisis percutánea intratisular (EPI®). Podología Clínica. 2010 2(1): 22-29.

Sánchez-Ibáñez JM. Evolución clínica en el tratamiento de la entesopatía rotuliana crónica mediante electro-estimulación percutánea ecodirigida: estudio de una serie de casos en población deportiva. Tesis Doctoral. Departamento de Medicina, Cirugía y Anatomía Veterinaria. Universidad de León, 2013.

Sánchez Ibáñez JM, Colmena C, Benabent J, García-Herreros S, Valles SL. New Technique in Tendon Sport Recovery. Percutaneous Electrolysis Intratissue (EPI®). International Journal of Physical Medicine & Rehabilitation. 2013; 1: 113.

Shrier I, Matheson GO, Kohl HW. Achilles tendonitis: are corticosteroid injections useful or harmful? Clin. J. Sport Med. 1996; 6:245-250.

Speed CA. Fortnightly review: corticosteroid injections in tendon lesions. BMJ. 2001; 323: 382-386.

Spiess BM. The use of laser in veterinary ophthalmology. Photon Laser Medicine, 2012; 1 : 91-102

Spreull, J.S.A., Surgery of the eyelids in small animals, Veterinary Annual, 1982. 22: 279-297.

Stades, FC; Gelatt, KN. Diseases and surgery of the canine eyelid. En Veterinary Ophthalmology, vol 2, Editado por Gelatt KN. Ed Blackwell publishing, Gainesville, Florida, USA. 2007, 563-574

Turner S M, Problemas de las pestañas: distiquiasis y pestañas ectópicas. En Oftalmología de pequeños animales (Primera edición), Ed Elsevier Saunders, Barcelona (España). 2010. 43-50.

Verboven CA *et al*. Distichiasis in a ferret (Mustela putorius furo).Veterinary Ophthalmology. 2014 Jul; 17(4):290-3

Zaragoza, J.R. Depilación Láser. Fundamentos, técnica y estado actual. 1999. http://www.med-estetica.com/Cientifica/Banco_Articulos/1999/01_DepLaser.htm

Figura
Lorem ipsum

Figura
Lorem ipsum

Figura
Lorem ipsum

Figura
Lorem ipsum

Journal section: Oral Medicine and Pathology
Publication Types: Research

doi:10.4317/medoral.22488
http://dx.doi.org/doi:10.4317/medoral.22488

Randomized, double-blind study comparing percutaneous electrolysis and dry needling for the management of temporomandibular myofascial pain

Ricardo Lopez-Martos [1], Luis-Miguel Gonzalez-Perez [2], Pablo Ruiz-Canela-Mendez [3], Francisco-Javier Urresti-Lopez [3], José-Luis Gutierrez-Perez [2], Pedro Infante-Cossio [2]

[1] MD, PhD, Department of Oral and Maxillofacial Surgery, Virgen del Rocio University Hospital. Seville. Spain
[2] MD, DDS, PhD, Department of Oral and Maxillofacial Surgery, Virgen del Rocio University Hospital. Seville. Spain
[3] DPTSc, Department of Oral and Maxillofacial Surgery, Virgen del Rocio University Hospital. Seville. Spain

Correspondence:
Department of Oral and Maxillofacial Surgery
Virgen del Rocio University Hospital
Av. Manuel Siurot s/n
41013 Seville. Spain
lumigon@telefonica.net

Received: 28/03/2018
Accepted: 08/06/2018

Lopez-Martos R, Gonzalez-Perez LM, Ruiz-Canela-Mendez P, Urresti-Lopez FJ, Gutierrez-Perez JL, Infante-Cossio P. Randomized, double-blind study comparing percutaneous electrolysis and dry needling for the management of temporomandibular myofascial pain. Med Oral Patol Oral Cir Bucal. 2018 Jul 1;23 (4):e454-62.
http://www.medicinaoral.com/medoralfree01/v23i4/medoralv23i4p454.pdf

Article Number: 22488 http://www.medicinaoral.com/

eMail: medicina@medicinaoral.com
Indexed in:
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare
Indice Médico Español

Abstract

Background: To assess whether the techniques of percutaneous needle electrolysis (PNE) and deep dry needling (DDN) used on trigger points (TrP) of lateral pterygoid muscle (LPM) can significantly reduce pain and improve function in patients with myofascial pain syndrome (MPS) compared to a control group treated with a sham needling procedure (SNP).

Material and Methods: Sixty patients diagnosed with MPS in the LPM were selected and randomly assigned to one of three groups. The PNE group received electrolysis to the LPM via transcutaneous puncture. The DDN group received a deep puncture to the TrP without the introduction of any substance. In the SNP group, pressure was applied to the skin without penetration. Procedures were performed once per week for 3 consecutive weeks. Clinical evaluation was performed before treatment, and on days 28, 42 and 70 after treatment.

Results: Statistically significant differences (p <0.01) were measured for the PNE and DDN groups with respect to pain reduction at rest, during chewing, and for maximum interincisal opening (MIO). Values for the PNE group showed significantly earlier improvement. Differences for PNE and DDN groups with respect to SNP group were significant (p <0.05) up to day 70. Evaluation of efficacy as reported by the patient and observer was better for PNE and DDN groups. No adverse events were observed for either of the techniques.

Conclusions: PNE and DDN of the LPM showed greater pain reduction efficacy and improved MIO compared to SNP. Improvement was noted earlier in the PNE group than in the DDN group.

Key words: *Myofascial pain syndrome, myofascial trigger points, percutaneous needle electrolysis, deep dry needling, lateral pterygoid muscle.*

Introduction

Myofascial pain syndrome (MPS) is a complex disorder of the musculoskeletal system, with multifactorial involvement, which has several clinical presentations in multiple areas of the body. One of these is the orofacial region, affecting the masticatory muscles and the temporomandibular joint (TMJ). MPS should be suspected in patients with pain and dysfunction of the masticatory muscles, together with the existence of trigger points (TrP) on palpation (1). TrPs are bands of muscle whose activation triggers tension and a deep and constant pain that can cause central excitation. The pain can be local or referred, and is characterized by its tendency to become chronic, limiting interincisal opening and causing muscle weakness as valid diagnostic criteria to differentiate myofascial temporomandibular disease from properly intra-articular disorders (1-3). It has been observed that the masseter and temporal muscles along with the lateral pterygoid muscle (LPM) are the muscles most frequently involved in active TrP in patients with temporomandibular disorders of myofascial origin (4).

In the temporomandibular area, TrPs associated with MPS usually do not resolve without treatment (4). Management can include the control of parafunctional habits, use of a mouth guard, and analgesic-anti-inflammatory therapy. This can be in conjunction with inactivation of TrPs by non-invasive methods, such as massages, ultrasound, muscle stretching with application of cold spray, and magnetic or electrical stimulation. Other mechanical treatments such as acupuncture or the direct application of medication to TrPs may be considered (5-7). To date, several minimally invasive methods have been described (8,9), with deep dry needling (DDN) being one of the techniques used to inactivate TrPs (1). Several studies in the literature have reported on its safety, efficacy and low cost in the management of MPS with LPM involvement (4,10,11).

Percutaneous needle electrolysis (PNE) consists in the application of a low intensity galvanic current through an acupuncture needle to accelerate tissue regeneration (12). It has been used successfully in various musculoskeletal pathologies, such as for the treatment of patellar tendinitis, tennis elbow, osteitis pubis and acute whiplash syndrome (13-16). However, to the best of our knowledge, no previous study has investigated the effect of PNE on TrPs of the masticatory muscles. The aim of the present study was to investigate if the PNE technique in LPM could reduce pain and improve mandibular mobility compared to DDN and a sham needling procedure (SNP). Secondary objectives were to assess the level of improvement in the general condition of the TMJ, as well as to assess the patient's tolerance to the treatments performed and to side effects.

Material and Methods

-Subjects:

A randomized, double-blind, single-centre clinical trial was carried out in the outpatient clinic of the Department of Oral and Maxillofacial Surgery of the Virgen del Rocío University Hospital, Seville (Spain), from June 2015 to June 2016.

The following diagnostic inclusion criteria were evaluated: a) age between 18 and 65 years, b) myogenic pain in the temporo-mandibular area of at least 6 months' duration, c) moderately limited mandibular movement (interincisal opening limited to <40 mm and requiring passive stretching to increase opening by > 5 mm), according to Group I criteria of the RDC/TMD Consortium (17), and d) criteria satisfied for active TrPs in the LMP (pain upon intraoral palpation, limited range of movement, painful chin protrusion against resistance, lateralization of the contralateral side with mouth opening, and pain in the ipsilateral TMJ) according to the protocol used previously (1), following confirmation according to magnetic resonance study and panoramic radiography to rule out the presence of other conditions.

Exclusion criteria were: a) the presence of TrPs in any other masticatory or cervical muscle, b) intra-articular pathology according to diagnostic criteria for temporomandibular disorders (17), c) dentofacial deformities, d) facial paralysis, e) vascular diseases, f) tension headache or migraine, g) previous infectious-inflammatory diseases of dental origin, h) belonephobia, i) fibromyalgia, j) depression or k) other medical comorbidities (diabetes, hypo- or hyperthyroidism).

The study was approved by the Hospital Ethics Committee (approval number 2014PI/083). All patients provided their informed consent prior to inclusion.

-Study design:

Patients were randomly assigned by Epidat 4.0 software to one of the three groups. The principal investigator and patients were all blinded to the assigned group until completion of the statistical analysis. The clinical evaluation of the patients was performed prior to treatment,

and on days 28, 42 and 70 after treatment. Data was collected at each visit by the same observer.

The PNE group received a transcutaneous puncture in the LPM, according to the technique described by Koole *et al*. (18). Sterile stainless-steel needles (length 40 mm/ caliber 0.25 mm, with a cylindrical plastic guide, Agu-punt ®, Barcelona, Spain) were used for the muscle puncture. The puncture needles were connected to an electrosurgical device, and the electrotherapy equipment (EPI® Advanced Medicine, Barcelona, Spain) produced a continuous galvanic current of 2 mA for 3 seconds, three times through the cathode (electrosurgical scalpel), while the patient held the anode (hand electrode).

The puncture technique used for the DDN group was performed as previously described (2,11). A deep intramuscular puncture of the TPs was carried out without the introduction of any substance (dry puncture) (19). The objective was to provoke a jump reaction or local twitch response when the needle was inserted in a TrP (8). During the procedure, the operator used the volume of the electrotherapy equipment as a guide, simulating the EPI® technique. For the SNP group, the needle was pressed against the skin with its plastic protective tube, simulating a puncture, with the same noise reproduced with the EPI® equipment.

In all cases, the preauricular area was cleaned with alcohol 90% prior to the procedure, and the unilateral upper and lower bellies of the LPM were located manually intra- and extraorally. The procedures were performed once per week, for 3 consecutive weeks. Two weeks after each procedure, all subjects were instructed to perform concentric exercises with the masticatory muscles.

-Measures:

The main parameters evaluated were: a) pain at rest and with mastication according to a visual analogue scale (VAS), ranging from 0 (without pain) to 10 (worst pain imaginable), b) maximum interincisal opening (MIO) without causing pain or discomfort, using a jaw motion ruler to evaluate the distance between the upper and lower incisor in millimetres (Therabite® System ruler), and c) involvement of the TMJ, assessed by a 100-point questionnaire (0 worst case, 100 optimal) based on pain in daily activities (maximum 40 points), function (45 points) and mastication (15 points). Secondary efficacy results were the overall efficacy scores evaluated by the patients and the observer using a 5-point scale, ranging from 0 worst-possible outcome to the optimum outcome of 4. Tolerability to the treatment was evaluated by the patient and the observer using a 5-point scale, ranging from 0-very bad to 4-excellent. The type and frequency of adverse events were recorded at each visit.

-Statistical analysis:

Data were analysed with SPSS statistical software (IBM Statistics 19.0). Pre- and post-intervention comparisons of the variables in each group were performed with the Friedman test, while variations within each group were analysed with the Wilcoxon signed-rank test (with Bonferroni correction). Comparisons between the study groups were made with the Kruskal-Wallis test for each time point. If differences were detected between groups, the Mann-Whitney U test was used to detect where the difference was. Values of $p < 0.05$ were considered to indicate statistical significance. When the Bonferroni correction was applied, the statistical significance was $p<0.016$.

Results

Sixty patients were included in the study and randomly assigned to one of the three groups (20 patients in each group), from June 2015 to June 2016. The three groups had similar number of patients, and similar age distributions (median age of 39, range 18 to 62). Table 1 shows the demographic characteristics and pain descriptions for the 60 participants. No significant differences were found between the 3 groups. Two patients from the DDN group and one patient from the SNP group dropped out of the trial. When performing the statistical analysis,

Table 1: Demographic characteristics and pain description of all participants.

	PNE	DDN	SNP	Significance (P)
Age (y), median (range)	38.5 (18-57)	36 (19-58)	42 (25-62)	0.3247
Gender Male/Female (n)	5 / 15	2 / 18	1 / 19	0.5273
Pain (VAS), Me (IQR) At rest Mastication	 6 (5-6.75) 7 (6-8.375)	 6 (5-7) 8 (7-8)	 5.5 (4-7) 7 (5-8.5)	 0.929 0.670
MIO, Me (IQR)	34.5 (29.5-36.75)	34 (30-35.5)	34 (25-39)	0.765
TMJ functionality test, Me (IQR)	38.5 (21.25-51.5)	45 (20-52.5)	35 (20-42)	0.312

VAS= visual analogue scale. Me= median. IQR= interquartile range. MIO= maximum interincisal opening. PNE= percutaneous needle electrolysis. DDN= deep dry needling. SNP= sham needling procedure. TMJ= temporo-mandibular joint.

the intention-to-treat analysis and the per-protocol analysis yielded identical results for all parameter measures; therefore, only the analysis per-protocol will be used to describe the results.

The reduction in pain at rest from day 0 to day 70 was statistically significant in the PNE and DDN groups (p <0.001) (Table 2). In the PNE group, this difference was first evident on day 28 (p<0.0001), while in the DDN

Table 2: Pain at rest and pain on mastication, as measured on a 10-cm VAS.

	Pain at rest: Intragroup analysis							
	Day 0	Day 28	Day 42	Day 70		Δ 0-28	Δ 28-42	Δ 42-70
	Me (IQR)	Me (IQR)	Me (IQR)	Me (IQR)	Significance (*P*) [1]	Significance (*P*) [2]	Significance (*P*) [2]	Significance (*P*) [2]
PNE group	6 (5-6.75)	1.5 (0.2-4)	1.25 (0-3)	1.5 (0-2	0.001*	<0,0001*	0.454	0.497
DDN group	6 (5-7)	5 (3.5-5)	3 (2-4)	2 (2-3.5)	0.001*	0.004*	0.008*	0.014*
SNP group	5.5 (4-7)	5 (3-7)	5 (4-7)	5 (3-6)	0.776			
	Pain at rest: Intergroup analysis							
	Day 0	Day 28	Day 42	Day 70				
Significance (*P*) [3]	0.929	0.002*	0.001*	<0.0001*				
PNE vs DDN Significance (*P*) [4]		0.007*	0.012*	0.033				
PNE vs SNP Significance (*P*) [4]		0.002*	0.001*	<0.0001*				
DDN vs SNP Significance (*P*) [4]		0.308	0.023	0.010 *				

	Pain on mastication: Intragroup analysis							
	Day 0	Day 28	Day 42	Day 70		Δ 0-28	Δ 28-42	Δ 42-70
	Me (IQR)	Me (IQR)	Me (IQR)	Me (IQR)	Significance (*P*) [1]	Significance (*P*) [2]	Significance (*P*) [2]	Significance (*P*) [2]
PNE group	7 (6-8.3)	4 (2-5)	2.7 (1-5.1)	2 (1-4)	<0.0001*	0.001*	0.077	0.351
DDN group	8 (7-8)	5 (4.5-6)	3 (3-5.5)	3 (2-5)	<0.0001*	<0.0001*	0.046	0.046
SNP group	7 (5-8.5)	6 (4-9)	8 (4-9)	3 (3-8)	0.303			
	Pain on mastication: Intergroup analysis							
	Day 0	Day 28	Day 42	Day 70				
Significance (P) [3]	0.670	0.016*	0.004*	0.004*				
PNE vs DDN Significance (P) [4]		0.173	0.161	0.279				
PNE vs SNP Significance (P) [4]		0.008*	0.005*	0.002*				
DDN vs SNP Significance (P) [4]		0.073	0.011*	0.016*				

Data from the tables are the median of the differences between the different days. VAS=visual analogue scale. Me=median. IQR=interquartile range. PNE=percutaneous needle electrolysis. DDN=deep dry needling. SNP=sham needling.
Significance (P)(1) = Friedman test for intragroup comparative analysis at each visit. * Results considered significant (p<0.05).
Significance (P)(2) = Wilcoxon test for the intragroup comparative analysis of VAS increase every two visits consecutive * Results considered significant (p<0.016).
Significance (P)(3) = Kruskal-Wallis test for intergroup comparative analysis at each visit. * Results considered significant (p<0.05).
Significance (P)(4) = Mann-Whitney U test for intergroup comparative analysis at each visit. * Results considered significant (p<0.016).

group it was significant at all time points (p= 0.004, p= 0.008 and p= 0.014). When comparing among the three groups, differences were statistically significant at all time-points in the study (p<0.001). Differences between the PNE and SNP groups were found for all three days in which data was collected (p = 0.002, p = 0.001 and p <0.001). Differences between the PNE and DDN groups were found between days 28 (p = 0.07) and 42 (p = 0.12), and between DDN and SNP at day 70 (p = 0.01). From day 0 to day 70, a significant reduction in pain with mastication was seen for the PNE and DDN groups (p <0.001) on day 28 (p = 0.001 and p <0.0001) (Table 2). When comparing between the three groups, significant differences were seen at all time-points of the study (p = 0.016, p = 0.004 and p = 0.004). Differences between the PNE and SNP groups were significant at all time-points (p = 0.08, p = 0.05 and p = 0.02), while between the DDN and SNP groups differences were found on days 42 and 70 (p = 0.011 and p = 0.016). MIO values improved significantly from day 0 to day 70 in both the PNE and DDN groups (p <0.001) (Table 3), with a significant reduction also seen for both groups on day 28 (p <0.0001 and p = 0.001). When comparing between the three groups, differences were obtained on all three days of the study in which data was collected (p <0.001, p = 0.002 and p = 0.001). For the PNE group, the increase in MIO was higher than in both the DDN group (p = 0.001, p = 0.007 and p = 0.003) and the SNP group (p <0.001, p = 0.002 and p = 0.001) at all times.

Values obtained in the 100-point questionnaire improved significantly between day 0 and day 70 in the three groups (p <0.001) (Table 4). Significant differences were also found on day 28 for the PNE and DDN groups (p <0.0001 and p = 0.001). Again, when the three groups were compared, differences were significant on each of the three days in which data were recorded (p = 0.009, p = 0.004 and p <0.001). Values for the PNE group were higher than those for the SNP group on all three days (p = 0.006, 0 = 0.003 and p <0.001), and higher than the DDN group on day 70 (p = 0.001).

The only reported adverse effect was a self-limiting hematoma in one patient in the PNE group. No statistically significant differences in treatment tolerance were found between the three groups (Table 4). The evaluation of the efficacy outcomes among the three groups was statistically significant both for the patient (p <0.0001) and the observer. When comparing between the three groups, this difference was greater for the PNE group than in the DDN and SNP groups, and in

Table 3: Maximal interincisal opening (MIO), as measured using a jaw motion ruler.

	Intragroup analysis							
	Day 0	Day 28	Day 42	Day 70		Δ 0-28	Δ 28-42	Δ 42-70
	Me (IQR)	Me (IQR)	Me (IQR)	Me (IQR)	Significance (P) (1)	Significance (P) (2)	Significance (P) (2)	Significance (P) (2)
PNE group	34.5 (29.5-36.75)	40 (38-45)	40 (36-45)	40 (38-45)	<0.0001*	<0.0001*	0.291	0.360
DDN group	34 (30-35.5)	37 (35-40)	37 (35-38)	37 (35-38.5)	<0.0001*	0.001*	0.811	0.020
SNP group	34 (25-39)	35 (28-40)	33 (26-40)	35 (28-40)	0.95			
	Intergroup analysis							
	Day 0	Day 28	Day 42	Day 70				
Significance (P) (3)	0.765	<0.0001*	0.002*	0.001*				
PNE vs DDN Significance (P) (4)		0.001*	0.007*	0.003*				
PNE vs SNP Significance (P) (4)		<0.0001*	0.002*	0.001*				
DDN vs SNP Significance (P) (4)		0.078	0.244	0.132				

Data from the tables are the median of the differences between the different days. Me = median. IQR = interquartile range. PNE = percutaneous needle electrolysis. DDN = deep dry needling. SNP = sham needling procedure.
Significance (P) (1) = Friedman test for intragroup comparative analysis at each visit. * Results considered significant (p<0.05).
Significance (P) (2) = Wilcoxon test for the intragroup comparative analysis of VAS increase every two visits. * Results considered significant (p<0.016).
Significance (P) (3) = Kruskal-Wallis test for intergroup comparative analysis at each visit. * Results considered significant (p<0.05).
Significance (P) (4) = Mann-Whitney U test for intergroup comparative analysis at each visit. * Results considered significant (p<0.016).

Table 4: Functionality of the TMJ, measured by the 100-point test, and tolerance to treatment and subjective evaluation, measured by the 5-point test.

A) Functionality of the TMJ, measured by the 100-point test:

	Intragroup analysis							
	Day 0	Day 28	Day 42	Day 70		Δ 0-28	Δ 28-42	Δ 42-70
	Me (IQR)	Me (IQR)	Me (IQR)	Me (IQR)	Significance (*P*) [1]	Significance (*P*) [2]	Significance (*P*) [2]	Significance (*P*) [2]
PNE group	38.5 (21.25-51.5)	75 (51.25-83.75)	75 (56.25-93.75)	82.5 (60-90)	<0.0001*	<0.0001*	0.529	0.028
DDN group	45 (20-52.5)	57 (52.5-70)	57 (53.5-70)	60 (52.5-70)	<0.0001*	0.001*	0.595	0.713
SNP group	35 (20-42)	45 (15-70)	37 (15-65)	37 (25-67)	<0.0001*	0.035	0.408	0.422
	Intergroup analysis							
	Day 0	Day 28	Day 42	Day 70				
Significance (*P*) [3]	0.312	0.009*	0.004*	<0.0001*				
PNE vs DDN Significance (*P*) [4]		0.064	0.022	0.001*				
PNE vs SNP Significance (*P*) [4]		0.006*	0.003*	<0.0001*				
DDN vs SNP Significance (*P*) [4]		0.087	0.109	0.244				

Data from the tables are the median of the differences between the different days.
Me = median. IQR = interquartile range. PNE = percutaneous needle electrolysis. DDN = deep dry needling. SNP = sham needling procedure.
Significance (P) [1] = Friedman test for intragroup comparative analysis at each visit. * Results considered significant (p<0.05).
Significance (P) [2] = Wilcoxon test for the intragroup comparative analysis of VAS increase every two visits. * Results considered significant (p<0.016).
Significance (P) [3] = Kruskal-Wallis test for intergroup comparative analysis at each visit. * Results considered significant (p<0.05).
Significance (P) [4] = Mann-Whitney U test for intergroup comparative analysis at each visit. * Results considered significant (p<0.016).

B) Tolerance to treatment and subjective evaluation, measured by the 5-point test:

	Tolerance to treatment at day 28		Subjective evaluation of improvement at day 70	
	Me (IQR)		Me (IQR)	
	Patient	Observer	Patient	Observer
PNE group	4 (3-4)	4 (3-4)	4 (3-4)	4 (4-4)
DDN group	4 (3-4)	4 (3-4)	3 (3-3)	3 (2,5-3)
SNP group	4 (4-4)	4 (4-4)	2 (1-2)	2 (1-2)
Significance (*P*) [1]	0,238	0,390	<0,0001*	<0,0001*
PNE vs DDN Significance (*P*) [2]			0.02088*	0.041*
PNE vs SNP Significance (*P*) [2]			<0.0001*	<0.0001*
DDN vs SNP Significance (*P*) [2]			0.00012*	0.0104*

Data from the tables are the median of the differences.
Me = median. IQR = interquartile range. PNE = percutaneous needle electrolysis. DDN = deep dry needling. SNP = sham needling procedure.
Significance (P) [1] = Kruskal-Wallis test for intergroup comparative analysis. * Results considered significant (p<0.05).
Significance (P) [2] = Mann-Whitney U test for intergroup comparative analysis. * Results considered significant (p<0.016).

turn greater in the DDN group than in the SNP group, in terms of both patient and observer perception.

Discussion

The objective of the present study was to evaluate the efficacy of PNE and DDN, two minimally-invasive techniques, applied three times to the LPM (once per week for three consecutive weeks). To do this, an analysis was made of the pain intensity at rest and with mastication, together with the measurements of the MIO ranges. The main findings can be outlined as follows: Compared to baseline values prior to treatment, PNE and DDN serve as effective treatments for MPS located in the LPM, improving pain, mandibular mobility and involvement of the TMJ ($p < 0.01$). Both techniques immediate pain relief, and provided a stable outcome throughout the follow-up period as evidenced by significant improvements maintained until day 70 ($p < 0.05$). It would seem that this effect was achieved earlier with PNE than with DDN. Pain reduction values were proportionately higher compared to those of improvements in MIO. And finally, when comparing these results with the SNP group, significant differences were generally obtained on all of the study days in which evaluations were made.

The therapeutic management of MPS should be based on a multidisciplinary approach where TrP inactivation is the fundamental objective. While various puncture methods have been described in the literature that attempt to inactivate myofascial TrPs (9,11), the principal difference between the different techniques consists of the injection, or not, of a substance into the TrP (dry puncture or wet puncture). No significant differences were reported in the literature between the use of DDN and the injection of any substance in the muscle belly (9).

DDN involves inactivation of TrPs via the insertion of an acupuncture needle without the administration of any substance. The mechanism of underlying the inactivation is not known, but the technique has been shown to provide effective pain relief and short-term functional recovery of muscles (20). The most accepted hypothesis of the technique's mechanism of action is that the needle damages the motor endplate, which in turn causes denervation of the distal axon, and interruption of the central pain circuit (21). To ensure the success of the procedure, the local twitch response that occurs when the needle enters the TrP seems to be the best indicator to establish the diagnosis (8), although occasionally, identification of the local twitch response can be extremely difficult. The local twitch response corresponds to a spinal reflex with a momentary contraction of the fibers that make up the taut band of muscle. The patient describes it as a cramp or tingling at the time of the puncture.

A limited number of studies have investigated the use of DDN to treat TrP in the orofacial area. Fernandez-Carnero *et al.* (4) studied the use of DDN of the masseter muscle. Gonzalez-Perez *et al.* (11) compared DDN with analgesic medication for MPS by treating TrPs in the LPM, with pain relief achieved almost immediately in the DDN group. Recently, Blasco-Bonora & Martín-Pintado-Zugasti (3) used DDN on the temporal and masseter muscles. Taken together, these studies have reported statistically and clinically significant results in reducing both pain and dysfunction.

PNE is an emerging, minimally invasive physiotherapeutic technique that involves the application of direct current (galvanic) through a puncture needle such that used in DDN, which acts as a negative electrode and induces an electrochemical reaction in the area to which it is applied. Cell necrosis is caused by this reaction, which results in a local inflammatory process in the soft tissue, inducing phagocytosis and repair of the affected tissue (12). Tissue regeneration induced by PNE can restore function to the muscle, which is usually structurally damaged. PNE has been used to the present time to treat pathologies of the muscles and tendons, particularly in the lower limbs (13-16). To the best of our knowledge, no study has provided data on its use in orofacial pain as in our clinical trial. The paucity of other studies means that we are not available to compare our findings with others, making it difficult to arrive at definitive conclusions.

When comparing PNE with DDN in the present study, it was found that pain at rest and upon mastication decreased earlier in the PNE group. This was possibly because the technique combines both mechanical (needle) and electrical (galvanic current) stimulation (14). This effect could be explained by the inactivation of TrPs and by the acceleration of the regeneration of the damaged muscle with PNE. Three punctures were performed (one per week for three weeks) with application of a low intensity galvanic discharge in the LPM, with the aim of inactivating the TrPs. The slower improvement in the DDN group could have been due to the effect of the SNP and the blinding of the patients. In general, patients in the PNE group reported less post-puncture pain than in the DDN group. Improvements in MIO and in the 100-point test score were similar in the PNE and DDN groups, generating an improvement in the perceived quality of life of patients owing to the larger variety of foods they could eat.

The diagnosis of the presence of a TrP in the LPM is difficult due to its deep location. Painful intraoral palpation or limited mandibular opening are two common indirect clinical signs. The most reliable clinical test seems to be the painful protrusion against resistance (1,11,18,19). Exact localization of the TrP before the puncture can be achieved by palpation, ultrasound or

electromyography, although their use is complex and not validated (22-25). In general, the precise puncture of the LPM is a simple, reliable and validated technique (11,18) achieved via a transcutaneous approach, with the two muscle bellies easily reached (26).

Tolerance to the treatment was the same in the three groups. The overall evaluation by the patients and observer of the effectiveness of the treatment, and the patients' evaluation of treatment tolerance, were better for PNE and DDN than for SNP. Similarly, the overall efficacy evaluated both by patients and the observer was better for the PNE and DDN groups. No adverse reactions were detected with DDN, whereas in the PNE group a self-limiting hematoma was detected in one patient. As for any minimally invasive technique, both PNE and DDN were well tolerated without significant contraindications or costs (16). The strengths of the present trial lie in the fact that it was randomized, blinded and controlled, comparing two active interventions. Furthermore, data collection at standardized time-points during the postoperative period facilitated comparisons with the pre-operative baseline status.

This study has some limitations. Maintaining the blinding of patients in a clinical trial based on an intervention involving a muscle puncture is challenging. This type of effect makes it extremely difficult to conduct studies with a SNP in which participants are truly blinded. In the SNP group of this study, a superficial puncture of the skin was performed with the plastic protection applied (sham dry needling). In this way, the influence of the placebo effect of the procedure and / or the natural evolution of the TMD was controlled throughout the study. Tekin *et al.* (27) blinded participants by applying gentle pressure to the skin with the plastic protection; they described a mild effect in the first days after treatment, which was attributed to the stimulation of superficial cutaneous receptors. To achieve a true placebo effect, Mayoral *et al.* (28) conducted a study in which patients were placed under general anesthesia, and therefore had no way of knowing afterwards what procedure they had been subjected to. Another of the limitations identified here was the infrequently identified, exclusive affectation of the LPM, since disorders of the LPM usually coexist with the involvement of other masticatory muscles such as the masseter or the temporal muscle (29). The evaluation was limited only to the effects observed in the short- and medium-term. To improve the validity of the study it would be important to increase the number of subjects, the time of follow-up, and the inclusion of patients in whom other masticatory muscles are affected. In addition, it would be interesting to assess the treatment in patients with fibromyalgia or depression (30), which in this study were excluded. The use of EMG in the diagnostic work-up, and as a treatment support for puncture of the LPM, could also be studied.

Conclusions

In comparison with SNP, PNE and DDN of the LPM showed greater efficacy in relieving pain and improving MIO in patients with MPS in that muscle. The improvement was seen earlier in the PNE group than in the DDN group. No serious adverse events were observed with respect to any of the techniques used. Future studies should aim for greater validity by enrolling more patients and patients with other disorders of the temporomandibular region, to determine the true role of PNE in the management of MPS in the orofacial area.

References

1. Gonzalez-Perez LM, Infante-Cossio P, Granados-Nunez M, Urresti-Lopez FJ. Treatment of temporomandibular myofascial pain with deep dry needling. Med Oral Patol Oral Cir Bucal. 2012;17:e781-5.
2. Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, et al. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: Recommendations of the International RDC/TMD Consortium Network and Orofacial Pain Special Interest Group. J Orofac Pain. 2014;28:6–27.
3. Blasco-Bonora PM, Martin-Pintado-Zugasti A. Effects of myofascial trigger point dry needling in patients with sleep bruxism and temporomandibular disorders: a prospective case series. Acupunct Med. 2017;35:69-74.
4. Fernandez-Carnero J, La Touche R, Ortega-Santiago R, Galan-del-Rio F, Pesquera J, Ge HY, et al. Short-Term effects of dry needling of active myofascial trigger points in the masseter muscle in patients with temporomandibular disorders. J Orofac Pain. 2010;24:106-12.
5. Shen YF, Younger J, Goddard G, Mackey S. Randomized clinical trial of acupuncture for myofascial pain of the jaw muscles. J Orofac Pain. 2009;23:353-9.
6. Lindfors E, Hedman E, Magnusson T, Ernberg M, Gabre P. Patient Experiences of Therapeutic Jaw Exercises in the Treatment of Masticatory Myofascial Pain: A Qualitative Study. J Oral Facial Pain Headache. 2017;31:46-54.
7. Fernandes AC, Duarte Moura DM, Da Silva LGD, De Almeida EO, Barbosa GAS. Acupuncture in Temporomandibular Disorder Myofascial Pain Treatment: A Systematic Review. J Oral Facial Pain Headache. 2017;31:225-32.
8. Hong CZ. Lidocaine injection versus dry needling to myofascial trigger point. The importance of the local twitch response. Am J Phys Med Rehabil. 1994;73:256–63.
9. Ay S, Evcik D, Tur BS. Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial. Clin Rheumatol. 2010;29:19–23.
10. Goddard G, Karibe H, McNeill C, Villafuerte E. Acupuncture and sham acupuncture reduce muscle pain in miofascial pain patients. J Orofac Pain. 2002;16:71-6.
11. Gonzalez-Perez LM, Infante-Cossio P, Granados-Nunez M, Urresti-Lopez FJ, Lopez-Martos R, Ruiz-Canela-Mendez P. Deep dry needling of trigger points located in the lateral pterygoid muscle: Efficacy and safety of treatment for management of myofascial pain and temporomandibular dysfunction. Med Oral Patol Oral y Cir Bucal. 2015;20:e326-33.
12. Abat F, Valles SL, Gelber PE, Polidori F, Stitik TP, Monllau JC. Mecanismos moleculares de reparación mediante la técnica Electrólisis Percutánea Intratisular en la tendinosis rotuliana. Rev Esp Cir Ortop Traumatol. 2014;58:201–5.
13. Abat F, Gelber PE, Polidori F, Monllau JC, Sanchez-Ibanez JM. Clinical results after ultrasound-guided intratissue percutaneous electrolysis (EPI®) and eccentric exercise in the treatment of patellar tendinopathy. Knee Surg Sports Traumatol Arthrosc. 2015;23:1046-52.
14. Arias-Buria JL, Truyols-Domínguez S, Valero-Alcaide R, Salom-Moreno J, Atin-Arratibel MA, Fernandez-de-Las-Pe-as C. Ul-

trasound-Guided Percutaneous Electrolysis and Eccentric Exercises for Subacromial Pain Syndrome: A Randomized Clinical Trial. Evid Based Complement Alternat Med. 2015;2015:315219.
15. Abat F, Sanchez-Sanchez JL, Martin-Nogueras AM, Calvo-Arenillas JI, Yajeya J, Mendez-Sanchez R, et al. Randomized controlled trial comparing the effectiveness of the ultrasound-guided galvanic electrolysis technique (USGET) versus conventional electro-physiotherapeutic treatment on patellar tendinopathy. J Exp Orthop. 2016;3:34.
16. Garcia Naranjo J, Barroso Rosa S, Loro Ferrer JF, Liminana Canal JM, Suarez Hernandez E. A novel approach in the treatment of acute whiplash syndrome: Ultrasound-guided needle percutaneous electrolysis. A randomized controlled trial. Orthop Traumatol Surg Res. 2017;103:1229-34.
17. Look JO, Schiffman EL, Truelove EL, Ahmad M. Reliability and validity of Axis I of the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) with proposed revisions. J Oral Rehabil. 2010;37:744-59.
18. Koole P, Beenhakker F, Jongh HJ de, Boering G. A standardized technique for the placement of electrodes in the two heads of the lateral pterygoid muscle. Cranio. 1990;8:154–62.
19. Simons DG. Review of enigmatic MTrPs as a common cause of enigmatic musculoskeletal pain and dysfunction. J Electromyogr Kinesiol. 2004;4:95-107.
20. Dıraçoglu D, Vural M, Karan A, Aksoy C. Effectiveness of dry needling for the treatment of temporomandibular myofascial pain: A double-blind, randomized, placebo controlled study. J Back Musculoskelet Rehabil. 2012;25:285–90.
21. Kietrys DM, Palombaro KM, Azzaretto E, Hubler R, Schaller B, Schlussel JM, et al. Effectiveness of dry needling for upper quarter myofascial pain: A systematic review and meta-analysis. J Orthop Sports Phys Ther. 2013;43:620-34.
22. Pal US, Kumar L, Mehta G, Singh N, Singh G, Singh M, et al. Trends in management of myofacial pain. Natl J Maxillofac Surg. 2014;5:109–16.
23. Martos-Diaz P, Rodriguez-Campo FJ, Bances-Del Castillo R, Altura-Guillen O, Cho-Lee GY, Mancha-De-La Plata M, et al. Lateral pterygoid muscle dystonia. A new technique for treatment with botulinum toxin guided by electromyography and arthroscopy. Med Oral Patol Oral Cir Bucal. 2011;16:9–12.
24. Turp J, Minagi S. Palpation of the lateral pterygoid region in TMD-where is the evidence? J Dent. 2001;29:475–83.
25. Stelzenmueller W, Umstadt H, Weber D, Goenner-Oezkan V, Kopp S, Lisson J. Evidence - The intraoral palpability of the lateral pterygoid muscle - A prospective study. Ann Anat. 2016;206:89-95.
26. Mesa-Jimenez J, Sanchez-Gutierrez J, De-la-Hoz-Aizpurua J. Cadaveric validation of dry needle placement in the lateral pterygoid muscle. J Manipulative Physiol Ther. 2015;38:145–50.
27. Tekin L, Akarsu S, Durmus O, Cakar E, Dincer U, Kiralp MZ. The effect of dry needling in the treatment of myofascial pain syndrome: A randomized double-blinded placebo-controlled trial. Clin Rheumatol. 2013;32:309–15.
28. Mayoral O, Salvat I, Martin MT, Martín S, Santiago J, Cotarelo J, et al. Efficacy of myofascial trigger point dry needling in the prevention of pain after total knee arthroplasty: a randomized, double-blinded, placebo-controlled trial. Evid Based Complement Alternat Med. 2013;2013:694941.
29. Itoh K, Asai S, Ohyabu H, Imai K, Kitakoji H. Effects of Trigger Point Acupuncture Treatment on Temporomandibular Disorders: A Preliminary Randomized Clinical Trial. J Acupunct Meridian Stud. 2012;5:57–62.
30. Castro-Sanchez AM, Garcia-Lopez H, Mataran-Penarrocha GA, Fernandez-Sanchez M, Aguilar-Ferrandiz ME. Effects of Dry Needling on Spinal Mobility and Trigger Points in Patients with Fibromyalgia Syndrome. Pain Physician. 2017;20:37–52.

Acknowledgments
The authors thank the Instituto de Salud Carlos III-Fondo de Investigación Sanitaria for financial support (grant number 00970), and also the patients who, without any economic or other benefits, participated in this study.

Conflicts of interest
The authors report no conflict of interest related to this study.

Abat et al. Journal of Experimental Orthopaedics (2016) 3:34
DOI 10.1186/s40634-016-0070-4

Journal of Experimental Orthopaedics

RESEARCH Open Access

Randomized controlled trial comparing the effectiveness of the ultrasound-guided galvanic electrolysis technique (USGET) versus conventional electro-physiotherapeutic treatment on patellar tendinopathy

F. Abat[1*], J. L. Sánchez-Sánchez[2], A. M. Martín-Nogueras[2], J. I. Calvo-Arenillas[2], J. Yajeya[3], R. Méndez-Sánchez[2], J. C. Monllau[4,5] and P. E. Gelber[4,6]

Abstract

Background: Patellar tendinopathy has a high prevalence rate among athletes. Different therapeutic options can be found in the current literature, but none of them has been clearly established as the gold standard. The purpose of this study is to compare, in a randomized controlled trial, the clinical efficacy of eccentric exercise combined with either an ultrasound-guided galvanic electrolysis technique (USGET) or conventional electrophysiotherapy to treat patellar tendinopathy.

Methods: Sixty patients diagnosed with patellar tendinopathy were randomized into two groups. Group 1 ($n = 30$) received electrophysiotherapy treatment consisting of ultrasound, laser and interferential current techniques. Group 2 ($n = 30$) received USGET. Both groups did the same standardized eccentric exercise program. Periodic assessments of the subjects were carried out with the Victorian Institute of Sport Assessment-Patella (VISA-P) score. An analysis of means and a survival study were performed.

Results: There were statistically significant differences in the VISA-P between the baseline and final follow-up in each treatment group. Group 1 (conventional electrophysiotherapy) went from 52.5 ± 18.8 to 61.9 ± 13.7 (in VISA-P < 90 subgroup) and from 69.1 ± 9.1 to 95.2 ± 2.5 (in VISA-P > 90 subgroup). Group 2 (USGET) went from 51.4 ± 17.9 to 63.3 ± 14.3 (in VISA-P < 90 subgroup) and from 66.3 ± 13.1 to 97.1 ± 1.7 (in VISA-P > 90 subgroup). There were statistically significant correlations between the baseline and final score in the VISA-P > 90 subjects upon completing the study but no statistically significant correlations between subjects with VISA-P < 90. The mean number of sessions applied was 22.6 ± 2.5 in Group 1 and 3.2 ± 0.9 in Group 2. The success probability in Group 1 was 36.1% versus 72.4% in Group 2. The difference was statistically significant.

Conclusion: The results obtained with the combination of USGET and eccentric exercise reported better outcomes than with the conventional electrophysiotherapy techniques in the treatment of patellar tendinopathy.

Keywords: USGET, Galvanic, Electrolysis, Treatment, Patellar, Tendinopathy, Electrophysiotherapy

* Correspondence: abat@resportclinic.com
[1]Department of Orthopaedic Sports Medicine, ReSport Clinic, Rambla Fabra i Puig 47, 08030 Barcelona, Spain
Full list of author information is available at the end of the article

Background

Patellar tendinopathy has a high prevalence rate among athletes (Larsson et al., 2012). This is especially so in sports that involve repetitive movements that cause an overload of the tendon like jumping, changes of pace and direction as well as racing and pedalling. It appears in both professional athletes and amateurs (Childress and Beutler, 2013). Classically, the term tendinitis was used considering that the fundamental lesion was an inflammation of the tendon. Today, we know, histologically speaking, that we can find degenerated tissue with fragmentation, an alteration of the collagen and vascular hyperplasia, with inflammatory cells almost absent (Cook and Purdam, 2009; Khan et al., 2002).

This increased understanding of the pathophysiology leads to a change in the therapeutic approach. At present, the therapeutic techniques used in the treatment of tendinopathy have abandoned the goal of eliminating inflammation of the tendon and instead try to impact on the biology of the tendon to stimulate its regeneration (Cook and Purdam, 2009).

Different therapeutic options for tendinopathy can be found in the current literature. None of them has been clearly established as the gold standard and the best option is still a matter of debate (Andres and Murrell, 2008; Childress and Beutler, 2013). Since the concept of tendinopathy as a defective healing process has broadened, therapeutic options have been progressively moving toward restoring natural tendon biology. Within the therapeutic arsenal, eccentric exercises play an important role although they have been proven insufficient when the tissue is significantly degenerated (Visnes et al., 2005). These exercises assist in the recovery of the biomechanical qualities of the tendon if the biology of previously damaged tissue can be restored (Childress and Beutler, 2013).

The USGET is a minimally invasive treatment with reported good clinical results in the medium (Abat et al. 2014a, b) and long-term follow-up (Abat et al., 2015). This technique consists in an ultrasound-guided application of a galvanic electrolytic current that causes a controlled local inflammatory process in the target tissue. This allows for phagocytosis and the subsequent regeneration of the affected tissue (Abat et al. 2014a, b).

The aim of this study was to determine whether the application of USGET and eccentric exercise in patellar tendinopathy reported better results than those obtained with conventional physiotherapy treatment in terms of pain and function.

Methods

Design

The subjects were randomly assigned to each group by a computer-generated number table (deterministic algorithm). An external assistant generated the tables and assigned the patients to the appropriate treatments group. Based on this statistical stratification, they were divided into two groups: The electro-physiotherapy group (Group 1) and USGET group (Group 2). The evaluator did not know this at any times. The patients included in the study were identified by a numerical code after signing informed consent. Within each group, subjects were divided based on the Victorian Institute of Sport Assessment-Patella (Visa-P) final score as a Visa-P <90 or Visa-P ≥ 90. Systematic assessments were performed every two weeks during follow-up. Subjects received treatment for 2 months or until the symptoms were not present (VISA-P value ≥ 90).

The study was carried out in accordance with the international standards for clinical trials, the declaration of Helsinki and the Good Clinical Practice Regulations. The study protocol was reviewed and approved by the Reference Ethics Committee (n° 201000005507). All patients who fulfilled the inclusion criteria signed informed consent for study inclusion.

Participants

Sixty-four patients were initially selected from the outpatient clinic to participate in the clinical trial. The inclusion criteria were being between 20 and 60 years of age, a clinical and ultrasound diagnosis of unilateral insertional patellar tendinopathy, having symptoms for more than one month and being athletically active before injury. The exclusion criteria were a prior knee surgery, associated lower limb injuries (like an anterior cruciate ligament injury or meniscopathy) or having received local steroid injections in the tendon prior to the study. Patients who took fluoroquinolones, anticoagulants or anti-inflammatory drugs were also excluded.

The study was composed of 32 subjects in Group 1 (24 males and 8 females with a mean age of 30.9 ± 5.9 years) and 32 subjects in Group 2 (27 men and 5 women with a mean age of 31.2 ± 6.5). There were four losses during follow up, two from each group, due to non-adherence to the treatment program. Thus, 60 subjects completed the study. Both groups were comparable with no statistical differences in any of the study variables (Table 1).

Intervention

Eccentric exercises were performed in both groups in combination with either standard electrotherapy (Group 1) or USGET (Group 2). The subjects in Group 1 passed through an electrophysiotherapy sessions of 50 min for three days a week over 8 weeks. Each session saw Ultrasound (Endomed 982) on the patellar tendon that was pulsed (1:5) for 2 milliseconds at a frequency of 100 Hz and an intensity of 0.5 W/cm2 for 10 min. Laser CO_2 (Asa Medical Laser) was also implemented with a fan

Table 1 Demographic and clinical data of participants separated by treatment group

	Group 1 (Electro-physiotherapy)	Group 2 (USGET)	*p.* value
Age (years)[a]	30.9 (5.9)	31.2 (6.5)	0.891
Sex (male:female)[b]	24:8	27:5	0.351
Weight (Kg)[a]	71.5 (11.2)	73.2 (11.1)	0.547
Height (m)[a]	174.7 (7.4)	175.8 (6.2)	0.501
BMI (kg/m2)[a]	23.3 (2.1)	23.6 (2.4)	0.631
Physical activity (days/week)[a]	3.8 (1)	4.3 (1.4)	0.055
Physical activity (hours/day)[a]	1.9 (1.5)	2.1 (1.2)	0.657
Laterality (Right:Left)[b]	24:8	23:9	0.719
Symptoms duration (months)[a]	29.5 (31.5)	28.8 (32.4)	0.929
# of previous episodes pain[a]	3.3 (2.3)	3.7 (2.6)	0.543
Time from the start of the last episode (months) [a]	2.2 (0.9)	2.8 (2.9)	0.277
Thickening of the tendon (Yes: No) [b]	32:0	32:0	1.000
Vascularization (Yes: No) [b]	23:9	22:10	1.000

[a] Statistics: Mean (standard deviation); p = Student t test. [b] Frequencies, p = Chi square

shaped cannon over the surface of the patellar tendon with an energy of 15 joules at a potency of 10 watts for 2 min and Interferential Currents (Endomed 982) in a tetrapolar application at a frequency of 80–100 Hz for 15 min. Finally, eccentric exercises based on those described for the conservative treatment of patellar tendinopathy were performed. A slow single-leg squat on an incline of 25° was done in 3 sets of 15 repetitions with a 3-min rest between sets. The exercise was conducted without an external load for 15 min.

The subjects in Group 2 underwent a treatment protocol consisting of USGET and eccentric exercises. The eccentric exercises were performed in the same manner as in Group 1. A USGET session was conducted every two weeks. USGET was performed with the patient supine with the knee flexed to 20° after the area had been disinfected with isopropanol. The galvanic electrolytic current was applied with a sterile 0.25x25 millimetre stainless steel acupuncture needle. This procedure was performed with ultrasound guided puncturing in the superficial paratendon, deep paratendon and the intratendonous area at the inferior pole of the patella in its deepest portion. In each of these locations, 3 punctures were made (without removing the needle from the skin) with an intensity of 2 milliamps until the injured area was completely debrided.

Outcome measures

A clinical history was completed on the first visit in which personal, physical, socio-demographic data, the medical history and symptoms were collected. A colour Doppler ultrasound was done to confirm the diagnosis of insertional patellar tendinopathy and the Victorian Institute of Sport Assessment-Patella (VISA-P) score (Hernandez-Sanchez et al., 2011) to assess symptoms, function and the ability to perform sport was completed (Hernandez-Sanchez et al., 2014). The VISA-P questionnaire was evaluated at the start point and at the end of the treatment at 2 months. The VISA-P consists of 8 items, 6 of which are analogue-visual scales from 0 to 10 where 10 represent the optimum. The first 6 questions cover the parameters of pain and function in different activities while the last 2 questions assess the parameters of function and the ability to perform sport. The maximum score is 100 points and corresponds to an asymptomatic and fully functional subject while the minimum score is 0 points. Visentini showed that it is a reliable tool for measuring the evolution of the PT and is validated by the scientific community (Visentini et al. 1998). During the study, patients with VISA-P values of less than 90 points were considered “not healed or symptomatic” and over 90 points as “healed or asymptomatic”.

An orthopaedic surgeon skilled in ultrasound diagnosis performed the ultrasonography evaluation. A protocol defined by the European Society of Musculoskeletal Radiology from the Musculoskeletal Ultrasound Technical Guidelines for the Knee was used (Beggs et al., 2012). This bilateral comparative evaluation was performed with the patient supine, the knee positioned at 0° and 20° of flexion and with a longitudinal and transversal view of the patellar tendon from its proximal insertion on the patella to its distal insertion in the tibial tuberosity. The parameters studied for diagnosis of patellar tendinopathy were: thickening of the tendon, the presence of an intra-tendinous hypoechoic areas, the presence or absence of irregularities in the cortical bone of the distal part of the patella and the presence or absence of intra-tendinous calcifications or hipervascularization.

Data analysis

The results are expressed as means, standard deviations (SD) and a confidence intervals of 95%. A p-value of less than 0.05 was considered statistically significant. A Kolmogorov normality test was done for the comparison study between the evaluation variables.

In cases of non-normality and asymmetries in the distributions of data variables, nonparametric tests (Mann–Whitney or Wilcoxon) were used. The comparison and correlation study of VISA-P scores between the final and baseline in each treatment groups and between asymptomatic and symptomatic subjects in the follow-up study was performed with the Student's T-tests and Pearson correlations. A study of survival with the Kaplan-Meier method, comparing the survival curves in each of the treatment groups with the Mantel-Haenszel test (log-rank), was done. The probability of success of each treatment was calculated and compared. The statistical power was 99.9%. Statistical analysis was performed using the SPSS 15 package (SPSS Inc., Chicago, Illinois).

Results

Research questions

The functional assessment according to the VISA-P showed statistically significant differences (p <0.05) between the initial and final assessment (Table 2) in the subjects with a VISA-P <90 (a difference of 10.1 points [95%CI 6.3 to 13.8]) and the ones with a VISA-P ≥ 90 (a difference of 29.2 points [95%CI 13.37 to 24.7]). These differences remained significant when analysing the results by groups (Fig. 1).

A correlation analysis was performed to study the relationship between the VISA-P scores at baseline and those at the last evaluation (the 5th evaluation or in those who were considered "cured") in all the subjects. For the total sample, a positive association between the initial and final VISA-P (n = 60; r2 = 0,457; p = 0,000) was observed. However, we observed different behaviors upon making correlations based on whether they were considered "healed or asymptomatic" or "not healed or symptomatic" at the last evaluation. In subjects with a final VISA-P ≥ 90, there were no statistically significant differences for either the total sample (n = 33) or for each of the intervention groups, 11 patients for electrophysiotherapy and 22 for USGET. For subjects with a VISA-P <90 at the end of the study, there were statistically significant differences (Fig. 2 and Table 3).

The number of sessions is not comparable between treatment groups due to the fact that the frequency in each case was different. In Group 1, an average 22.6 ± 2.5 sessions were performed, while 3.2 ± 0.9 USGET application sessions were needed in Group 2. There were no statistically significant differences in terms of the time in treatment between groups (Table 4). No adverse events were found in either group during the study.

The survival analysis showed that patients who received conventional electro-physiotherapy had a 36.1% chance of success versus 72.4% of the group treated with USGET at the end of the follow up period. In the survival analysis, the fact that subjects had a VISA-P ≥ 90 ("cured") was considered an event of interest (cutoff). At that point, regardless of the evaluation, the follow up period in the study terminated. That is, Group 2 showed a 36.3% greater heal rate [95% CI 36.1 to 36.5] at the final follow-up than Group 1. This difference was statistically significant (χ^2 = 10.312; df = 1; p = 0.001). In Group 2, 50% of subjects healed at between 28 and 56 days, somewhere between the second and the fourth USGET sessions. At 42 days, the probability of treatment success in Group 1 was 12.5% compared to 58.7% for Group 2 (Fig. 3).

Discussion

The results of this study using the VISA-P score evaluation show that the use of USGET and eccentric exercise is more effective in dealing with patellar tendinopathy than treatment with conventional electro-physiotherapy.

One explanation for the difference in efficacy between the treatments might be in the pathophysiological process of tendinopathy. Chronic pathologies are histologically characterized by tendon tissue degeneration with failure in the repair response in which hyperplasia and pathological neovascularization fibroblasts have been seen (Cook and Purdam, 2009; Khan et al., 2002).

Table 2 Score on the VISA-P scale at the initial and final evaluation by treatment Group

		VISA-p Initial Eval.[a]	VISA-p Final Eval.[a]	p. value[b]
Group 1 (Electro-physiotherapy) n = 30	VISA-p < 90 n = 19	52.5(18.8) [43.5-61.6]	61.9 (13,7) [55.3–68.5]	p < 0.001
	VISA-p > 90 n = 11	69.1 (9.1) [62.9-75.2]	95.2 (2.5) [93.5-96.9]	p < 0.003
Group 2 (USGET) n = 30	VISA-p < 90 n = 8	51.4 (17.9) [36.4-66.3]	63.3 (14.3) [51.3-75.2]	p < 0.021
	VISA-p > 90 n = 22	66.3 (13.1) [60.5-72.1]	97.1 (1.7) [96.3-97.8]	p < 0.001
TOTAL n = 60	VISA-p < 90 n = 27	52.2 (18.2) [44.9-59.4]	62.3 (13.6) [56.9-67.7]	p < 0.001
	VISA-p > 90 n = 33	67.2 (11.2) [63.0-71.4]	96.4 (2.1) [95.7-97.2]	p < 0.001

[a] Victorian Institute of Sport Assessment-Patella (VISA-P) values expressed as mean (±SD) and [coefficient interval]. [b] p = non-parametric Wilcoxon test Ranked as not healed (VISA-P < 90) and healed (VISA-P ≥ 90) at the final follow-up



Fig. 1 Error bar chart for the confidence interval at 95% at the start and end VISA-P scores in each treatment group. Subjects ranked as VISA-P > 90 and VISA-P < 90



Fig. 2 Scatter plot between the scores at the start and end VISA-P in each treatment group. It distinguishes subjects with VISA-P > 90 and VISA-P < 90

Table 3 Correlation analysis for the whole series

CORRELATIONS				
				VISA-P Last Eval.
TOTAL	Group 1 (Electro-physiotherapy)	VISA-P Initial Eval.	(r)	0,774
			(r^2)	0,599 (59,9%)
			p (value)	0,000
	Group 2 (USGET)	VISA-P Initial Eval.	(r)	0,57
			(r^2)	0,325 (32,5%)
			p (value)	0,001
	TOTAL	VISA-P Initial Eval.	(r)	0,676
			(r^2)	0,457 (45,7%)
			p (value)	0,000
VISA-P < 90 Final Eval.	Group 1 (Electro-physiotherapy)	VISA-P Initial Eval.	(r)	0,88
			(r^2)	0,774 (77,4%)
			p (value)	0,000
	Group 2 (USGET)	VISA-P Initial Eval.	(r)	0,818
			(r^2)	0,669 (66,9%)
			p (value)	0,013
	TOTAL	VISA-P Initial Eval.	(r)	0,859
			(r^2)	0,738 (73,8%)
			p (value)	0,000
VISA-P ≥ 90 Final Eval.	Group 1 (Electro-physiotherapy)	VISA-P Initial Eval.	(r)	−0,491
			(r^2)	0,241 (24,1%)
			p (value)	0,125
	Group 2 (USGET)	VISA-P Initial Eval.	(r)	−0,136
			(r^2)	0,018 (1,8%)
			p (value)	0,548
	TOTAL	VISA-P Initial Eval.	(r)	−0,262
			(r^2)	0,069 (6,9%)
			p (value)	0,140

Victorian Institute of Sport Assessment-Patella (VISA-P). Pearson Correlation Coefficient (r). Coefficient of Determination (r2) (% of Variance Explained). *p* = non-parametric Wilcoxon test

Alfredson et al. (Alfredson et al., 2003) suggested that these new vessels and nerves that accompany them were involved in the mechanisms of tendinopathy pain but the answer to the origin of the pain is an issue that is still undetermined.

The lower prevalence of healing in Group 1 suggests that addressing patellar tendinopathy with the conventional electro-physiotherapy techniques studied should not be the basis of the strategy for the treatment for this disease. This approach is justified in the literature. Although there are some studies that have been published on the benefits of pain and soft tissue regeneration by applying laser (Bjordal et al., 2006), ultrasound (Fu et al., 2008) or electro-therapy (Chang et al., 2015), many more

Table 4 Number of sessions and duration of treatment by Group and ranked as not healed (VISA-p < 90) or healed (VISA-p ≥ 90) at the final follow-up

	GROUP 1 (Electro-physiotherapy) *n* = 30			Group 2 (USGET) *n* = 30		
	Not healed *n* = 19	Healed *n* = 11	TOTAL *n* = 30	Not healed *n* = 8	Healed *n* = 22	TOTAL *n* = 30
NUMBER SESSIONS[a]	24(0) [24–24]	36.3(5.04) [32.9–39.7]	38.7(3.5) [37.3–39.9]	4(0) [4–4]	3.0(0.9) [2.6–3.4]	3.3(0.9) [2.9–3.6]
TREATMENT TIME (Days)[a]	56(0) [56–56]	50.9(7.1) [46.1–55.6]	54.1(4.8) [52.3–55.9]	56(0) [56–56]	42.0(13.6) [35.9–48.0]	45.7(13.2) [40.8–50.6]

[a] Statistics: Mean (standard deviation) [95% confidence interval]. No statistically significant differences were seen when comparing the number of sessions or time of treatment used in the comparison of both groups



Fig. 3 Cumulative survival graph in each of the treatment groups, VISA-P > 90 being the event studied

authors have concluded that there is no scientific evidence to attribute any clinical significance to these techniques in the treatment of tendinopathy (Andres and Murrell, 2008; Leadbetter, 2005).

The results show that the USGET could be a technique capable of acting on tendon biology by destroying the degenerated tissue and causing an inflammatory response that could trigger the biological process of collagen repair (Abat et al. 2014a, b). The only technique in common in the two intervention groups was eccentric exercise. The benefits of eccentric training in tendinopathy have been extensively studied (Jonsson and Alfredson, 2005; Young et al., 2005; Larsson et al., 2012; Visnes and Bahr, 2007). An effect on the biomechanics of the tendons is attributed to it, producing a stimulus in the voltage load and stretching, which are required in directing the orientation of collagen in the process of proliferation and maturation. However, with the application of the same exercise protocol in both groups, the cure rate was different. Therefore, the better results in Group 2 cannot be attributed to eccentric training only as one would expect a similar outcome in Group 1. The explanation for this greater effectiveness might be based on the combined application of a technique capable of eliciting a regenerative response a priori in tendinopathy as is USGET. It would be followed by another that would cause sufficient mechanical stimulation of the tendon tissue, producing a positive effect on cellular activity and the restructuring of the extracellular matrix.

The work has some limitations, including the fact that the study has divided the final score obtained on the scale VISA-P into two categories; VISA-P < 90 and VISA-P ≥ 90. Patients within the first category (VISA-P < 90) were considered as having symptoms and functional deficits and those in the second (VISA-P ≥ 90) were considered asymptomatic. Based on the literature, it is difficult to establish a clear boundary for the normal value in the VISA-P score and it is also very difficult to establish the score that a subject must have to consider them completely asymptomatic (Visnes and Bahr, 2007; Jonsson and Alfredson, 2005). Furthermore, failure to present symptoms or have no functional deficits implies that the structure and morphology of the tendon has been completely restored to normal (Coleman et al., 2000). We still consider the division into these categories to be helpful in understanding the results.

On the other hand, an ultrasound assessment of changes that the applied treatment might produce is not included at the end of the study. However, a morphological picture is not predictive of the symptoms of the patellar tendon (Warden et al., 2007) and ultrasound imaging is unable to distinguish changes caused by short-term treatment (Coleman et al., 2000).

An important limitation might be that various treatments were carried out together. Nevertheless, that fact represents the reality in current treatment protocols for tendinopathies.

Another limitation of the study is the short symptom duration before the treatment (1 month) and the relative short follow-up time. Moreover, other randomized trials have used intervention periods of equal length or even shorter (Stasinopoulos and Stasinopoulos, 2004). Additionally a longer duration of symptoms before treatment may have had an influence on the results. However, previous studies of this scientific group have shown that the effectiveness of the proposed treatment protocol is

maintained even during much longer periods of symptomatology (Abat et al. 2014a, b). Despite all this, it is possible that a period of longer intervention might affect the results. Therefore, future studies will be necessary.

Conclusion

The results obtained with the combination of USGET and eccentric exercise have reported better outcomes than conventional electro-physiotherapy techniques in the treatment of patellar tendinopathy.

Abbreviations

SD: Standard deviations; USGET: Ultrasound-guided galvanic electrolysis technique; Visa-P: Victorian Institute of Sport Assessment-Patella

Acknowledgments

We are grateful to Eric Goode for his help in correcting the manuscript.

Authors' contributions

Conceived and designed the experiments: SSJL. Performed the experiments: SSJL, CAJI, YJ, MSR. Analyzed the data: FA, SSJL, GPE, MNAM. Contributed analysis tools: FA, MNAM, CAJI, YJ, MSR. Wrote the paper: FA, SSJL, GPE, MJC. Pre-submission manuscript review and correction: FA, SSJL, MJC, GPE. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

All patients included in the study provided informed consent and the procedures were in accordance with the Helsinki Declaration. The study was approved by the Ethics Committee of the University of Salamanca (Nr. n° 201000005507).

Author details

[1]Department of Orthopaedic Sports Medicine, ReSport Clinic, Rambla Fabra i Puig 47, 08030 Barcelona, Spain. [2]Department of Physiotherapy, University of Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain. [3]Department of Physiology, University of Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain. [4]Catalan Institut of Traumatology and Sports Medicine (ICATME), Hospital Universitari Dexeus, Universitat Autónoma de Barcelona, Sabino Arana 5-19, 08028 Barcelona, Spain. [5]Department of Orthopedic Surgery and Traumatology, Parc de Salut Mar, Universitat Autónoma de Barcelona, Passeig Marítim, 25-29, 08003 Barcelona, Spain. [6]Department of Traumatology and Orthopaedic Surgery, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Sant Quintí 89, 08041 Barcelona, Spain.

Received: 17 August 2016 Accepted: 8 November 2016
Published online: 16 November 2016

References

Abat F, Diesel WJ, Gelber PE, Polidori F, Monllau JC, Sanchez-Ibañez JM (2014a) Effectiveness of the Intratissue Percutaneous Electrolysis (EPI®) technique and isoinertial eccentric exercise in the treatment of patellar tendinopathy at two years follow-up. Muscles Ligaments Tendons J 4(2):188–93

Abat F, Valles SL, Gelber PE, Polidori F, Stitik TP, García-Herreros S, Monllau JC, Sanchez-Ibánez JM (2014b) Molecular repair mechanisms using the Intratissue Percutaneous Electrolysis technique in patellar tendonitis. Rev Esp Cir Ortop Traumatol 58(4):201–5. doi:10.1016/j.recot.2014.01.002

Abat F, Gelber PE, Polidori F, Monllau JC, Sanchez-Ibañez JM (2015) Clinical results after ultrasound-guided intratissue percutaneous electrolysis (EPI®) and eccentric exercise in the treatment of patellar tendinopathy. Knee Surg Sports Traumatol Arthrosc 23(4):1046–52. doi:10.1007/s00167-014-2855-2

Alfredson H, Ohberg L, Forsgren S (2003) Is vasculo-neural ingrowth the cause of pain in chronic Achilles tendinosis? An investigation using ultrasonography and colour Doppler, immunohistochemistry, and diagnostic injections. Knee Surg Sports Traumatol Arthrosc 11(5):334–8

Andres BM, Murrell GA (2008) Treatment of tendinopathy: what works, what does not, and what is on the horizon. Clin Orthop Relat Res 466(7):1539–54. doi:10.1007/s11999-008-0260-1

Beggs I (2012) ESSR Ultrasound Group Protocols 2012 Musculoskeletal Ultrasound Technical Guidelines: V. Knee. Available via https://essr.org/. Accessed 8 Aug 2016

Bjordal JM, Lopes-Martins RA, Iversen VV (2006) A randomised, placebo controlled trial of low level laser therapy for activated Achilles tendinitis with microdialysis measurement of peritendinous prostaglandin E2 concentrations. Br J Sports Med 40(1):76–80

Chang YP, Chiang H, Shih KS, Ma HL, Lin LC, Hsu WL, Huang YC, Wang HK (2015) Effects of Therapeutic Physical Agents on Achilles Tendon Microcirculation. J Orthop Sports Phys Ther 45(7):563–9. doi:10.2519/jospt.2015.5681

Childress MA, Beutler A (2013) Management of chronic tendon injuries. Am Fam Physician 87(7):486–90

Coleman BD, Khan KM, Kiss ZS, Bartlett J, Young DA, Wark JD (2000) Open and arthroscopic patellar tenotomy for chronic patellar tendinopathy. A retrospective outcome study. Victorian Institute of Sport Tendon Study Group. Am J Sports Med 28(2):183–90

Cook JL, Purdam CR (2009) Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy. Br J Sports Med 43(6):409–16. doi:10.1136/bjsm.2008.051193

Fu SC, Shum WT, Hung LK, Wong MW, Qin L, Chan KM (2008) Low-intensity pulsed ultrasound on tendon healing: a study of the effect of treatment duration and treatment initiation. Am J Sports Med 36(9):1742–9. doi:10.1177/0363546508318193

Hernandez-Sanchez S, Hidalgo MD, Gomez A (2011) Cross-cultural adaptation of VISA-P score for patellar tendinopathy in Spanish population. J Orthop Sports Phys Ther 41(8):581–91. doi:10.2519/jospt.2011.3613

Hernandez-Sanchez S, Hidalgo MD, Gomez A (2014) Responsiveness of the VISA-P scale for patellar tendinopathy in athletes. Br J Sports Med 48(6):453–7. doi:10.1136/bjsports-2012-091163

Jonsson P, Alfredson H (2005) Superior results with eccentric compared to concentric quadriceps training in patients with jumper's knee: a prospective randomised study. Br J Sports Med 39(11):847–50

Khan KM, Cook JL, Kannus P, Maffulli N, Bonar SF (2002) Time to abandon the "tendinitis" myth. BMJ 324(7338):626–7

Larsson ME, Käll I, Nilsson-Helander K (2012) Treatment of patellar tendinopathy-a systematic review of randomized controlled trials. Knee Surg Sports Traumatol Arthrosc 20(8):1632–46. doi:10.1007/s00167-011-1825-1

Leadbetter JD (2005) The effect of therapeutic modalities on tendinopathy. In: Maffull N, Renstrom P, Leadbetter WB (eds) Tendon Injuries. Basic sciencie and clinical medicine. Springer, London, pp 233–241

Stasinopoulos D, Stasinopoulos I (2004) Comparison of effects of exercise programme, pulsed ultrasound and transverse friction in the treatment of chronic patellar tendinopathy. Clin Rehabil 18(4):347–52

Visentini PJ, Khan KM, Cook JL, Kiss ZS, Harcourt PR, Wark JD (1998) The VISA score: an index of severity of symptoms in patients with jumper's knee (patellar tendinosis). Victorian Institute of Sport Tendon Study Group. J Sci Med Sport 1(1):22–8

Visnes H, Bahr R (2007) The evolution of eccentric training as treatment for patellar tendinopathy (jumper's knee): a critical review of exercise programmes. Br J Sports Med 41(4):217–23

Visnes H, Hoksrud A, Cook J, Bahr R (2005) No effect of eccentric training on jumper's knee in volleyball players during the competitive season: a randomized clinical trial. Clin J Sport Med 15(4):227–34

Warden SJ, Kiss ZS, Malara FA, Ooi AB, Cook JL, Crossley KM (2007) Comparative accuracy of magnetic resonance imaging and ultrasonography in confirming clinically diagnosed patellar tendinopathy. Am J Sports Med 35(3):427–36

Young MA, Cook JL, Purdam CR, Kiss ZS, Alfredson H (2005) Eccentric decline squat protocol offers superior results at 12 months compared with traditional eccentric protocol for patellar tendinopathy in volleyball players. Br J Sports Med 39(4):246

Medical Hypotheses 112 (2018) 35–36

Contents lists available at ScienceDirect

Medical Hypotheses

journal homepage: www.elsevier.com/locate/mehy

Ultrasound-guided percutaneous electrolysis: A new therapeutic option for mammary fistulas

Juan D. Berná-Serna[a,*], José A. García-Vidal[b], Pilar Escolar-Reina[b], Juan D. Berná-Mestre[a]

[a] Department of Radiology, Virgen de la Arrixaca University Clinical Hospital, IMIB, Ctra. Madrid-Cartagena, 30120 El Palmar (Murcia), Spain
[b] Department of Physical Therapy, University of Murcia, Murcia, Spain

ARTICLE INFO

Keywords:
Mammary fistulas
Percutaneous electrolysis
Ultrasound

ABSTRACT

Mammary fistula (MF) is a recurrent condition characterised by the draining of abscesses around the areola. The best management for MF remains challenging. Moreover, the main problem is the high recurrence rate of this disease. MF is considered a chronic process. The percutaneous electrolysis (PE) technique involves the application of a galvanic current with an ultrasound-guided needle to induce ablation and repair of the affected tissue. Good results have been obtained with PE in chronic tendinopathies. Below we present a hypothesis that PE may be a new therapeutic option for MF.

Introduction

Mammary fistula (MF) is commonly associated with a non-lactating subareolar abscess. It is characterised by the draining of abscesses around the areola and affects young women, the average age being 37 years [1–6]. The disease can cause prolonged morbidity and is often difficult to manage, which is often a frustrating problem for both the patient and the physician and has a profound impact on quality of life.

The aetiology of MFs is still unknown. This entity is commonly considered to be closely linked to squamous metaplasia with keratinisation and/or epidermisation of the lactiferous duct [7,8]. However, it is also postulated that MFs might be due to a chronic inflammatory process of the pilosebaceous follicles in an areolar–periareolar location [9]. On the basis of this hypothesis, intralesional triamcinolone has been used as a treatment [5,10]. Nevertheless, the main problem is recurrence [11,12] and the resulting reoperations. The best management of MFs is not standardised and remains a great challenge.

On the other hand, percutaneous electrolysis (PE) is a technique that involves the application of a galvanic current through an ultrasound-guided (USG) needle in the affected tissue [13,14]. This procedure has proved useful in chronic tendinopathies [13,15].

Hypothesis

Our hypothesis is that the PE may be a therapeutic option for MFs.

Testing the hypothesis

PE is a technique that involves galvanic current transfer within the treatment-targeted tissue via a USG needle. The application of PE brings about a chemical reaction, which causes the dissociation of sodium chloride and water molecules [14]. This process results in the formation of molecules of sodium hydroxide, which cause the destruction of the damaged tissue that produces localised inflammation, exclusively in the treatment zone, that leads to rapid regeneration of the affected tissue [13–15]. These effects produced by applying the PE technique may promote MF healing.

We are currently conducting a series of case studies to investigate the effectiveness of applying the PE technique in patients with MF. The following protocol is proposed: injection of local anaesthetic into the puncture site and insertion of a USG 14G needle into the FM area. Fig. 1 shows an example of how the procedure is carried out.

Discussion

MFs are uncommon and the appropriate management is not well-established. Various options for the management of MFs have been mentioned in the literature [3–6,8,10–12,16,17]. Nevertheless, none of them has been clearly established as the gold standard and the best option is still a matter of debate. MF is a debilitating process causing considerable morbidity and a high incidence of recurrence [11,12,17].

USGPE is a minimally invasive technique that produces a non-thermal electrochemical ablation exclusively in the treatment zone and development of a localised inflammatory process that leads to rapid

* Corresponding author.
E-mail address: jdberna@gmail.com (J.D. Berná-Serna).

https://doi.org/10.1016/j.mehy.2018.01.013
Received 14 November 2017; Accepted 19 January 2018



Fig. 1. (A) 45-year-old woman with a mammary fistula. (B) Ultrasound-guided insertion of the needle.

regeneration of the injured area [13–15]. The application of PE has proved effective in the treatment of chronic tendinopathies as patellar tendinopathy [13] and chronic lateral epicondylitis [15]. Moreover, a recent experimental study [18] showed an increase in anti-inflammatory mediators with the use of the PE technique in patellar tendinopathy.

To our knowledge, a study describing USGPE for MF therapy has not been reported previously. Preliminary research has shown that this technique has a beneficial effect on MFs, with the added advantage of being safe, tolerable and minimally invasive. Its future use is proposed as a treatment solution for MF. Future studies are needed to investigate the effectiveness of this new therapeutic modality in MF management.

Sources of support in the form of grants

None.

Conflicts of interest statement

None.

References

[1] Zuska JJ, Crile Jr G, Ayres WW. Fistulas of lactiferous ducts. Am J Surg 1951;81:312–7.
[2] Bundred NJ, Dixon JM, Chetty U, Forrest APM. Mammillary fistula. Br J Surg 1987;74:466–8.
[3] Lannin DR. Twenty-two year experience with recurring subareolar abscess andlactiferous duct fistula treated by a single breast surgeon. Am J Surg 2004;188:407–10.
[4] Versluijs-Ossewaarde FN, Roumen RM, Goris RJ. Subareolar breast abscesses: characteristics and results of surgical treatment. Breast J 2005;11:179–82.
[5] Berná-Serna JD, Berná-Mestre JD, Piñero A, Carrascosa MC. Sonographically guided percutaneous intralesional triamcinolone injection: a new treatment for mamillary fistulas: preliminary results. J Ultrasound Med 2012;31:617–21.
[6] Kasales CJ, Han B, Smith Jr JS, Chetlen AL, Kaneda HJ, Shereef S. Nonpuerperal mastitis and subareolar abscess of the breast. AJR Am J Roentgenol 2014;202:W133–9.
[7] Habif DV, Perzin KH, Lipton R, Lattes R. Subareolar abscess associated with squamous metaplasia of lactiferous ducts. Am J Surg 1970;119:523–6.
[8] Meguid MM, Oler A, Numann PJ, Khan S. Pathogenesis based treatment of recurring subareolar breast abscesses. Surgery 1995;118:775–82.
[9] Berná-Serna JD, Berná-Mestre JD. Follicular occlusion due to hyperkeratosis: a new hypothesis on the pathogenesis of mammillary fistula. Med Hypotheses 2010;75:553–4.
[10] Berná-Serna JD, Berná-Mestre JD, Piñero A, Canteras M. Efficacy of intralesional triamcinolone injection in the treatment of mammary fistulas: a prospective study. Acta Radiol 2013;54:739–41.
[11] Lannin DR. Twenty-two year experience with recurring subareolar abscess andlactiferous duct fistula treated by a single breast surgeon. Am J Surg 2004;188:407–10.
[12] Hanavadi S, Pereira G, Mansel RE. How mammillary fistulas should be managed. Breast J 2005;11:254–6.
[13] Sanchez-Ibañez JM. Clinical course in the treatment of chronic electrolysis intratissue (EPI®): study of a population series of cases in sport [PhD. Thesis]. Leon. Spain: Universidad de Leon; 2013.
[14] Abat F, Diesel WJ, Gelber PE, Polidori F, Monllau JC, Sanchez-Ibañez JM. Effectiveness of the Intratissue Percutaneous Electrolysis (EPI®) technique and isoinertial eccentric exercise in the treatment of patellar tendinopathy at two years follow-up. Muscles Ligaments Tendons J 2014;4:188–93.
[15] Valera-Garrido F, Minaya-Muñoz F, Medina-Mirapeix F. Ultrasound-guided percutaneous needle electrolysis in chronic lateral epicondylitis: short-term and long-term results. Acupunct Med 2014;32:446–54.
[16] Dixon JM, Thompson AM. Effective surgical treatment for mammary duct fistula. Br J Surg 1991;78:1185–6.
[17] Taffurelli M, Pellegrini A, Santini D, Zanotti S, Di Simone D, Serra M. Recurrent periductal mastitis: surgical treatment. Surgery 2016;160:1689–92.
[18] Abat F, Valles SL, Gelber PE, Polidori F, Stitik TP, García-Herreros S, et al. Molecular repair mechanisms using the Intratissue Percutaneous Electrolysis technique in patellar tendonitis. Rev Esp Cir Ortop Traumatol 2014;58:201–5.

Fisioterapia

www.elsevier.es/ft

ORIGINAL

Estudio de coste-efectividad de la electrólisis percutánea intratisular (EPI®) en las epicondilalgias

F. Minaya Muñoz[a,*], F. Valera Garrido[a], J.M. Sánchez Ibáñez[b] y F. Medina i Mirapeix[c]

[a] *Servicio de Fisioterapia MVClinic, Madrid, Hospital Fremap-Majadahonda, Madrid, Facultad de Enfermería y Fisioterapia Salus Infirmorum, UPSA-MAPFRE, Madrid, España*
[b] *Fisioterapia, CEREDE, Barcelona, España*
[c] *Fisioterapia, Departamento de Fisioterapia, Universidad de Murcia, Murcia, España*

Recibido el 21 de febrero de 2012; aceptado el 16 de abril de 2012
Disponible en Internet el 2 de junio de 2012

PALABRAS CLAVE
Electrolisis;
Tendinosis;
Epicondilalgia

Resumen
Introducción: La electrólisis percutánea intratisular (EPI®) es una técnica mínimamente invasiva que consiste en la aplicación de una corriente galvánica de alta intensidad que produce en el tejido blando un proceso inflamatorio local permitiendo la fagocitosis y la reparación del tejido afectado. El objetivo fue analizar el coste-efectividad de la EPI® en las epicondilalgias crónicas.
Material y método: Estudio de coste-efectividad de un programa de fisioterapia basado en la aplicación semanal de EPI® de forma aislada asociada con carácter domiciliario a ejercicios excéntricos y estiramientos diarios. El coste por proceso se analizó comparándolo con los casos quirúrgicos y el gasto asociado (fisioterapia, cirugía, estancia, baja laboral) y se basó sobre criterios de reducción de la intensidad del dolor.
Resultados: Se incluyó a 36 sujetos, 52,8% hombres (47,2% mujeres), con una media de 38 años. El 80,5% de los sujetos alcanzaron la curación tras 4 sesiones de EPI®. El coste por proceso del programa inicial y de seguimiento basado en EPI® es 16 veces inferior que el coste estimado a los casos quirúrgicos.
Conclusiones: El programa combinado de EPI® más ejercicios excéntricos y estiramientos constituye un tratamiento con una relación coste-efectividad muy aceptable.

KEYWORDS
Electrolysis;
Tendinosis;
Epicondylalgia

The clinical and cost-effectiveness of percutaneous electrolysis intratissue (EPI®) in lateral epicondylalgia

Abstract
Introduction: Percutaneous electrolysis intratissue (EPI®) is a minimally invasive technique that involves the application of a high intensity galvanic current that produces a local inflammatory

* Autor para correspondencia.
Correo electrónico: franminaya@mvclinic.es (F. Minaya Muñoz).

0211-5638/$ - see front matter
http://dx.doi.org/10.1016/j.ft.2012.04.001

process in the soft tissue, allowing phagocytosis and the reparation of the affected tissue. This study aimed to evaluate the cost-effectiveness of EPI® in chronic lateral epicondylalgia.
Material and method: This was a cost-effectiveness study of a physiotherapy program based on the weekly application of EPI® technique alone associated with daily at home eccentric exercises and stretching. Cost per patient was analyzed in comparison to surgical cases and associated cost (physiotherapy, surgery, sick leave) and was based on pain intensity reduction criteria.
Results: A total of 36 subjects were included in the study, 52.8% men (47.2% women) with mean age of 38 years. Of these, 80.5% of subjects reached complete response after four sessions of EPI®. The cost per process in the initial program and follow-up based on EPI® is 16 times less than the estimated cost in the group surgery.
Conclusions: The combined program of EPI® plus eccentric exercises and stretching is a very acceptable cost-effectiveness treatment.

Introducción

La *epicondilitis* (epicondilalgia o codo de tenis, «*tennis elbow*») se manifiesta clínicamente por dolor en la inserción de la musculatura epicondílea que aumenta con la presión local sobre el epicóndilo lateral, con la extensión activa de la muñeca y por el estiramiento de dicha musculatura. Es una de las lesiones más frecuentes en el codo, que afecta entre el 1-3% de la población, los síntomas generalmente tienen un comienzo insidioso y más raramente de carácter agudo ligado a un proceso traumático[1]. Dos de las principales preocupaciones actuales con respecto a la *epicondilitis* son la revisión del modelo patológico subyacente y los análisis coste-efectividad de sus intervenciones. Respecto de la primera, tradicionalmente se ha definido, diagnosticado y tratado la *epicondilitis* como un proceso inflamatorio de carácter insercional; sin embargo, diversos estudios han demostrado[2,3] que se trata de un proceso degenerativo con roturas microscópicas en el tendón e infiltración de fibroblastos, hiperplasia vascular-hipervascularización y desorganización de las fibras de colágeno, compatible con el concepto de tendinosis. Bales[4] identificó áreas hipovasculares y el mecanismo lesional de fricción del *extensor carpi radialis brevis* (ECRB) (2.° radial) sobre el capitelium en los movimientos de extensión repetidos de la muñeca. En la misma línea, Zeisig[5] demostró la presencia de áreas de hipervascularización en la unión tenoperióstica de la musculatura epicondílea. Por todo ello, el concepto de *epicondilitis* está siendo sustituido por los términos de epicondilalgia, epicondilitis crónica o epicondilosis, refiriéndose a un proceso degenerativo. Este cambio de paradigma está trasladando los abordajes terapéuticos basados en una perspectiva inflamatoria hacia una de carácter degenerativo[6]. Las intervenciones basadas en una perspectiva inflamatoria de la *epicondilitis* se han asociado a cuadros recidivantes y con mal pronóstico[7]. Las revisiones sistemáticas publicadas sobre *epicondilitis* hasta fechas recientes (agosto del 2011) indican que los tratamientos actuales de fisioterapia son poco efectivos a corto plazo, e incluso sin diferencias significativas a largo plazo con la política de esperar y ver qué pasa «*wait and see*»[8,9]. No obstante, sí que son más efectivos a largo plazo comparados con las infiltraciones con corticoides, con un menor porcentaje de recidivas[10,11].

En este sentido, la racionalización de los recursos sanitarios y su optimización es una de las cuestiones más importantes para la viabilidad de los sistemas de salud en el mundo occidental. Actualmente, son diversos los modelos utilizados en la evaluación económica de las intervenciones (minimización de costes, coste-efectividad, coste-utilidad, coste-beneficio). En España, hasta el momento no se ha formalizado el uso de las intervenciones sanitarias financiadas por el Sistema Nacional de Salud (SNS) con el coste derivado de la utilización de las mismas. En la *epicondilitis*, el interés por los aspectos económicos de las intervenciones es reciente, y están especialmente asociados a su intervención quirúrgica. Se ha puesto de manifiesto que la duración media tras la intervención quirúrgica de la *epicondilitis* lateral es de 60 días[12] y se ha estimado el gasto asociado en 5.095 € por paciente, por la suma de los costes de la cirugía ambulatoria, la estancia hospitalaria, el tratamiento de fisioterapia postquirúrgico y los costes por baja laboral. Es necesario indicar que son inexistentes los análisis de coste-efectividad de intervenciones basadas en la concepción degenerativa de la *epicondilitis*. Así pues, existe un importante vacío de conocimiento sobre el impacto que pueden tener las terapias cuyo fundamento de intervención se basa en un modelo degenerativo como es la electrólisis percutánea intratisular (EPI®). La EPI® es una técnica mínimamente invasiva que consiste en la aplicación de una corriente galvánica de alta intensidad a través de una aguja de acupuntura, que produce en el tejido blando un proceso inflamatorio local permitiendo la fagocitosis y la reparación del tejido afectado, que ha demostrado ser efectiva en otros procesos de carácter degenerativo insercionales como las tendinosis del tendón rotuliano[13]. El objetivo de estudio fue realizar un análisis de coste-efectividad de un programa de fisioterapia con EPI® dirigido a pacientes con tendinopatía crónica insercional del tendón conjunto de la musculatura epicondílea.



Figura 1 Imagen comparativa: codo afectado vs. contralateral (izquierda) y área de hipervascularización en la prueba de eco-Doppler color. Tendón conjunto de musculatura epicondílea (derecha).

Material y método

Diseño y participantes

Se realizó un estudio prospectivo para evaluar el coste-efectividad de un programa de intervención para reducir el dolor y mejorar la funcionalidad en una muestra de sujetos con epicondilalgia derivados al Servicio de Fisioterapia MVClinic (Madrid). La muestra fueron todos los pacientes derivados al referido servicio de fisioterapia durante el período de marzo del 2009 a septiembre del 2010 que cumplían los siguientes criterios de inclusión: *a)* diagnóstico médico de *epicondilitis* (o sus sinónimos para definir la misma entidad clínica; epicondilalgia, epicondilosis, epicondilitis lateral, codo del tenista) con más de 3 meses de evolución desde el inicio de los síntomas y que presentaran cambios degenerativos insercionales en la ecografía musculoesquelética y test positivo en la prueba ortopédica de Cozen o Thomson; *b)* edad comprendida entre los 18 y los 45 años, ya que existe evidencia que indica que las propiedades del tendón y su función se alteran con edades superiores[14,15], y *c)* haber participado previamente en algún programa de fisioterapia y no haber alcanzado una significativa y mantenida reducción del dolor. Se excluyó a aquellos sujetos con: *a)* diagnóstico médico de cervicoartrosis avanzada en los segmentos C4-C6, por si el dolor que presentara el paciente tuviera un origen cervical; *b)* diagnóstico médico de epicondilitis bilateral con sensibilización central; *c)* cirugías previas en el tendón conjunto de la musculatura epicondílea o con fracturas asociadas; *d)* historia previa de desórdenes reumáticos; *e)* síntomas compatibles con atrapamiento nervioso, y *f)* sujetos a los cuales se les realizó infiltración con corticoides en los 3 meses previos al programa de intervención, ya que existe evidencia que indica que este tipo de tratamiento altera las propiedades del tejido de colágeno e inhibe la respuesta inflamatoria[16,17].

El fisioterapeuta responsable del paciente evaluó a cada paciente los criterios de elegibilidad durante la primera visita y reclutó a los pacientes elegibles. El criterio de inclusión relativo a la existencia de signos degenerativos se efectuó in situ mediante prueba de ecografía musculoesquelética. Para ello, se empleó el equipo portátil de ecografía Logiq-E de General Electric® con sonda lineal 12L-RS (5-13Mhz). Se evaluó la presencia de signos inflamatorios o degenerativos (inflamación, hipervascularización, engrosamiento o adelgazamiento del tejido, fibrosis, regiones focales hipoecoicas, irregularidad en la cortical, calcificaciones). El tendón sin síntomas (contralateral) se consideró como control para analizar las alteraciones ecográficas (fig. 1). La prueba ecográfica fue llevada a cabo indistintamente por 2 fisioterapeutas expertos en ecografía musculoesquelética. Ambos utilizaron un protocolo consensuado y testado de evaluación para el tendón de la musculatura epicondílea a partir del *Musculoskeletal Ultrasound Technical Guidelines: Elbow*, definido por la *European Society of MusculoSkeletal Radiology*[18]. La exploración ecográfica constaba de una secuencia longitudinal desde el origen proximal del tendón hasta el músculo y cortes transversales sobre la cabeza del radio, cuerpo del tendón e inserción en epicóndilo lateral del húmero. Igualmente, se realizó la prueba de eco-Doppler color para analizar la presencia de hipervascularización en la zona, ya que se ha observado «in vivo» que la neovascularización es frecuente en sujetos con dolor en el tendón de la musculatura epicondílea[19] (fig. 1).

Descripción del programa de intervención

El programa tuvo 2 fases: una primera denominada intervención inicial y otra de seguimiento. El programa de intervención inicial consistió en un tratamiento semanal mediante electrólisis percutánea intratisular (EPI®) combinado con un programa de ejercicios domiciliarios de trabajo excéntrico y estiramientos. El programa se aplicó a cada paciente y todos los fisioterapeutas del centro participantes en el estudio aplicaron el mismo protocolo en el tratamiento. El programa de excéntricos y estiramientos era enseñado por el fisioterapeuta en la primera sesión y supervisado en las sucesivas sesiones. La EPI® se realizó de forma ecoguiada sobre el área clínicamente relevante en la zona insercional de la musculatura epicondílea con una intensidad entre 4-6 mA. 3 s en diferentes abordajes (fig. 2). Para ello, se empleó el equipo EPI® (Cesmar Electromedicina S.L., 08810 Sant Pere de Ribes, Barcelona). De forma previa, todos los sujetos fueron informados del procedimiento y firmaron el consentimiento informado.

El programa de excéntricos fue adaptado de Finestone, Stasinopoulos y Malliaras[20–22] y constaba de un ejercicio con 3 series de un máximo de 10 repeticiones de trabajo excéntrico, 2 veces al día (mañana y tarde), con la máxima carga posible (inicialmente con un kilogramo), en un rango óptimo funcional sin dolor, desde la máxima extensión de muñeca e inclinación radial se realizaba de forma rápida el gesto de descenso (fig. 3B), manteniendo 2 s la posición final, con un descanso

Figura 2 Aplicación ecoguiada de EPI® sobre tendón de la musculatura epicondílea.

mínimo de 2-3 min entre series, durante las semanas que durara el programa de fisioterapia. La fase concéntrica de vuelta a la posición de inicio se anulaba con la ayuda de la otra mano (fig. 3A). El programa de estiramientos constaba de un ejercicio de estiramiento para la musculatura epicondílea con 3 series de 7 repeticiones 2 veces al día (mañana y tarde) realizado en sedestación con flexión de muñeca y dedos, inclinación cubital y extensión de codo alcanzando el límite de estiramiento sin rebote durante 45 s.

El programa de seguimiento, que se realizó tras la intervención inicial a las 6 semanas, consistió en una entrevista telefónica para evaluar la sintomatología y una visita —a los casos con sintomatología o por solicitud del paciente— para



Figura 4 Algometría digital sobre el epicóndilo.

reexaminar la estructura del tendón, valorar la pertinencia de una sesión adicional de la EPI® y, si procedía, ejecutarla.

Mediciones

Características demográficas y clínicas de los participantes al inicio

Las características demográficas medidas fueron edad (años cumplidos) y sexo. Las características clínicas fueron la presencia de prácticas de riesgo laborales y deportivos (sí/no), ecografía compatible con procesos degenerativos (sí/no), tendón más afectado, duración de los síntomas (semanas), intensidad del dolor (mediante escala analógica visual de 0 a 100 mm), valores de presión con algometría digital sobre el epicóndilo lateral del húmero (mediante equipo de algometría digital Sundoo representado en fig. 4), resultado del test de Cozen y del test de Thomson (positivo/negativo) y la función física mediante el cuestionario DASH *(Disabilities of the Arm & Shoulder and Hand)* validado al castellano[23] (de 0 a 100 puntos).

Estimación de los costes

Se establecieron 3 pasos sucesivos para determinar el coste de la intervención: identificación, cuantificación y valoración. Se calcularon los costes directos de cada sesión terapéutica teniendo en cuenta los materiales utilizados en la realización de la EPI® ecoguiada, los costes de mantenimiento y del tiempo empleado por el equipo de fisioterapeutas para aplicar la EPI® y para la enseñanza y supervisión de los ejercicios domiciliarios.



Figura 3 Ejercicio con carga excéntrica. A) Fase ascenso. B) Fase descenso.

Se obviaron los costes asociados a la sala de fisioterapia y al personal auxiliar, ya que el tratamiento se aplicó de forma individualizada en la consulta de fisioterapia. La unidad monetaria utilizada para la estimación de los costes fue el euro y se omitieron los costes asociados a desplazamientos y tiempo invertido del paciente.

Mediciones de la efectividad

La medición de la efectividad del programa de intervención se realizó al término del programa de intervención inicial y tras 6 semanas posteriores al mismo, y se basó sobre criterios de reducción de la intensidad del dolor. Para este objetivo, la efectividad del programa de intervención, en sus 2 fases, se basó en términos de: *a)* el porcentaje de pacientes sin dolor (o inferior a 2) en la escala analógica visual, y *b)* el porcentaje de pacientes a los que no se les reprodujo el dolor durante las pruebas ortopédicas de Cozen y Thomson.

Análisis estadístico

La introducción, la gestión y el análisis de los datos se han realizado utilizando el programa estadístico SPSS 15.0 para Windows. Se calcularon los estadísticos descriptivos de las características de los participantes y de las principales variables relativas a la efectividad y al coste total del programa, así como la ratio coste-efectividad.

Resultados

Características de los participantes

Se incluyó en el estudio a 36 sujetos, 52,8% hombres, con una media ± DE de edad de 38 ± 6,4 años. El 88,9% de los sujetos realizaban una actividad laboral con posturas mantenidas o gestos de repetición que afectaban a la musculatura epicondílea (como, por ejemplo; administrativos, fontaneros, camareros o bomberos) y el 75% practicaba algún tipo de deporte con solicitación mecánica de esta musculatura (p. ej., pádel). El 100% de los sujetos tenían cambios compatibles con un proceso degenerativo del tendón: engrosamiento del mismo y regiones focales hipoecoicas en la parte más profunda del tendón a nivel del epicóndilo lateral. El 16,7% de esos sujetos presentaban hipervascularización. Las pruebas clínicas mostraban que el músculo extensor carpi radialis brevis (2.° radial) era en un 83,3% de los casos el tendón más afectado. La duración de los síntomas tuvo un rango de 4 a 24 meses (media: 9,6 meses). La intensidad media del dolor al inicio fue de 6,2 puntos y los valores de algometría tuvieron una media de 7,9 kg en la presión sobre el epicóndilo lateral. Las pruebas ortopédicas de provocación de la musculatura epicondílea fueron positivas en el 100% de los casos para los test de Cozen y Thomson. La puntuación media ± DE obtenida con el cuestionario DASH fue de 63,4 ± 9 puntos. Los ítems que alcanzaron peor puntuación fueron (en una escala de 1 [sin dificultad]) a 5 puntos [incapaz]): *abrir un bote apretado o nuevo* con una media de 3,1 puntos, *empujar una puerta pesada* con una media de 3,2 puntos, *llevar un objeto pesado (de más de 5 kg)* con una media de 3,3 puntos y *actividades recreativas (como jugar al tenis)* con una media de 3,6 puntos.

Tabla 1 Costes del programa según las fases y sus participantes

Programa	Participantes	Coste total	Coste por persona
Fase inicial	36	10.080	280
Fase seguimiento			
Entrevista	36	180	5
Examen	20	800	40
Sesión EPI®	6	360	60
Total		1.340	38,9
Total	–	11.420	308,9

Efectividad del programa de intervención

Tras 4 sesiones, el 80,5% de los sujetos terminaron el programa de intervención inicial sin dolor (o inferior a 2) en la escala analógica visual, el 86,2% no se les reprodujo el dolor ni en la prueba de Cozen ni en la de Thomson y los valores de algometría se elevaron de forma muy significativa desde los 7,9 kg en la presión sobre el epicóndilo lateral a los 29,3 kg. El análisis de la funcionalidad a través del cuestionario DASH mostró cambios importantes, la puntuación media obtenida en el total de 36 sujetos fue de 37,4 puntos, lo que significa que se obtuvo una mejoría de más del 40% en la capacidad funcional. Ninguno de los sujetos abandonó el tratamiento. En ningún caso aparecieron complicaciones ni reacciones adversas durante la aplicación de la EPI®.

En la fase de seguimiento, tan solo el 16,7% de los casos necesitó de una última sesión de EPI® para abordar algún punto localizado de dolor residual. Tras la misma, esos pacientes no presentaron dolor.

Costes del programa de intervención

El coste de cada una de sus fases del programa y del total se detalla en la tabla 1. El coste total estimado del programa de intervención inicial fue de 10.080 €. Este coste se derivó de la realización de una media de 4 sesiones de fisioterapia a los 36 participantes en el estudio. Los costes derivados de la fase de seguimiento (1.340 €) fueron ostensiblemente menores que en la fase inicial debido al menor número de participantes en los exámenes y aplicaciones de EPI®. El coste total del programa para los 36 participantes fue de 11.420 € (308,9 € por persona).

Razón coste-efectividad

La razón coste-efectividad del programa total es de 392,3 € por paciente sin dolor (o inferior a 2) y de 367,1 € por paciente sin dolor reproducido por las pruebas de Cozen

Tabla 2 Costes, efectividad y razones coste-efectividad del programa y de sus fases

	Fase inicial del programa	Fase de seguimiento del programa	Programa completo
Costes			
Totales	10.080	1.340	11.420
Efectividad			
% pacientes sin dolor (n)	80,5% (29 sujetos)	83,3% (30 sujetos)	
% pacientes que no reproducen dolor prueba ortopédica (n)	86,2% (31 sujetos)	88,9% (32 sujetos)	
Coste-efectividad			
Coste por paciente sin dolor	347,6	44,7	392,3
Coste por paciente que no se le reproduce dolor con prueba ortopédica	325,2	41,9	367,1

y Thomson (tabla 2). Estas ratios serían aun menores si el programa se hubiera limitado a la fase inicial. Los costes del programa de seguimiento fueron ostensiblemente menores.

Discusión

El énfasis actual sobre el control de los costes por proceso ha puesto en evidencia la necesidad de cuantificar la relación coste-efectividad de las terapias utilizadas. El programa de abordaje a la epicondilalgia analizado en este estudio muestra una aceptable relación coste-efectividad. Los costes por proceso resultantes del programa estudiado difieren notablemente con los costes asociados a la intervención quirúrgica de la epicondilalgia, que se han cifrado en torno a los 5.095 €[12]. En términos comparativos, el coste por proceso del programa basado en la EPI® (308,9 €) es 16 veces inferior que el coste estimado asociado a los casos quirúrgicos —18 veces si se hubiese limitado a la fase inicial—[24]. Los resultados alcanzados permiten inferir que el abordaje mediante intervenciones basadas en una concepción de la tendinopatía como un proceso degenerativo asociado a un proceso de reparación del tendón[25] puede tener una buena relación coste-beneficio. En opinión de algunos profesionales, el abordaje mediante intervenciones de fisioterapia orientadas a provocar un cambio en la biología del tendón del ECRB y un estímulo en su reparación o remodelación son apropiadas en la epicondilalgia crónica, mientras que las dirigidas a disminuir la inflamación no tienen sentido si verdaderamente no se trata de un proceso inflamatorio reactivo[26].

Aportaciones al modelo de la tendinopatía

Nuestro estudio aporta evidencia de que las denominadas *epicondilitis* tienen un sustrato de proceso degenerativo. En nuestra serie, en el 83,3% de los casos el tendón del ECRB era el tendón más afectado. Según algunos autores, es este tendón el responsable en gran medida de la clínica que presenta el individuo[4,5]. Otra aportación importante del programa estudiado es la baja presencia de recidivas que aparecieron durante el periodo de seguimiento, si se compara con la frecuencia de recidivas evidenciada en otros estudios (entre el 34 y el 72%) que utilizaron programas basados en una orientación antiinflamatoria[11]. Es habitual que los pacientes mejoren con estos programas convencionales de fisioterapia y el reposo deportivo, pero cuando vuelven a la actividad deportiva o realizan actividades de igual o más intensidad los síntomas vuelven a estar presentes. En nuestra serie, el seguimiento a 6 semanas no reveló recaídas en el grupo de pacientes, a pesar de que el 75% realizaba algún tipo de actividad deportiva. Tan solo el 16,7% de los casos necesitó de una última sesión de EPI® para abordar algún punto localizado de dolor residual.

El programa de Fisioterapia aplicado a este tipo de pacientes incluía, además de la EPI®, ejercicios de carácter excéntrico y estiramientos de la musculatura implicada con carácter domiciliario. La hipótesis nuestra es que la EPI® estimula la biología del tendón al provocar la fase inflamatoria inicial de reparación del mismo y que la carga mecánica precoz controlada (excéntricos y estiramientos) facilita el proceso de proliferación del tejido de colágeno, mejorando así las propiedades biomecánicas del tendón estimulado. En este sentido, se ha estudiado el efecto del plasma rico en plaquetas (PRP) sobre el tendón de Aquiles de la rata sometido a carga o descarga posterior y las conclusiones indican que a los 14 días en el grupo en descarga desaparecen los efectos del PRP y las propiedades mecánicas del tejido estimulado se reducen a menos de la mitad respecto al tejido sano[27]. Por otra parte, el tipo de ejercicio (carga mecánica) puede desempeñar un papel crucial, según la evidencia disponible el entrenamiento excéntrico parece ser la mejor opción en este tipo de pacientes[20–22,28]. No obstante, la aplicación aislada de ejercicios excéntricos y estiramientos resulta insuficiente para obtener un resultado funcional óptimo[29]. Quizás por ello, otros autores están —como nosotros— proponiendo programas combinados de intervenciones sobre el tendón conjunto de la musculatura epicondílea (p. ej., PRP) y programas de entrenamiento excéntrico y estiramientos[30]. No obstante, aún no se incorporaron al programa de tratamiento otras medidas que, teóricamente, podrían ser útiles para potenciar el proceso de proliferación del colágeno como el ultrasonido o el láser tras conseguir reagudizar el tejido con la EPI®. Más investigaciones serían necesarias para averiguar si la incorporación de este tipo de medidas consigue mejorar los resultados finales.

Limitaciones del estudio

Nuestros resultados deberían ser interpretados teniendo en cuenta las limitaciones metodológicas de nuestro estudio. Primero, el análisis de costes se limitó a los gastos del centro y omitió los gastos del paciente. No obstante, quizás debido al bajo número de sesiones terapéuticas utilizadas, probablemente su uso contribuiría a incrementar las diferencias con otros programas convencionales que usan mayor número de sesiones. Segundo, hubo una ausencia de un programa de fisioterapia alternativo con el que comparar la relación coste-efectividad hallada. La comparación con intervenciones quirúrgicas se tomó de referencia, pero para mayor generalización, es necesario comprobar que ambas muestras fueron comparables. Tercero, el seguimiento realizado fue relativamente corto. Es necesario realizar un seguimiento más a largo plazo.

Implicaciones para la práctica clínica

Los estudios de coste-efectividad como el presente deben servir para que las instituciones sanitarias opten por solicitar y demandar este tipo de servicios de fisioterapia. Así también, desde el punto de vista ético, los profesionales deben ofrecer al paciente la atención más eficiente posible. A partir de este momento, la fisioterapia puede ofrecer una opción terapéutica alternativa que por coste y efectividad debe ser considerada.

Aunque los síntomas y los signos que definen la *epicondilitis* son evidentes y su diagnóstico clínico e instrumental claro, existen actualmente más de 40 tratamientos diferentes publicados en la literatura científica[11]. Tal variedad de estrategias de tratamiento sugiere que no existe la opción idónea hasta la fecha y hace necesario establecer algoritmos decisionales e indicadores de calidad en la atención prestada a este tipo de pacientes. Todas estas técnicas consiguen en mayor o menor medida disminuir el dolor y mejorar la función pero fracasan en la reparación del tendón ya que no logran remodelar la estructura o reagudizar el tejido para conseguir una nueva proliferación. Tradicionalmente, se ha atribuido esa posibilidad de reagudizar e incluso romper el tejido de colágeno a determinadas técnicas de terapia manual (como la técnica Cyriax); sin embargo, hoy día podemos afirmar que solo tienen un carácter analgésico[31,32]. De forma similar, las infiltraciones con corticoides conseguirían un efecto analgésico potente (superior a la fisioterapia a corto plazo) pero podrían provocar un mayor deterioro del tejido[16,17], con un porcentaje de recaídas mayor[10,11]. La solución actual en los procesos crónicos consiste en llegar al tejido degenerado y estimularlo de forma real, este es el mecanismo de acción de técnicas como la electrólisis percutánea intratisular[13,29], el plasma rico en plaquetas[30] o la radiofrecuencia[33]. En este tipo de tratamientos el éxito en gran medida depende del abordaje ecoguiado. La ecografía musculoesquelética, lejos de un enfoque dirigido al diagnóstico médico, constituye actualmente una herramienta muy importante para el fisioterapeuta, ya que le permite evaluar el tendón, planificar mejor el programa de fisioterapia y monitorizar la evolución del paciente.

Conclusiones

El programa combinado de EPI® y ejercicios de fortalecimiento excéntrico y estiramiento constituye un tratamiento con una relación coste-efectividad muy aceptable.

Conflicto de intereses

Los autores declaran no tener ningún conflicto de intereses.

Bibliografía

1. Faro F, Wolf JM. Lateral epicondylitis: review and current concepts. J Hand Surg Am. 2007;32:1271–9.
2. Jobe FW, Ciccotti MG. Lateral and medial epicondylitis of the elbow. J Am Acad Orthop Surg. 1994;2:1–8.
3. Bishai SK, Plancher KD. The basic science of lateral epicondylosis: update for the future. Tech Orthop. 2006;21:250–5.
4. Bales CP, Placzek JD, Malone KJ, Vaupel Z, Arnoczky SP. Microvascular supply of the lateral epicondyle and common extensor origin. J Shoulder Elbow Surg. 2007;16:497–501.
5. Zeisig E, Öhberg L, Alfredson H. Extensor origin vascularity related to pain in patients with tennis elbow. Knee Surg Sports Traumatol Arthrosc. 2006;14:659–63.
6. Coombes BK, Bisset L, Vicenzino B. A new integrative model of lateral epicondylalgia. Br J Sports Med. 2009;43:252–8.
7. Alvarez-Nemegyei J. Prognostic indicators in lateral epicondylitis: is it possible to predict pain outcomes? Nat Clin Pract Rheumatol. 2007;3:138–9.
8. Bisset L, Beller E, Jull G, Brooks P, Darnell R, Vicenzino B. Mobilisation with movement and exercise, corticosteroid injection, or wait and see for tennis elbow: randomised trial. BMJ. 2006;333:939–44.
9. D'Vaz AP, Ostor AJ, Speed CA, Jenner JR, Bradley M, Prevost AT, et al. Pulsed low-intensity ultrasound therapy for chronic lateral epicondylitis: a randomized controlled trial. Rheumatology (Oxford). 2006;45:566–70.
10. Tonks JH, Pai SK, Murali SR. Steroid injection therapy is the best conservative treatment for lateral epicondylitis: a prospective randomised controlled trial. Int J Clin Pract. 2007;61:240–6.
11. Barr S, Cerisola FL, Blanchard V. Effectiveness of corticosteroid injections compared with physiotherapeutic interventions for lateral epicondylitis: a systematic review. Physiotherapy. 2009;95:251–65.
12. Tiempos estándar en incapacidad temporal. Instituto Nacional de Seguridad Social; 2009. Disponible en: http://www.tt.mtas.es/periodico/seguridadsocial/200907/INCAPACIDAD_TEMPORAL_2009.pdf
13. Valera F, Minaya F, Sánchez JM. Efectividad de la electrólisis percutánea intratisular (EPI®) en las tendinopatías crónicas del tendón rotuliano. Trauma Fund MAPFRE. 2010;21:227–36.
14. Macaluso A, De Vito G. Muscle strength, power and adaptations to resistance training in older people. J Appl Physiol. 2004;91:450–72.
15. Maganaris CN, Narici MV, Reeves ND. In vivo human tendon mechanical properties: effect of resistance training in old age. J Musculoskelet Neuronal Interact. 2004;4:204–8.
16. Haraldsson BT, Aagaard P, Crafoord-Larsen D, Kjaer M, Magnusson SP. Corticosteroid administration alters the mechanical properties of isolated collagen fascicles in rat-tail tendón. Scand J Med Sci Sports. 2009;19:621–6.
17. Halpern AA, Horowitz BG, Nagel DA. Tendon ruptures associated with corticosteroid therapy. West J Med. 1977;127:378–82.
18. Beggs I, Bianchi S, Bueno A, Cohen M, Court-Payen M, Grainger A, et al. ESSR Ultrasound Group Protocols. Musculoskeletal

ultrasound technical guidelines: knee [consultado 25 Jul 2010]. Disponible en: http://www.essr.org/html/img/pool/knee.pdf
19. Poltawski L, Jayaram V, Watson T. Measurement issues in the sonographic assessment of tennis elbow. J Clin Ultrasound. 2010;38:196–204.
20. Finestone H, Rabinovitch DL. Tennis elbow no more: practical eccentric and concentric exercises to heal the pain. Can Fam Physician. 2008;54:1115–6.
21. Stasinopoulos D, Stasinopoulou K, Stasinopoulos I, Manias P. Comparison of effects of a home exercise programme and a supervised exercise programme for the management of lateral elbow tendinopathy. Br J Sports Med. 2010;44: 579–83.
22. Malliaras P, Maffulli N, Garau G. Eccentric training programmes in the management of lateral elbow tendinopathy. Disabil Rehabil. 2008;30:1590–6.
23. Hervás M, Navarro Collado MJ, Peiró S, Rodrigo JL, López P, Martínez I. Versión española del cuestionario DASH. Adaptación transcultural, fiabilidad, validez y sensibilidad a los cambios. Med Clin (Barc). 2006;127:441–7.
24. Valera F, Minaya F, Sánchez JM. Estudio de coste-efectividad de la electrólisis percutánea intratisular (EPI®) en las epicondilalgias crónicas. En: X Congreso Nacional SETLA: ponencias y comunicaciones. 2010. p. 75–6.
25. Cook JL, Purdam CR. Is tendon pathology a continuum. A pathology model to explain the clinical presentation of load induced tendinopathy. Br J Sports Med. 2009;43: 409–16.
26. Valera F, Minaya F, Sánchez JM, Martínez R. Mitos y realidades en fisioterapia. Tendinitis vs. tendinosis. En: I Congreso Internacional EPI®: ponencias y comunicaciones. 2011. p. 100–1.
27. Virchenko O, Aspenberg P. How can one platelet injection after tendon injury lead to a stronger tendon after 4 weeks. Interplay between early regeneration and mechanical stimulation. Acta Orthop. 2006;77:806–12.
28. Croisier JL, Foidart-Dessalle M, Tinant F, Crielaard JM, Forthomme B. An isokinetic eccentric programme for the management of chronic lateral epicondylar tendinopathy. Br J Sports Med. 2007;41:269–75.
29. Minaya F, Valera F, Sánchez JM. Uso de la electrólisis percutánea intratisular (EPI®) en la epicondilagia crónica: caso clínico. Fisioter Calid Vida. 2011;14:13–6.
30. Thanasas C, Papadimitriou G, Charalambidis C, Paraskevopoulos I, Papanikolaou A. Platelet-rich plasma versus autologous whole blood for the treatment of chronic lateral elbow epicondylitis: a randomized controlled clinical trial. Am J Sports Med. 2011.
31. Pohl H. Changes in the structure of collagen distribution in the skin caused by a manual technique. J Bodyw Mov Ther. 2010;14:27–34.
32. Vicenzino B, Cleland JA, Bisset L. Joint manipulation in the management of lateral epicondylalgia: a clinical commentary. J Man Manip Ther. 2007;15:50–6.
33. Lin CL, Lee JS, Su WR, Kuo LC, Tai TW, Jou IM. Clinical and ultrasonographic results of ultrasonographically guided percutaneous radiofrequency lesioning in the treatment of recalcitrant lateral epicondylitis. Am J Sports Med. 2011.

Percutaneous electrochemical debridement of the Plantaris tendon: a novel option in the treatment...

Article *in* Journal of the American Podiatric Medical Association · June 2017

CITATIONS
0

READS
23

2 authors, including:

Gabriele Mattiussi
Udinese Calcio Spa
5 PUBLICATIONS **3** CITATIONS

SEE PROFILE

COVER SHEET

TITLE

Percutaneous electrochemical debridement of the Plantaris tendon: a novel option in the treatment of midportion Achilles tendinopathy.

AUTHORS:

Gabriele MATTIUSSI[1] and Carlos MORENO[1, *]

Affiliation:

1. Udinese Football Club – Medical Services

***Corresponding author:**

Carlos Moreno

Udinese Football Club – Medical Services

Viale A. e A. Candolini, 2

33100 – Udine (Italy)

Phone: +39 0432 544911

Fax: +39 0432 544933

E-mail: carlos.moreno@udinesespa.it

Authors' contribution: GM and CM were responsible for the study concept and design. GM drafted the manuscript. All authors approved the final manuscript.

BLINDED MANUSCRIPT

TITLE

Percutaneous electrochemical debridement of the Plantaris tendon: a novel option in the treatment of midportion Achilles tendinopathy.

ABSTRACT

Plantaris tendon disorders are a well-known source of midportion Achilles tendinopathy. Plantaris tendon thickening and fibrous tissue formation between the tendons are the histological abnormalities which are typically observed. Surgical approaches (scraping of the Achilles medial and ventral paratendinous tissues and excision of the Plantaris tendon) have already shown good clinical outcomes; despite this, cost-benefit ratio of these interventions may be unfavourable and their accessibility is limited. Percutaneous needle electrolysis is a minimally invasive ablative technique of increasing consideration in the treatment of tendinopathies and associated conditions. The purpose of this article is to introduce a novel procedure to treat Plantaris tendon-related midportion Achilles tendinopathy. The procedure starts with the insertion of a non-coated needle (diameter: 0.30-0.40 millimetres; length: 30 millimetres) between the Plantaris and Achilles tendons, under ultrasound guidance. Subsequently, galvanic current (intensity: 2 mA) is locally transferred. This, in turn, induces instant non-thermal electrochemical ablation of the intertendinous tissues in close proximity to the needle, finally debriding the Plantaris tendon. In order to further promote its release, second part of the procedure involves partial tenotomy of the lateral peripheral aspects of the Plantaris tendon. Usually, the total duration of the session does not exceed thirty minutes. Percutaneous needle electrolysis may be considered as a valid alternative to surgery. The out-patient procedure presented in this article is, in fact, safe and quick to perform. Additionally, long suspension of working or sporting activities after the treatment is not required. Future investigations are needed to ascertain the short- and long-term therapeutic outcomes in the treatment of Plantaris tendon-related midportion Achilles tendinopathy, in particular by comparing them with those obtained with other mini-invasive interventions.

KEYWORDS

Ablative techniques – Electrolysis – Interventional ultrasonography – Tendon injuries

INTRODUCTION

The role of the Plantaris tendon in the etiopathogenesis of midportion Achilles tendinopathy has been certified over the last decade [1–3]. However, research of highly specific diagnostic modalities and optimal treatment strategies is still ongoing. Plantaris tendon-related midportion Achilles tendinopathy is clinically characterised by debilitating pain and swelling, which are typically localised in the medial aspects of the Achilles tendon body [2–3]. Friction and compression traumas between the tendons are likely to be the biomechanical disorders that lead to the histological changes observed in many researches, such as Plantaris tendon thickening, fibrous tissue formation between the tendons and alteration of the vascularisation and innervation patterns of the Achilles paratenon [1–4].

Surgical scraping of the Achilles medial and ventral paratendinous tissues has shown good clinical results in many trials, especially when associated with excision of the Plantaris tendon [5–8]. Despite this, cost-benefit ratio of these interventions may be unfavourable and their accessibility is relatively limited. Additionally, post-surgery rehabilitation protocols may last several months. As a consequence of this, there is need to identify new therapeutic solutions which may be as effective as surgery but without having these relevant weak points.

Thus, the main purpose of this article is to introduce the debridement of the Plantaris tendon via electrochemical ablation, induced by cathode-centred percutaneous needle electrolysis. The latter is an ultrasound-guided and minimally invasive technique which may be considered a valid alternative to surgery or, at least, a treatment option to contemplate before performing it. In support of this hypothesis, minimally invasive techniques (needle scraping or sclerosing polidocanol injections) have already shown encouraging clinical results in the treatment of Plantaris tendon-related midportion Achilles tendinopathy [9] and, on the other hand, percutaneous needle electrolysis is generally of increasing consideration in the treatment of tendinopathies and associated conditions [10–13].

PERCUTANEOUS NEEDLE ELECTROLYSIS

This study was designed and conducted according to national and international standards and in compliance with the Helsinki Declaration and the International Principles governing research on humans. Considering the typology of this article (clinically illustrated – technical note), *material and methods* and *results* sections are neither required nor presented.

Equipment

The Authors apply the technique using a specifically developed and medically certified device (EPI Advanced

Medicine®, Barcelona, Spain; directive 93/42/EEC). This instrumentation permits intratissue galvanic current transfer, at settable intensities, through an appropriate non-coated needle (diameter: 0.30-0.40 millimetres; length: 30 millimetres; same manufacturer as above). While the needle acts as the cathode, the anode can be handled by the patient or applied on the skin. The cathodic flow is the only one that is used during the procedure (cathode-centred electrolysis). When the current is transferred, the basic electrochemical process of saltwater electrolysis instantly develops, inducing the non-thermal ablation of the tissue in close proximity to the needle. The latter is inserted under ultrasound guidance in order to precisely treat the target tissue, without involving other structures. For this purpose, the Authors use the GE Healthcare® Logiq S7 Expert ultrasound equipped with the ML6-15 (50mm; 6-15 MHz) and L8-18I-D (25mm; 8-18 MHz) linear probes.

Preliminary ultrasound investigation

The patient lies on his or her side, with the medial aspects of the Achilles tendon directed upwards. The region is shaved and disinfected by applying a proper protocol. A preliminary ultrasound is carried out in order to accurately detect the portions of the Plantaris tendon in anatomical relationship with the medial aspects of the Achilles tendon body. It may be helpful to delimit the region to be treated, marking its distal and proximal limits with a sterile dermographic pencil. It is also advisable to mark the points at which the patient complains about having more pain and swelling ("critical areas") and where the major anatomical alterations are discernible (figures 1–2).

Description of the procedure

The procedure is graphically represented in figure 3. First, the needle is inserted between the Plantaris and Achilles tendons, under ultrasound guidance (figure 4). Subsequently, the galvanic current is transferred (intensity is pre-set to 2mA). Doing this, the local ablation of the fibrous intertendinous and Achilles paratenon tissues is instantaneously obtained, anatomically debriding the Plantaris tendon (figure 5). The single applications of current last 2-3 seconds.

Then, the needle is partially withdrawn and pointed toward the Plantaris tendon. In order to further promote its release, a partial tenotomy of the lateral peripheral aspects of the tendon is performed (figure 6). To this effect, the single application can have a variable duration, between 2-6 seconds, depending of the mechanical resistance offered by the tendinous tissue to the needle penetration (the lower the resistance, the shorter the application).

All the actions presented above are repeated approximatively every five millimetres (or less, in the "critical areas"; see above), in distal-proximal direction, throughout the region previously skin-marked. Typically, the total duration of the session does not exceed thirty minutes (including disinfection and dressing processes).

Tolerability of pain and side effects

The insertion of the needle typically cause minimal discomfort. By contrast, the patients may experience moderate strong pain during the applications of galvanic current. Anyway, anaesthetics are usually not locally injected before percutaneous electrolysis, since the procedure is generally well-tolerated by the patients (the single galvanic current application can be stopped at any time if the pain is not bearable) and because the use of syringes would substantially increase the overall invasiveness of the intervention. Anyway, use of anaesthetics remains a considerable option. Relevant vagal reactions during and immediately after the intervention are possible [14]. Bleeding in area of needle insertion and intervention-related discomfort in the treatment area (up to 48 hours) are the most common side effects. Infection-related issues are extremely rare, as the technique is minimally invasive and the electrolytic process has a substantial bactericidal effect.

DISCUSSION

The main purpose of this article is to introduce the debridement of the Plantaris tendon, via electrochemical ablation induced by cathode-centred percutaneous needle electrolysis, to treat Plantaris-related midportion Achilles tendinopathy. This novel procedure permits to eliminate the fibrous tissue interposed between the Plantaris and the Achilles tendons, debriding the Plantaris tendon and improving the local biomechanics.

The main practical value of this technique is the possibility of performing it in out-patient clinics, reducing considerably the costs, the waiting lists-related issue and the other implication and side effects of Achilles tendon surgery, such as suture reactions, incisional neuromas, and granuloma formation [15]. Furthermore, it should be reminded that post-surgery protocols may last several months. On the contrary, consistent with our experience, in particular with professional football (soccer) player, it is not necessary to completely suspend the sporting (or working) activities for more than 24-48 hours, after percutaneous needle electrolysis treatment. In fact, the side effects tend to be very moderate. However, many authors that use this technique, including us, find it helpful to implement a complementary protocol of active physical therapy [10–13]. Preliminary studies carried out by our research group indicate that the short-term clinical results (not yet published) after percutaneous needle electrolysis treatment in professional athletes are very promising but that it commonly necessary to conduct at least 3-5 sessions (one per week) to obtain long-lasting results. However, to date, clinical or imaging predictors of outcome are substantially unknown.

CONCLUSION

Percutaneous needle electrolysis is an ultrasound-guided and minimally invasive technique that allows specific treatment of the anatomical alterations that cause Plantaris tendon-related midportion Achilles tendinopathy. Since it is safe and quick to perform, it may be considered as a valid alternative to surgery. Future investigations are needed to ascertain the short- and long-term therapeutic outcomes in the treatment of Plantaris tendon-related midportion Achilles tendinopathy, in particular by comparing them with those obtained with other mini-invasive interventions.

REFERENCES

1. Olewnik L, Wysiadecki G, Polguj M, et al: Anatomic study suggests that the morphology of the plantaris tendon may be related to Achilles tendonitis. Surg Radiol Anat 39(1): 69, 2016.
2. Masci L, Spang C, van Schie HTM, et al: How to diagnose plantaris tendon involvement in midportion Achilles tendinopathy - clinical and imaging findings. BMC Musculoskeletal Disorders 17: 97, 2016.
3. van Sterkenburg MN, van Dijk CN: Mid-portion Achilles tendinopathy: why painful? An evidence-based philosophy. Knee Surg Sports Traumatol Arthrosc 19: 1367, 2011.
4. Spang C, Harandi VM, Alfredson H, et al: Marked innervation but also signs of nerve degeneration in between the Achilles and plantaris tendons and presence of innervation within the plantaris tendon in midportion Achilles tendinopathy. J Musculoskelet Neuronal Interact 15(2): 197, 2015.
5. Perace CJ, Carmichael J, Calder JD: Achilles tendinoscopy and plantaris tendon release and division in the treatment of non-insertional Achilles tendinopathy. Foot Ankle Surg 18: 124, 2012.
6. van Sterkenburg MN, Kerkhoffs GMMJ, van Dijk CN: Good outcome after stripping the plantaris tendon in patients with chronic mid-portion Achilles tendinopathy. Knee Surg Sports Traumatol Arthrosc 19: 1362, 2011.
7. Bedi HS, Jowett C, Ristanis S, et al: Plantaris Excision and Ventral Paratendinous Scraping for Achilles Tendinopathy in an Athletic Population. Foot Ankle Int 37(4): 386, 2016.
8. Calder JDF, Stephens JM, van Dijk CN: Plantaris Excision Reduces Pain in Midportion Achilles Tendinopathy Even in the Absence of Plantaris Tendinosis. Orthop J Sports Med 4(12): 2325967116673978, 2016.
9. Alfresdon H, Ohberg L, Zeisig E, et al: Treatment of midportion Achilles tendinosis: similar clinical results with US and CD-guided surgery outside the tendon and sclerosing polidocanol injections. Knee Surg Sports Traumatol Arthrosc 15: 1504, 2007.
10. Abat F, Diesel WJ, Gelber PE, et al: Effectiveness of the Intratissue Percutaneous Electrolysis (EPI®) technique and isoinertial eccentric exercise in the treatment of patellar tendinopathy at two years follow-up. Muscles

Ligaments Tendons J 4(2): 188, 2014.

11. Valera-Garrido F, Minaya-Munoz F, Medina-Mirapeix F: Ultrasound-guided percutaneous needle electrolysis in chronic lateral epicondylitis: short-term and long-term results. Acupunct Med 32: 446, 2014.

12. Moreno C, Mattiussi G, Nunez FJ, et al. Intratissue Percutaneous Electolysis (EPI®) combined with Active Physical Therapy for the treatment of Adductor Longus Enthesopathy-related Groin Pain: a randomised trial. J Sports Med Phys Fitness, 2017.

13. Arias-Buria JL, Truyols-Dominguez S, Valero-Alcaide R, et al: Ultrasound-Guided Percutaneous Electrolysis and Eccentric Exercises for Subacromial Pain Syndrome: A Randomized Clinical Trial. Evid Based Complement Alternat Med: 315219, 2015.

14. de la Cruz Torres B, Albornoz Cabello M, Garcia Bermejo P, et al: Autonomic responses to ultrasound-guided percutaneous needle electrolysis of the patellar tendon in healthy male footballers. Acupunct Med 34(4): 275, 2016.

15. Saxena A, Maffulli N, Nguyen A, et al: Wound Complications from Surgeries Pertaining to the Achilles Tendon. JAPMA 98(2): 995, 2008.

FIGURES

Figure 1. Plantaris tendon morphological abnormalities are commonly observed in case of mid-portion Achilles tendinopathy. The transversal, grey-scale, high resolution ultrasound image presented shows increasing of the thickness and width of the Plantaris tendon (indicated by the *dashed arrow*). In order to complete an accurate investigation, it is advisable to compare the tendon dimensions with those of the contralateral one and to take into high consideration the data concerning the normal morphology of the Plantaris tendon presented by Olewnik et al [1]. *Ach* = Achilles tendon; *K* = Kager's fat pad. Probe used: ML6-15 (50mm footprint).

Figure 2. Transversal, high resolution ultrasound image showing high blood flow (*filled arrows*) in the medial aspects of the Achilles tendon (*Ach*) and paratenon, between the Achilles and Plantaris tendon (indicated by the *dashed arrow*) and around the latter. In case of mid-portion Achilles tendinopathy, these signs may be discernible also in the ventral portions of the Achilles tendon [2]. Probe used: ML6-15 (50mm footprint).

Figure 3. Schematic diagram of the percutaneous needle electrolysis procedure, for the debridement of the Plantaris tendon. The needle is initially inserted between the Plantaris (*dashed arrow*) and the Achilles (*Ach*) tendons, as indicated

by the *line 1*, and, subsequently, within the lateral peripheral aspects of the Plantaris tendon, as indicated by the *dashed line 2*. *Asterisk* = tibial neurovascular bundle.

Figure 4. Ultrasound-guided insertion of the needle between the Achilles and the Plantaris tendons. Considering their anatomical relationship, the preferred approach is in posterior-to-anterior and medial-to-later direction. Inclination of the needle is variable and depends upon the specific morphological features of the tendons.

Figure 5. An iperechoic area (*arrows*) is typically observable around the needle immediately after the application of galvanic current and consequent development of the electrochemical process. This should confirm that only the intertendinous tissues have been treated, without involvement of other structures (first part of the procedure). *Dashed arrow*=Plantaris tendon; *Ach*=Achilles tendon. Probe used: L8-18I-D (25mm footprint).

Figure 6. After the ablation of the intertendinous fibrotic tissues, the needle (*asterisks*) is partially withdrawn and inserted in the lateral peripheral aspects of the Plantaris tendon (second part of the procedure). *Dashed arrow*=Plantaris tendon; *Ach*=Achilles tendon. Probe used: L8-18I-D (25mm footprint).

COMPETING INTERESTS: none.

FINANCIAL SUPPORT: none.

FUNDACIÓNMAPFRE Trauma
Vol 21 nº 4 Octubre/Diciembre 2010

ORIGINAL

Efectividad de la electrólisis percutánea intratisular (EPI®) en las tendinopatías crónicas del tendón rotuliano

Effectiveness of electrolysis percutaneous intratisular (EPI®) in chronic insertional patellar tendinopathy

Valera Garrido F [1], Minaya Muñoz F [1], Sánchez Ibáñez JM [2]

[1] Fisioterapeuta. Servicio de Fisioterapia MVClinic (Madrid). Hospital Fremap-Majadahonda (Madrid). Profesor de la Escuela de Fisioterapia «Salus Infirmorum». UPSA-MAPFRE. (Madrid). [2] Fisioterapeuta. CEREDE (Barcelona).

Resumen

Objetivo: El objetivo del estudio es evaluar la efectividad de la electrólisis percutánea intratisular (EPI®) en la tendinopatía rotuliana crónica.

Material y método: Estudio observacional en 32 pacientes (59,4% hombres), con una media de edad de 35 años (DE: 8) diagnosticados de tendinopatía rotuliana con más de 6 meses de evolución desde el inicio de los síntomas. Se evaluó la estructura del tendón a través de ecografía y la función con la escala VISA-P. Los sujetos fueron incluidos en el grupo 1 (VISA<50 puntos) y en el grupo 2 (VISA>50 puntos). Se aplicó la EPI® de forma aislada en cada sesión asociada con carácter domiciliario a trabajo excéntrico y estiramientos. En la evaluación inicial, todos presentaban cambios compatibles con un proceso degenerativo, el 50% presentaban hipervascularización (100% con VISA<50). Trece pacientes obtuvieron una puntuación VISA<50 y 19 VISA>50.

Resultados: En el Grupo 1, el 80% de los pacientes alcanzaron el alta en fisioterapia a las 6 semanas desde el inicio de tratamiento con EPI®, con una media de 6 sesiones de EPI®. En el Grupo 2 (VISA>50) todos lograron el alta tras 4 sesiones de EPI®.

Conclusiones: La EPI® constituye un tratamiento efectivo para la tendinopatía rotuliana crónica.

Palabras clave:
EPI®, tendinosis, tendón rotuliano.

Abstract

Objective: This study aimed to evaluate the effectiveness of the electrolysis percutaneous intratisular (EPI®) in chronic patellar tendinopathy.

Material and method: Observational study in 32 subjects, 59.4% men, with a mean age of 35 years (SD: 8) with diagnosis of patellar tendinopathy with more than six months of evolution from the onset of symptoms. We evaluated the structure of the tendon through musculoskeletal ultrasound and function through the VISA-P scale. The subjects were classified into: Group 1 (VISA <50 points) and Group 2 (VISA> 50 points). EPI® was applied in isolation in each session associated with eccentric character home to work and stretching. On the first assessment, all the patients had changes consistent with a degenerative process, 50% showed hypervascularity (100% VISA <50). Thirty patients achieved a VISA score <50 and 19 VISA> 50.

Results: In Group 1 (VISA <50), 80% of subjects achieved a cure at 6 weeks after beginning treatment with EPI®, with an average of 6 sessions of EPI®. In Group 2 (VISA> 50) all the subjects achieved a cure after four sessions of EPI®.

Conclusions: The EPI ® is an effective treatment for chronic patellar tendinopathy.

Keywords:
EPI ®, tendinosis, patellar tendon.

Correspondencia
F. Valera
MVClinic. Servicio de Fisioterapia
Hermanos García Noblejas 101, 3ºA
ferminvalera@mvclinic.es

FUNDACIÓNMAPFRE Trauma
Vol 21 nº 4 Octubre/Diciembre 2010

Introducción

El modelo tradicional de las «tendinitis» como un proceso inflamatorio está actualmente en desuso a partir de las diversas publicaciones que han descrito el proceso patológico del tendón principalmente como degenerativo, debido a la ausencia de células inflamatorias y a la presencia de zonas de degeneración del colágeno, degeneración mixoide e incremento de la sustancia fundamental, asociado a un fallo en el proceso de reparación del tendón [1-4]. De ahí, que el término «tendinitis» se esté sustituyendo por el de «tendinosis» o «tendinopatía» [5][6].

El análisis microscópico e histológico del tendón afectado ha permitido identificar cuatro cambios clave en las tendinopatías, denominados de forma global como hiperplasia angiofibroblástica, que se caracteriza por: 1) incremento de la celularidad y la sustancia fundamental; 2) hipervascularización (también denominada hiperplasia vascular o neovascularización); 3) incremento en la concentración de neurotransmisores y 4) desorganización del colágeno inmaduro [2][3].

Actualmente, se establecen tres factores relacionados entre sí como las posibles causas en las tendinopatías: lesión local en el propio tendón (frecuentemente insercional), cambios en el sistema de modulación del dolor y deficiencias en el sistema motor [1][6][7].

La tendinopatía del tendón rotuliano causa dolor sobre el polo inferior de la rótula [8], tiene un componente degenerativo asociado a lo que se conoce como lesiones por sobreuso [9][10], siendo frecuente entre deportistas que llevan a cabo un tipo de actividad repetitiva como el salto (voleibol, baloncesto), el golpeo (fútbol), las frenadas y arranques rápidos (tenis, pádel, squash) o la carrera (corta y larga distancia), con una prevalencia de hasta el 40% en jugadores de baloncesto y voleibol [11].

En esta situación, el programa de tratamiento ante una tendinopatía degenerativa debería incluir técnicas que incidieran sobre la biología del tendón para estimular la actividad celular y la producción de colágeno y sobre la biomecánica del tendón para conseguir una reestructuración de la matriz. En el caso de la tendinopatía del tendón rotuliano, cuando el tratamiento conservador fracasa, la mayoría de los pacientes optan por el tratamiento quirúrgico que obtiene buenos o excelentes resultados en el 45% de los casos aunque éstos no son superiores al trabajo excéntrico [12]. Recientemente, se han propuesto nuevas soluciones al tratamiento de la tendinopatía como son factores de crecimiento [13][14], infiltraciones con polidocanol [15], aprotinina [16] y la fisioterapia ha hecho lo propio con la electrólisis percutánea intratisular (EPI®). La EPI® es una técnica mínimamente invasiva que consiste en la aplicación de una corriente galvánica de alta intensidad a través de una aguja de acupuntura que provoca, en los tejidos blandos, un proceso inflamatorio local permitiendo la fagocitosis y la reparación del tejido afectado [17][18].

El objetivo del presente estudio es evaluar la efectividad de la electrólisis percutánea intratisular (EPI®) en las tendinopatías crónicas insercionales del tendón rotuliano.

Material y método

Diseño del estudio

Se realizó un estudio prospectivo entre enero de 2009 y enero de 2010, en el que participaron todos los pacientes diagnosticados de tendinopatía crónica del tendón rotuliano, derivados al Servicio de Fisioterapia de MVClinic (Madrid).

Se seleccionaron aquellos pacientes que cumplían los siguientes criterios: diagnóstico médico de tendinopatía rotuliana (tendinitis, tendinosis, entesitis…) con más de 6 meses de evolución desde el inicio de los síntomas, con edad comprendida entre 18 y 45 años, que hubiesen realizado previamente programas de fisioterapia sin alcanzar una recuperación funcional adecuada. Fueron excluidos los pacientes a los cuales se les realizó infiltraciones con corticoides en los 3 meses previos al tratamiento con EPI®, ya que aunque no es una contraindicación para la aplicación de la técnica puede alterar las propiedades del tejido de colágeno e inhibir la respuesta inflamatoria [19][20]. Se excluyeron los pacientes con cirugías previas en el tendón rotuliano y con alteraciones biomecánicas de pelvis, articulación coxo-femoral, fémoro-patelar y en tobillo y pie, que pudieran ser factores etiológicos en la tendinopatía que provocaran diferencias con el resto de la muestra.

Finalmente, se incluyeron 32 pacientes (59,4% hombres; 40,6% mujeres), con una media de edad de 35 años (DE: 8). El 50% de los sujetos realizaban una actividad deportiva semiprofesional o profesional.

Variables analizadas

En la primera evaluación se realizó, para analizar la estructura del tendón, una prueba de ecografía musculoesquelética con un ecógrafo portátil (M-Turbo de Sonosite®) con sonda lineal L38x/5-10MHz, realizada indistintamente por dos fisioterapeutas expertos en ecografía musculoesquelética. De forma previa al estudio se llevó a cabo un análisis de la fiabilidad interobservador.

Se definió un protocolo de evaluación para el tendón rotuliano a partir del Musculoskeletal Ultrasound Technical Guidelines: Knee, definido por la European Society of Mus-

FUNDACIÓNMAPFRE Trauma
Vol 21 nº 4 Octubre/Diciembre 2010

culoSkeletal Radiology [21]. La exploración ecográfica constaba de una secuencia longitudinal desde el origen proximal del tendón a la inserción distal y cortes transversales sobre el pico de rótula, cuerpo del tendón e inserción en tuberosidad anterior de tibia, de forma bilateral, con el sujeto en decúbito supino, con 20º de flexión de rodilla, con una cuña en el hueco poplíteo. Se evaluó la presencia de signos degenerativos compatibles con el diagnóstico médico de tendinopatía crónica (engrosamiento del tendón, imágenes hipoecoicas, irregularidades en la cortical, calcificaciones) que pudieran ser importantes en la planificación del programa de fisioterapia y su posterior seguimiento. Igualmente, se realizó la prueba de eco-doppler color para analizar la presencia de hipervascularización, con el sujeto en decúbito supino con la rodilla totalmente extendida y relajada.

La evaluación del paciente se completó con la escala VISA-P (Victorian Institute of Sport Assessment-Patella) para evaluar la función del individuo (puntuación de 0 a 100 puntos) [22] y la escala visual analógica de dolor (EVA).

Dependiendo de los resultados de la escala VISA-P en la primera evaluación, los pacientes fueron englobados en dos grupos según fuera la puntuación inferior (Grupo 1, peor pronóstico, 13 pacientes) o superior a 50 puntos (Grupo 2, mejor pronóstico, 19 pacientes) (Tabla 1). Ninguno abandonó el tratamiento durante el periodo de estudio y en ningún caso aparecieron complicaciones ni reacciones adversas durante la aplicación de la EPI®.

Programa de fisioterapia

Se aplicó como tratamiento la electrólisis percutánea intratisular (EPI®) de forma aislada en cada sesión asociada con carácter domiciliario a un programa de trabajo excéntrico y estiramientos miotendinosos. La EPI® se realizó de forma semanal sobre el polo inferior de la rótula con una intensidad entre 4-6 mA en diferentes abordajes (Figura 1). Para ello, se empleó el equipo EPI® (Cesmar Electromedicina SL, 08810 Sant Pere De Ribes, Barcelona). El programa de excéntricos [23-26] constaba de un ejercicio de «squat» con tres series de un máximo de 15 repeticiones de trabajo excéntrico unilateral (figura 2), sobre un desnivel de 25º (cuña rotuliana-MVClinic) dos veces al día (mañana y tarde), con la máxima carga posible, en un rango óptimo funcional sin dolor. Desde la extensión completa se realizaba de forma rápida el gesto, manteniendo 2 segundos la posición final, con un descanso mínimo entre 2 y 3 minutos entre las series, durante las semanas que durara el programa de fisioterapia. La fase concéntrica de vuelta a la posición de inicio se anulaba.

Fig. 1. Aplicación de EPI® ecoguiada sobre el tendón rotuliano.

Tabla 1. Género y VISA-Patella

		VISA-Patella		Total
		VISA-P < 50 puntos	VISA-P > 50 puntos	
Género: hombre	Recuento	6	13	19
	% de género	31,6%	68,4%	100,0%
	% del total	18,8%	40,6%	59,4%
Género: mujer	Recuento	7	6	13
	% de género	53,8%	46,2%	100,0%
	% del total	21,9%	18,8%	40,6%
Total	Recuento	13	19	32
	% de género	40,6%	59,4%	100,0%
	% del total	40,6%	59,4%	100,0%

FUNDACIÓNMAPFRE Trauma
Vol 21 nº 4 Octubre/Diciembre 2010

Fig. 2. Ejercicio excéntrico.



Fig. 3. Imagen hipoecoica en polo de rótula.

El programa de estiramientos constaba de un ejercicio de estiramiento para el músculo cuádriceps con tres series de 7 repeticiones dos veces al día (mañana y tarde) realizado en bipedestación, con flexión de rodilla y extensión de cadera, alcanzando el límite de estiramiento sin rebote durante 40-60 segundos.

Todos los fisioterapeutas participantes en el estudio aplicaron el mismo protocolo de tratamiento. El programa de excéntricos y estiramientos era enseñado por el fisioterapeuta en la primera sesión y supervisado en las sesiones sucesivas.



Fig. 4. VISA-Patella. Puntuación total inicio-alta (color azul-verde).

Análisis estadístico

La introducción, gestión y análisis de los datos se ha realizado utilizando el programa estadístico SPSS 15.0 para Windows y se eligió un valor de $p<0,05$ como nivel de significación estadística. Se cuantificaron las frecuencias absolutas y relativas y un análisis de tendencias mediante la prueba de χ^2 para analizar la relación entre las variables estudiadas. Para analizar si la distribución de la puntuación total en el test VISA-P al inicio del tratamiento y al alta era o no más homogénea (presenta menor varianza) en función al género se llevó a cabo la prueba de Levene, basándose en la media como valor central.

Resultados

La ecografía musculoesquelética mostró que todos los pacientes presentaban cambios compatibles con un proceso degenerativo del tendón (engrosamiento del tendón e imágenes hipoecoicas) (Figura 3). El 50% de los sujetos presentaban hipervascularización (todos aquellos englobados en el Grupo 1). Los valores obtenidos en la prueba de χ^2 mostraron que la hipervascularización se asociaba de forma significativa ($p<0.05$) en el grupo 1 (VISA <50 puntos). Después del periodo de tratamiento (entre 4 y 6 semanas) no se apreciaron cambios significativos en la evaluación ecográfica.

En la primera evaluación, la puntuación media obtenida con la escala VISA-P fue de 53 puntos (DE:18) de media del total; siendo 33 puntos (DE: 8) en el grupo 1 y 66 puntos (DE: 7) en el grupo 2 (Tabla 2) (Figura 4).

Los ítems que alcanzaron peor puntuación en el análisis de la funcionalidad fueron (en una escala de 0 a 10 puntos):

FUNDACIÓNMAPFRE Trauma
Vol 21 nº 4 Octubre/Diciembre 2010

Tabla 2. VISA-Patella (P1-P6)

	Muestra total		Grupo VISA-P <50 puntos		Grupo VISA-P >50 puntos	
VISA-Patella	1ª Evaluación Media* (DE)	Alta Media* (DE)	1ª Evaluación Media* (DE)	Alta Media* (DE)	1ª Evaluación Media* (DE)	Alta Media* (DE)
P1: ¿Cuántos minutos puede estar sentado sin dolor?	7,8 (2,0)	8,9 (1,1)	5,9 (1,5)	8,1 (0,7)	9,0 (1,0)	9,5 (0,6)
P2: ¿Tiene dolor bajando escaleras con un ciclo de marcha normal?	6,2 (2,2)	8,2 (1,0)	4,0 (1,1)	7,2 (0,4)	7,7 (1,2)	8,8 (0,7)
P3: ¿Tiene dolor de rodilla en un trabajo activo de extensión sin carga?	6,1 (1,6)	8,1 (0,8)	4,3 (0,9)	7,3 (0,5)	7,3 (0,6)	8,6 (0,7)
P4: ¿Tiene dolor cuando se apoya en flexión de rodilla después de un movimiento repentino hacía delante?	5,8 (1,6)	7,7 (0,8)	4,2 (0,9)	6,9 (0,3)	6,8 (0,8)	8,3 (0,6)
P5: ¿Tiene problemas al hacer cuclillas?	5,2 (1,8)	7,7 (0,9)	3,3 (1,0)	7,0 (0,4)	6,4 (0,9)	8,2 (0,8)
P6: ¿Tiene algún dolor durante o inmediatamente después de hacer 10 saltos a la pata coja?	4,7 (2,0)	7,5 (0,9)	2,7 (1,4)	6,7 (0,5)	6,1 (0,6)	8,1 (0,8)
Puntuación Total (Score)**	52,6 (18,2)	79,9 (11,9)	32,7 (8,5)	68,5 (7,2)	66,2 (6,6)	87,7 (7,4)

**Puntuación de 0 a 10; **Puntuación de 0 a 100.*

ítem P6: Dolor durante o inmediatamente después de hacer 10 saltos a la pata coja con una media de 4,7 puntos (DE:2) alcanzando tan sólo 2,7 puntos (DE:1,4) en el grupo 2 (VISA-P <50 puntos), seguido del ítem P5: Problemas al hacer cuclillas con una media de 5,2 puntos (DE:1,8) y de 3,3 puntos (DE:1) y 6,4 puntos (0,9) en los grupos 1 y 2 respectivamente y del ítem P2: Dolor al bajar escaleras en un ciclo normal de marcha con una media de 4 puntos (DE:1,1) en el grupo de peor pronóstico (grupo 2) (Tabla 2).

El 69,2% de los sujetos del grupo 1 no podían realizar ningún tipo de deporte al inicio del tratamiento y tan sólo el 7,7% eran capaces de llevar a cabo un entrenamiento completo o competición pero no al mismo nivel que cuando empezaron los síntomas. En el grupo 2, todos los sujetos podían realizar alguna actividad deportiva pero ninguno de ellos era capaz de competir al mismo nivel o mayor nivel que cuando empezaron los síntomas (tabla 3).

El estadístico F de la prueba de Levene fue igual a 0,014 y 2,623 respectivamente para el grupo 1 y 2, con un nivel de significación crítico igual a 0,908 y 0,124 en función al género (hombres y mujeres). Esto significa que no puede rechazarse la hipótesis nula para los niveles de significación habituales y, por lo tanto, se puede concluir que la diferencia de varianzas muestrales no es significativa, no hay diferencias en la puntuación total al inicio por género en el grupo 1 o 2.

Al final del tratamiento se apreciaron cambios importantes en el análisis de la funcionalidad, la puntuación media obtenida en el total de 32 sujetos con la escala VISA-P fue de 80,0 puntos (DE: 12) (27 puntos más que al inicio), siendo de 69 puntos (DE:7) (36 puntos más que al inicio, lo que constituye más del 100% de la puntuación inicial) en el grupo 1; VISA-P con menos de 50 puntos y 88 puntos (DE:7) (20 puntos más que al inicio) en el grupo 2; VISA-P con más de 50 puntos (Tabla 2) (Figura 4).

FUNDACIÓNMAPFRE Trauma
Vol 21 nº 4 Octubre/Diciembre 2010

Tabla 3. VISA-Patella (P7)

VISA-Patella		Grupo VISA-P <50 puntos 1ª Evaluación %	Grupo VISA-P <50 puntos Alta %	Grupo VISA-P >50 puntos 1ª Evaluación %	Grupo VISA-P >50 puntos Alta %
P7: ¿Realizas habitualmente deporte o alguna actividad física?	No, Nada	69,2	-	-	-
	Entrenamiento modificado ± modificando la competición	23,1	30,8	21,1	-
	Entrenamiento completo ± competición pero no al mismo nivel que cuando empezaron los síntomas	7,7	61,5	78,9	31,6
	Competición al mismo nivel o mayor nivel que cuando empezaron los síntomas	-	7,7	-	68,4
% Total		100	100	100	100

Los ítems que alcanzaron peor puntuación en la primera evaluación obtuvieron una mejoría importante tanto en el grupo 1 como en el 2 tras el tratamiento. En el grupo 1, el ítem 6 Dolor durante o inmediatamente después de hacer 10 saltos a la pata coja fue el que alcanzó una mejoría mayor (con un incremento medio de 4 puntos), seguido del ítem P5: Problemas al hacer cuclillas, con 3,7 puntos de diferencia media entre la primera evaluación y al alta y del ítem P2: Dolor al bajar escaleras en un ciclo normal de marcha, con 3,2 puntos. En el grupo 2 el incremento más notable se alcanzó en el ítem Dolor durante o inmediatamente después de hacer 10 saltos a la pata coja con un incremento medio de 2 puntos, alcanzando 8,1 puntos de media con una desviación estándar de 0,8 (Tabla 2).

En cuanto a la actividad física que eran capaces de llevar a cabo tras el tratamiento, en el grupo 1 (peor funcionalidad) el 61,5% podían realizar un entrenamiento completo o competición pero no al mismo nivel que cuando empezaron los síntomas frente al 7,7% del inicio (un incremento de más del 50%). En el grupo 2, el 60,4% de los sujetos podían realizar una competición al mismo nivel o mayor nivel que cuando empezaron los síntomas (al inicio ningún sujeto podía realizarlo) (Tabla 3).

El estadístico F de la prueba de Levene (basándose en la media como valor central) fue igual a 0,283 y 0,103 para el Grupo 1 y 2, respectivamente, que presenta un nivel de significación crítico igual a 0,605 y 0,753 en función al género (hombres y mujeres), por lo que se puede concluir que no hay diferencias en la puntuación total al alta por género en el grupo 1 o 2.

En el grupo 1 (VISA < 50 puntos), el 80% de los sujetos alcanzaron el alta en fisioterapia a las 6 semanas desde el inicio de tratamiento con EPI®, con una media de 6 sesiones de EPI®. En el Grupo 2 (VISA >50) el 100% de los sujetos lograron el alta tras 4 sesiones de EPI®. A largo plazo, dos de los pacientes incluidos en el grupo 1 (peor pronóstico) que obtuvieron una mejoría clínica significativa tuvieron una recaída y decidieron operarse.

Discusión

La experiencia clínica sugiere que el reposo aislado, lo que se denomina «esperar y observar» no es suficiente para solucionar la tendinopatía. A corto plazo las infiltraciones consiguen reducir el dolor pero tienen un alto porcentaje de recaídas mientras que la fisioterapia consigue mejorar los resultados a medio y largo plazo [27-28].

El objetivo de las técnicas de fisioterapia en las «tendinitis», ha sido llegar al lugar de la lesión y actuar de forma terapéutica aplicando un estímulo suficiente que fuera capaz de provocar en el tejido afectado un cambio; reagudizar la lesión para poner en marcha el proceso de reparación del tendón. No obstante, actualmente no se pueden defender afirmaciones pasadas sobre la rotura del tejido de colágeno con las técnicas de terapia manual, tipo método Cyriax [29].

Las intervenciones basadas en programas de entrenamiento excéntrico o en sobrecarga excéntrica sobre el tendón, son una opción entre el tratamiento convencional y la cirugía. Los estudios actuales, sobre todo en tendinopatías de Aquiles [30-32], muestran resultados excepcionales. Sin embargo, en nuestros pacientes no hemos alcanzado esos logros y frecuentemente obtuvimos resultados insuficientes

y el deportista no ha podido volver a la práctica deportiva como antes del inicio de los síntomas.

La pregunta sería: ¿por qué para algunos sujetos la fisioterapia es efectiva y para otros no? Quizá la respuesta esté en la solicitación mecánica posterior, nuestra experiencia clínica nos dice que cuando el sujeto después del tratamiento convencional continua con los gestos de repetición o las posturas mantenidas que realizaba de forma previa, son muy frecuentes las recaídas y cuando intensifica su actividad laboral o deportiva los síntomas siempre están presentes. Seríamos capaces de disminuir o eliminar el dolor pero no de cambiar la biología y la estructura del tendón que es mecánicamente insuficiente.

Basados en la evidencia disponible, no es posible decidir cuál es el tratamiento más efectivo para la tendinopatía rotuliana [33-35]. Las infiltraciones con corticoides, las ondas de choque, los programas de entrenamiento excéntrico, el ultrasonido, el láser o las técnicas de terapia manual como el método Cyriax o la fibrolisis diacutánea son frecuentemente utilizados en la práctica clínica diaria pero el efecto sobre el tejido blando no es del todo conocido. La fricción ha demostrado en animales un incremento en la producción de proteínas pero en humanos las pocas investigaciones existentes tienen resultados variables [36-37]. Clínicamente, comparado con los ejercicios las fricciones son menos efectivas en reducir el dolor [38]. Las ondas de choque se han estudiado en diversos tendones pero no son superiores al placebo [39] y el ultrasonido consigue aumentar la producción de proteínas pero de forma similar a las fricciones y es menos efectivo que los ejercicios en la tendinopatía patelar [40-41]. De esta forma, el entrenamiento excéntrico ha sido propuesto como la mejor opción en la tendinopatía rotuliana pero los resultados no son concluyentes [42-44].

Los resultados obtenidos con la EPI® en el presente estudio serían los mejores publicados hasta el momento pero el protocolo aplicado a este tipo de pacientes incluía, además de la EPI®, un programa de entrenamiento excéntrico y estiramientos de la musculatura implicada. El efecto aislado de la EPI® no se ha analizado y se podría discutir el efecto real de la técnica o si éste es debido sólo al programa excéntrico, sólo a los estiramientos o bien es el producto de una combinación. En este sentido, un grupo de pacientes que participaron en el estudio, realizaron un programa de trabajo excéntrico previo al programa de EPI® siguiendo las pautas que han demostrado efectividad [23-26] y no obtuvieron una mejoría significativa. Este grupo mejoró su condición clínica basal pero cuando intentaban realizar actividad deportiva intensa aparecían molestias similares a las previas que les impedían volver a competir.

Para aislar el efecto de la EPI® no se incluyeron en el programa de tratamiento otras medidas que teóricamente podrían ser útiles en el proceso de proliferación del colágeno como el ultrasonido o el láser tras conseguir reagudizar el tejido.

A corto plazo, en el momento del alta (con una media de 4-6 semanas desde el inicio del programa) no se apreciaron cambios significativos en la estructura del tendón a través de la imagen ecográfica, pero sí en la función a través de la escala VISA-P. La hipótesis sería que la EPI® actuaría sobre la zona insercional afectada poniendo en marcha el proceso biológico de reparación del colágeno y conseguiría mejorar la funcionalidad rápidamente mientras que los cambios en la propia estructura del tendón (sobre el engrosamiento, las imágenes hipoecoicas, o la hipervascularización) tardarían más en llegar ya que requieren de un proceso biomecánico de remodelación y maduración del tendón. Este planteamiento se ve reforzado por el seguimiento realizado al grupo de sujetos a medio y largo plazo, que ha permitido comprobar a través de la ecografía los cambios que suceden en la estructura del tendón.

Según nuestra experiencia clínica la EPI® es capaz de actuar sobre la biología del tendón y el programa excéntrico sobre la biomecánica del mismo con un estímulo positivo sobre la actividad celular y la reestructuración de la matriz.

Desde el punto de vista del razonamiento fisiopatológico, el seguimiento a medio y largo plazo parece confirmar la importancia del programa de excéntricos y estiramientos como elementos que permitirían dirigir la orientación del tejido de colágeno en el proceso de proliferación y maduración hasta conseguir la remodelación con un tendón menos engrosado y con ausencia de otros cambios degenerativos.

En relación a los cambios observados en la ecografía, las imágenes hipoecoicas no pueden ser interpretadas como cambios degenerativos sintomáticos ya que están presentes en el 39% de los sujetos asintomáticos a los que se exploró con la ecografía en otros estudios [45][46]. Desde nuestro punto de vista las imágenes hipoecoicas no constituyen por si solas una lesión en el tejido pero indican un cambio en la estructura del tendón que puede ser la manifestación preclínica del cuadro. En los sujetos explorados, la imagen hipoecoica aparecía en ambos tendones rotulianos, generalmente más engrosado el sintomático y, si éste tenía una funcionalidad peor, se asociaba a hipervascularización de forma significativa ($p<0,05$). En este sentido, la ecografía musculoesquelética lejos de un enfoque dirigido al diagnóstico médico constituye una herramienta muy importante para el fisioterapeuta ya que le permite analizar las deficiencias que presenta el individuo, planificar mejor el programa de fisioterapia y monitorizar la evolución del pacien-

te. La formación resuelve la dificultad del uso de esta herramienta teniendo en cuenta el buen conocimiento previo de la anatomía topográfica del fisioterapeuta.

La principal limitación del estudio es la ausencia de un grupo control que permita comparar los resultados obtenidos con un placebo u otra intervención. El presente estudio confirma los resultados obtenidos previamente [47-48]. Otra limitación está derivada de las herramientas de valoración de resultados empleadas. Por una parte, al igual que ocurre con la mayoría de los cuestionarios, el test VISA-P no ha sido validado en castellano. Se optó por este test ya que tiene una fiabilidad alta, es fácilmente interpretable, frecuentemente empleado en la práctica clínica y ha sido validado al italiano, sueco y holandés manteniendo las mismas propiedades psicométricas [49-51].

Por otra parte, la resolución de la imagen ecografía puede no ser totalmente sensible para identificar cambios en la estructura a corto plazo, podríamos tener modificaciones no perceptibles al ojo humano en la escala de grises que requieran de un *software* que permita un análisis más detallado.

En la tendinopatía degenerativa del tendón rotuliano, la EPI® es un tratamiento efectivo ya que logra mejorar la funcionalidad de los sujetos estudiados tanto en aquellos que obtienen una mejor puntuación con la escala VISA-P como en aquellos con peor pronóstico.

Agradecimientos

Los autores agradecen a Sonosite® Ibérica su colaboración en el desarrollo del estudio. Especial mención al Dr. Manuel Leyes y al Dr. Martín Buenadicha por el interés mostrado y la confianza depositada en nosotros. Los autores declaran no tener conflicto de intereses.

Referencias bibliográficas

1. Cook JL, Purdam CR. Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy. Br J Sports Med 2009; 43:409-16.
2. Abate M, Gravare-Silbernagel K, Siljeholm C, Di lorio A, De Amicis D, Salini V, et al. Pathogenesis of tendinopathies: inflammation or degeneration?. Arthritis Research & Therapy 2009; 11:1-15.
3. Fredberg U, Stengaard-Pedersen K. Chronic tendinopathy tissue pathology, pain mechanisms, and etiology with a special focus on inflammation. Scand J Med Sci Sports 2008; 18:3-15.
4. Alfredson H, Ljung BO, Thorsen K, Lorentzon R. In vivo investigation of ECRB tendons with microdialysis technique--no signs of inflammation but high amounts of glutamate in tennis elbow. Acta Orthop Scand 2000; 71:475-9.
5. Maffulli N, Khan KM, Puddu G. Overuse tendon conditions: time to change a confusing terminology. Arthroscopy 1998; 14:840-3.
6. Khan KM, Cook JL, Kannus P, Maffulli N, Bonar SF. Time to abandon the «tendinitis» myth. BMJ 2002; 324:626-7.
7. Coombes BK, Bisset L, Vicenzino B. A new integrative model of lateral epicondylalgia. Br J Sports Med 2009; 43:252-8.
8. Ramos L, Teixeira de Carvalho R, Garms E, Schmith M, Abdalla RJ, Cohen M. Prevalence of pain on palpation of the inferior pole of the patella among patients with complains of knee pain. Clinics 2009; 64:199-202.
9. Khan KM, Cook JL, Taunton JE, Bonar F. Overuse tendinosis, not tendinitis part 1: a new paradigm for a difficult clinical problem. Phys Sportsmed 2000; 28:38-48.
10. Cook JL, Khan KM, Maffulli N, Purdam C. Overuse tendinosis, not tendinitis part 2: applying the new approach to patellar tendinopathy. Phys Sportsmed 2000; 28:31-46.
11. Lian OB, Engebretsen L, Bahr R. Prevalence of jumper's knee among elite athletes from different sports: a cross-sectional study. Am J Sports Med. 2005; 33:561-7.
12. Bahr R, Fossan B, Løken S, Engebretsen L. Surgical treatment compared with eccentric training for patellar tendinopathy (Jumper's Knee). A randomized, controlled trial. J Bone Joint Surg (Am) 2006; 88-A:1689–98.
13. de Vos RJ, Weir A, van Schie HT, Bierma-Zeinstra SM, Verhaar JA, Weinans H, Tol JL. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA 2010; 303:144-9.
14. Anitua E, Andía I, Sánchez M, Azofra J, del Mar Zalduendo M, de la Fuente M, et al. Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. J Orthop Res 2005; 23:281-6.
15. Brown R, Orchard J, Kinchington M, Hooper A, Nalder G. Aprotinin in the management of Achilles tendinopathy: a randomised controlled trial. Br J Sports Med 2006; 40:275-9.
16. Hoksrud A, Ohberg L, Alfredson H, Bahr R. Ultrasound-guided sclerosis of neovessels in painful chronic patellar tendinopathy: a randomized controlled trial. Am J Sports Med 2006; 34:1738-46.
17. Sánchez JM. Modelos teóricos del dolor en la tendinopatía rotuliana del deportista, 2003.<http://www.efisioterapia.net/articulos/leer [Consulta: 25 jul. 2010].
18. Sánchez JM. Terapia acelerada de la tendinopatía rotuliana del deportista mediante la técnica de Electrólisis Percutánea

Transtendinosa (EPI), 2001. <http://www.efisioterapia.net/articulos/leer [Consulta: 25 jul. 2010].
19. Haraldsson BT, Aagaard P, Crafoord-Larsen D, Kjaer M, Magnusson SP. Corticosteroid administration alters the mechanical properties of isolated collagen fascicles in rat-tail tendón. Scand J Med Sci Sports 2009; 19:621-6.
20. Wong MW, Tang YN, Fu SC, Lee KM, Chan KM. Triamcinolone suppresses human tenocyte cellular activity and collagen synthesis. Clin Orthop Relat Res 2004; 241: 277–81.
21. Beggs I, Bianchi S, Bueno A, Cohen M, Court-Payen M, Grainger A, et al. ESSR Ultrasound Group Protocols. Musculoskeletal Ultrasound Technical Guidelines: Knee. <http://www.essr.org/html/img/pool/knee.pdf> [Consulta: 25 jul. 2010].
22. Visentini PJ, Khan KM, Cook JL, Kiss ZS, Harcourt PR, Wark JD. The VISA score: an index of severity of symptoms in patients with jumper's knee (patellar tendinosis). J Sci Med Sport 1998; 1:22-8.
23. Purdam CR, Johnsson P, Alfredson H, Lorentzon R, Cook JL, Khan KM. A pilot study of the eccentric decline squat in the management of painful chronic patellar tendinopathy. Br J Sports Med 2004; 38:395-7.
24. Young MA, Cook JL, Purdam CR, Kiss ZS, Alfredson H. Eccentric decline squat protocol offers superior results at 12 months compared with traditional eccentric protocol for patellar tendinopathy in volleyball players. Br J Sports Med 2005; 39:102-5.
25. Frohm A, Saartok T, Halvorsen K, Renström P. Eccentric treatment for patellar tendinopathy: a prospective randomised short-term pilot study of two rehabilitation protocols. Br J Sports Med 2007; 41.
26. Visnes H, Bahr R. The evolution of eccentric training as treatment for patellar tendinopathy (jumper's knee): a critical review of exercise programmes. Br J Sports Med 2007; 41:217-23.
27. Rompe JD, Nafe B, Furia JP, Maffulli N. Eccentric loading, shock-wave treatment, or a wait-and-see policy for tendinopathy of the main body of tendo Achillis: a randomized controlled trial. Am J Sports Med 2007; 35:374-83.
28. Barr S, Cerisola FL, Blanchard V. Effectiveness of corticosteroid injections compared with physiotherapeutic interventions for lateral epicondylitis: a systematic review. Physiotherapy 2009; 95:251-65.
29. Pohl H. Changes in the structure of collagen distribution in the skin caused by a manual technique. J Bodyw Mov Ther 2010; 14:27-34.
30. Jonsson P, Alfredson H, Sunding K, Fahlström M, Cook J. New regimen for eccentric calf-muscle training in patients with chronic insertional Achilles tendinopathy: results of a pilot study. Br J Sports Med 2008; 42:746-9.
31. Ohberg L, Lorentzon R, Alfredson H. Eccentric training in patients with chronic Achilles tendinosis: normalised tendon structure and decreased thickness at follow up. Br J Sports Med 2004; 38:8-11.
32. Jonsson P, Wahlström P, Ohberg L, Alfredson H. Eccentric training in chronic painful impingement syndrome of the shoulder: results of a pilot study. Knee Surg Sports Traumatol Arthrosc 2006; 14:76-81.
33. Wilson JK, Sevier TL, Helfst R, Honing EW, Thomann A. Comparison of rehabilitation methods in the treatment of patellar tendinitis. Journal of Sport Rehabilitation 2000; 9:304-14.
34. Rees JD, Maffulli N, Cook J. Management of tendinopathy. Am J Sports Med 2009; 37:1855-67.
35. Tan SC, Chan O. Achilles and patellar tendinopathy: current understanding of pathophysiology and management. Disabil Rehabil 2008; 30:1608-15.
36. Wilson JK, Sevier TL, Helfst R, Honing EW, Thomann A. Comparison of rehabilitation methods in the treatment of patellar tendinitis. Journal of Sport Rehabilitation 2000; 9:304-14.
37. Gehlsen GM, Ganion LR, Helfst R. Fibroblast responses to variation in soft tissue mobilisation pressure. Med Sci Sports Exerc 1999; 31:531-5.
38. Stasinopoulos D, Stasinopoulos I. Comparison of effects of exercise programme, pulsed ultrasound and transverse friction in the treatment of patellar tendinopathy. Clin Rehabil 2004; 18:347-52.
39. Maier M, Milz S, Wirtz DC, Rompe JD, Schmitz C. Basic research of applying extracorporeal shockwaves on the musculoskeletal system. An assessment of current status. Orthopade 2002; 31:667-77.
40. Warden SJ, Metcalf BR, Kiss ZS, Cook JL, Purdam CR, Bennell KL, Crossley KM. Low-intensity pulsed ultrasound for chronic patellar tendinopathy: a randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford) 2008; 47:467-71.
41. Peers KH, Lysens RJ, Brys P, Bellemans J. Cross-sectional outcome analysis of athletes with chronic patellar tendinopathy treated surgically and by extracorporeal shock wave therapy. Clin J Sport Med 2003; 13:79-83.
42. Visnes H, Hoksrud A, Cook J, Bahr R. No effect of eccentric training on jumper's knee in volleyball players during the competitive season: a randomized clinical trial. Clin J Sport Med 2005; 15:227-34.
43. Jonsson P, Alfredson H. Superior results with eccentric compared to concentric quadriceps training in patients with

jumper's knee: a prospective randomised study. Br J Sports Med 2005; 39:847-50.
44. Woodley BL, Newsham-West RJ, Baxter GD. Chronic tendinopathy: effectiveness of eccentric exercise. Br J Sports Med 2007; 41:188-98.
45. Cook JL, Khan KM, Kiss ZS, Coleman BD, Griffiths L. Asymptomatic hypoechoic regions on patellar tendon ultrasound: a 4-year clinical and ultrasound follow-up of 46 tendons. Scand J Med Sci Sports 2001; 11: 321-7.
46. Cook JL, Khan KM, Kiss ZS, Purdam CR, Griffiths L. Prospective imaging study of asymptomatic patellar tendinopathy in elite junior basketball players. J Ultrasound Med 2000; 19:473-9.
47. Sánchez JM. Tratamiento de la tendinopatía rotuliana del deportista mediante Electrólisis Percutánea Intratendinosa (EPI), 2003. <http://www.efisioterapia.net/articulos/leer [Consulta: 25 jul. 2010].
48. Valera F, Minaya FJ, Sánchez JM. Efectividad de la electrólisis percutánea intratisular (EPI®) en las tendinopatías del tendón rotuliano. XI Jornadas Nacionales y I Congreso Internacional de Fisioterapia en la Actividad Física y el Deporte. Libro de comunicaciones y ponencias. Madrid: 2009.
49. Zwerver J, Kramer T, van den Akker-Scheek I. Validity and reliability of the Dutch translation of the VISA-P questionnaire for patellar tendinopathy. BMC Musculoskelet Disord 2009; 10:102.
50. Frohm A, Saartok T, Edman G, Renstrom P. Psychometric properties of a Swedish translation of the VISA-P outcome score for patellar tendinopathy. BMC Musculoskelet Disord 2004; 5:49.
51. Maffulli N, Longo UG, Testa V, Oliva F, Capasso G, Denaro V. VISA-P score for patellar tendinopathy in males: adaptation to Italian. Disabil Rehabil 2008, 30:1621-4.

Conflicto de intereses
Los autores no hemos recibido ayuda económica alguna para la realización de este trabajo. Tampoco hemos firmado ningún acuerdo por el que vayamos a recibir beneficios u honorarios por parte de alguna entidad comercial.
Ninguna entidad comercial ha pagado, ni pagará, a fundaciones, instituciones educativas u otras organizaciones sin ánimo de lucro a las que estamos afiliados.

Online version at http://www.minervamedica.it

The Journal of Sports Medicine and Physical Fitness 2017 ????;57(??):000-000
DOI: 10.23736/S0022-4707.16.06466-5

ORIGINAL ARTICLE

Intratissue percutaneous electolysis combined with active physical therapy for the treatment of adductor longus enthesopathy-related groin pain: a randomized trial

Carlos MORENO [1] *, Gabriele MATTIUSSI [1], Francisco J. NÚÑEZ [2], Giovanni MESSINA [3], Enrico REJC [4]

[1]Medical Staff, Udinese Calcio Spa, Udine, Italy; [2]Department of Sports and Computing. Sport Faculty, Pablo de Olavide University of Sevilla, Sevilla, Spain; [3]Department of Medical and Biological Sciences, School of Motor Sciences, University of Udine, Udine, Italy; [4]Kentucky Spinal Cord Injury Research Center, University of Louisville, KY, USA

*Corresponding author: Carlos Moreno, Medical Staff, Udinese Calcio Spa, Stadio Friuli, Viale A. e A. Candolini 2, 33100 Udine, Italy.
E-mail: Carlos.Moreno@udinesespa.it

ABSTRACT

BACKGROUND: *Adductor longus* enthesopathy-related groin pain (ALErGP) is the most common cause of groin pain in soccer players. The aim of this study was to evaluate the therapeutic utility of intratissue percutaneous electrolysis (EPI®) technique in combination with an active physical therapy (APT) program to treat ALErGP.
METHODS: Twenty-four non-professional male soccer players diagnosed with ALErGP were included in this study and randomly divided into two groups. Group A was treated with EPI® technique in combination with a standardized APT program. Group B only underwent the APT program. The Numeric Rating Scale (NRS) and the Patient Specific Functional Scale (PSFS) were used to assess the effectiveness of the two interventions. The follow-up covered a 6-month period.
RESULTS: Both groups significantly improved pain and functional scores after treatment and maintained this therapeutic result throughout the follow-up. The combined intervention of APT program and EPI® ensured a greater and faster reduction of pain in group A. In addition, functional recovery tended to be greater in group A than B after the treatment and throughout the follow-up by 7.8±3.8% (P=0.093).
CONCLUSIONS: EPI® treatment in association with APT ensured a greater and more rapid reduction of pain and tended to promote greater functional recovery in soccer players with ALErGP compared to APT only. This positive therapeutic result lasted for at least 6 months after the end of the treatment. These findings support the combined use of EPI® and APT to treat ALErGP.

(*Cite this article as:* Moreno C, Mattiussi G, Núñez FJ, Messina G, Rejc E. Intratissue percutaneous electolysis combined with active physical therapy for the treatment of adductor longus enthesopathy-related groin pain: a randomized trial. J Sports Med Phys Fitness 2017;57: DOI: 10.23736/S0022-4707.16.06466-5)

Key words: Tendinopathy - Soccer - Electrolysis - Ultrasonography.

Groin pain (GP) can generally be defined as a syndrome characterized by pain in the pubic and inguinal regions,[1] which results in a functional deficit that can lead to severe impairment of different motor tasks, such as kicking and twisting movements while running,[2] and to the suspension of athletic activities.[3] In soccer, the incidence of this condition ranges between 10% and 18% of all time-loss injuries with relapse rates as high as 30%.[3, 4] In fact, the term "longstanding" GP is often used to describe the impact of the syndrome in the long term.[5] The anatomy of the region is extremely complex and many different conditions provoking GP can be factors into a differential diagnosis.[1, 6-8] Hence, the identification of the primary cause of GP can be challenging. Despite the difficulties in diagnosis, adductor-related GP has been identified as the most common clinical pattern of GP in soccer players.[9] This is clinically characterized by pain that is exacerbated by the palpation of the inser-



Figure 1.—Longitudinal ultrasound section of the *adductor longus* (AL). The tendon insertion on the pubic tubercle (PT) is recognized as a hypoechoic area (arrow). Additionally, the intramuscular tendon, or central aponeurosis, of the *adductor longus* (the hyper-echoic horizontal structure indicated by an asterisk), and the *adductor brevis* (AB) can also be seen.



Figure 2.—Anatomic changes of the proximal tendon/enthesis of the *adductor longus (*AL) in the ultrasound examination. In the vicinity of the pubic tubercle (PT) the presence of significant calcification of the tendon can be seen (dotted box), as well as many fibrotic areas at the level of the enthesis (small arrows), which appears to be clearly deconstructed. Furthermore, it is possible to identify significant fibrotic thickening near the myotendinous unit of the muscle (thick arrow). AB: adductor brevis.

tion of the *adductor longus* (AL) on the pubic tubercle (unilaterally or bilaterally), as well as by the counter-resistance contraction of the muscle.[1, 9] This clinical condition is often associated with AL enthesopathy, which involves also alterations of the tendon portion in close proximity to its insertion (Figure 1),[10] and is recognized as the most common disease in athletes with pain localized in the proximity of the pubic symphysis.[6, 11] Therefore, *adductor longus* enthesopathy-related GP (ALErGP) is identified as one of the main causes of GP in soccer players. Etiopathogenesis of AL enthesis degeneration is associated with repeated functional overloading, as the fibrocartilaginous enthesis is vulnerable to prolonged biomechanical stimuli over time.[12, 13] Repeated functional overloading results in the progressive manifestation of histological and anatomical alterations, detectable with ultrasound and MRI.[11, 14-17] The fibrosis and the formation of calcifications (Figure 2) are compatible with a chronic failure of the physiological processes of adaptation and healing, resulting in ineffective microcycles of injury repair.[12, 13] Also, histological alterations of the enthesis contribute to the progressive loss of the biomechanical properties of the tissue and finally to the onset of symptoms and functional deficits typical of an overuse injury.[1, 11, 15]

Physiotherapy is usually preferred over surgical intervention to treat GP. On the other hand, surgery is considered when the rehabilitative programs are unsuccessful.[18] The more conservative treatments usually involve: rest (or restriction of activities); passive physiotherapy (*i.e.* massage, laser and transcutaneous electrical nerve stimulation) [19] to recover the joint mobility of the hip, sacroiliac joints, and lumbar spine, as well as the restoration of the visco-elastic properties of the muscles (the adductors, in particular); active physiotherapy targeted at improving the stabilizing ability of the abdominal and pelvic muscles, especially the *Transversus Abdominis*.[2, 20-23] It has been shown that a program of active physiotherapy is more effective than one of exclusively passive physiotherapy in the care of Adductor-related GP,[19] and that a multimodal program promotes even faster results than active physical therapy *per se*.[24] The physical therapy interventions usually last for 6 to 8 weeks.[25]

In addition to the abovementioned interventions, another therapeutic approach to consider is intratissue percutaneous electolysis (EPI®), a novel technique that plays a role in the treatment of tendinopathy, enthesopathy, and fibrosis.[26-28] Furthermore, a recent study reported the use of this technique for the treatment of muscular lesions as well.[29] EPI® is an ultrasound-guided minimally invasive technique that makes it possible to degrade the diseased tissue through the electrolytic action of EPI® (electrochemical ablation), as well as to develop an extremely localized inflammatory process that can induce the heal-

TABLE I.—*Enrollment phase: inclusion and exclusion criteria.*

	Inclusion criteria	Exclusion criteria
General criteria	Non-professional soccer players	Previous Groin/Hip surgery
	Age 18-35 years	
Clinical criteria	Presence of pain upon palpation of the enthesis of the *adductor longus* (unilaterally or bilaterally)	Adductor-related Groin Pain is not the primary clinical entity
	Presence of pain upon contraction against resistance (Adductor Squeeze Test) of the enthesis of the *adductor longus* (unilaterally or bilaterally)	
Imaging criteria	The ultrasound testing revealed anatomical alterations of the proximal tendon/enthesis of the adductor longus, which was painful during clinical examination	The ultrasound and MRI showed and absence of anatomical alterations of the enthesis of the *adductor longus*, which was painful during clinical examination
		Presence of major pathologies revealed by the MRI
After randomization		Consumption of NSAIDs or local infiltration during treatment
		Absence from more than 20% of scheduled physiotherapy sessions or absence from more than one scheduled EPI® session.

ing process in the treated structure (indirect reparative action).[29] Other works described the therapeutic benefits of EPI® technique in the treatment of patellar tendinopathy and how this technique, in conjunction with a program of active physical therapy — eccentric exercises in particular — can promote considerable structural and functional benefits that are maintained in the long term.[26, 27] However, further studies are still needed to evaluate the usefulness of this technique in the treatment of other tendinopathies and enthesopathies.

The aim of this study was to evaluate the therapeutic utility of the EPI® technique in combination with an APT program to treat ALErGP, while comparing the results achieved solely from the APT program in a group of non-professional soccer players. We hypothesized that 1) the combination of EPI® and APT can promote greater and faster clinical and functional improvements than treatment relying solely on an APT program; and that 2) the functional improvements obtained in the study group will be more solidly maintained over time compared to the control group that underwent APT program alone.

Materials and methods

Participants and sample size

Between February and July 2014, 37 male soccer players affected by generic GP were clinically and instrumentally evaluated (see below). These athletes usually performed 2 to 4 training sessions per week, thus were considered non-professional players.[24] Twenty-



Figure 3.—Study profile.

four of these athletes (age: 26.0±4.7 year; stature: 178.7±8.0 cm; body mass: 73.9±6.9 kg) were diagnosed with ALErGP, satisfied the inclusion and exclusion criteria (Table I) and thus were initially enrolled in the study (Figure 3). Two subjects did not complete the study protocol; hence, data recorded from 22 players were taken into account for further analysis.

The study was ethically designed and conducted according to national and international standards. The research reported in the paper was undertaken in compliance with the Helsinki Declaration and the International Principles governing research on humans. All participants were informed of the experimental risk and gave written informed consent. In addition, the present study was designed taking into consideration the guidelines on reporting standards for clinical research on groin pain in athletes indicated by Delahunt *et al.*[30]

Patients initially took part in a medical interview. Their anthropometric data were collected, as well as sport-specific (level of activity, position, dominant foot) and GP-specific (laterality and duration of the symptoms) information. The final part of the interview involved the registration of Patient-Specific Functional Scale (PSFS) values. This was followed by the clinical evaluation, including recordings of the Numeric Rating Scale (NRS) values. After this evaluation, an ultrasound examination was administered. If the inclusion criteria were met, the patient was asked to undergo an MRI scan. Based on an analysis of the final report, a decision was made whether to enrol the subject. MRI scans were performed by a private clinical facility, while all other assessments and therapeutic interventions were performed within the facilities of the "Friuli" Stadium, in Udine (Italy), the sporting venue of Udinese Football Club.

Clinical evaluations

For the clinical evaluation, a standardized assessment protocol was used for athletes with GP.[31] This protocol was shown to be particularly valuable because it was subject to limited variation between operators. All the clinical assessments were performed by a well-trained physiotherapist who followed precisely the protocol details found in the appendix "Examination techniques for the evaluation of GP in athletes" used in the intra-observer and interobserver reliability study.[31] The assessor was not aware of the treatment type received by every subject.

Pain assessment

The NRS Scale,[32-34] which showed high test-retest reliability,[32] was selected among the available scales for pain assessment in adults. The patient was asked to verbally assign a value to his pain, ranging from 0 (total absence of pain) to 10 (the most intense pain imaginable). The NRS values were collected to assess the pain: upon palpation of the insertion of the AL into the pubic tubercle (NRSpalp) (if pain is present bilaterally, the highest value was always recorded); upon bilateral isometric contraction against resistance (NRScontr). The values were recorded at enrolment, at the end of treatment, and at 2, 4, and 6 months after treatment (follow-up).

Functional assessment

As suggested by Hedegus et al.,[33] the PSFS was chosen to assess the functional level of subjects with GP. The patient was asked to select the activities with a reduced level of performance and to assign them with increasing values from 0 to 10, representing a complete deficit in the performance of the activity and the ability to perform the activity at the highest level of performance, respectively. To ensure uniform assessment in the sample, the authors selected 10 activities to which the patient was asked to assign a performance level, 6 non-sport specific and 4 sport specific (SS): linear running; linear sprinting; rapid braking in a sprint; twisting movements; jumping, pulling with dominant foot; jumping, pulling with the non-dominant foot; passing with the dominant foot (SS); passing with the non-dominant foot (SS); kicking with the dominant foot (SS); and kicking with the non-dominant foot (SS). The sum of the values obtained could range from 0 to 100, where 100 is the maximum level of athletic performance. The values were recorded at enrolment, at the end of treatment, and at 2, 4, and 6 months after treatment (follow-up). PSFS showed also high test-retest reliability for evaluation of the functional level for chronic syndromes such as low back pain and chronic lateral epicondylitis.[35]

Instrumental evaluations

Ultrasound assessment was performed by a well-trained operator (more than 10 years of experience in evaluating the lower limb muscle-skeletal system in professional and non-professional soccer players) us-

ing the GE Healthcare Logiq S7 Expert ultrasound (GE Healthcare®, Milwaukee, WI, USA) with a linear probe (6-15 MHz). Ultrasound assessment was performed only before the intervention; it was aimed at evaluating any eventual anatomical alterations of the proximal tendon and enthesis of the *adductor longus*, which was painful during clinical examination, in order to define the inclusion/exclusion criteria (Table I). The assessor was neither aware of the clinical evaluation results nor the type of treatment that the subject would have received.

Ultrasound evaluation was followed by an MRI of the pubic region which was necessary to confirm the diagnosis and to rule out any other condition: subjects with significant comorbidities (such as inguinal hernia, muscle injuries, femoroacetabular impingement, visceral diseases, etc.) were excluded from the study.

Treatment protocols

Two randomized groups were created: the study group, or group A, and the control group, or group B. In group A, the EPI® technique was used along with a standardized APT program, whereas group B only underwent the APT program. To randomize the groups, the following tool was used: "Create a blocked randomization list" (Sealed Envelope Ltd. 2014), available online from: https://www.sealedenvelope.com/simple-randomiser/v1/lists. The block size was set at 10 subjects (1:1 allocation). The tool also generated a unique randomization code. After the assessments, each subject included in the study was given their personal code assigning them to one of the two groups. The code was enclosed in sealed envelopes (numbered to identify the block).

Eco-guided EPI® intervention

The patient was placed in a supine position, with the limb in slight abduction and external rotation of the hip in order to better expose the enthesis of the AL to be treated. The entire pubic and inguinal region was previously disinfected with isopropyl alcohol. The treatment was performed by a well-trained operator (more than 10 years of experience in applying this technique for ALErGP in professional and non-professional soccer players) using a specifically developed medically



Figure 4.—Ultrasound-guided intratissue percutaneous electrolysis. The operator inserts the needle (asterisk) into the treatment area.

certified (Directive 93/42/EEC) device (EPI Advanced Medicine®, Barcelona, Spain). The chemical process of electrolysis is induced by the modulated galvanic current generated by the device. The current is transferred to the tissue to be treated using an appropriate needle (0.33x50 mm); its insertion is ultrasound-guided in order to reach precisely the targeted area. In the present study, the GE Healthcare Logiq S7 Expert® ultrasound with a linear probe (6-15 MHz) was used to guide the insertion of the needle (Figure 4). Group A subjects received EPI® intervention during Phase 1 of the APT program. EPI® intervention protocol was similar to that reported by Abat *et al.*[26, 27] for the treatment of patellar tendinopathy. In particular, two treatment sessions were held each week during Phase 1 of the APT program (EPI® intervention was completed 15 minutes prior to the start of the physical therapy session). The pre-set program "Adductors Tendinopathy" was used, with the device set at 3mA (current intensity). Each session consisted of 3 applications (3 right + 3 left if the ALErGP was present bilaterally), with a duration of 5 seconds each. Each session had a maximum duration of 10 minutes.

EPI® intervention was overall well tolerated by the subjects. Some of them experienced minor discomfort during needle insertion. In addition, the electrolytic treatment caused moderate to moderately strong pain in some of the participants; however, the short duration of every stimulus, 5 seconds, resulted in a tolerable pain. Indeed, none of the subjects asked to pause or stop the treatment, being these options available after every single 5-second stimulus. Furthermore, no adverse events

TABLE II.—*The standardized Active Physical Therapy program: description of the exercises and method of administration.*

Phase 1	1) Bilateral isometric contraction of the AL: patient in supine position. Isometric adduction against a fit ball (Ø=30cm) positioned between the knees.	10 s of holding (+20 s pause) for 8 repetitions
	2) Bilateral isometric contraction of the AL: patient in supine position, hips flexed at 45°. Isometric adduction against a fit ball (Ø=30 cm) positioned between the knees.	10 s of holding (+20 s pause) for 8 repetitions
	3) Unilateral eccentric contraction of the AL: patient in supine position, hip in neutral position. The physiotherapist slowly abducts the hip up to 45° and the patient is asked to slow down the muscle elongation.	5 s of contraction (+5 s pause) for 8 repetitions for 4 sets (2 for each leg)
	4) Bilateral eccentric contraction of the AL: patient in supine position, hips flexed at 45° and fully adducted. The physiotherapist slowly abducts both hips up to 30°, while the patient is asked to slow down the muscle elongation.	5 s of contraction (+10 s pause) for 8 repetitions for 2 sets
Phase 2	1) Spinning bike (warm up).	10 min
	2) Bilateral eccentric contraction of the AL: patient in supine position, hips flexed at 45° and fully adducted. The physiotherapist slowly abducts both hips up to 30°, while the patient is asked to slow down the muscle elongation (warm up).	5 s of contraction (+10 s pause) for 8 repetitions for 4 sets
	3) Isoinertial eccentric training for AL: patient in supine position. Overload: 2 Kg (Concentric + Eccentric phases duration: ~3 s).	6 repetitions for 4 sets (2 for each leg)
	4) Isoinertial eccentric training for AL: patient in upright position. Overload: 4 Kg (Concentric + Eccentric phases duration: ~3 s).	6 repetitions for 4 sets (2 for each leg)
Phase 3	1) Spinning bike (warm up)	10 min
	2) Bilateral eccentric contraction of the AL: patient in supine position, hips flexed at 45° and fully adducted. The physiotherapist slowly abducts both hips up to 30°, while the patient is asked to slow down the muscle elongation (warm up).	5s of contraction (+10s pause) for 8 repetitions for 4 sets
	3) Isoinertial eccentric training for AL: patient in supine position. Overload: 3 kg (concentric + eccentric phases duration: ~3 s).	6 repetitions for 4 sets (2 for each leg).
	4) Isoinertial eccentric training for AL: patient in supine position. Overload: 4 kg (concentric + eccentric phases duration: ~6 s).	4 repetitions for 4 sets (2 for each leg).
	5) Isoinertial eccentric training for AL: patient in upright position. Overload: 4 kg (concentric + eccentric phases duration: ~3 s).	6 repetitions for 4 sets (2 for each leg).
	6) Isoinertial eccentric training for AL: patient in upright position. Overload: 6 kg (concentric + eccentric phases duration: ~6 s).	4 repetitions for 4 sets (2 for each leg).

AL: adductor longus.

such as fainting or nausea occurred during the treatment. Some patients reported minor pain in the treated location up to 12 hours after the end of EPI® intervention.

The standardized active physical therapy program

For all participants, the program began within 10 days of enrolment and was performed under the constant supervision of a physical therapist, who did not know which subjects were also treated with Eco-Guided EPI® intervention. Table II specifically shows the therapeutic proposals of each of the 3 phases comprising the treatment. The APT protocol was defined taking into consideration: 1) previous studies that investigated the effects of active physiotherapy (*i.e.* isometric and eccentric muscle contractions performed against manual resistance) on GP;[19, 24]; 2) previous studies aimed at examining the combined effects of EPI® technique and isoinertial eccentric exercises on the treatment of patellar tendinopathy;[27] 3) previous studies that examined the effects of isoinertial eccentric exercises on muscle function in healthy athletes;[36, 37] 4) pilot studies carried out by our research group. The duration of each phase depended on the functional and symptomatic improvement shown by each individual. In particular, the achievement of specific NRSpalp, NRScontr and PSFS threshold values (see below) resulted in the phase completion. However, each subject was required to perform at least 1 week of training for each phase.

PHASE 1

The aim of this phase was to reduce the ALErGP symptoms. Subjects were required to completely suspend all sport-related activities and perform three rehabilitative sessions per week, which included isometric

lower limb adductions and AL eccentric contractions performed against manual resistance (Table II). The duration of each session was about 30 minutes. At the beginning of each session, NRSpalp and NRScontr tests were replicated. When the values of both tests were ≤3/10, subjects advanced to Phase 2.

Phase 2

The objective was non-sport specific functional recovery. As in the previous phase, 3 sessions per week (30 minutes/session) were performed by the subjects. Phase 2 involved the use of a machine (Element Sport™, Sevilla, Spain; Figure 5) for performing isoinertial eccentric exercises. This isoinertial machine was equipped with a 7 kg flywheel (moment inertia: 0.09 kg/m^2) and additional overloads (between 3 and 6 kg) that were appropriately set by the operator (Table II), and was very similar to those described in other studies that used isoinertial exercise as an intervention.[27, 36, 37] In particular, an important feature of this machine is that the concentric-eccentric phase transition is extremely fast (*i.e.* the isometric phase is negligible). During the concentric contraction phase, the kinetic energy is transmitted to the spinning cone (flywheel) through the extraction of the nylon cord wrapped around it. When the cord is completely extended, the stored energy causes the cone to continue its rotation through inertia, in turn rewinding of the cord. At this point the subject is required to perform an eccentric contraction (proportional to the effort exerted during the concentric phase) in order to break and stop the rotation of the cone, thereby completing the repetition. During APT phase 2 (as well as phase 3), the two initial exercises were proposed as controlled warm-up activity (Table II). The initial 3 repetitions of each of the subsequent exercises were performed by the subjects at a lower intensity because they were aimed at familiarizing with the isoinertial equipment. It is worth noting that eccentric exercise was reported to be effective as an "active stretching" intervention for tendon tissue.[38] In addition, isoinertial eccentric exercise was shown to be effective for increasing muscle mass and improving muscle function.[36, 37] At the beginning of each session, the PSFS was assessed for the non-sport specific activities. When the score of this test was ≥8, subjects advanced to phase 3.

During phase 2, subjects were also allowed to perform



Figure 5.—Isoinertial machine. The nylon cord (NC) is wrapped around the flywheel (FW) and secured at the athlete's ankle. A concentric contraction (CON) of the adductor muscles results in the initiation of FW rotation while unwinding the NC. Once the pushing CON phase has been completed, the NC rewinds because of the kinetic energy of the FW and pulls the lower limb toward the machine. Hence, the athlete is required to perform an eccentric contraction (proportional to the effort exerted during the concentric phase) in order to break and stop the rotation of the FW, thereby completing the repetition. After bringing the FW to a stop, a subsequent CON muscle contraction is instantly initiated.

up to two unsupervised training sessions per week, performing linear running, sprinting, twisting movements and jumping; during these sessions, the use of the ball was not allowed. The duration of the first unsupervised training sessions was 10 minutes; if no adverse events occurred, the subject was allowed to increase the duration of the subsequent session by 10 minutes. Duration increments were allowed in order to reach a maximum session length of 40 minutes. In addition, subjects were required to limit the exercise intensity during the unsupervised training sessions. In particular, the perceived exertion should have been lesser than 3/10 (moderate exertion) referring to the Borg CR-10 Scale, which is commonly used for rating the perceived exertion in male soccer players.[39]

Phase 3

The goal was to restore a level of physical performance sufficient for participating consistently in subsequent full training sessions as well as soccer matches. The endeavors started in phase 2 were continued, while increasing the sessions load. Each session lasted up to 40 minutes, and was performed twice a week. In order to achieve the goal of this phase and complete the APT program, preliminary observations carried out by our team suggested that the player was required to obtain

TABLE III.—*Baseline characteristics of the participants.*

	Group A	Group B	P value
Age (years) (mean±SD)	26.9±4.5	25.2±4.9	0.384
Stature (cm) (mean±SD)	176.3±7.9	180.7±7.8	0.164
Body mass (kg) (mean±SD)	74.5±8.3	73.4±5.7	0.816
Position			
Goalkeeper	1	1	
Defender	2	5	
Midfielder	3	4	
Striker	5	3	
Dominant foot			
Right	7	11	
Left	4	2	
Athletic activity/week			
<6 hours	1	2	
>6, <10 hours	7	7	
>10 hours	3	4	
Activity status			
Normal	5	6	
Restricted	3	3	
Suspended	3	4	
Duration of the symptoms			
0-4 weeks	5	6	
4-10 weeks	4	3	
10-26 weeks	2	3	
>26 weeks	0	1	
Groin pain			
First case	0	3	
Recurrent	11	10	
ALErGP laterality			
Right	7	7	
Left	1	2	
Bilateral	3	4	

ALErGP: *adductor longus* enthesopathy-related groin pain.

at least 80 points on the PSFS, assigning each of the sport specific and non-sport specific activities a score of ≥8. We did not set a "complete recovery" threshold (100/100) because this would have exponentially delayed the restart of individual soccer activities, conceivably impairing the compliance to the study protocol and increasing dropout.

During phase 3, subjects were allowed to perform two unsupervised soccer-specific training sessions per week, the maximal duration of which was set as 60 minutes. Similar to phase 2, the maximal duration of the first unsupervised training sessions was 20 minutes; if no adverse events occurred, subjects were allowed to increase the duration of the subsequent session by 20 minutes. Also, the perceived exertion of each session was required to be equal or lesser than 5/10 (hard exertion) referring to the Borg CR-10 Scale.[39] During these soccer-specific training sessions, subjects were allowed to perform passing and kicking as well as running, sprinting, twisting movements and jumping.

FOLLOW-UP

From the end of APT program to the end of the follow-up period (6 months), subjects were allowed to perform up to 3 soccer-specific training sessions (duration: 60 minutes) and one official game every week.

Statistical analysis

Data are reported as means±standard deviation (SD). The distribution of quantitative variables was tested for normality using the Kolmogorov-Smirnov Test with the Lilliefors correction to apply a parametric or non-parametric test for group comparison. Since the assumption of normality distribution for the investigated variables was not met, the differences between independent samples were analyzed using the non-parametric Mann-Whitney *U* test, and the differences between related samples were analyzed using the non-parametric Friedman Test and Kendall Coefficient of concordance. Alpha level for all of these analyses was set at $P<0.05$ (two-tail test). Data were analyzed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA).

Results

Characteristics of the participants

Group A and B presented similar characteristics at baseline. Age, stature and body mass were not significantly different between the two groups (Table III). Also, when the medical interview occurred, soccer-related activities were already restricted or suspended for 6 players (group A) and 7 players (group B). In addition, GP was recurrent in all group A subjects and in 10 out of 13 players enrolled in group B.

Pain and functional assessments

Both Groups significantly improved pain and functional scores after treatment ($P<0.001$, Table IV). Furthermore, NRSpalp, NRScontr, and PSFS values recorded after treatment were similar to those recorded throughout the follow-up in both groups ($P>0.05$).

TABLE IV.—*Numeric Rating Scale (NRS) and Patient Specific Functional Scale (PSFS) values registered at the end of treatment and during the follow-up (2, 4, and 6 months).*

		Pre	End	2 months	4 months	6 months	Time	Group	Time x group
NRSpalp	Group A	7.5±1.9 #	1.6±1.1	0.7±0.8 **	1.0±0.9 **	1.1±0.9	<0.001	0.010	0.457
	Group B	8.1±1.9 #	2.5±1.5	2.4±1.3	2.3±0.9	2.0±1.5			
NRScontr	Group A	8.5±1.4 #	1.3±0.9 *	1.3±1.1 *	0.7±0.7 *	0.5±0.7 *	<0.001	0.011	0.013
	Group B	8.0±1.6 #	2.2±1.7	2.8±1.6	2.2±1.4	1.6±1.3			
PSFS	Group A	55.5±22.2 #	91.6±3.8	93.7±3.6	93.8±4.2	95.4±4.1	<0.001	0.093	0.200
	Group B	56.7±20.6 #	87.5±5.6	81.5±10.8	86.3±7.5	89.9±6.8			

NRSpalp: Numeric Rating Scale: pain upon palpation of the insertion of the adductor longus. Scale: 0-10; lower score indicates better outcome.
NRScontr: Numeric Rating Scale: pain upon bilateral isometric adductor longus contraction against resistance. Scale: 0-10; lower score indicates better outcome.
PSFS: Patient Specific Functional Scale: 0-100; higher score indicates better outcome.
Time effects. Values recorded at Pre were significantly different (P<0.01) than those recorded at the other time points; *Significant differences between the two groups; *P<0.05; **P<0.01.

TABLE V.—*Active physical therapy program duration.*

	Group A	Group B	P value
Phase 1 (days)	11.9±4.7	20.7±9.3	0.048
Phase 2 (days)	14.8±4.8	16.0±4.2	0.948
Phase 3 (days)	11.0±3.8	12.7±3.3	0.512
Total duration (days)	37.9±8.5	48.8±9.4	0.098

When comparing the two groups, baseline values of NRSpalp and NRScontr were also similar between group A and B (P=0.442 and P=0.505, respectively; Table IV). However, at the end of the APT program, NRScontr was significantly lower in group A (0.9 points, P=0.047). Lower NRScontr values in group A were also recorded at the three follow-up time points (P<0.05). Furthermore, time x group interaction was also significant for this parameter (P=0.013, Table IV). NRSpalp showed a trend similar to NRScontr, with values that tended to be lower in group A than group B at the end of treatment and follow-up (Table IV); however, statistical significance was achieved only at the 2- and 4-month follow-up (P=0.003 and P=0.005, respectively).

On the other hand, no significant difference for PSFS between the two groups was found (P=0.093, Table IV). However, while the PSFS baseline value was very similar between group A and B (55.5±22.2 and 56.7±20.6, respectively), it tended to be greater in group A after treatment and throughout the follow-up by 7.8±3.8%.

It is also worth noting that the duration of Phase 1 was on average 8.8 days shorter in group A (P=0.048). The same trend, without statistical significance, was also shown by Phase 2, 3 and total duration (Table V).

Discussion

This study investigated the therapeutic utility of the EPI® technique in combination with a standardized APT program to treat ALErGP in non-professional soccer players. The assessment of pain- and functional-related outcomes in the experimental group (A), who underwent the APT program in combination with EPI® treatment, and in the control group (B), who underwent the APT program only, revealed that: 1) both groups significantly improved pain and functional scores after treatment and maintained this therapeutic result throughout the 6 months after treatment; 2) the combined intervention of APT program and EPI® ensured a greater and faster reduction of pain compared to the APT programme alone; 3) functional recovery was not significantly different between the two groups, although it tended to be greater in group A after the treatment and throughout the follow-up.

APT program with and without EPI® effectively reduced pain and improved functional recovery

High quality studies on non-surgical treatment of long-standing adductor-related GP are rather scanty.[40] For example, Hölmich *et al.*[19] showed that 79% of the patients with adductor-related GP that were treated with exercise therapy (static and dynamic exercises aimed to improve strength and coordination of the pelvic muscles) resumed their usual physical activity without symptoms. On the other hand, in the study conducted by Weir *et al.*,[24] the success rate of an active physiotherapy programme aimed at the strengthening of adduc-

tor and core muscles, associated to a return-to-running programme, decreased to 50%. The present study supports the view that an active physiotherapy programme that promotes significant eccentric muscle contraction of the AL via isoinertial eccentric training is conceivably a valuable intervention for long-lasting pain reduction and functional improvement. Indeed, both group A and B significantly improved pain and functional scores after the treatment. Generally, the time course of these improvements throughout the ATP program was related to the initial GP symptoms of each individual: the more severe the symptoms, the longer the duration phases. Also, pain and functional scores were similar at the end of the ATP program and throughout the subsequent 6-month follow-up.

The positive effects of active physiotherapy on adductor-related GP can be related to the connective tissue remodeling that occurs physiologically as a result of the mechanical stimulation exerted by the exercise.[38, 41] In particular, Apostolakos *et al.*[12] emphasized that biological factors are important for the proper modulation and regulation of collagen production, while mechanical stimuli are crucial for the proper collagen fibers orientation; thus, both factors are essential for the proper healing of the degenerated enthesis. For this reason, eccentric exercise represents one of the most considered therapeutic solutions in the treatment of collagen-rich tissues pathologies,[38, 41-43] and isoinertial eccentric training one of the effective methods to perform eccentric exercise.[27, 36, 37]

The integration of EPI® and APT interventions promoted greater and faster pain reduction compared to APT intervention alone

The pain-related clinical testing proposed in the present study showed substantial differences between group A and group B after the treatment and during the 6-month follow up. In particular, the scores of the active test form proposed in the present study (NRScontr) were significantly lower in group A than group B at the end of the treatment and for the entire duration of the follow-up. The "time x group" interaction was also significant for this parameter. In addition, NRSpalp values tended also to be lower in Group A after the treatment, and significantly lower at the 2-month and 4-month follow up. Interestingly, Mosler *et al.*[44] supported the view that NRScontr is better than NRSpalp for evaluating and quantifying GP in athletes.

The relevant effect of EPI® treatment integration with the APT intervention on GP was also underlined by the fact that the duration of phase I of the APT programme, which was focused on pain reduction, was significantly shorter (-8.8 days) in group A than in group B. These results support the view that the combination of EPI® and APT interventions was more effective than APT intervention alone for reducing AL enthesopathy-related symptoms. It is plausible that EPI® electrolytic action promoted the removal of excessive deposits of connective tissue (fibrosis), so decreasing the tendon tissue tension [28] and consequently reducing GP. It is worth noting that EPI® intervention initially induces a local and controlled inflammatory process that subsequently promotes the histological enthesis healing process,[28] the duration of which is reported to be longer than 14 days.[12] Hence, a proper protocol of active exercises should be proposed as a parallel intervention to the EPI® treatment in order to ensure that the new production of collagen (resulting from the inflammatory process) develops adequately from a biomechanical point of view.[40] With this respect, the association of EPI® intervention and isoinertial eccentric exercises has already produced encouraging results in the treatment of patellar tendinopathy, and in particular for the tendon tissue repair.[26, 27]

Effects of EPI® intervention on functional recovery

In the present study, functional recovery was evaluated by PSFS, which consisted of 10 motor tasks (see Methods) that did not require a selective, sustained and maximal AL muscle contraction. For example, maximal effort soccer kick requires a substantial level of AL activation during a limited part of the kicking swing phase (30% to 45%);[45] furthermore, AL activation is primarily aimed at controlling the hip extension rather than contributing substantially to hip flexion and to completing this complex motor task.[45] In addition, Delmore *et al.*[46] underlined that AL activation intensity recorded by EMG during twisting movements was about half of that observed during Adductor Squeeze Test. In the present study, the experimental group that underwent EPI® intervention and APT programme tended to achieve greater functional recovery after treatment and throughout the follow up (+7.8±3.8%) compared to the control

group that underwent APT programme only. However, this difference was not statistically significant. The fact that PSFS lacks in motor tasks that specifically and substantially involve AL activation is conceivably one of the main causes of this finding. The total duration of the treatment was also not significantly different between the two groups, although it tended to be shorter (-10.9 days) in group A. These data suggest that further studies are required to better assess the effectiveness of EPI® treatment on functional recovery in soccer players suffering from ALErGP. It is also worth noting that an intrinsic limit of the non-surgical treatments is that they reduce only to some extent the anatomical alterations of the enthesis. Therefore, while the functional recovery and symptoms reduction can be achieved by these non-surgical treatments, the connective tissue alteration often persists,[15] even in asymptomatic patients.[17] As a consequence, these residual anatomical alterations of the enthesis might result more likely in a premorbid condition. From this perspective, further studies should investigate whether the substantial reduction of the enthesis anatomical alteration brought about by EPI® intervention may eliminate or reduce such premorbid condition.

Limitations of the study

One of the limitations of this study is the lack of a graduation in the severity of the ultrasound imaging of the proximal tendon of the AL: we differentiated between "tendons with anatomical changes" and "healthy tendons". However, we hypothesize that a worse ultrasound image could potentially be associated with a lower expectation of therapeutic success, regardless of the intervention. In addition: 1) the EPI® intervention protocol lacks validation (the technique has recently been developed); 2) research participants were not blinded with respect to the treatment received; thus, placebo effect could have played a role in the subjective scoring, especially in the earlier stage of the study protocol. On the other hand, it is less likely that any eventual EPI®-related placebo effect could have lasted throughout the follow-up; 3) the copresence of GP secondary clinical patterns (*i.e. iliopsoas*-related GP, *rectus abdominis*-related GP) or comorbility (snapping *iliopsoas*, hip arthrosis, ilioinguinal nerve entrapment) could have potentially played the role of confounding variables. Finally, 5) the subjects of this study resumed independent soccer-related activities without supervision after the end of the treatment. So, different factors such as amount and characteristics of the physical activity performed by each individual could also have influenced the follow-up results.

Conclusions

EPI® treatment in association with active physiotherapy ensured a greater and more rapid reduction of pain and tended to promote greater functional recovery in soccer players with ALErGP compared to active physiotherapy only. This positive therapeutic result lasted for at least 6 months after the end of the treatment. This finding, together with the fact that EPI® treatment is minimally invasive and was overall well tolerated by the patients, support the combined use of EPI® and active physiotherapy in soccer players with GP syndrome. Further studies on the effects of EPI® treatment on functional recovery in ALErGP and on clinical conditions similar to ALErGP (*i.e. rectus abdominis* enthesopathy and tendinopathy, *gracilis* enthesopathy, degenerative pubic symphysis, *iliopsoas* syndrome, *rectus femoris* aphophysitis) are needed to gain more insight into the effectiveness of EPI® treatment on GP syndromes.

References

1. Falvey EC, Franklyn-Miller A, McCrory PR. The groin triangle: a patho-anatomical approach to the diagnosis of chronic groin pain in athletes. Br J Sports Med 2009;43:213-220. doi:10.1136/bjsm.2007.042259
2. Sheen AJ, Stephenson BM, Lloyd DM, Robinson P, Fevre P, Paajanen H, *et al.* Treatment of the Sportsman's groin: British Hernia Society's 2014 position statement based on the Manchester Consensus Conference. Br J Sports Med 2014;48:1079-87.
3. Werner J, Hägglund M, Waldén M, Ekstrand J. UEFA injury study:a prospective study of hip and groin injuries in professional football over seven consecutive seasons. Br J Sports Med 2009;43:1036-40.
4. Hägglund M, Walden M, Ekstrand J. Injury incidence and distribution in elite football - a prospective study of the Danish and the Swedish top divisions. Scand J Med Sci Sports 2005;15:21-8.
5. Bradshaw CJ, Bundy M, Falvey E. The diagnosis of longstanding groin pain:a prospective clinical cohort study. Br J Sports Med 2008;42:851-4.
6. Davies A, Clarke A, Gilmore J, Wotherspoon M, Connell DA. Review: imaging of groin pain in the athlete. Skeletal Radiol 2010;39:629-44.
7. LeBlanc KE, LeBlanc KA. Groin pain in athletes. Hernia 2003;7:68-71.
8. Robertson BA, Barker PJ, Fahrer M, Schache AG. The anatomy of the pubic region revisited. Implications for the pathogenesis and clinical management of chronic groin pain in athletes. Sports Med 2009;39:225-34.
9. Hölmich P. Long-standing groin pain in sportspeople falls into three primary patterns, a "clinical entity" approach:a prospective study of 207 patients. Br J Sports Med 2007;41:247-52.

10. Silvestri E, Muda A, Orlandi D. Adductor, gracilis and pectineus. In: Silvestri E, Muda A, Orlandi D, Maffulli N. Ultrasound anatomy of lower limb muscles: a practical guide. Milan: Spinger; 2015. p. 75-89.
11. Robinson P, Barron DA, Parsons W. Adductor-related groin pain in athletes:correlation of MR imaging with clinical findings. Skeletal Radiol 2004;33:451-7.
12. Apostolakos J, Durant T, Dwyer C, Russel R, Weinreb J, Alaee F, *et al.* The enthesis: a review of the tendon-to-bone insertion. Muscles Ligaments Tendons J 2014;4:333-42.
13. Bunker DLJ, Ille Vi, Ille Vl, Nicklin S. Tendon to bone healing and its implications for surgery. Muscles Ligaments Tendons J 2014;4:343-50.
14. Balconi G. US in pubalgia. J Ultrasound 2011;14:157-66.
15. Branci S, Thorborg K, Nielsen MB, Hölmich P. Radiological findings in symphyseal and adductor-related groin pain in athletes:a critical review of the literature. Br J Sports Med 2013;47:611-9.
16. Palisch A, Zoga A, Meyers W. Imaging of athletic pubalgia and core muscle injuries. Clinical and therapeutic correlations. Clin Sports Med 2013;32:427-47.
17. Silvis ML, Mosher TJ, Smetana BS, Chinchili VM, Flemming DJ, Walker EA, *et al.* High prevalence of Pelvic and Hip Magnetic Resonance Imaging Findings in Asymptomatic Coleegiate and Professional Hockey Players. Am J Sports Med 2011;39:715.
18. Kingston JA, Jegatheeswaran S, Macutkiewicz C, Campanelli G, Lloyd MD, Sheen AJ. A European survey on the aetiology, investigation and management of the "Sportsman's Groin". Hernia 2014;18:803-10.
19. Hölmich P, Uhrskou P, Ulnits L, Kanstrup I-L, Nielsen M, Bjerg A, Krogsgaard K. Effectiveness of active physical training as treatment for longstanding adductor-related groin pain in athletes: randomised trial. Lancet 1999;353:439-43.
20. Ellsworth A, Zoland M, Tyler T. Atletic pubalgia and associated rehabilitation. Int J Sports Phys Ther 2014;9:774-84.
21. Kachingwe AF, Grech S. Proposed algorithm for the management of athletes with athletic pubalgia (sports hernia): a case series. J Orthop Sports Phys Ther 2008;38:768-81.
22. Machotka Z, Kumar S, Perraton LG. A systematic review of the literature on the effectiveness of exercise therapy for groin pain in athletes. Sports Med Arthrosc Rehabil Ther Technol 2009;1:5.
23. Weir A, Jansen J, Van Keulen J, Mens J, Backx F, Stam H. Short and mid-term results of a comprehensive treatment program for longstanding adductor-related groin pain in athletes: A case series. Physical Therapy in Sport 2010;11:99-103.
24. Weir A, Jansen JA, van de Port IG, van de Sande HB, Tol JL, Backx FJ. Manual or exercise therapy for long-standing adductor-related groin pain:a randomized controlled clinical trial. Man Ther 2011;16:148-54.
25. Jansen JACG, Mens JMA, Backx FJG, Kolfschoten, Stam HJ. Treatment of longstanding groin pain in athletes:a systematic review. Scand J Med Sci Sports 2008:18:263-74.
26. Abat F, Gelber GP, Polidori F, Monllau JC, Sanchez-Ibañez JM. Clinical results after ultrasound-guided intratissue percutaneous electrolysis (EPI®) and eccentric exercise in the treatment of patellar tendinopathy. Knee Surg Sports Traumatol Arthrosc 2015;23:1046-52.
27. Abat F, Diesel W, Gelber P, Polidori F, Monllau JC, Sanchez-Ibañez JM. Effectiveness of the Intratissue Percutaneous Electrolysis (EPI®) technique and isoinertial eccentric exercise in the treatment of patellar tendinopathy at two years follow-up. Muscles Ligaments Tendons J 2014;4:188-93.
28. Sanchez-Ibañez JM, Colmena C, Benabent J, Garcia-Herreros S, Valles SL. New technique in tendon sport recovery. Percutaneous electrolysis intratissue (EPI®). Int J Phys Med Rehabil 2013;1:113.
29. Abat F, Valles SL, Gelber PE, Polidori F, Jorda A, Garcia-Herreros S, *et al.* An experimental study of muscular injury repair in a mouse model of notexin-induced lesion with EPI® technique. BMC Sports Sci Med Rehabil 2015;7:7.
30. Delahunt E, Thorborg K, Khan KM, Robinson P, Hölmich P, Weir A. Minimum reporting standards for clinical research on groin pain in athletes. Br J Sports Med 2015;49:775-81.
31. Hölmich P, Hölmich LR, Bjerg AM. Clinical examination of athletes with groin pain:an intraobserver and interobserver reliability study. Br J Sports Med 2004;38:446-51.
32. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain. Arthritis Care Res (Hoboken) 2011;63:S240-S252.
33. Hegedus EJ , Stern B, Reiman MP, Tarara D, Wright AA. A suggested model for physical examination and conservative treatment of athletic pubalgia. Phys Ther Sport 2013;14:3-16.
34. Loos MJA, Houterman S, Scheltinga MRM, Roumen RMH. Evaluating postherniorrhaphy groin pain:Visual Analogue or Verbal Rating Scale? Hernia 2008;12:147-51.
35. Horn KK, Jennings S, Richardson G, Van Vliet D, Hefford C, Abbott JH. The patient-specific functional scale: psychometrics, clinimetrics, and application as a clinical outcome measure. J Orthop Sports Phys Ther 2012;42:30-40.
36. Norrbrand L, Fluckey JD, Pozzo M, Tesch PA. Resistance training using eccentric overload induces early adaptations in skeletal muscle size. Eur J Appl Physiol 2008;102:271-81.
37. Lundberg TR, Fernandez-Gonzalo R, Gustafsson T, Tesch PA. Aerobic exercise does not compromise muscle hypertrophy response to short-term resistance training. J Appl Physiol 2012;114:81-9.
38. Rees JD, Wolman RL, Wilson A. Eccentric exercises; why do they work, what are the problems and how can we improve them? Br J Sports Med 2009;43:242-6.
39. Jeong TS, Reilly T, Morton J, Bae SW, Drust B. Quantification of the physiological loading of one week "pre-season" and one week of "in-season" training in professional soccer players. J Sports Sci 2011;29:1161-6.
40. Serner A, van Eijck CH, Beumer BR, Hölmich P, Weir A, de Vos RJ. Study quality on groin injury management remains low:a systematic review on treatment of groin pain in athletes. Br J Sports Med 2015;49:813.
41. Kjaer M, Langberg H, Heinemeier K, Bayer ML, Hansen M, Holm L, *et al.* From functional loading to collagen synthesis, structural changes and function in human tendon. Scand J Med Sci Sports 2009:19:500-10.
42. Woodley BL, Newsham-West RJ, Baxter GD. Chronic tendinopathy:effectiveness of eccentric exercise. Br J Sports Med 2007;41:188-99.
43. Frizziero A, Trainito S, Oliva F, Nicoli Aldini N, Masiero S, Maffulli N. The role of eccentric exercise in sport injuries rehabilitation. Br Med Bull 2014;110:47-75.
44. Mosler AB, Agricola R, Weir A, Hölmich P. Which factors differentiate athletes with hip/groin pain from those without? A systematic review with meta-analysis. Br J Sports Med 2015;49:810.
45. Charnock BL, Lewis CL, Garrett JR WE, Queen RM. Adductor Longus mechanics during the maximal effort soccer kick. Sports Biomech 2009;8:223-34.
46. Delmore RJ, Laudner KG, Torry MR. Adductor longus activation during common hip exercises. J Sports Rehabil 2014;23:79-87.

Conflicts of interest.—The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Article first published online: January 23, 2017. - Manuscript accepted: October 7, 2016. - Manuscript revised: August 30, 2016. - Manuscript received: February 5, 2016.

Treatment of proximal hamstring tendinopathy-related sciatic nerve entrapment: presentation of an ultrasound-guided "Intratissue Percutaneous Electrolysis" application

Gabriele Mattiussi
Carlos Moreno

Udinese Calcio Spa, Udine, Italy

Corresponding author:
Carlos Moreno
Udinese Calcio Spa
Viale A. e A. Candolini, 2
33100 Udine, Italy
E-mail: carlos.moreno@udinesespa.it

Summary

Background: **Proximal Hamstring Tendinopathy-related Sciatic Nerve Entrapment (PHTrSNE) is a neuropathy caused by fibrosis interposed between the semimembranosus tendon and the sciatic nerve, at the level of the ischial tuberosity.**
Methods: **Ultrasound-guided Intratissue Percutaneous Electrolysis (US-guided EPI) involves galvanic current transfer within the treatment target tissue (fibrosis) via a needle 0.30 to 0.33 mm in diameter. The galvanic current in a saline solution instantly develops the chemical process of electrolysis, which in turn induces electrochemical ablation of fibrosis. In this article, the interventional procedure is presented in detail, and both the strengths and limits of the technique are discussed.**
Results: **US-guided EPI eliminates the fibrotic accumulation that causes PHTrSNE, without the semimembranosus tendon or the sciatic nerve being directly involved during the procedure. The technique is however of limited use in cases of compression neuropathy.**
Conclusion: **US-guided EPI is a technique that is quick to perform, minimally invasive and does not force the patient to suspend their activities (work or sports) to make the treatment effective. This, coupled to the fact that the technique is generally well-tolerated by patients, supports use of US-guided EPI in the treatment of PHTrSNE.**

KEY WORDS: ablation techniques, entrapment neuropathies, tendon injuries, ultrasonography.

Introduction

Proximal hamstring tendinopathy (PHT) is an overuse injury of current interest in orthopaedic and sports medicine. PHT is clinically characterised by pain in the subgluteal region, at the proximal insertion of the hamstring muscles onto the ischial tuberosity, with possible radiation to the posterior region of the thigh; sprinting and sitting for long periods are the activities in which the symptoms are typically exacerbated[1, 2]. The proximal insertion of the semimembranosus (SM) muscle onto the ischial tuberosity is superior-lateral, relative to the insertion of the conjoint tendon of the biceps femoris and semintendinosus.[1,3-5]. In patients with PHT, the proximal SM tendon is the one that is typically degenerated, appearing thickened at the lateral edge[1].
In addition to this, the SM tendon is located in the vicinity of the Sciatic Nerve (SN)[6, 7] which runs just lateral to the tendon (Fig. 1). In patients with PHT, fibrotic adhesions between the SM tendon and the SN occasionally form[1,3,6,8]; this anatomical alteration can cause entrapment syndrome of the SN, overlapping symptoms of tendinopathy, and those typical of an irritation of the nerve (sudden stabbing pain, sciatica, burning sensation or other paraesthesias). Proximal Hamstring Tendinopathy-related Sciatic Nerve Entrapment (PHTrSNE) therefore represents a possible complication of PHT. Rapid movements of hip flexion and extension or maximum hip flexion can worsen



Figure 1. Transversal ultrasound section of the proximal semimembranosus tendon (*asterisked*) on the ischial tuberosity (IT). The sciatic nerve (indicated by the *arrow*) is easily recognizable lateral to the tendon. GM=gluteus maximus. Q=quadratus femoris.

the symptoms, being the SN bound to the hamstring tendon complex (anchoring fibrosis)[1,3,6,8]. However, distinguishing symptoms of tendinopathy from those of neuropathy is fairly complicated.

Conservative treatment and infiltrative therapies for the treatment of PHT are generally preferred to surgery, which is considered when these do not lead to satisfactory results. Potentially applicable treatments are numerous: shockwaves, injections of PRP or corticosteroids, eccentric exercises and others (review[2]). In addition to the dearth of scientific evidence about their effectiveness, the limitation of these therapies is that they are unspecific and most likely ineffective for the treatment of PHTrSNE, in case the latter has been detected and taken into consideration. One scenario that can occur is that symptoms related to tendinopathy recede, while those derived from irritation of the SN persist.

Surgical treatment for managing PHT involves tenotomy of the SM tendon, which is sutured to the tendon of the biceps femoris[1-2]. The positive outcome of SM tenotomy is that the SN is anatomically unbridled from the tendon; the intervention is therefore also valid for the treatment of PHTrSNE. The only significant disadvantage of the intervention is the long post-surgical recovery time (from 1 to 12 months)[2,9]; this point certainly has a significant impact, especially for professional athletes, who may decide to postpone excessively or not to undergo surgery at all.

Finding a technique that can eliminate fibrosis between the SM tendon and the SN without requiring long periods of post-interventional recovery is therefore challenging. Ultrasound-guided Intratissue Percutaneous Electrolysis fulfils these requirements. The aims of this article are: i) to present the rationale for using this technique in the treatment of PHTrSNE; ii) to present the method of application and iii) to discuss both the strengths and limitations of the technique. The hypothesis of the Authors is that Ultrasound-guided Intratissue Percutaneous Electrolysis may be a useful complement to non-surgical proposals in the treatment of PHT with concomitant PHTrSNE.

Materials and methods

This study was conducted in accordance with the Declaration of Helsinki and complied with the ethical standards of the Muscles, Ligaments and Tendons Journal[10].

Ultrasound-guided Intratissue Percutaneous Electrolysis

Intratissue Percutaneous Electrolysis (also known as Electrólisis Percutánea Intratisular or EPI) is a minimally invasive technique that involves galvanic current transfer within the treatment target tissue via a needle 0.30 to 0.33 mm in diameter. The galvanic current in a saline solution rapidly develops the chemical process of electrolysis, which in turn induces tissue ablation[11]. The EPI technique finds indications in the treatment of tendinopathies and fibrosis[12-16].



Figure 2. Proximal hamstring tendinopathy-related sciatic nerve entrapment. Between the sciatic nerve (indicated by *arrow*) and the tendon of the semimembranosus (*SM*) a fibrotic accumulation is interposed (hyper-echoic area visible within the *dashed box*) which makes it difficult to distinguish the anatomical limits of the structures. IT=ischial tuberosity.

The rationale for using EPI in the treatment of PHTrSNE is the ability of the technique to specifically degrade fibrotic adhesions that bind the SN and SM tendon. Use of the technique is indicated only when le evident ultrasound signs of fibrosis between the SN and SM tendon are identifiable (Fig. 2) concomitant to the presence of the clinical pattern of PHTrSNE. Clinical assessment is needed, but is not sufficient to diagnose PHTrSNE, as the SN can be trapped in many other areas in the sub-gluteal region[6].

We apply the EPI technique using a specifically developed and medically certified (Directive 93/42/EEC) device (EPI Advanced Medicine® Barcelona, Spain). The main feature of the device is that the cathodic flow is the only one usable. To ensure maximum precision, the technique must be performed in an ultrasound-guided manner (US-guided EPI). We use the GE Healthcare Logiq S7 Expert® ultrasound with a linear probe (6-15 MHz) to guide the insertion of the needle. The operator must be well-trained in the use of the technique, and must have experience in the ultrasound examination of the lower limb.

Procedure for the US-guided EPI intervention

The patient lies in a prone position. The gluteal, subgluteal and trochanteric regions are disinfected by applying an appropriate protocol. The proximal tendon insertions of the hamstring muscles on the ischial tuberosity are identified by the operator guiding the ultrasound probe using their non-dominant hand; a transversal section is required to be able to simultaneously view the tendon complex and the SN[7].

The needle is inserted by the operator with the dominant hand between the two structures through the gluteus maximus muscle, with an inclination of 0+30° around the vertical axis, in the medial-lateral direction



Figure 3. Ultrasound-guided insertion of the needle. Being the needle inserted perpendicular to the skin, it is displayed through movement of surrounding tissues.



Figure 4. Schematic diagram of the Ultrasound-guided Intratissue Percutaneous Electrolysis intervention. The medial edge of the sciatic nerve and associated vessels is represented by *the vertical dashed line A*. The lateral limit of the semimembranosus tendon is represented by *the vertical dashed line B*. The needle is inserted into the area bounded by *line 1* (perpendicular to the axis joining lines A and B) and by *line 2* (tangent to the superior-lateral point of the semimembranosus tendon). In this way, the technique can be performed safely, without structures other than the fibrosis being involved in the intervention.

(Figs. 3, 4); the SN, the SM tendon, the inferior gluteal artery and the inferior gluteal vein must be avoided during insertion. Depending on the physical characteristics of the patient, the needle can have a variable length, starting at 50 millimetres.

When the needle tip is positioned inside the fibrosis, the galvanic current can be transferred; the intensity of the current is pre-set to 4 mA. The single application can have a variable duration between 2-10 seconds, depending on the tolerability of the technique to the patient (later) and the mechanical resistance offered by the tissue: where it is possible to penetrate the fibrosis with the needle by applying minimum pressure, the single application can be interrupted. At this point the needle is partially withdrawn (without exiting from the skin) and inserted again with a slight deviation to treat a different portion of the fibrotic accumulation.

One session can consist of 2-15 individual applications depending on the extent and hardness of the fibrosis. Consequently, administration of the galvanic current does not exceed 150 seconds in any one session; this should be taken into consideration as local anaesthetic drugs are not used. The session, including disinfection and dressing processes, lasts a maximum of 20 minutes in total.

Tolerability of pain

US-guided EPI is generally well-tolerated by patients. Some may have minor discomfort during the insertion of the needle. Application of the technique can cause mild to moderately strong pain. In addition to this, it is possible that the posterior femoris cutaneous nerve will be indirectly stimulated, causing tingling in the back of the thigh. Vagal reactions (nausea, headache, fainting) are rare but possible[17]; in this sense it is advisable to remind the patient before each session that he or she can ask for the session to be interrupted or stopped at any time. Bleeding in the area of needle insertion may occasionally occur. Patients sometimes report mild tenderness in the treated area, which generally does not last longer than 12-48 hours. The Authors do not advise conducting more than one session per week.

Discussion

The aims of this article are: i) to present the rationale for using US-guided EPI in the treatment of PH-TrSNE; ii) to present the method of application and iii) to discuss both the strengths and limitations of the technique. The hypothesis of the Authors is that Ultrasound-guided EPI may be an useful complement to conservative proposals when treating PHT with concomitant PHTrSNE. By using the US-guided EPI technique it is possible to eliminate the fibrosis interposed between the SN and SM tendon, degrading it by electrolytic ablation, without expecting the patient to suspend sporting or work activities for more than 48 hours after the intervention.

Strengths and limitations of the technique

US-guided EPI is a technique that allows specific treatment of the fibrotic adhesions that cause PH-TrSNE. The minimal invasivity and lack of necessity of suspending activities (work or sports) after treatment are the main strengths of this technique. The main limitation of the technique is the impossibility of completely resolving the symptoms if nerve irritation is caused by SN compression and not by its entrapment by the SM tendon.

EPI is an ultrasound-guided minimally invasive technique in which the needle is inserted with maximum precision into the structure to be treated, with minimal structural damage to any of the other tissues. In this way, one can eliminate a biomechanical cause of neuropathic symptoms, or the fibrosis that binds the SN to the SM tendon, without the nerve and the tendon being directly involved in the intervention. A further advantage of the mini-invasivity is the low chance of experiencing adverse events (in particular damage of the peri-nervous blood vessels).

One point that is certainly an advantage is that the patient does not need to undergo a specific rehabilitative intervention post US-guided EPI to render the treatment effective; this is particularly important for athletes suffering from PHTrSNE who will be required to suspend activities for 24-48 hours at most. US-guided EPI intervention does not therefore have a significant impact on the scheduling of sporting activities for an athlete.

The main limitation of the technique depends upon the type of anatomical alteration that has caused the neuropathy. In this article, SN entrapment neuropathy has been presented. It is however possible that the neuropathy is not derived from SN entrapment, but from compression of the nerve due to SM tendon hypertrophy[1,3]. The two conditions can be concomitant. Using the US-guided EPI intervention, it is not possible to reduce SM tendon hypertrophy in a consistent way; furthermore, on debriding the SN, it is possible that symptoms will persist because of compressive trauma suffered by the nerve. In such case, surgery remains the only therapeutic solution that can be considered.

Another possible scenario is the one in which the symptomatology persists due to irritation of the nerve at another location despite resolution of the PH-TrSNE. The anatomy of the sub-gluteal region is in fact highly complex and many different conditions (e.g. piriformis syndrome, gemelli-obturator internus syndrome, quadratus femoris pathology and gluteal disorders) provoking sciatica fall within differential diagnosis[1,6]. As a consequence of this, identification of the primary etiological cause determining the symptoms can be challenging. Instrumental investigations have an important role in detecting anatomical alterations[1]; to date, Magnetic Resonance Imaging (MRI) is typically the procedure of choice[1-3,6,9,18], especially when lower back pain is concomitant (the exam is useful to exclude other pathologies). However, MRI findings can be not associated with symptoms. Medical history and clinical examination[1, 2] can be helpful but, considering that different conditions present similar symptoms, only few tests have shown to have good sensibility and specificity in the diagnosis of SN entrapment[6,19]. For all these reasons, PHTrSNE remains fundamentally a diagnosis of exclusion.

Consequently, in order to evaluate the benefit of the US-guided EPI technique in the treatment of PH-TrSNE, the operator shall continuously monitor the evolution of the symptoms related to the disease. The Visual Analogic Scale (VAS)[9,18] and the Victorian Institute of Sport Assessment-Proximal Hamstring Tendons (VISA-H) questionnaire[20] are useful for this purpose. In particular, VISA-H has proven to have high degree of internal consistency and high test-retest reliability[20].

Ultrasound-guided EPI in the treatment of tendinopathies

US-guided EPI finds indications in the treatment of tendinopathies and fibrosis. To date however, few studies have tested the effectiveness of the technique. The therapeutic utility of EPI (by some Authors replaced with the acronym PNE, Percutaneous Needle Electrolysis) was tested for the treatment of patellar tendinopathy[12,13], sub-acromial syndrome[14], chronic lateral epicondylitis[15] and rectus abdominis-related groin pain[16]. The clinical results presented in this work are somewhat in conflict, especially given the different methodological choices of the Authors, in particular relative to the intensity and duration of administration of the galvanic current (which varied from 0.3 mA for 1.2 minutes to 3 mA for a few seconds) and suggested physiotherapy administered in combination with the technique.

The desired effects with the US-guided EPI are, on the one hand, elimination of the degenerated portion of the tendon and, on the other, development of an extremely localized and controlled inflammatory process, that may promote the tendon healing process. The histological effects of administering galvanic current within the tendon tissue are, however, only partially understood[11,21-24]. The method of applying the US-guided EPI technique presented in this article however differs to the one described in the arti-

cles listed above. In those articles, the technique is performed by inserting the needle within the degenerated portion of the tendon; the tendon is therefore the target of the therapy. In this work, the purpose was the electrolytic elimination of peri-tendinous fibrotic tissue, without treating the tendon. The ablative action is therefore the only one that has been fundamentally investigated. This also means there is no need to propose a specific rehabilitation protocol after the intervention.

Conclusions

US-guided EPI is a technique that allows specific treatment of the anatomical alterations that cause PHTrSNE, eliminating the fibrosis that binds the SN to the SM tendon. US-guided EPI is a technique that is quick to carry out, minimally invasive and does not force the patient to suspend their activities (work or sporting) to make the treatment effective. This, coupled to the fact that the technique is generally well-tolerated by patients, supports use of US-guided EPI in the treatment of PHTrSNE. Future studies with high quality designs are needed to test the efficacy of US-guided EPI in the treatment of PHTrSNE.

Conflicts of interest

The Authors declare no conflicts of interest concerning this article.

References

1. Lempainen L, Sarimo J, Mattila K, Vaittinen S, Orava S. Proximal Hamstring Tendinopathy. Am J Sports Med. 2009; 37:727.
2. Lempainen L, Johansson K, Banke IJ, et al. Expert opinion: diagnosis and treatment of proximal hamstring tendinopathy. Muscles Ligaments Tendons J. 2015;5(1):23-28.
3. Beltran L, Ghazikhanian V, Padron M, Beltran J. The proximal hamstring muscle-tendon-bone unit: A review of the normal anatomy, biomechanics and pathophysiology. Eur J Radiol. 2012;81:3772-3779.
4. Obey MR, Broski SM, Spinner RJ, Collins MS, Krych AJ. Anatomy of the Adductor Magnus Origin. Implication for Proximal Hamstring Injuries. Orthop J Sports Med. 2016;4(1):1-6.
5. Feucht MJ, Plath JE, Seppel G, Hinterwimmer S, Imhoff AB, Brucker PU. Gross anatomical and dimensional characteristics of the proximal hamstring origin. Knee Surg Sports Traumatol Arthrosc. 2015;23:2576-2582.
6. Hernando MF, Cerezal L, Perez-Carro L, Abascal F, Canga A. Deep gluteal syndrome: anatomy, imaging, and management of sciatic nerve entrapments in the subgluteal space. Skeletal Radiol. 2015;44:919-934.
7. Silvestri E, Muda A, Orlandi D. Hamstrings. In: Ultrasound Anatomy of Lower Limb Muscles. A practical Guide. Foreword by Nicola Maffulli. Springer International Publishing Switzerland. 2015;101-113.
8. McGregor C, Ghosh S, Young DA, Maffulli N. Traumatic and overuse injuries of the ischial origin of the hamstrings. Disabil Rehabil. 2008;30(20-22):1597-1601.
9. Benazzo F, Marullo M, Zanon G, Indino C, Pelillo F. Surgical management of chronic proximal hamstring tendinopathy in athletes: a 2 to 11 years of follow-up. J Orthopaed Traumatol. 2013;14:83-89.
10. Padulo J, Oliva F, Frizziero A, Maffulli N. Muscles, Ligaments and Tendons Journal. Basic principles and recommendations in clinical and field science research: 2016 update. MLTJ. 2016;6(1):1-5.
11. Sanchez-Ibañez JM, Colmena C, Benabent J, Garcia-Herreros S, Valles SL. New Technique in Tendon Sport Recovery. Percutaneous Electrolysis Intratissue (EPI®). Int J Phys Med Rehabil. 2013;1(2):1000113.
12. Abat F, Gelber PE, Polidori F, Monllau JC, Sanchez-Ibañez JM. Clinical results after ultrasound-guided intratissue percutaneous electrolysis (EPI®) and eccentric exercise in the treatmentof patellar tendinopathy. Knee Surg Sports Traumatol Arthrosc. 2014.
13. Abat F, Diesel WJ, Gelber PE, Polidori F, Monllau JC, Sanchez-Ibañez JM. Effectiveness of the Intratissue Percutaneous Electrolysis (EPI®) technique and isoinertial eccentric exercise in the treatment of patellar tendinopathy at two years follow-up. Muscles Ligaments Tendons J. 2014;4(2):188-193.
14. Arias-Buria JL, Truyols-Dominguez S, Valero-Alcaide R, Salom-Moreno J, Atin-Arratibel MA, Fernandes de-las-Peñas C. Ultrasound-Guided Percutaneous Electrolysis and Eccentric Exercises for Subacromial Pain Syndrome: A Randomized Clinical Trial. Evid Based Complement Alternat Med. 2015: 315219.
15. Valera-Garrido F, Minaya-Muñoz F, Medina-Mirapeix F. Ultrasound-guided percutaneous needle electrolysis in chronic lateral epicondylitis: short-term and long-term results. Acupunct Med. 2014;32:446-454.
16. Moreno C, Mattiussi G, Nuñez FJ. Therapeutic results after ultrasound-guided Intratissue Percutaneous Electrolysis (EPI®) in the treatment of rectus abdominis-related groin pain in professional footballers: a pilot study. J Sport Med Phys Fitness. 2016.
17. de la Cruz Torres B, Albornoz Cabello M, Garcia Bermejo P, Naranjo Orellana J. Autonomic responses to ultrasound-guided percutaneous needle electrolysis of the patellar tendon in healthy male footballers. Acupunct Med. 2016.
18. Fader RR, Mitchell JJ, Traub S, et al. Platelet-rich plasma treatment improves outcomes for chronic proximal hamstring injuries in an athletic population. Muscles Ligaments Tendons J. 2015;4(4):461-466.
19. Martin HD, Kivlan BR, Palmer IJ, Martin RL. Diagnostic accuracy of clinical tests for sciatic nerve entrapment in the gluteal region. Knee Surg Sports Traumatol Arthrosc. 2014;22(4):882-888.
20. Cacchio A, De Paulis F, Maffulli N. Development and validation of a new visa questionnaire (VISA-H) for patients with proximal hamstring tendinopathy. Br J Sports Med. 2014;48 (6):448-452.
21. Abat F, Valles SL, Monllau JC, Sanchez-Ibañez JM. Molecular repair mechanisms using the Intratissue Percutaneous Electrolysis technique in patellar tendonitis. Rev Esp Cir Ortop Traumatol. 2014;58(4):201-205.
22. Almeida Mdos S, Oliveira LP, Vieira CP, Guerra Fda R, Pimentel ER. Birefringence of collagen fibres in rat calcaneal tendons treated with acupuncture during three phases of healing. Acupunct Med. 2016;34(1):27-32.
23. Inoue M, Nakajima M, Oi Y, Hojo T, Itoi M, Kitakoji H. The effect of electroacupuncture on tendon repair in a rat Achilles tendon rupture model. Acupunct Med. 2015;33(1):58-64.
24. de Almeida Mdos S, de Aro AA, Guerra Fda R, Vieira CP, de Campos Vidal B, Rosa Pimentel E. Electroacupuncture increases the concentration and organization of collagen in a tendon healing model in rats. Connect Tissue Res. 2012;53 (6):542-547.

Journal of
Clinical Medicine

MDPI

Article

Changes in Gene Expression Associated with Collagen Regeneration and Remodeling of Extracellular Matrix after Percutaneous Electrolysis on Collagenase-Induced Achilles Tendinopathy in an Experimental Animal Model: A Pilot Study

José Luis Sánchez-Sánchez [1], Laura Calderón-Díez [1,2], Javier Herrero-Turrión [3,4], Roberto Méndez-Sánchez [1], José L. Arias-Buría [5,6] and César Fernández-de-las-Peñas [5,6,*]

[1] Department of Physical Therapy, Universidad de Salamanca, 37007 Salamanca, Spain; jlsanchez@usal.es (J.L.S.-S.); lauca@usal.es (L.C.-D.); ro_mendez@usal.es (R.M.-S.)
[2] Physical Therapy Department, Mutua Accidentes Laborales, FREMAP, 37007 Salamanca, Spain
[3] Instituto de Neurociencias de Castilla y León, Universidad de Salamanca, 37007 Salamanca, Spain; mjaviht@usal.es
[4] Instituto Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, 37007 Salamanca, Spain
[5] Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos (URJC), Alcorcón, 28922 Madrid, Spain; joseluis.arias@urjc.es
[6] Cátedra Institucional en Docencia, Clínica e Investigación en Fisioterapia: Terapia Manual, Punción Seca y Ejercicio Terapéutico, Universidad Rey Juan Carlos, Alcorcón, 28922 Madrid, Spain
* Correspondence: cesar.fernandez@urjc.es; Tel.: +34-91-488-88-84

Received: 29 July 2020; Accepted: 12 October; Published: 16 October 2020

Abstract: Percutaneous electrolysis is an emerging intervention proposed for the management of tendinopathies. Tendon pathology is characterized by a significant cell response to injury and gene expression. No study investigating changes in expression of those genes associated with collagen regeneration and remodeling of extracellular matrix has been conducted. The aim of this pilot study was to investigate gene expression changes after the application of percutaneous electrolysis on experimentally induced Achilles tendinopathy with collagenase injection in an animal model. Fifteen Sprague Dawley male rats were randomly divided into three different groups (no treatment vs. percutaneous electrolysis vs. needling). Achilles tendinopathy was experimentally induced with a single bolus of collagenase injection. Interventions consisted of 3 sessions (one per week) of percutaneous electrolysis or just needling. The rats were euthanized, and molecular expression of genes involved in tendon repair and remodeling, e.g., *Cox2, Mmp2, Mmp9, Col1a1, Col3a1, Vegf and Scx*, was examined at 28 days after injury. Histological tissue changes were determined with hematoxylin–eosin and safranin O analyses. The images of hematoxylin–eosin and Safranin O tissue images revealed that collagenase injection induced histological changes compatible with a tendinopathy. No further histological changes were observed after the application of percutaneous electrolysis or needling. A significant increase in molecular expression of *Cox2*, *Mmp9 and Vegf* genes was observed in Achilles tendons treated with percutaneous electrolysis to a greater extent than after just needling. The expression of *Mmp2, Col1a1, Col3a1, or Scx* genes also increased, but did not reach statistical significance. This animal study demonstrated that percutaneous electrolysis applied on an experimentally induced Achilles tendinopathy model could increase the expression of some genes associated with collagen regeneration and remodeling of extracellular matrix. The observed gene overexpression was higher with percutaneous electrolysis than with just needling.

Keywords: Achilles; percutaneous electrolysis; tendinopathy; gene expression

1. Introduction

The prevalence of lower extremity injuries is extremely common in sport players but also in the general population [2]. Among injuries within the lower extremity, Achilles tendinopathy is highly prevalent and affects approximately 9% of recreational runners, 5% of professional athletes, and 5.6% of the sedentary population [3]. Tendinopathy can occur in tendons that receive excessive loads and can result in considerable pain and related-disability.

Cook et al. proposed a continuum model for human tendinopathy with three progressive and continuous potential stages: 1) initial reactive stage characterized by a noninflammatory proliferative tissue reaction with minimal collagen damage; 2) a second disrepair stage characterized by a greater tissue collagen disruption/tearing due to a failed attempt of the tendon to properly heal; in this stage proliferation of abnormal tenocytes and neovascularization can be present; 3) a degenerative stage characterized by further disruption of collagen, cell response, and the presence of neovascularization [4]. These authors emphasized the relevance of associating structural tendon changes with the clinical presentation of the patient due to the complexity in this association (or lack of). In fact, they proposed the tendinopathy as a hybrid reactive and degenerative pathology [4].

Based on current evidence, the pathophysiology of tendinopathy is not yet completely understood, different and multifactorial theories are plausible [5]. The first mechanism includes the presence of collagen degradation, disorganization and fragmentation of the cellular matrix, and increase of proteoglycan content [6]. The presence of neovascularization with the appearance and organization of a new non-functional vascular/neural network has also been proposed as a second theory [7]. These hypotheses have been confirmed by several experimental animal studies showing histopathological changes including proteoglycan accumulation, collagen fiber disorganization, increased blood vessel infiltration, increased cellularity, and cellular rounding in injured tendons [8,9]. In addition to histological changes, it has been observed that increases in gene expressions of proteoglycans, and disturbances in expression of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) exist in pathological and healing tendons [10,11]. Current evidence supports that, regardless of the initiating event or the phase of the process, tendon pathology is characterized by a significant cell response to injury [4].

A better understanding of molecular changes accounting for tendinopathies could improve their management. In fact, the continuum model suggests that management may be optimized by tailoring therapeutic interventions to the stage of pathology and targeting the primary driver (cell activation) and inter-related alterations in tendon matrix integrity [4]. Currently, a wide range of interventions, i.e., extracorporeal shockwave therapy [12], injections [13], platelet-rich plasma [14], or exercises [15] have been proposed for the treatment of tendinopathies. These interventions can influence tendon biology by promoting its regeneration, but they are not able to influence the inflammatory process. An emerging strategy, i.e., percutaneous electrolysis, has been proposed for the management of tendinopathies [16]. Percutaneous electrolysis consists of the application of a continuous (galvanic) electrical current through a filament needle in a targeted tissue, usually tendon or muscle. There is preliminary evidence suggesting that application of percutaneous electrolysis is effective for patellar [17], plantar [18], elbow [19], or supraspinatus [20,21] tendinopathies; although more clinical trials are needed.

It is proposed that percutaneous electrolysis combines two physiological effects, a mechanical effect resulting from the needle insertion and a biological effect associated with the galvanic electrical current [16]. By inducing a non-thermal electrolytic reaction in the tendon, percutaneous electrolysis could potentially lead to a controlled inflammatory response, which may facilitate an organic reaction ultimately leading to the regeneration of the injured and healed tendon [16]. These hypotheses have been confirmed by recent studies. There is evidence suggesting that percutaneous electrolysis is able to induce an acute inflammatory reaction, mainly characterized by the presence of polymorphonuclear neutrophils and macrophages, in both healthy tendon [22] and collagenase-

induced tendinopathy [23] in animals. The inflammatory response was most remarkable 7 and 14 days after the intervention [22,23]. Similarly, percutaneous electrolysis has been also able to induce an immediate and transitory vasodilation effect when applied to healthy animal tendons, which could facilitate the arrival of pro-inflammatory cells (essential for the regeneration of a healed tendon) and the drainage of nociceptive substances [24]. Although it seems that percutaneous electrolysis is able to promote an inflammatory response, the underlying mechanisms of this process are not yet known. In fact, a recent study found that changes in pH after the application of percutaneous electrolysis were relatively small and could not fully explain the neurophysiological and clinical effects of this intervention [25].

No previous study has investigated changes in expression of genes associated with collagen regeneration and remodeling of extracellular matrix in an experimentally injured tendon model after the application of percutaneous electrolysis. The use of animal models assists in understanding tendinopathies because they allow for the study of each progressive stage of the process in a controlled and reproducible environment. In the current animal pilot study, we used an experimentally induced tendinopathy model with a single collagenase injection in the Achilles tendon of rats to investigate gene expression changes after the application of percutaneous electrolysis. We hypothesized that the application of percutaneous electrolysis will be able to promote the healing process of an injured tendon by increasing the gene expression when compared with no intervention.

2. Methods

2.1. Experimental Design

This animal study was conducted at the Institute of Neurosciences of Castilla y Leon (University of Salamanca), and fulfilled the ethical requirements of and was approved by the Bioethics Committee of this institution (201899900014183). Procedures were conducted according to the European (Directive 2010/63/EU) and Spanish legislation (Royal Decree 53/2013; BOE 34/11370-421,2013) on experimental animal studies. All environmental conditions such as light or temperature during the experiment followed the regulations contained in Royal Decree 1201/2005. The study was designed to minimize the number of sacrificed rats.

Fifteen (n = 15) Sprague-Dawley male rats, aged 8 weeks, weighing approximately 250 g, were used. Rats were randomly divided into different groups according to the nature of the tissue (healthy vs. injured based on whether a tendinopathy was or not induced) or treatment applied (no treatment vs. percutaneous electrolysis vs. needling). The first groups (C, T1) were used to determine if changes induced by the collagenase injection were compatible with those observed in tendinopathies. The remaining groups were used for comparing the application of percutaneous electrolysis (T2 + PE) or control needling (T2 + N) versus no treatment (T2). Table 1 shows the distribution of the rats on the different groups.

Table 1. Random Distribution of Rats with Experiment Procedures by Group.

Group Number	Group	Number of Rats	Collagenase Injection	Day Collagenase Injection	PE Treatment	Days of PE Intervention	Needling Treatment	Day of Needling Treatment	Day of Sacrifice
Validation of Collagenase-Induced Tendinopathy									
1	C *	3	No		No		No		7
2	T1 #	3	Yes	1	No		No		7
Experimental Study									
3	T2 # (no treatment)	3	Yes	1	No		No		28
4	T2 + PE	3	Yes	1	Yes	7, 14, 21	No		28
5	T2 + N	3	Yes	1	No		Yes	7, 14, 21	28

C: control; T: Tendinopathy model; PE: Percutaneous Electrolysis; N: Needling. * Control group (C) was injected with saline solution; # Experimentally induced tendinopathy groups (T1 and T2) were injected with collagenase. T1: Experimentally induced tendinopathy group used for confirming the collagenase model. Rats were sacrificed 7 days after the collagenase injection.

T2: Experimentally induced tendinopathy groups randomly assigned to no treatment, percutaneous electrolysis (PE) or needling (N). Rats were sacrificed 28 days after the collagenase injection.

2.2. Collagenase Experimentally induced Tendinopathy

Rats were individually placed in a chamber. Anesthesia was induced with isoflurane (concentration 4–5%, oxigen 0.5–1 L/min). Subsequently, a collagenase injection was carried out with a 30-gauge needle 2 mm away from each rat Achilles osteotendinous junction. To induce Achilles tendon injury, a total of 250 units (30 μL) of collagenase (in 0.9% saline solution; bacterial type I; Sigma-Aldrich) previously filtered throughout a 0.22 μm Nalgene filter was injected [26]. We used one bolus injection of collagenase to mimic the acute reactive phase of a tendinopathy [26]. Rats serving as controls were injected with 30 μL of sterile saline solution (0.9% NaCl) to validate the injured model.

2.3. Percutaneous Electrolysis

The application of percutaneous electrolysis treatment was performed by using an approved EPI® device (Epiadvanced, Barcelona, Spain), certified according to the Directive 93/42/CEE. The positive electrode was placed on the tail of the rat with a cinch. The negative electrode consisted of a sterile solid needle (0.3 mm diameter; 0.25 mm length; Agupunt, Barcelona, Spain). The needle was inserted at an angle of approximately 70° with the tip oriented towards the calcaneous bone of the rat (Figure 1).



Figure 1. Application of Percutaneous Electrolysis (EPI© device) on the Achilles tendon of a rat. The positive electrode was placed on the tail of the rat with a cinch (figure on the left top corner).

Each percutaneous electrolysis session consisted of three punctures targeting the Achilles intratendon 2 mm away from the osteotendinous junction. The intensity of the continuous (galvanic) electrical current was set at 3 mA and applied for 4 sec on each puncture [22,23]. A total of three

sessions (a total of 9 punctures), once per week, were applied 7, 14, and 21 after the application of collagenase (Figure 2).

2.4. Control Needling

To determine if the observed changes were related to the electrical current applied during the percutaneous electrolysis and not just to the needle, a group of rats receiving the same needle insertion procedure was used as a control. Rats received needling for three sessions (3 punctures on 3 sessions) following the same procedure than for percutaneous electrolysis, i.e., 7, 14, and 21 after the application of collagenase, but without application of electrical current (Figure 2).



Figure 2. Flow Diagram summarizing the Experiment Groups.

2.5. Tissue Sampling Preparation

Rats were euthanized by exsanguination while deeply anesthetized one week after collagenase injection in both groups to validate the collagenase model (C, T1) and 7 days after the last experimental session (28 days after collagenase injection) within the remaining groups (Table 1), and tissue samples were obtained.

The Achilles tendon was surgically removed from each rat leg using a sterile surgical knife. The skin was longitudinally cut from the calcaneous osteotendinous junction to the musculotendinous junction of the soleus and twin muscle.

Tissue samples for the histological analyses were embedded into an Optical Cutting Temperature compound (OTC) and frozen in methylbutane precooled to its freezing point using liquid nitrogen and stored at -80 °C until analysis.

Samples allocated to genetic analysis were embedded in 1 mL of Trizol®, frozen under liquid nitrogen, and stored at -80 °C until analysis.

2.6. Histological Analysis

Tissue samples were longitudinally cut into 10 µm sections on a cryostat (HM550, Thermo Fisher Scientific, Waltham, MA, USA) and mounted on poly-L-lysine-coated (Menzel-Glazer) microscopic slides. Samples were stained with hematoxylin-eosin and safranin O. The hematoxylin-eosin staining allows observation of collagen structures and identification of tenocyte nuclei and muscular fibres, whereas safranin staining allows the identification of cartilaginous tissue cells.

Stained tissue samples were observed using an Olympus AX-70 microscope coupled with an Olympus Apogee digital camera. Images brightness and contrast were adjusted using Adobe Photoshop CS4.

2.7. Genetic Analysis

Ribonucleic acid (RNA) was extracted using a modified version of the procedure described by Chomczynsky and Sacchi [27]. Total RNA was sequentially extracted using 1 mL of Trizol® per 100 mg of tissue and purified using a commercial kit (RNeasy Mini Kit® Qiagen, Hilden, Germany). The RNA was quantified and its quality assessed by using an Agilent 2100 Bioanalyzer. Only samples with an RNA integrity number (RIN) >8.0 were used.

Complementary DNA (cDNA) was synthesized using messenger RNA (mRNA) contained in purified RNAs via a retrotranscription enzymatic reaction using the kit ImProm-IITM Reverse Transcripción System (Promega). Total RNA (2 μg), primed with a mix of oligo-dT and random hexamer primers, was reverse-transcribed into cDNA at 37 °C for 2 h using the first-strand cDNA synthesis kit (Promega Corporation, Madison, WI, USA) into a 20 μL volume, and stored at −20 °C of temperature until use, according to the manufacturer's instructions. In all cases, a reverse transcriptase negative control was performed to rule out genomic DNA contamination.

The DNA was amplified using polymerase chain reaction (PCR) and quantified using real time quantitative PCR (RT-qPCR). Before quantification of amplified DNA samples, efficiency analysis for each primer (specific for each targeted gene) was performed (Table 2). These analyses allowed us to establish the expression dynamic range for each primer. The RT-qPCR was performed following the SYBR-Green method [28] and using the primers listed in Table 2. Three genes (β-actin, β-act; 60 S ribosomal protein L19, Rpl19; and glyceraldehyde 3-phosphate dehydrogenase, Gapdh) were selected as internal standards to allow RT-qPCR data normalization. The NormFinder software was used to calculate the intra- and inter-group variations in their expressions. Finally, the mean of the threshold cycle (Ct) value and the primer efficiency value of Gapdh were used for normalization, as Gapdh was the most stable gene.

Table 2. Oligonucleotide Primer Sequences used for qPCR.

Gene Name	GenBank Number *	Oligonucleotide Primer Sequence (Forward; 5′-3′)	Forward Location *	Oligonucleotide Primer Sequence (Reverse; 3′-5′)	Reverse Location	Amplicon Size	Primer Efficiency
Cox2	S67722	CCCATGGGTGTGAAAG GAAA	566–586	GGGATCCGGGATGAAC TCTC	636–655	90	1.96
Col1a1	NM_053304	GCCTCAGCCACCTCAA GAGA	3681–3701	GGCTGCGGATGTTCTC AATC	3801–3820	140	2.06
Col3a1	NM_032085	CCAGGACAAAGAGGG GAACC	1194–1213	CCATTTCACCTTTCCCA CCA	1277–1297	103	1.99
Mmp2	NM_031054	ACACCTGACCTGGACC CTGA	615–634	TTCCCCATCATGGATTC GAG	700–719	105	1.98
Mmp9	NM_031055	GCAGGGCCCCTTTCTT ATTG	1659–1679	CTGGCCTGTGTACACC CACA	1769–1788	130	2.02
Vegf	NM_031836	GCAATGATGAAGCCCT GGAG	1271–1290	GCTGGCTTTGGTGAGGT TTG	1338–1357	87	1.97
Scx	NM_001130508	GAGAACACCCAGCCC AAACA	700–720	CGAATCGCCGTCTTTCT GTC	769–788	89	2.00
β-act	NM_031144	AGCCATGTACGTAGCC ATCC	415–434	ACCCTCATAGATGGGC ACAG	510–529	115	1.98
Gapdh	NM_017008	ACATGCCGCCTGGAGA AACCT	805–824	GCCCAGGATGCCCTTT AGTGG	874–894	90	1.96
Rpl19	NM_031103	TCGCCAATGCCAACTC TCGTC	123–143	AGCCCGGGAATGGACA GTCAC	191–211	89	2.07

Oligonucleotide location within its corresponding GenBank sequence. *Scx*: Scleraxis; *Vegf*: vascular endothelial growth factor; *Cox2*: cyclooxygenase 2; *Col1a1*: collagen type I alpha 1 chain; *Col3a*1: Collagen type III alpha 1 chain; *Mmp2*: Matrix metalloproteinase 2; *Mmp9*: Matrix metalloproteinase 9: *β-act*: Beta actin; *Gapdh*: Glyceraldehyde-3-phosphate; *Rpl19*: 60 S ribosomal protein L19.

The comparative Ct method was used for presenting quantitative data [29]. Following removal of outliers, raw fluorescence data were used to determine PCR amplification efficiency (E) as follows:

$$E = [10^{(-\frac{1}{slope})}100]$$

All amplifications had an E value of 100 ± 10%, an E value close to 100% being an indicator of efficient amplification.

$$FC = E^{-\Delta\Delta Ct}$$

The statistical significance level of qPCR analysis was determined using a one-sample t-test for each gene, testing whether $|FC| > 1$ is significant ($p < 0.05$).

The targeted genes for the current study included the cyclooxygenase 2 (*Cox2*) gene, which triggers inflammatory processes and the expression of some proteinases such as matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). The expression of metalloproteinase 2 and 9 (*Mmp2 and Mmp9*), Collagen type I alpha 1 chain (*Col1a1*) and collagen type III alpha 1 chain (*Col3a1*) genes were also evaluated, all components of the tendon extracellular matrix. We also analyzed growth factor genes, particularly the vascular endothelial growth factor (*Vegf*) gene, which is able to promote angiogenesis and vascular permeability, as well as the Scleraxis gene (*Scx*), a relevant gene key in the development of fetal tenocytes and in tendon remodeling processes in adults.

3. Results

3.1. Changes after Collagenase Injection (C vs. T1)

The images of hematoxylin–eosin and Safranin O stained tissue corresponding to the injured tendon of rats euthanized one week after the injection of collagenase (induced tendinopathy, T1) showed substantial damage as compared with tissue images from the tendon acting as control (C) one week after the injection of sterile saline solution (Figures 3 and 4). In particular, increased tenocyte number, misalignment of collagen fibres, and loss of extracellular matrix organization as well as increased vascularization (Figure 3B) was seen in the experimentally induced Achilles tendinopathy. Safranin O staining images also identified the presence of fibrocartilaginous tissue (Figure 4B).



Figure 3. Stained longitudinal images with hematoxylin–eosin of a normal Achilles tendon (**A**) and of an injured Achilles tendon of rats euthanized after one week after injection of collagenase (**B**). The scale bar is at 50 μm.



Figure 4. Stained longitudinal images with Safranin O of a normal Achilles tendon (**A**) and of an injured Achilles tendon of rats euthanized after one week after injection of collagenase showing the presence of fibrocartilaginous tissue (**B**). The scale bar is at 50 μm.

In addition, a significant increase in the expression of *Cox2*, *Mmp2*, *Mmp9*, *Col1a1*, *Col3a1*, *Vegf* and *Scx* genes (Figure 5) was also observed within the experimentally induced tendinopathy group compared with the control group (Table 3).

Table 3. Gene Expression Levels in healthy (C) and experimentally injured (T1) Achilles Tendons of Rats (sacrificed at 7 days after the injection).

Gene Name	Group	Fold Change	Standard Deviation	*p*-Value
Cox2	Healthy tendon (C)	1.001	0.049	
	Injured tendon (T1)	3.367	1.184	0.02
Mmp2	Healthy tendon (C)	0.941	0.106	
	Injured tendon (T1)	7.137	2.783	0.02
Mmp9	Healthy tendon (C)	1.004	0.128	
	Injured tendon (T1)	8.972	4.478	0.015
Col1a1	Healthy tendon (C)	0.923	0.158	
	Injured tendon (T1)	6.691	2.801	0.025
Col3a1	Healthy tendon (C)	0.967	0.062	
	Injured tendon (T1)	3.119	0.631	0.004
Vefg	Healthy tendon (C)	1.011	0.183	
	Injured tendon (T1)	1.708	0.274	< 0.001
Scx	Healthy tendon (C)	1.023	0.221	
	Injured tendon (T1)	6.935	2.851	0.004

Cox2: cyclooxygenase 2; *Mmp2*: Matrix metalloproteinase 2; *Mmp9*: Matrix metalloproteinase 9; *Col1a1*: collagen type I alpha 1 chain; *Col3a*1: Collagen type III alpha 1 chain; *Vegf*: vascular endothelial growth factor; *Scx*: Scleraxis.



Figure 5. Levels of expression of *Cox2 (A), Mmp2 (B), Mmp9 (C), Col1a1 (D), Col3a1 (E), Vegf (F) and Scx* (G) genes in an healthy control Achilles tendon (C) and experimentally induced tendinopathy tendon (T1). Data were quantified and normalized by using the RT-qPCR procedure. Each bar represents the fold change (FC) ± standard deviation (SD) of the normalized values. *** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$.

3.2. Percutaneous Electrolysis on Experimentally Induced Achilles Tendon

The images of hematoxylin–eosin- and Safranin O-stained tissue revealed similar histological changes, e.g., increase of tenocytes, loss in extracellular matrix organization, misalignment of collagen fibers and striking neovascularization, between injured Achilles tendons subjected to no treatment (T2, Figure 6A), Achilles tendon treated with percutaneous electrolysis (T2 + PE, Figure 6B,C) and injured tendon treated with needling (T2 + N, Figure 6D). Nevertheless, tendinous tissues of injured Achilles tendons treated with percutaneous electrolysis showed slightly more signs of inflammation (presence of leukocytes) than others, but this was not significant.



Figure 6. Stained longitudinal images with hematoxylin–eosin of injured Achilles tendon with collagenase injection by group: no intervention (**A**), treated with percutaneous electrolysis (**B**,**C**), or treated needling (**D**). Arrows in C shows several leucocyte cells. The scale bar is at 50 μm (**A**,**B**,**D**) and 10 μm (**C**).

A significant increase in the expression of *Cox2, Mmp9 and Vegf* genes was observed in the injured Achilles tendons treated with percutaneous electrolysis (Figure 7A,C,F; Table 4) in comparison with Achilles tendons without treatment (T2). Expression of *Mmp2, Col1a1, Col3a1 and Scx* genes was also higher in the group treated with percutaneous electrolysis, but this did not reach statistical significance (Figure 7B,D,E,G; Table 4). The application of a needling procedure only on injured Achilles tendons (T2 + N) also increased the expression of *Mmp2, Mmp9, Col1a1 and Vegf* genes when compared to non-treated injured Achilles tendons (T2), but to a lesser extent than after percutaneous electrolysis (Table 4).



Figure 7. Levels of expression of *Cox2 (A), Mmp2 (B), Mmp9 (C), Col1a1 (D), Col3a1 (E), Vegf (F) and Scx (G)* genes in an injured Achilles tendon with collagenase injection by group: no intervention (T2), percutaneous electrolysis (T2 + PE) and needling (T2 + N). Data were quantified and normalized by using the RT-qPCR procedure. Each bar represents the fold change (FC) ± standard deviation (SD). *** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$.

Table 4. Gene Expression Levels in Experimentally induced Tendinopathy Achilles Tendon of Rats (T2) according to intervention (no intervention, percutaneous electrolysis and needling).

Gene Name	Group	Fold Change	Standard Deviation	*p*-Value (T2 vs. T2 + PE/T2 + N)	*p*-Value (T2 + PE vs. T2 + N)
Cox2	T2 (28 days)	0.056	0.031		
	T2 + PE	1.392	0.697	*0.03* *	
	T2 + N	0.937	0.365	*0.05*	0.3

	T2 (28 days)	0.523	0.163		
Mmp2	T2 + PE	3.468	2.251	*0.07*	
	T2 + N	2.275	0.911	*0.03* *	0.3
	T2 (28 days)	0.040	0.006		
Mmp9	T2 + PE	8.977	5.069	*0.02* *	
	T2 + N	0.658	0.225	*0.01* *	0.02
	T2 (28 days)	0.364	0.345		
Col1a1	T2 + PE	3.875	2.547	*0.07*	
	T2 + N	2.009	0.336	*<0.001* ***	0.25
	T2 (28 days)	0.452	0.348		
Col3a1	T2 + PE	4.654	2.972	*0.06*	
	T2 + N	0.219	0.026	*0.15*	0.05
	T2 (28 days)	0.133	0.001		
Vefg	T2 + PE	2.229	0.117	*0.025* *	
	T2 + N	1.248	0.462	*0.005* **	0.007 **
	T2 (28 days)	2.256	1.087		
Scx	T2 + PE	2.886	1.373	*0.5*	
	T2 + N	1.860	0.672	*0.45*	0.25

Cox2: cyclooxygenase 2; *Mmp2*: Matrix metalloproteinase 2; *Mmp9*: Matrix metalloproteinase 9; *Col1a1*: collagen type I alpha 1 chain; *Col3a*1: Collagen type III alpha 1 chain; *Vegf*: vascular endothelial growth factor; *Scx*: Scleraxis; *** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$.

4. Discussion

This animal study found that application of percutaneous electrolysis in experimentally induced Achilles tendinopathy with collagenase injection increased the expression of some genes related to collagen regeneration and tissue remodeling of extracellular matrix, without significant induction of further histological changes. Gene overexpression was higher than that observed after application of a needling procedure. In particular, we observed changes in three (i.e., *Cox2, Mmp9, and Vegf*) out of seven of the gene expressions analyzed.

4.1. Experimentally induced Tendinopathy with Collagenase Injection

Before determining the effect of percutaneous electrolysis, we determined if the experimentally induced model with collagenase injection was able to mimic acute tendinopathy changes. We found an increase in the number of tenocytes, misalignment of collagen fibers, loss of extracellular matrix organization, and increased vascularization in experimentally injured Achilles tendons of rats. The presence of these changes agrees with previous experimental studies in animal models [30–32].

An increase in the expression of *Cox2, Mmp2, Mmp9, Col1a1, Col3a1, Vegf and Scx* genes is also consistent with data reported in previous human studies [11,33,34]. Riley found an overexpression of the collagen genes *Col1a1 and Col3a1* in human tendinous tissue was correlated with extracellular matrix organization loss in the acute phase [11]. Past studies have also reported an overexpression of these pro-inflammatory genes as well as significant increases within the expression of extracellular matrix metalloproteinases (MMPs) such as *Mmp2 and Mmp9* [35,36]. Finally, an overexpression of *Vegf* has been also reported to be present in tendinopathies and is attributed to an increase in vascularization due to the creation of new, but not functional, blood vessels [37,38].

Previous studies have also reported overexpression of proinflammatory genes such as *Cox2* during the healing process after a tendon injury [39,40]. Another important gene related to tendon remodeling is *Scx*, which also plays a relevant role in triggering *Col1a1* gene transcription [41,42]. This generalized gene overexpression has been related to the synthesis of new collagen, necessary to restore the tendon extracellular matrix organization. We found overexpression of all these genes in experimentally induced Achilles tendinopathy 7 days after injection of collagenase in the rats.

In conclusion, tissue images of Achilles tendons of rats euthanized one week after a collagenase injection showed histological and genetic changes that were characteristic of human tendinopathy,

which was also observed in previous experimentally induced animal models. These results suggest that the collagenase-induced model used in our study was adequate.

4.2. Gene Expression Changes after Percutaneous Electrolysis

It has been suggested that percutaneous electrolysis triggers an acute inflammatory response in the tendon leading to activation of restoring and healing tissue mechanisms [16]. The hypothesis of an inflammatory response after the application of percutaneous electrolysis has been confirmed in animal models [22,23]. This study is the first experimental animal model investigating changes in gene expression in an injured tendon. We observed a statistically significant increase in expression of *Cox2, Mmp9 and Vegf* genes, but a non-significant increase in *Mmp2, Col1a1, Col3a1 and Scx* genes after the application of three sessions of percutaneous electrolysis in comparison with no treatment. The application of a needling procedure also resulted in increases in gene expression, but to a lesser extent than with percutaneous electrolysis.

Previous studies have reported an overexpression of *Cox2* [43], *Mmp2* [44], *Mmp9* [45], *Col1a1* [39], *Col3a1* [46], *Vegf* [47,48], and *Scx* [49] genes at the initial stage of an inflammatory process after acute tendon injury but with a progressive decrease during the following 7–28 days. This time trend suggests that these proinflammatory genes and metalloproteinases participate in the initial (acute) degradation of extracellular matrix, but their long-term overexpression plays a relevant role within collagen regeneration and extracellular matrix remodeling during tendon healing [39,43–49]. In this pilot study, rats with experimentally induced Achilles tendinopathy treated with percutaneous electrolysis exhibited a generalized increase in gene expression in comparison with the needling intervention or no treatment at 28 days after collagenase injection; however, only overexpression of *Cox2, Mmp9 and Vegf* genes was statistically significant. Although *Mmp9, Col1a1, Col3a1 and Scx* gene expression also increased after percutaneous electrolysis application, the changes did not reach statistical significance. A possible explanation is that rats were euthanized 28 days after collagenase injection and 7 days after the last treatment session, a potential time window for the natural decrease in gene expression [43–49]. A second potential reason explaining the lack of statistical significance in the *Mmp2, Col1a1, Col3a1 and Scx* genes could be related to the small number of rats included in this pilot study, which could lead to underpowered results.

The fact that greater gene expression changes were observed after the application of percutaneous electrolysis than with just the needling application provides preliminary evidence suggesting that the application of continuous (galvanic) current leads to a greater (or faster) increase of gene expression than with application of a needling procedure. A facilitated-gene overexpression could promote collagen regeneration and extracellular matrix remodeling in healed tendons supporting the potential clinical application of this intervention for the treatment of tendinopathies.

An important finding of the current study was that histological images did not reveal significant changes between experimental groups, suggesting that the application of percutaneous electrolysis or needling promoted overexpression of genes associated with tendon healing but without inducing further histological damage to the tendon. Nevertheless, these findings should be considered in the scenario of the current study, since only three sessions of percutaneous electrolysis were applied, which may have been not enough to observe changes within the extracellular tendon matrix, as well as the small number of rats included. It is possible that a greater number of sessions or a greater electrical current voltage could lead to structural tendon changes and higher gene overexpression.

4.3. Clinical Implications

Our results have potential implications for clinical practice. All genes investigated in this study were present at the initial stage of the inflammatory process after a healed tendon but they progressively decrease over the following 7–28 days [43–49]. A long-term overexpression, as observed after the application of percutaneous electrolysis, may play a role for promoting collagen regeneration and extracellular matrix remodeling in a healed tendon. Nevertheless, the current study did not assess changes in protein levels; therefore, we cannot conclude that gene overexpression observed after the application of percutaneous electrolysis was able to produce better regeneration

of the tendon matrix and, hence, to improve collagenase-induced tendinopathy. Future studies should investigate changes in protein levels after the application of percutaneous electrolysis. Current and previous data suggest that application of percutaneous electrolysis can trigger an initial biological (inflammatory) response in the tendon, preparing the tissue for better loading. In fact, controlled tendon loads with exercise will be clearly needed to be combined with percutaneous electrolysis to facilitate the process of collagen tissue proliferation, thus improving the biomechanical properties of the tendon. This hypothesis is partially supported by randomized clinical trials showing that combining percutaneous electrolysis with a progressive exercise program represents a promising management strategy for tendinopathies of the elbow [20], shoulder [22], or knee [18]. Future trials determining the biological effects of combing percutaneous electrolysis with active therapies such as exercise would help to elucidate the underlying mechanisms of the clinical benefits of this intervention.

4.4. Limitations

Finally, we should recognize potential limitations to the current study. First, the number of rats on each group was small, which could lead to a lack of power in some comparisons. Therefore, this study should be considered as a pilot study. Due to the lack of previous studies investigating changes in gene expression, it was not possible to make "a priori" calculation of the most appropriate sample size. Considering the data obtained in this pilot study, an estimated sample size calculation was conducted to get statistical significance in all the analyzed genes. Assuming a pooled standard deviation ranging from 0.1 to 2.1 units, a two-tailed alpha level (α) of 0.05 and a desired power (1-β) of 80%, it was estimated that a sample of 5 to 7 rats per group would be required to detect between-group differences from 1.0 to 3.0 units. Nevertheless, it is important to consider that we found significant differences in three out of seven gene expressions with the current sample of rats. Second, it seems that the dosage of the galvanic electric current plays a relevant role in the inflammatory response elicited by percutaneous electrolysis. Future studies should investigate changes in gene expression with different dosages. In fact, clinicians apply this intervention with different doses and frequencies of sessions depending on the clinical presentation of the patient. Therefore, current results should be considered in the investigated scenario. Finally, the application of percutaneous electrolysis is usually ultrasound-guided [17–22]. In the current study, the technique was not ultrasound-guided, which could have influenced the results.

5. Conclusions

This experimental animal pilot study found that the application of three sessions (once a week) of percutaneous electrolysis into an experimentally induced Achilles tendinopathy with collagenase injection increases the expression of some genes related to collagen regeneration and remodeling of extracellular matrix, particularly the *Cox2, Mmp9 and Vegf* genes. These changes were greater than those observed after the application of a needling procedure. No additional histological changes were found with either intervention, suggesting that both interventions did not provide further damage into the tendon. Current results should be considered as preliminary and need to be confirmed in future studies.

Author Contributions: Conceptualization: all authors; methodology: J.L.S.-S.; L.C.-D., J.H.-T. and R.M.-S.; software and formal analysis: J.L.S.-S.; L.C.-D., J.H.-T. and C.F.-d.-l.-P.; writing—original draft: all authors; writing—review and editing: all authors; visualization: all authors; supervision: J.L.A.-B. and C.F.-d.-l.-P. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sobhani, S.; Dekker, R.; Postema, K.; Dijkstra, P.U. Epidemiology of ankle and foot overuse injuries in sports: A systematic review. *Scand. J. Med. Sci. Sports* **2013**, *23*, 669–686, doi:10.1111/j.1600-0838.2012.01509.x.
2. Waldecker, U.; Hofmann, G.; Drewitz, S. Epidemiologic investigation of 1394 feet: Coincidence of hindfoot malalignment and Achilles tendon disorders. *Foot Ankle Surg.* **2012**, *18*, 119–123, doi:10.1016/j.fas.2011.04.007.
3. Cook, J.L.; Rio, E.; Purdam, C.R.; Docking, S.I. Revisiting the continuum model of tendon pathology: What is its merit in clinical practice and research? *Br. J. Sports Med.* **2016**, *50*, 1187–1191, doi:10.1136/bjsports-2015-095422.
4. Xu, Y.; Murrell, G.A. The Basic Science of Tendinopathy. *Clin. Orthop. Relat. Res.* **2008**, *466*, 1528–1538, doi:10.1007/s11999-008-0286-4.
5. Wu, F.; Nerlich, M.; Docheva, D. Tendon injuries: Basic science and new repair proposals. *EFORT. Open. Rev.* **2017**, *2*, 332–342.
6. Järvinen, T.A. Neovascularisation in tendinopathy: From eradication to stabilisation? *Br. J. Sports Med.* **2020**, *54*, 1–2, doi:10.1136/bjsports-2019-100608.
7. Jacobsen, E.; Dart, A.J.; Mondori, T.; Horadogoda, N.; Jeffcott, L.B.; Little, C.; Smith, M.M. Focal Experimental Injury Leads to Widespread Gene Expression and Histologic Changes in Equine Flexor Tendons. *PLoS ONE* **2015**, *10*, e122220, doi:10.1371/journal.pone.0122220.
8. Cadby, J.A.; David, F.; van de Lest, C.; Bosch, G.; van Weeren, P.R.; Snedeker, J.G.; van Shie, H.T.M. Further characterization of an experimental model of tendinopathy in the horse. *Equine. Vet. J.* **2013**, *45*, 642–648.
9. Jones, G.C.; Corps, A.N.; Pennington, C.J.; Clark, I.M.; Edwards, D.R.; Bradley, M.M.; Hazleman, B.L.; Riley, G.P. Expression profiling of metalloproteinases and tissue inhibitors of metalloproteinases in normal and degenerate human achilles tendon. *Arthritis Rheum.* **2006**, *54*, 832–842, doi:10.1002/art.21672.
10. Ireland, D.; Harrall, R.; Curry, V.; Holloway, G.; Hackney, R.; Hazleman, B.; Riley, G. Multiple changes in gene expression in chronic human Achilles tendinopathy. *Matrix Biol.* **2001**, *20*, 159–169, doi:10.1016/s0945-053x(01)00128-7.
11. Van Leeuwen, M.T.; Zwerver, J.; Akker-Scheek, I.V.D. Extracorporeal shockwave therapy for patellar tendinopathy: A review of the literature. *Br. J. Sports Med.* **2009**, *43*, 163–168, doi:10.1136/bjsm.2008.050740.
12. Kearney, R.; Parsons, N.; Metcalfe, D.; Costa, M.L. Injection therapies for Achilles tendinopathy. *Cochrane Database Syst. Rev.* **2015**, 5, CD010960, doi:10.1002/14651858.cd010960.pub2.
13. Dupley, L.; Charalambous, A.C.P. Platelet-Rich Plasma Injections as a Treatment for Refractory Patellar Tendinosis: A Meta-Analysis of Randomised Trials. *Knee Surg. Relat. Res.* **2017**, *29*, 165–171, doi:10.5792/ksrr.16.055.
14. Murphy, M.C.; Travers, M.J.; Chivers, P.; Debenham, J.R.; Docking, S.I.; Rio, E.; Gibson, W. Efficacy of heavy eccentric calf training for treating mid-portion Achilles tendinopathy: A systematic review and meta-analysis. *Br. J. Sports Med.* **2019**, *53*, 1070–1077, doi:10.1136/bjsports-2018-099934.
15. Sanchez-Ibáñez, J.M. *Clinical Course in the Treatment of Chronic Patellar Tendinopathy through Ultrasound Guided Percutaneous Electrolysis Intratissue (EPI®): Study of a Population Series of Cases in Sport*; Atlantic International University: Honolulu, HI, USA, 2009.
16. Abat, F.; Sánchez-Sánchez, J.L.; Martín-Nogueras, A.; Calvo-Arenillas, J.I.; Yajeya, J.; Méndez-Sánchez, R.; Monllau, J.C.; Gelber, P.E. Randomized controlled trial comparing the effectiveness of the ultrasound-guided galvanic electrolysis technique (USGET) versus conventional electro-physiotherapeutic treatment on patellar tendinopathy. *J. Exp. Orthop.* **2016**, *3*, 34, doi:10.1186/s40634-016-0070-4.
17. Iborra-Marcos, Álvaro; Ramos-Álvarez, J.J.; Rodriguez-Fabián, G.; Del Castillo-González, F.; López-Román, A.; Polo-Portes, C.; Villanueva-Martínez, M. Intratissue Percutaneous Electrolysis vs Corticosteroid Infiltration for the Treatment of Plantar Fasciosis. *Foot Ankle Int.* **2018**, *39*, 704–711, doi:10.1177/1071100718754421.
18. Almeida, M.D.L.C.; Góngora-Rodríguez, J.; Lomas-Vega, R.; Martín-Valero, R.; Díaz-Fernández, Ángeles; Obrero-Gaitán, E.; Ibáñez-Vera, A.J.; Rodríguez-Almagro, D. Percutaneous Electrolysis in the Treatment of Lateral Epicondylalgia: A Single-Blind Randomized Controlled Trial. *J. Clin. Med.* **2020**, *9*, E2068, doi:10.3390/jcm9072068.
19. Valtierra, L.D.M.; Moreno, J.S.; Fernández-Muñoz, J.J.; Cleland, J.A.; Arias-Buría, J.L. Ultrasound-Guided Application of Percutaneous Electrolysis as an Adjunct to Exercise and Manual Therapy for Subacromial Pain Syndrome: A Randomized Clinical Trial. *J. Pain* **2018**, *19*, 1201–1210, doi:10.1016/j.jpain.2018.04.017.

20. Almeida, M.D.L.C.; Góngora-Rodríguez, J.; Rodríguez-Huguet, P.; Ibáñez-Vera, A.J.; Rodríguez-Almagro, D.; Martín-Valero, R.; Díaz-Fernández, Ángeles; Lomas-Vega, R. Effectiveness of Percutaneous Electrolysis in Supraspinatus Tendinopathy: A Single-Blinded Randomized Controlled Trial. *J. Clin. Med.* **2020**, *9*, E1837, doi:10.3390/jcm9061837.
21. Medina-Mirapeix, F.; García-Vidal, J.A.; Escolar Reina, P.; Martínez Cáceres, C.M. Histopathological analysis of the inflammatory response of two invasive techniques in the calcaneal tendon of a mouse (Abstract). *Rev. Fisioter. Invasiva* **2019**, *2*, 91.
22. García-Vidal, J.A.; Pelegrín Vivancos, P.; Escolar Reina, P.; Medina-Mirapeix, F. Inflammatory response of two invasive techniques in the mouse with collagenase induced tendinopathy. *Rev. Fisioter. Invasiva* **2019**, *2*, 80.
23. Margalef, R.; Minaya Muñoz, F.;Valera Garrido, F.; Santafe, M.M. Vasodilation secondary to exposure to galvanic currents. *Rev. Fisioter. Invasiva* **2019**, *2*, 107, doi:10.1055/s-0039-3401880.
24. Margalef, R.; Minaya-Muñoz, F.; Valera-Garrido, F.; Bosque, M.; Santafé, M.M. Changes in pH as a result of galvanic currents used in percutaneous needle electrolysis. *Rev. Fisioter. Invasiva J. Invasive Tech. Phys. Ther.* **2020**, *3*, 2–6, doi:10.1055/s-0040-1712511.
25. De Cesar Netto, C.; Godoy-Santos, A.L.; Augusto Pontin, P.; Mendonca Natalino, R.J.; Martins Pereira, C.A.; de Oliveira Lima, F.D.; Da Fonseca, L.F.; Staggers, J.R.; Cavinatto, L.M.; Schon, L.C.; et al. Novel animal model for Achilles tendinopathy: Controlled experimental study of serial injections of collagenase in rabbits. *PLoS ONE* **2018**, *13*, e192769, doi:10.1371/journal.pone.0192769.
26. Chomczynski, P.; Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* **1987**, *162*, 156–159, doi:10.1016/0003-2697(87)90021-2.
27. Herrero-Turrión, M.J.; Rodríguez-Martín, I.; López-Bellido, R.; Rodríguez, R. Whole-genome expression profile in zebrafish embryos after chronic exposure to morphine: Identification of new genes associated with neuronal function and mu opioid receptor expression. *BMC Genom.* **2014**, *15*, 874, doi:10.1186/1471-2164-15-874.
28. Schmittgen, T.D.; Livak, K.J. Analyzing real-time PCR data by the comparative C(T) method. *Nat. Protoc.* **2008**, *3*, 1101–1108.
29. Lee, S.Y.; Chieh, H.F.; Lin, C.J.; Jou, I.M.; Sun, Y.N.; Kuo, L.C.; Wu, P.T.; Su, F.C. Characteristics of Sonography in a Rat Achilles Tendinopathy Model: Possible Non-invasive Predictors of Biomechanics. *Sci. Rep.* **2017**, *7*, 5100, doi:10.1038/s41598-017-05466-y.
30. Orfei, C.P.; Lovati, A.B.; Viganò, M.; Stanco, D.; Bottagisio, M.; Di Giancamillo, A.; Setti, S.; De Girolamo, L. Dose-Related and Time-Dependent Development of Collagenase-Induced Tendinopathy in Rats. *PLoS ONE* **2016**, *11*, e161590, doi:10.1371/journal.pone.0161590.
31. Biasutti, S.; Dart, A.; Smith, M.; Blaker, C.; Clarke, E.; Jeffcott, L.; Little, C. Spatiotemporal variations in gene expression, histology and biomechanics in an ovine model of tendinopathy. *PLoS ONE* **2017**, *12*, e185282, doi:10.1371/journal.pone.0185282.
32. Eriksen, H.A.; Pajala, A.; Leppilahti, J.; Risteli, J. Increased content of type III collagen at the rupture site of human Achilles tendon. *J. Orthop. Res.* **2002**, *20*, 1352–1357, doi:10.1016/s0736-0266(02)00064-5.
33. Maffulli, N.; Ewen, S.W.B.; Waterston, S.W.; Reaper, J.; Barrass, V. Tenocytes from Ruptured and Tendinopathic Achilles Tendons Produce Greater Quantities of Type III Collagen than Tenocytes from Normal Achilles Tendons: An in Vitro Model of Human Tendon Healing. *Am. J. Sports Med.* **2000**, *28*, 499–505, doi:10.1177/03635465000280040901.
34. Riley, G. The pathogenesis of tendinopathy. A molecular perspective. *Rheumatology* **2004**, *43*, 131–142, doi:10.1093/rheumatology/keg448.
35. Jelinsky, S.; Rodeo, S.A.; Li, J.; Gulotta, L.V.; Archambault, J.M.; Seeherman, H.J. Regulation of gene expression in human tendinopathy. *BMC Musculoskelet. Disord.* **2011**, *12*, 86, doi:10.1186/1471-2474-12-86.
36. Karousou, E.; Ronga, M.; Vigetti, D.; Passi, A.; Maffulli, N. Collagens, Proteoglycans, MMP-2, MMP-9 and TIMPs in Human Achilles Tendon Rupture. *Clin. Orthop. Relat. Res.* **2008**, *466*, 1577–1582, doi:10.1007/s11999-008-0255-y.
37. Fu, B.S.C.; Wang, W.; Pau, H.M.; Wong, Y.P.; Chan, K.M.; Rolf, C.G. Increased Expression of Transforming Growth Factor-beta1 in Patellar Tendinosis. *Clin. Orthop. Relat. Res.* **2002**, *400*, 174–183, doi:10.1097/00003086-200207000-00022.

38. Alfredson, H.; Ohberg, L.; Forsgren, S. Is vasculo-neural ingrowth the cause of pain in chronic Achilles tendinosis? An investigation using ultrasonography and colour Doppler, immunohistochemistry, and diagnostic injections. *Knee Surg. Sports. Traumatol. Arthrosc.* **2003**, *11*, 334–338.
39. Juneja, S.C.; Schwarz, E.M.; O'Keefe, R.J.; Awad, H.A. Cellular and Molecular Factors in Flexor Tendon Repair and Adhesions: A Histological and Gene Expression Analysis. *Connect. Tissue Res.* **2013**, *54*, 218–226, doi:10.3109/03008207.2013.787418.
40. Manning, C.N.; Havlioglu, N.; Knutsen, E.; Sakiyama-Elbert, S.E.; Silva, M.J.; Thomopoulos, S.; Gelberman, R.H. The early inflammatory response after flexor tendon healing: A gene expression and histological analysis. *J. Orthop. Res.* **2014**, *32*, 645–652, doi:10.1002/jor.22575.
41. Eliasson, P.; Andersson, T.; Aspenberg, P. Rat Achilles tendon healing: Mechanical loading and gene expression. *J. Appl. Physiol.* **2009**, *107*, 399–407, doi:10.1152/japplphysiol.91563.2008.
42. Liu, H.; Zhu, S.; Zhang, C.; Lu, P.; Hu, J.; Yin, Z.; Ma, Y.; Chen, X.; Ouyang, H. Crucial transcription factors in tendon development and differentiation: Their potential for tendon regeneration. *Cell Tissue Res.* **2014**, *356*, 287–298, doi:10.1007/s00441-014-1834-8.
43. Sharma, P.; Maffulli, N. Biology of tendon injury: Healing, modeling and remodeling. *J. Musculoskelet. Neuronal Interact.* **2006**, *6*, 181–190.
44. Sugg, K.B.; Lubardic, J.; Gumucio, J.P.; Mendias, C.L. Changes in macrophage phenotype and induction of epithelial-to-mesenchymal transition genes following acute Achilles tenotomy and repair. *J. Orthop. Res.* **2014**, *32*, 944–951, doi:10.1002/jor.22624.
45. Oshiro, W.; Lou, J.; Xing, X.; Tu, Y.; Manske, P.R. Flexor tendon healing in the rat: A histologic and gene expression study. *J. Hand Surg.* **2003**, *28*, 814–823, doi:10.1016/s0363-5023(03)00366-6.
46. Loiselle, A.E.; Bragdon, G.A.; Jacobson, J.A.; Hasslund, S.; Cortes, Z.E.; Schwarz, E.M.; Mitten, D.J.; Awad, H.A.; O'Keefe, R.J. Remodeling of murine intrasynovial tendon adhesions following injury: MMP and neotendon gene expression. *J. Orthop. Res.* **2009**, *27*, 833–840, doi:10.1002/jor.20769.
47. Voleti, P.B.; Buckley, M.R.; Soslowsky, L.J. Tendon Healing: Repair and Regeneration. *Annu. Rev. Biomed. Eng.* **2012**, *14*, 47–71, doi:10.1146/annurev-bioeng-071811-150122.
48. Chen, C.H.; Cao, Y.; Wu, Y.F.; Bais, A.J.; Gao, J.S.; Tang, J.B. Tendon Healing In Vivo: Gene Expression and Production of Multiple Growth Factors in Early Tendon Healing Period. *J. Hand Surg.* **2008**, *33*, 1834–1842, doi:10.1016/j.jhsa.2008.07.003.
49. Tan, C.; Lui, P.P.Y.; Lee, Y.W.; Wong, Y.M. Scx-Transduced Tendon-Derived Stem Cells (TDSCs) Promoted Better Tendon Repair Compared to Mock-Transduced Cells in a Rat Patellar Tendon Window Injury Model. *PLoS ONE* **2014**, *9*, e97453, doi:10.1371/journal.pone.0097453.